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Resumo 
 
 
Este trabalho teve como principal objetivo estudar os efeitos metabólicos de 
alguns fármacos (três fármacos convencionais e um em desenvolvimento) em 
células de osteossarcoma (OS) e osteoblastos, através da medição de 
alterações dos perfis metabólicos celulares por metabolómica usando 
espectroscopia de Ressonância Magnética Nuclear (RMN). 
O Capítulo 1 apresenta um enquadramento teórico deste trabalho, começando 
por identificar as principais características metabólicas que descrevem o 
cancro em geral, assim como as famílias e mecanismos de ação dos fármacos 
usados no seu tratamento. São ainda apresentados os fármacos usados 
atualmente na quimioterapia do OS, bem como o complexo de Paládio (II) com 
espermina, Pd2Spm, com potencial atividade anticancerígena. Seguidamente, 
é explicada a estratégia da metabolómica celular e apresentado o estado da 
arte de estudos metabolómicos do efeito de agentes anticancerígenos em 
células. No Capítulo 2, apresentam-se os princípios das técnicas analíticas 
usadas neste trabalho, nomeadamente ensaios biológicos, espectroscopia de 
RMN e análise multivariada e estatística dos resultados. Os detalhes e 
procedimentos experimentais relativos aos métodos usados são descritos no 
Capítulo 3. 
O estudo da reprodutibilidade analítica e biológica do perfil metabólico de 
células MG-63 medido por RMN de alta resolução e rotação segundo o ângulo 
mágico (HRMAS) é apresentado no Capítulo 4. Avalia-se o impacto de vários 
fatores (integridade celular, velocidade de rotação da amostra, temperatura, 
duração e parâmetros de aquisição) nas características e qualidade do 
espectro de RMN HRMAS de 1H, definindo-se então os parâmetros de 
aquisição dos espectros a adquirir subsequentemente. Avaliam-se também os 
efeitos do nº de passagens celulares e do tempo de armazenamento no perfil 
metabólico de células MG-63. 
O Capítulo 5 descreve o impacto metabólico de fármacos convencionais 
usados atualmente na quimioterapia do OS, estudado por metabolómica por 
RMN de células lisadas e análise de extratos celulares aquosos. Os resultados 
mostram que as células MG-63 tratadas com cisplatina (cDDP) sofrem um 
aumento dramático do teor de lípidos, alterações dos níveis de constituintes 
dos fosfolípidos (compostos de colina) e de indicadores de degradação do 
DNA, associados a fenómenos de apoptose. Nas células expostas a 
doxorrubicina (DOX) ou a metotrexato (MTX) foram identificadas alterações 
metabólicas mais ténues, com a quase total ausência de alterações no teor de 
lípidos. Foram também detetadas alterações em metabolitos relacionados com 
o ciclo de Krebs, stress oxidativo e metabolismo de nucleótidos, interpretadas 
tentativamente à luz dos mecanismos de ação de cada um dos fármacos. O 
impacto metabólico da exposição de células MG-63 e osteoblastos a cDDP e 
ao complexo de Pd2Spm é apresentado no Capítulo 6. Os resultados mostram 
que, apesar de ambos os fármacos poderem ligar ao DNA, as alterações 
metabólicas que decorrem da sua ação são muito distintas, nomeadamente no 
que respeita às variações nos teores de lípidos (ausentes para Pd2Spm). 
Ensaios de medição de apoptose mostraram que, contrariamente ao verificado 
para células MG-63 expostas a cDDP, a redução do número de células por 
exposição a Pd2Spm não se deve a fenómenos de morte celular por apoptose 
ou necrose. Além disso, este último complexo exerce um efeito mais marcado 
em osteoblastos do que nas células cancerígenas, o inverso parecendo 
acontecer com a exposição a cDDP. Contudo, os resultados da exposição de 
células MG-63 a regimes de tratamento combinado com base em cocktails de 
cDDP ou Pd2Spm, descritos no Capítulo 7, mostram que, em combinação, os 
dois agentes induzem respostas metabólicas semelhantes entre si, 
decorrentes de mecanismos de sinergia entre fármacos. Finalmente, 
sumariam-se no Capítulo 8 as conclusões deste trabalho e apontam-se 
perspetivas de trabalho futuro. 
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Abstract 
 
 
The main scope of this work was to evaluate the metabolic effects of anticancer 
agents (three conventional and one new) in osteosarcoma (OS) cells and 
osteoblasts, by measuring alterations in the metabolic profile of cells by nuclear 
magnetic resonance (NMR) spectroscopy metabolomics. 
Chapter 1 gives a theoretical framework of this work, beginning with the main 
metabolic characteristics that globally describe cancer as well as the families 
and mechanisms of action of drugs used in chemotherapy. The drugs used 
nowadays to treat OS are also presented, together with the Palladium(II) 
complex with spermine, Pd2Spm, potentially active against cancer. Then, the 
global strategy for cell metabolomics is explained and the state of the art of 
metabolomic studies that analyze the effect of anticancer agents in cells is 
presented. In Chapter 2, the fundamentals of the analytical techniques used in 
this work, namely for biological assays, NMR spectroscopy and multivariate 
and statistical analysis of the results are described. A detailed description of the 
experimental procedures adopted throughout this work is given in Chapter 3. 
The biological and analytical reproducibility of the metabolic profile of MG-63 
cells by high resolution magic angle spinning (HRMAS) NMR is evaluated in 
Chapter 4. The metabolic impact of several factors (cellular integrity, spinning 
rate, temperature, time and acquisition parameters) on the 1H HRMAS NMR 
spectral profile and quality is analysed, enabling the definition of the best 
acquisition parameters for further experiments. The metabolic consequences of 
increasing number of passages in MG-63 cells as well as the duration of 
storage are also investigated. 
Chapter 5 describes the metabolic impact of drugs conventionally used in OS 
chemotherapy, through NMR metabolomics studies of lysed cells and aqueous 
extracts analysis. The results show that MG-63 cells treated with cisplatin 
(cDDP) undergo a strong up-regulation of lipid contents, alterations in 
phospholipid constituents (choline compounds) and biomarkers of DNA 
degradation, all associated with cell death by apoptosis. Cells exposed to 
doxorubicin (DOX) or methotrexate (MTX) showed much slighter metabolic 
changes, without any relevant alteration in lipid contents. However, metabolic 
changes associated with altered Krebs cycle, oxidative stress and nucleotides 
metabolism were detected and were tentatively interpreted at the light of the 
known mechanisms of action of these drugs. The metabolic impact of the 
exposure of MG-63 cells and osteoblasts to cDDP and the Pd2Spm complex is 
described in Chapter 6. Results show that, despite the ability of the two agents 
to bind DNA, the metabolic consequences that arise from exposure to them are 
distinct, namely in what concerns to variation in lipid contents (absent for 
Pd2Spm). Apoptosis detection assays showed that, differently from what was 
seen for MG-63 cells treated with cDDP, the decreased number of living cells 
upon exposure to Pd2Spm was not due to cell death by apoptosis or necrosis. 
Moreover, the latter agent induces more marked alterations in osteoblasts than 
in cancer cells, while the opposite seemed to occur upon cDDP exposure. 
Nevertheless, the results from MG-63 cells exposure to combination regimens 
with cDDP- or Pd2Spm-based cocktails, described in Chapter 7, revealed that, 
in combination, the two agents induce similar metabolic responses, arising from 
synergy mechanisms between the tested drugs. 
Finally, the main conclusions of this thesis are summarized in Chapter 8, and 
future perspectives in the light of this work are presented. 
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1. Introduction 
The term cancer designates an extensive group of diseases that can affect any part of the 
body, also known as malignant tumours or neoplasms. Cancer is generally the result of an 
accumulation of mutations in oncogenes and tumour suppression genes, the latter encoding 
regulatory proteins that normally control cell division (Nelson and Cox, 2005).  
According to the World Cancer Report 2014 of the International Agency for Research on 
Cancer (IARC), the specialized cancer agency of the World Health Organization (WHO), in 2012 the 
worldwide burden of cancer increased to 14 million new cases per year and is expected to rise to 
22 million annually within the next two decades (World Cancer Report, 2014). During the same 
period, the number of deaths attributed to cancer is expected to rise from 8.2 to 13 million per 
year. As shown is Figure 1.1, in 2012 the most frequently detected cancers were those of the lung 
(1.8 million cases), breast (1.7 million) and colorectum (1.4 million), while the most deadly were 
lung (1.6 million), liver (0.8 million) and stomach (0.7 million) cancers. The cancer statistics based 
on gender reveal that the overall incidence rate is almost 25% higher in men than in women 
(World Cancer Report, 2014). 
 
Figure 1.1. Cancer statistics for both genders: a) incidence and b) mortality data for all ages, based 
on 2012 average population (World Cancer Report, 2014). 
Developing countries are noted to be disproportionately affected by cancer, given that 
more than 60% of the world’s total cases are registered in Africa, Asia and Central and South 
America and 70% of the world’s deaths by cancer also occur in these regions, due to the lack of 
early detection and poor access to treatment. Despite all the investment in investigation and 
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health care, it is thought that around half of the diagnosed cancers could be avoided if current 
knowledge was adequately applied (World Cancer Report, 2014). 
This chapter begins by reviewing the metabolic alterations that describe carcinogenesis, 
followed by an overview of anticancer drugs categories and known mechanisms of action. Then, 
focus is given to osteosarcoma (OS) and to the drugs commonly used for its treatment, including 
an introduction to a new Pd(II) agent potentially active against OS. Finally, the state of the art 
regarding the application of metabolomics to assess the impact of drugs on cultured cancer cells. 
 
1.1. Metabolic Hallmarks of Cancer 
The transformation of a normal cell into a neoplastic one occurs through a multistage 
process, from a pre-cancerous lesion to a malignant tumour, as a result of the interaction 
between individual genetic factors and three categories of external agents: physical carcinogens 
(e.g. ultraviolet and ionizing radiations), chemical carcinogens (e.g. tobacco smoke and arsenic) 
and biological carcinogens (infections from viruses, bacteria or parasites) (World Cancer Report, 
2014). Furthermore, the probability of developing cancer dramatically increases with age, 
probably due to an accumulation of exposure to risk factors in combination with a reduced ability 
of cellular repair mechanisms upon ageing (World Cancer Report, 2014). 
Initial Considerations: the Tumor Microenvironment 
Research has shown that the complexity of the tumor microenvironment is at least 
comparable to that of normal/healthy tissues (Hanahan and Weinberg, 2011). Accordingly, in 
order to understand the biology of tumours, it is important to consider the different specialized 
cell types within them (Figure 1.2a), as well as the microenvironment in which the tumorigenesis 
process takes place (Figure 1.2b). 
Cancer cells carrying genetic mutations, both in oncogenes and tumour suppression genes, 
are responsible for initiating and driving tumorigenesis. These cells form a relatively 
homogeneous cell population until late stages of tumorigenesis, when increased cell proliferation 
and genetic instability promote the emergence of distinct subpopulations. Cancer stem cells are 
rare tumour-initiating cells that share transcriptional characteristics with normal stem cell 
population. The origin of these cells in solid tumours is not yet clear and may vary between 
tumour types: they may either originate from normal stem cells or from progenitor cells that 
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undergo oncogenic transformation. Once primary tumours are formed, cancer stem cells have the 
ability of self-renewal and generation of further differentiated cells (Hanahan and Weinberg, 
2011).  
 
Figure 1.2. Cells in tumour microenvironments: a) assembly of cells that constitute most solid tumors 
and b) distinct tumour microenvironments (adapted from Hanahan and Weinberg, 2011). 
Other types of cells associated to the neoplastic process comprise endothelial cells, 
pericytes and fibroblasts. Endothelial cells are involved in a series of signal-transduction pathways 
functionally implicated in developmental and tumour-associated angiogenesis processes. 
Pericytes are specialized mesenchymal cells with finger-like projections that surround the 
endothelial tubing of blood vessels. These cells also cooperate with endothelial cells in the 
synthesis of vascular basement membranes that serve as an anchor for both types of cells, thus 
displaying a vital role in supporting the tumour endothelium. In contrast to normal wound healing 
where they appear transiently, tumors can be associated with sites of chronic inflammation 
where inflammatory cells persist. This has been associated with a series of tissue pathologies 
apart from neoplasia (e.g. fibrosis, aberrant angiogenesis). Inflammatory cells, in turn, are able to 
release a variety of signalling molecules that act as effectors in fostering tumorigenesis. 
Fibroblastic cells are responsible for the enhancement of tumour phenotype through the 
promotion of cancer cell proliferation, angiogenesis, invasion and metastasis. The complete list of 
contributions from cancer-associated fibroblasts to tumour pathogenesis is far from complete, 
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but these cells are already known to be undoubtedly associated with the formation of 
desmoplastic stroma, characteristic of many advanced carcinomas (Hanahan and Weinberg, 
2011). 
The formation of the tumor complex environment is only made possible through the 
biological capabilities acquired by cancer cells during the multistep development of human 
tumors (Hanahan and Weinberg, 2011). These capabilities, also called hallmarks, constitute an 
organizing principle to rationalize the complexities of neoplastic disease development. The first 
paper on the subject proposed eight hallmarks of cancer (Hanahan and Weinberg, 2000) and in 
2011, the same authors proposed two additional hallmarks (Hanahan and Weinberg, 2011). This 
will be the basis of the following description of the characteristics of cancer. Cancer hallmarks 
include sustaining proliferative signalling, evading growth suppressors, resisting cell death, 
inducing angiogenesis, enabling replicative immortality, activating invasion and metastasis, 
reprogramming energy metabolism and evading immune destruction (Figure 1.3). 
 
Figure 1.3. The hallmarks of cancer (adapted from Hanahan and Weinberg, 2011). 
Sustaining Proliferative Signalling 
Cancer cells are able to sustain proliferative signalling in several different ways: by 
producing growth factor ligands themselves, resulting in self proliferative stimulation; by sending 
signals that stimulate normal cells within the supporting tumour-associated stroma; by elevating 
the levels of the signal receptor proteins at the cancer cell surface; or through activation of 
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components of the signalling pathway, downstream of receptors (Hanahan and Weinberg, 2011). 
As an example, it is currently known that around 40% of the diagnosed human melanomas 
acquire mutations that affect the structure of the B-Raf protein, resulting in a constitutive 
signalling through Raf to the mitogen-activated protein (MAP)-kinase pathway (Davies and 
Samuels, 2010). 
Evading Growth Suppressors 
In order to keep growing, cancer cells must circumvent pathways that negatively regulate 
their proliferation, many of these depending on the action of tumour suppressor genes. Two 
important tumour suppressors are known to encode the retinoblastoma-associated and TP53 
proteins which play important roles in two key complementary cellular regulatory pathways, 
responsible for cell proliferation or, alternatively, activate senescence and apoptotic programs 
(Hanahan and Weinberg, 2011). Cancer cells with alterations in the retinoblastoma pathway 
display continuous cell proliferation. In normal cells, whereas retinoblastoma transduces growth 
inhibitory signals originating outside the cell, TP53 responds to stress and abnormalities within 
the cell thus stopping the progression of the cell cycle until their correction, or triggering 
apoptosis. Changes in TP53 protein in cancer cells lead to a weakening of this monitoring and 
regulatory system (Olivier et al., 2010). 
Resisting Cell Death 
Tumor cells may adopt several strategies to circumvent apoptosis. One of the most 
frequent one is the elimination of the TP53 tumor suppressor function, resulting in the loss of one 
critical damage sensor of the apoptotic pathway (Olivier et al., 2010). Additionally, tumors may 
also increase the expression of antiapoptotic regulators (e.g Bcl-2) by downregulating pro-
apoptotic factors (e.g Bax) (Yip and Reed, 2008). Autophagy also mediates tumour cell survival. 
Autophagy enables the cells to break down cellular organelles (like ribosomes and mitochondria) 
allowing the resultant catabolites to be recycled for biosynthesis and energy metabolism. Recent 
studies have shown that nutrient starvation, radiotherapy and specific cytotoxic drugs induce 
elevated levels of autophagy, which seem to be cytoprotective for cancer cells (White and 
DiPaola, 2009; Apel et al., 2009; Amaravadi and Thompson, 2007; Mathew et al., 2007). Necrosis 
has also shown to have pro-inflammatory and tumour promoting potential. Differently from 
normal tissues, in which inflammatory cells are recruited to eliminate necrotic debris, in tumour 
tissues evidences suggest that inflammatory cells are capable of fostering angiogenesis, cancer 
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cell proliferation and invasiveness. Moreover, in neoplasia, necrotic cells seem to release 
bioactive factors that stimulate viable cells to proliferate thus promoting tumorigenesis. (Hanahan 
and Weinberg, 2011; Grivennikov et al., 2010). 
Inducing Angiogenesis 
In healthy tissues, the development of the vasculature occurs during embryogenesis, after 
which normal vasculature remains quite quiescent. Generally, angiogenesis is only transiently 
reactivated in situations of wound healing or female reproductive cycling. In the case of tumour 
tissue, the angiogenesis process remains, inducing a continuous spread out of vessels to sustain 
neoplastic expansion. Two of the most well-known angiogenesis inducers and inhibitors are the 
vascular endothelial growth factor A (VEGF-A) (Goel and Mercurio, 2013) and thrombospondin-1 
(TSP-1) (Wang et al., 1996), respectively. In fact, recent work showed that the expression of the 
gene that encodes for VEGF can be upregulated both by hypoxia and oncogene signalling (Ferrara, 
2009; Mac Gabhann and Popel, 2008). Additionally, pericytes have been found to be associated 
with the neovasculature of several tumors (Raza et al., 2010; Bergers and Song, 2005).  
Activating Invasion and Metastasis 
The process of invasion and metastasis occurs through multistep biological changes, which 
begin in local invasion, followed by intravasation by cancer cells into surrounding blood and 
lymphatic vessels. These are used to drive cancer cells to distant tissues, where they leave the 
vessels and form small nodules of cancer cells. The final step encompasses the growth of the 
micrometastatic lesions into macroscopic tumors, through a process named colonization 
(Hanahan and Weinberg, 2011). Recent research has shown that the ability of cancer cells to 
invade, resist apoptosis and disseminate is acquired in the context of a regulatory program, 
refered as epithelial-mesenchymal transition (EMT) (Klymkowsky and Savagner, 2009; Polyak and 
Weinberg, 2009). This program can be permanently or transiently activated by cancer cells in the 
course of invasion and metastasis. 
Enabling Replicative Immortality 
The immortalization of a reduced number of cells that precedes the tumour formation has 
been associated with their capacity to maintain telomeric DNA in such acceptable length in order 
to prevent the triggering of senescence and/or apoptosis. This is achieved mainly through the 
upregulation of telomerase expression, but also via an alternative recombination-based telomere 
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maintenance mechanism. Multiple evidences suggest that the telomeres that protect the end of 
chromosomes are key players in cells’ ability for unlimited proliferation (Blasco, 2005; Shay and 
Wright, 2000). 
Reprogramming of Energy Metabolism 
This issue is a particularly relevant one in relation to the theme of the present thesis. The 
deregulated cell proliferation that drives tumorigenesis is necessarily accompanied by 
adjustments in energy metabolism in order to fuel cell growth and division (Hanahan and 
Weinberg, 2011). Under aerobic conditions, normal cells produce pyruvate from glucose through 
glycolysis in the cytosol and then convert it to carbon dioxide in the mitochondrial Krebs cycle. 
This reaction originates NADH that in turn fuels oxidative phosphorylation for ATP production, 
with reduced production of lactate. Only when submitted to anaerobic conditions do healthy cells 
produce large amounts of lactate. On the contrary, in cancer cells, increased lactate production 
occurs regardless of oxygen availability. This metabolic adaptation of cancer cells is known as 
aerobic glycolysis or Warburg effect (Warburg, 1924; Warburg, 1956) (Figure 1.4). 
 
Figure 1.4. Schematic representation of the differences between oxidative phosphorylation, 
anaerobic glycolysis and Warburg effect (adapted from Heiden et al., 2009). 
This lower efficiency of ATP production afforded by glycolysis in relation to mitochondrial 
oxidative phosphorylation  in cancer cells is in part compensated by the upregulation of glucose 
transporters, namely GLUT1, resulting in an increased rate of glucose import into the cytoplasm. 
These and other glycolytic fuelling adaptations of cancer cells have been related to activated 
oncogenes, namely RAS and MYC, and tumour mutant suppressors, as TP53 (Jones and 
Thompson, 2009; DeBerardinis et al., 2008). Some of the many recent articles that review the 
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Warburg effect (Weljie and Jirik, 2010; Heiden et al., 2009; Ferreira, 2010; Antone, 2012; 
Annibaldi and Widmann, 2010) have also highlighted the additional knowledge acquired in recent 
years on other altered metabolic pathways as a consequence of the hypoxic conditions felt by 
cancer cells, namely those concerning glutamine metabolism and de novo lipid and nucleic acid 
synthesis.  
The role of glutamine in tumorigenesis has been very recently reviewed (Daye and Wellen, 
2012; Hensley et al., 2013).Glutamine metabolism is crucial for cell proliferation due to the use of 
this amino acid as a primary carbon source for energy production and biosynthesis, combined 
with its role in cell signalling and redox homeostasis regulation (Figure 1.5). 
 
Figure 1.5. Coordination of glucose and glutamine utilization in cancer (adapted from Daye and 
Wellen, 2012). 
The regulation of the redox homeostasis by glutamine is due to its central contribution to 
glutamate biosynthesis from which, together with cysteine and glycine, a potent endogenous 
antioxidant is built: glutathione. Moreover, the normalization of the levels of the reduced form of 
glutathione requires NADPH, which production can be potentiated by the metabolism of 
glutamine through malic enzyme (Wise and Thompson, 2010). Additionally, recent studies suggest 
that cells actively regulate the metabolism of glucose and glutamine, depending on their 
reciprocal availability: glucose availability was shown to modulate the cellular uptake of glutamine 
through the hexosamine biosynthetic pathway, a branch of glucose metabolism that generates 
UDP-N-acetyl-glucosamine (UDP-GlcNAc) (Figure 1.5). In short, the glucose flux into the 
hexosamine biosynthetic pathway to support the glycosylation of surface receptors may serve as 
metabolic checkpoint, through which cells can control growth-factor-dependent uptake of 
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glutamine, in a glucose dependent manner (Daye and Wellen, 2012). As a key player in cancer cell 
proliferation, glutamine metabolism is regulated by oncogenes and tumour suppressors. 
Increasing evidence shows that cancer cells possess altered lipid metabolism (Podo, 1999; 
Fernandis and Wenk, 2009; Santos and Schulze, 2012). Several types of cancer cells present 
increased rates of de novo lipid synthesis in order to fulfil their metabolic requirements. The 
increased proliferation rate of cancer cells demand increased fatty acid production for the 
production of phosphoglycerides which, together with cholesterol, can be used to build cell 
membranes. The mobilization of fatty acids from lipid stores and its degradation in the 
mitochondria through β-oxidation can provide energy when required. The oncogenic activation of 
the PI3K/Akt pathway induces the uptake of glucose and its use for lipid synthesis through 
activation of the transcription factor sterol regulatory element-binding proteins (SREBPs). AMPK is 
activated in response to low cellular energy levels, preventing lipid synthesis and promoting its β-
oxidation. The activation of HIF1 (Hypoxia Inducible Factor 1) by hypoxic conditions of tumour 
tissues reduces the flux of glucose to acetyl-CoA through mitochondria. The production of α-
ketoglutarate from glutamine provides the cytoplasmatic citrate in tumour cells, which can in turn 
be used to fatty acid synthesis (Figure 1.6) (Santos and Schulze, 2012). 
 
Figure 1.6. Regulation of lipid metabolism by oncogenic signalling pathways (adapted from Santos 
and Schulze, 2012). 
Lipolysis
Glutaminolysis
Lipid droplets
Glycolysis
GlutamineGlutamateα-ketoglutarateCitrate
Acetoacetyl-CoA
Cholesterol
Lactate Lactate
Glucose
Glucose
Lipid uptake
Acetyl-CoA
Glyceraldeyde
3-phosphate
Glycerol
3-phosphate
Saturated 
fatty acids
Unsaturated 
fatty acids
AMPK
Dietary 
lipids Triacylglycerides
Phosphoglycerides
Akt
SREBP
Target 
genes
Pyruvate
Triacylglycerides
Acyl-CoA
Introduction 
 
_________________________________________________________________________________ 
 _________________________________________________________________________________ 
 
32 
 
Nucleotide metabolism is also altered in tumour cells, as proven by their larger nucleotide 
pool (necessary to ensure the proliferative activity), the higher activity of the nucleotide anabolic 
pathway and its reduced catabolic pathway (Tong et al., 2009). The biosynthesis of purines and 
pyrimidines needs ribose-5-phosphate (R5P), produced from glycolytic intermediates that enter 
the pentose phosphate pathway (PPP) and nonessential amino acids derived from glucose and 
glutamine catabolism. In turn, ribose-5-phosphate can be either synthesized from glucose-6-
phosphate (through oxidative branch of the PPP) or from fructose-6-phosphate and 
glyceraldehydes-3-phosphate (GA3P, through non-oxidative branch of PPP). In normal cells, 
ribose-5-phosphate is preferentially produced via PPP, while in tumour cells the non-oxidative 
pathway constitutes the main source of ribose-5-phosphate production (Boros et al., 1998). 
Besides its role in the stimulation of anaerobic glycolysis, HIF1 is also crucial in this preference for 
the non-oxidative PPP. Thus, tumour cells possess a complex interplay between glycolysis, 
glutaminolysis and the de novo nucleotides synthesis (Figure 1.7) (Tong et al., 2009). 
 
Figure 1.7. Regulation of glycolysis, glutaminolysis and de novo nucleotide biosynthesis in tumour 
cells (adapted from Tong et al., 2009). 
All the steps in the non-oxidative PPP are reversible, which means that the relative levels of 
metabolic substrates and products drive the direction of the pathway. Thus, with the purpose of 
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diverting glycolytic compounds into PPP (through the non-oxidative pathway) tumour cells need 
to maintain high levels of fructose-6-phosphate and/or GA3P (Tong et al., 2009). 
Evading Immune Destruction 
Increasing evidence suggests that solid tumours somehow evade detection by the immune 
system, or at least are able to restrict the extent of immunological activity, thereby evading 
immune destruction (Yang et al., 2010; Shields et al., 2010). One of the main strategies of tumors 
to evade eradication seems to lie on the disabling of the components of the immune system that 
are activated to eliminate them. For instance, cancer cells may stop cytotoxic T lymphocytes and 
natural killer cells, by secreting TGF-β or other immunosuppressive factors. Other strategies of the 
tumour tissues to suppress cytotoxic lymphocytes consist of the recruitment of inflammatory cells 
that are actively immunosuppressive, as regulatory T cells and myeloid-derived suppressor cells 
(Hanahan and Weinberg, 2011). 
 
The enormous complexity of the tumorigenesis process seems to be far beyond the above 
briefly referred topics. Several recent papers offer very interesting reviews about general findings 
on cancer cell metabolism and recent knowledge on cancer cell reprogramming (Locasale and 
Cantley, 2010; Negrini et al., 2010; Cantor and Sabatini, 2012; Dang, 2012; Fiachi and Chiarugi, 
2012; Jones and Schulze, 2012; Schulze and Harris, 2012; Ward and Thompson, 2012; Dang, 2013; 
Wu and Zhao, 2013; Gaude and Frezza, 2014; Phan et al., 2014) 
 
1.2. Drugs Used in Cancer Treatment: Families and Mechanisms 
The metabolic hallmarks of cancer described in the previous section constitute potential 
therapeutic targets. Inhibition of cancer specific pathways is prone to limit tumor growth and 
promote its eventual shrinkage. With this purpose, several drugs have been investigated and 
taken from in vitro testing to clinical trials. This section comprises the description of the agents 
presently used in anticancer research according to their targets and mechanisms of action and the 
classes hereby presented reflect those proposed by specific literature (Skeel, 2007). 
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1.2.1. Alkylating Agents 
Alkylating agents are among the first type of drugs used in systemic chemotherapy and 
include nitrogen mustards (e.g. cyclophosphamide and ifosfamide), alkyl sulphonates, aziridines 
and nitrosoureas (e.g. chloroethyl nitrosourea, CENU). The general mode of action of these drugs 
is based on the formation of an ethyleneimonium intermediate ion which, due its high instability, 
forms covalent bonds with DNA bases (Warwick, 1963). Bifunctional alkylating agents possess two 
reactive groups characterized by the presence of a lone pair of electrons on the nitrogen atom, 
the donation of which gives rise to an unstable ethyleneimonium ion followed by loss of a 
negatively charged chloride radical. The ethyleneimonium ion may further destabilized to form a 
carbonium ion, both intermediates being able to sequentially bond to guanine residues within the 
DNA double helix, yielding either intra- or inter-strand adducts (Figure 1.8) (Airley, 2009).  
 
Figure 1.8. General mode of action of alkylating agents (adapted from Airley, 2009). 
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1.2.2. Metal-based Anticancer Agents 
In the case of platinum-containing drugs (cisplatin or cDDP, oxaplatin and carboplatin), the 
formation of an intermediate occurs when the drug enters the cell, where hydrolysis of the 
chlorine atoms takes place, due to lower intracellular concentration of Cl- ions. An unstable aquo 
intermediate is formed (drug activation step), which then binds to DNA bases (mostly guanine and 
adenine), through Pt-N7 bonds (Airley, 2009). 
 
1.2.3. Antimetabolites 
Several drugs act by mimicking the structure of natural occurring molecules and, for this 
reason they are generally designated as antimetabolites (Bardos, 1974). Their designation is based 
on the type of agent they mimic: 1) inhibitors of purine and pyrimidine biosynthesis: the structure 
is similar to those of enzymes involved in DNA synthesis; 2) purine analogues: similar to purine 
free bases, thus being incorporated into nucleotides; 3) nucleosides analogues: comprising a 
purine or pyrimidine base linked to a deoxyribose sugar that is intracellularly phosphorylated, 
therefore interfering with DNA elongation; 4) pyrimidine analogues (e.g. 5-Fluorouracil); or 5) 
antifolates (e.g. methotrexate), which antagonise folic acid activity. (Airley, 2009) 
 
1.2.4. Antitumor Antibiotics 
Anthracyclines (e.g. doxorubicin, daunorubicin, epirubicin) are a group of antitumor 
antibiotics and are among the most potent chemotherapeutic agents (Hortobágyi, 1997). These 
agents have several modes of actions: 1) intercalation in the DNA double helix, thus disrupting 
base pairing and base stacking, subsequently interfering with DNA synthesis and replication; 2) 
production of free radicals through the interaction between anthracyclines and molecular oxygen, 
thus resulting in the production of peroxides, superoxide and hydroxyl radicals responsible for 
injury of several cellular components; 3) inhibition of topoisomerase II, yielding a stable DNA-
enzyme complex that prevents the rejoining of DNA breaks (Airley, 2009). Antitumour antibiotics 
that are not anthracyclines include actinomycin-D, bleomycin and mitomycin-C (Airley, 2009).  
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1.2.5. Mitotic Inhibitors 
Mitotic inhibitors alter the dynamics of the mitotic spindle by targeting tubulin, the main 
structural protein constituent of microtubules. As cell-cycle dependent agents, these drugs act at 
the M-phase, i.e., when the chromosomes are aligned on the mitotic spindle (Senese et al., 2014). 
Vinca alkaloids (e.g. Vincrastine), derived from the plant Vinca rosea are an example of these 
agents, and act by binding to one of the soluble subunits of the tubulin, inducing a conformational 
change responsible for an increase in the affinity between tubulin filaments. These agents reduce 
the rate of microtubules growth by stabilising them, hence compromising the dynamics necessary 
for mitotic spindle formation during metaphase. Taxanes represent another group of mitotic 
inhibitors, namely the frequently used paclitaxel and docetaxel. Contrary to Vinca alkaloids, these 
agents promote tubulin polymerisation by binding to a subunit in the inner surface of the 
microtubule cylinder. This induces a conformational change in the tubulin molecules which 
promotes its self-assembly and function loss (Airley, 2009). 
 
1.2.6. Hormonal Agents 
Breast, prostate, ovary, cervix and testicles carcinomas are examples of hormone-
dependent neoplasias. The regulation of growth and differentiation of tissues that suffer the 
influence of hormones is dependent on their binding to the respective receptor. Estrogens and 
androgens are examples of hormones, the interaction of which with specific receptors triggers a 
series of events responsible for cell proliferation (Airley, 2009). 
This class of anticancer drugs encompasses four main types of compounds: aromatase 
inhibitors (e.g.Anastrazole), that block the action of aromatase (or estrogen synthase) involved in 
the final step of estrogen synthesis from androgens; anti-androgens (e.g. flutamide), which 
compete with natural androgens for the binding to androgen receptors; endocrine agents (e.g. 
leuprolide),which modulate the hypothalamus-hypophysis axis in order to inhibit the production 
of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), responsible for the production 
of male and female hormones; and estrogen antagonists (e.g. tamoxifen) (Airley, 2009). 
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1.2.7. Antiangiogenic and Antivascular Agents 
The growth and survival of solid tumours depend on the correct supply of nutrients through 
functional vasculature networks (Jain, 2002). Based on this, antiangiogenic and antivascular 
disrupting agents have emerged as important players in chemotherapy. 
Antiangiogenic drugs hinder the process of new blood vessel formation in cancer tissues, 
thus targeting angiogenesis and blocking the ability of a cancer cells population to proliferate, 
survive and invade surrounding tissues, either by tumour growth or metastasis (Airley, 2009). 
Agents like HIF-1 or VEGF (vascular endothelial growth factor) have the ability to promote 
angiogenesis in hypoxic conditions. In the search for novel antiangiogenic agents, a number of 
possible sites of pharmacological intervention must be taken into account: using angiostatic 
agents like endostatin, an inhibition of angiogenesis is supposed to be achieved; targeting growth 
factors, for example by using growth factor receptor antagonist will suppress their action on 
endothelial cell growth; matrix metalloproteinase inhibitors will inhibit invasion of surrounding 
tissues by tumour cells; inhibitors of cell adhesion molecules and cell junctions (integrin inhibitors) 
will difficult cell survival in a solid tumour (Figure 1.9). 
 
Figure 1.9. Sites of pharmacological intervention when designing angiogenesis inhibitors (adapted 
from Airley, 2009) 
Vascular disrupting agents intend to destroy the structural and functional integrity of 
existent vasculature (Liu and Deisseroth, 2006). The use of this kind of agents aims at inducing the 
collapse of existing tumour blood vasculature, leading to ischemia (oxygen privation) and tumour 
cell death. Vascular disrupting agents act upon endothelial cells in a similar way of that of tubulin 
binding drugs such as Vinca alkaloids and taxanes. Because tumour vascular endothelium shows 
differences from normal vasculature (increased rate of endothelium proliferation, lack of 
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extravascular pericytes and increased fragility due to abnormal basement membrane and thin 
muscular wall), tubulin-binding vascular disrupting agents can directly target malignant vessels. 
 
1.2.8. Topoisomerase Inhibitors 
Topoisomerase I and II have little similarity in terms of amino acid sequence and are 
different in what concerns molecular mass and function, although both play a very important role 
in DNA replication and packaging. Topoisomerase I is responsible for a single DNA strand break 
and enables the unwinding of the broken single strand through the other, in a process that does 
not depend on ATP, once this enzyme preserves the energy of the phosphodiester linkage break 
through a covalent link between the phosphate group and the enzyme itself, at the cleavage 
point. Then it uses this preserved energy to restore the phosphodiester linkage and seal its break 
to the strand. On the other hand, topoisomerase II induces breaks in the two DNA strands and at 
the same time, it can twist or unwind them through an ATP-dependent process (Airley, 2009). 
irinotecan and etoposide are examples of Topoisomerase I and II inhibitors, respectively (Lindskog 
et al., 2004). 
 
1.2.9. Molecularly Targeted 
Tumor Hypoxia – HIF-1 Inhibitors 
As mentioned before, tumour hypoxia is a phenomenon that is usually associated with solid 
tumours. Because tumour cells proliferation rate is very high, there is not enough time to correct 
angiogenesis and some cancer cells even experiment complete anoxia, a condition in which cells 
are able to survive only for short periods of time. In order to survive this hostile environment, 
cancer cells undergo a number of adaptive modifications regulated by the transcription factor 
hypoxia-inducible factor 1 (HIF1) (Semenza, 2003). HIF1 is a complex constituted by two subunits, 
HIF1α and HIF1β. The first can rapidly be degraded under normal oxygen conditions, whereas HIF-
1β exists independently of tissue oxygenation. In hypoxic conditions both subunits are present, 
and so they complex. The formation of this dimer induces a conformational change that enables 
this transcription factor to bind hypoxia-response element (an enhancer sequence of DNA 
localized in the promoter region of hypoxia-inducible genes). This ends by activating genes that 
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encode for proteins involved in response to hypoxia. HIF1 inhibitors as anticancer drugs, block the 
adaptive response of cancer tissues to hypoxia, thus contributing for tumour remission (Airley, 
2009). 
Tyrosine Kinase Inhibitors 
Tyrosine kinase is a very important player in malignant progression since the expression of 
receptors and proteins that result from its activation play a role in many important metabolic 
pathways related to cancer. Tyrosine kinase catalyses the transfer of a phosphorous group from 
ATP to a tyrosine residue on effector proteins. This phosphorylation act as a signal that regulates 
the expression of genes that control among others, cell survival, proliferation and the capacity to 
metastasize. There are two types of tyrosine kinases: receptor tyrosine kinases, where the 
enzyme is part of a membrane bound receptor and non receptor tyrosine kinases that frequently 
lie in the cytoplasm or in the internal surface of the cell (Gottschalk et al., 2004). 
Ras Inhibitors 
Ras is a 3-member family of proto-oncogenes (H-Ras, N-Ras, K-Ras) that codes for a GTPase 
located in the inner surface of the plasma membrane, and activates growth factor-mediated 
signal transduction pathways, responsible for the regulation of cell proliferation and survival. 
Single point mutations in specific codons of Ras are responsible for its oncogenic transformation 
and subsequent prevalence of the constitutively active GTP form. For this reason, in tumours that 
express the Ras oncogene, there is an amplification of the signal transduction pathways that 
mediates malignant transformation progression (Baines et al., 2011). In order to be functional, 
Ras must undergo post-translational modifications that allow its anchorage to the inner surface of 
the plasma membrane. Farnesyl transferase is a heterodimeric metalloenzyme that is responsible 
for this. Due to its crucial importance for Ras activation, Ras farnesyl transferase has become a 
target in novel anticancer agents development (Airley, 2009). 
Heat Shock Protein (HSP) 90 inhibitors 
Heat shock proteins (HSP) are a family of proteins produced in response to heat stress, with 
the particular objective of protecting specific proteins, vulnerable to damage and denaturation in 
these conditions. HSP90 (90 kDa) has a wide range of binding proteins, but is its action on proteins 
involved in signal transduction of tumour proliferative and regulatory processes, that attract more 
interest and promotes many studies on anticancer drug design. HSP90 binding proteins interfere 
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in processes like: oncogene expression, signal transduction, transcription factor HIF-1 and TP53 
(Gomez-Monterrey et al., 2012). Therefore, HSP90 inhibitors have multiple modes of action, such 
as the suppression of growth factor production, inhibition of kinases associated with progression 
through cell cycle, inhibition of oestrogen-induced cellular proliferation (hormone-dependent 
cancers) and the induction of apoptosis (Airley, 2009). 
Histone Deacetylase (HDAC) inhibitors 
DNA packaging into chromosomes depends on the action of histones. Histone deacetylases 
(HDAC) are enzymes that change chromatic structure and promote altered gene expression in 
cancer. By removing acetyl groups from lysine residues, HDAC restores positive charge enabling 
DNA condensation and repressing transcription of specific genes that may inhibit cellular 
proliferation and tumour growth. In the contrary, inhibition of HDAC leads to an accumulation of 
hyperacetylated histones, inhibiting tumour growth by activating the transcription of genes 
responsible for cell cycle arrest, differentiation and/or apoptosis (Atadja, 2011). 
Phosphoinositide 3-kinase (PI3K) inhibitors 
Phosphoinositide 3-kinases (PI3K) are a family of lipid kinases that catalyse the formation of 
phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-triphosphate. These 
molecules selectively bind many signalling proteins, leading to activation of downstream signalling 
pathways. The three main classes of members of this family mediate many key cellular processes 
including growth and survival, cell cycle entry, adhesion and migration. For this reason PI3K looks 
like an attractive target for novel mechanism-based anticancer treatment (Beloueche-Babari et 
al., 2006). 
Choline Kinase inhibitors 
Choline kinase catalyses the phosphorylation of choline by ATP in the presence of Mg2+, 
yielding phosphocholine. This enzyme step commits choline to Kennedy pathway for the 
biosynthesis of phosphatidylcholine, the major phospholipid constituent of biomembranes. 
Increased activity of choline kinase has been reported to be associated with an enhanced 
generation of PC, mostly independently of the rate of net PtdCho biosynthesis. In addition, 
chemical carcinogens have been shown to cause induction of choline kinase activity, leading to PC 
accumulation. Recently, increased activity of this enzyme has been shown in human tumour-
derived cell lines and in a variety of human tumours compared with their corresponding normal 
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tissues (Al-Saffar et al., 2006). These findings strongly suggest the role of choline kinase as a 
potential target for the development of anticancer drugs. 
PPARγ receptor 
The peroxisome proliferator-activated receptor-γ (PPARγ) plays a central role in the process 
of adipocyte differentiation and is expressed at high levels in each of the major histological types 
of human liposarcoma. Ligands to the PPARγ nuclear receptor induce terminal adipocyte 
differentiation of preadipocytes and primary human liposarcoma cells. The induction of adipocyte 
differentiation by PPARγ ligands results in the expression of adipocyte-specific genes, a rapid 
accumulation of intracellular triglycerides, and withdrawal from the cell cycle. This induction of 
terminal differentiation by synthetic ligands to the nuclear receptors that regulate growth and 
differentiation represents a promising therapy for the treatment of certain malignancies (Chen et 
al., 2002). 
 
1.3. Drugs Commonly used in Osteosarcoma Treatment 
This section begins by presenting osteosarcoma (OS) and the current clinical protocols for 
its treatment as well as new OS treatment strategies and agents. The currently most used drugs 
for OS treatment (cisplatin, doxorubicin and methotrexate) are addressed later, focusing on their 
particular mechanisms of action, in the light of the previously defined families of compounds.   
1.3.1. Osteosarcoma: Definition and Prevalence 
In the human body, new bone is permanently being formed, while old one is dissolved. The 
interior of most bones is hollow (containing the bone marrow) and their outer part is a network of 
fibrous tissue called matrix, in which calcium ions are deposited. Osteoblast is the name given to 
the cells that lay down new bone and osteoclasts are those responsible for dissolving old bone 
tissue. Figure 1.10a schematically represents the elements that constitute the bone architecture. 
Cells from any part of the bone can differentiate into a tumour. Primary bone cancers are 
called sarcomas and their origin is the bone itself. There are benign (not cancerous) and malignant 
(cancerous) primary bone tumors, of different types, whose names are based on the area of bone 
or surrounding tissue that is affected and on the type of cells forming the tumour. 
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Figure 1.10. a) Schematic representation of the bone constituting elements (adapted from 
www.cancer.org/cancer/bonecancer) and b) X-ray image of an OS lesion (adapted from Ta et al., 2009). 
Bone cancers are rare events and, according to the American Cancer Society, they account 
for less than 0.2% of all diagnosed cancers. In adults, more than 40% of primary bone 
malignancies are chondrosarcomas, followed by osteosarcoma (28%), chordomas (10%), Ewing 
tumors (8%) and malignant fibrosarcomas (4%). Osteosarcoma is the most common solid tumour 
of bone affecting pediatric and adolescent age groups with an incidence of 56%, followed by 
Ewing tumors (34%) and chondrosarcomas (6%) (www.cancer.org/cancer/bonecancer). 
Unlike most other primary tumors of bone, Ewing sarcoma involves a translocation in the 
eleventh and twenty second chromosomes. The result of that translocation is the protein EWS-
FLI1, which has been pointed as an aberrant transcription factor that drives the pathogenesis of 
this type of tumour (Schwab et al., 2012). Ewing sarcomas predominantly occur in the pelvis, the 
diaphyseal regions of long bones and bones of the chest wall. Chondrosarcoma is a vast group of 
malignant bone tumors that originate a cartilaginous (chondroid) matrix, often found in bones 
that elongate due to endochondral ossification. They can emerge as primary or secondary 
(associated with metastatic phenomena) tumors in benign precursor lesions, they are generally 
slow growing and seldom metastasize (van Driel and van Leeuwen, 2014). Fibrosarcomas develop 
more often in soft tissues than in bones, and when in the latter the most affected are those from 
the legs, arms and jaw. Chordoma usually occurs in the base of the skull and bones of the spine. It 
is about twice as common in men that in women, it tends to grow slowly and rarely metastasizes, 
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although it often reappears in the same area if not removed completely. Osteosarcoma (also 
named osteogenic sarcoma) usually appears between the ages of 10 and 30, it rarely develops in 
middle-aged people and is more common in male than females. It mostly affects the bones of the 
arms, legs and pelvis. (www.cancer.org/cancer/bonecancer) 
Specifically in relation to OS, it produces osteoid tissue and is characterized by spindle-
shaped cells. Osteosarcoma generally presents as a high grade sarcoma and possesses an 
increased ability to metastasize, especially to the lung (van Driel and van Leeuwen, 2014). Several 
factors have been identified as contributing to the pathology of OS: mutation in p53 and RB 
tumour suppressor pathways, teenage growth spurt, Paget’s disease, chemical agents (e.g. 
beryllium), radiation and viruses containing the Src oncogene (Dai et al., 2011). Despite being 
rare, OS has been pointed as the third most common cancer in adolescence with an incidence rate 
lower than only lymphomas and brain tumors in this age group. Metastatic disease is an 
important concern in this malignancy: about 10-20% of patients present macroscopic evidence of 
metastatic disease at the time of OS diagnosis, but around 30-40% patients with localized OS will 
develop a local or distant relapse. The relapse within 5 years after the initial treatment of OS is 
rare (between 1-2% of all OS patients), but when occurs is associated with a poor prognosis. The 5 
years overall survival for recurrent OS is around 23-29% (Luetke et al., 2014). 
With regard to OS symptomatology, patients usually refer local pain, localized swelling and 
limitation of joint movement. Medical evaluation begins with a full clinical history, physical 
examination and radiographs (Figure 1.10b), the latter being useful to evaluate osseous changes. 
Magnetic Resonance Imaging (MRI) is used to assess the soft tissue component, its relation to 
surrounding tissues, vessels and nerves, being essential for safe definitive surgery. The diagnosis 
of OS must always include a histological verification of biopsies (Ritter and Bielack, 2010). 
 
1.3.2. Clinical Protocols in Osteosarcoma 
In osteosarcoma, local therapy alone is often insufficient, since 80-90% of all patients with 
localized disease develop metastasis (Ritter and Bielack, 2010). For this reason, current treatment 
modalities comprehend preoperative (also called neoadjuvant) induction therapy, followed by 
surgical removal of tissue and then postoperative (adjuvant) chemotherapy, resulting in the cure 
of approximately two-thirds of patients with localized disease (Ritter and Bielack, 2010). The 
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whole process of chemotherapy usually lasts for 6-8 months. OS was long considered as a 
radiotherapy-resistant tumour, thus limited knowledge on this field is available. However, recent 
studies demonstrated that radiotherapy might improve the outcome of patients further treated 
with multiagent chemotherapy who showed unable to undergo complete resection, a modality 
that would require additional evaluation in controlled clinical trials (Ritter and Bielack, 2010). 
Currently, cisplatin, doxorubicin, high-dose methotrexate and ifosfamide are considered 
the most active agents (in combined regimens) for OS therapy (Ta et al., 2009), but there is still a 
need for optimizing treatment strategies. In this line, a randomized trial of the European and 
American Osteosarcoma Study (EURAMOS) group is ongoing since 2001, to optimize treatment 
schemes for resectable OS based on the histological response to preoperative chemotherapy 
(http://212.219.75.232/euramos/euramos_i_trial.asp).  
 
EURAMOS 1 is a protocol that joins together four leading groups in the field of 
osteosarcoma research: the Children’s Oncology Group (COG), the Cooperative Osteosarcoma 
Study Group (COSS), the European Osteosarcoma Intergroup (EOI) and the Scandinavian Sarcoma 
Group (SSG). Focusing on a low incidence disease, the collaboration between these groups 
broadens the sharing of knowledge between healthcare professionals and enables the evaluation 
of a higher number of patients. This study includes all patients with resectable high grade OS, with 
either localized and primarily metastasized tumours. All registered patients are exposed to a three 
drug treatment that consists of two cycles of cisplatin and doxorubicin, together with four cycles 
of methotrexate. Once the patients have recovered from chemotherapy, they undergo surgical 
removal of the tumour. If postoperative tumour biopsies still reveal malignance traces, adjuvant 
chemotherapy, α-interferon or ifosfamide combined with etoposide, being added to the 
previously referred therapeutic regimen, is applied for a new cycle of treatment.  Accordingly, the 
study also intended to understand the differences in regard to disease outcome resulting from 
the use of α-interferon and ifosfamide/etoposide (Figure 1.11). 
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Figure 1.11. Strategy flowchart adopted in EURAMOS protocol trial (adapted from 
http://212.219.75.232/euramos/ euramos_i_trial.asp) 
The scheduled treatment dates adopted in the EURAMOS protocol trial is depicted in Figure 
1.12. Prior to surgical removal of the tumour the patients are submitted to two cycles of chemical 
treatment (5 weeks each), each constituted by one administration of cisplatin and doxorubicin 
and (during the first week) and two administrations of methotrexate (in weeks 4 and 5). 
 
Figure 1.12. Scheduled treatment dates adopted in the EURAMOS protocol trial (adapted from 
http://212.219.75.232/euramos/ euramos_i_trial.asp). 
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Despite the findings achieved so far and the current attempt to optimize the dosing 
regimen of these drugs through the large scale EURAMOS protocol, the search for more effective 
agents and treatment modalities against OS continues. Table 1.1 lists some of the emerging 
strategies, molecular targets and respective drugs which have recently being studied for the 
treatment of OS. As shown, strategies under investigation include overcoming drug resistance 
(e.g. inhibiting drug efflux), inhibition of signalling receptors and transduction (e.g. mTOR 
pathway), inhibition of osteoclasts-mediated bone destruction and inhibition of angiogenesis 
(Luetke et al., 2014). 
Table 1.1. Novel strategies and molecular targets for OS treatment (adapted from Luetke et al., 2014). 
 Strategy/Molecular target Drug 
N
ov
el
 d
el
iv
er
y 
 m
ec
ha
ni
sm
s 
Overcoming drug resistance  
o Inhibition of cellular DNA synthesis and cell 
growth 
o Induction of apoptosis and cell cycle arrest 
o Novel antifolates 
o Inhibition of drug efflux 
SLITTM cDDP 
Gemcitabine 
Docetaxel 
Trimetrexate (RCF independent) 
Curcumin 
Inhibition of signaling receptors and transduction  
o IGF/IGF-1R pathway  
o mTOR pathway 
o Src pathway 
o HER2 overexpression 
Robatumumab, Figitumab, 
Cixutumumab 
Ridaforolimus, Everolimus 
Sorafenib, Dasatinib, Saracatinib 
Trastuzumab 
Al
te
ri
ng
 th
e 
tu
m
or
 
m
ic
ro
en
vi
ro
nm
en
t Inhibition of osteoclasts-mediated bone destruction  
o Biphosphonates 
o RANKL inhibitors 
Zoledronic acid, Pamidronate 
Denosumab 
Inhibition of angiogenesis  
o VEGF inhibitors 
o Collagen XVIII-α 1 
Bevacizumab 
Endostar 
SLIT: sustain lipid inhalation targeting (aerosolizes liposomal formulation), RCF: reduced folate carrier, IGF-
1R: insulin-like growth factor 1, mTOR: mammalian target of rapamycin, Src: membrane-associated tyrosine 
kinase, HER2: human epidermal growth factor receptor 2, RANKL: receptor activator of nuclear factor-κB 
ligand. 
The effect of interferon and ifosfamide/etoposide administration is beyond the scope of 
this thesis which is focused on the metabolic effects of the drugs conventionally used in OS 
treatment - cisplatin, doxorubicin and methotrexate - alone or in combination. 
 
1.3.3. Cisplatin (cDDP), Doxorubicin (DOX) and Methotrexate (MTX) 
Cisplatin, doxorubicin and methotrexate are the most effective known agents in OS 
treatment (Ta et al., 2009). This motivated their choice for single- and drug-combination 
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experiments in a cell culture model of OS (MG-63 cell line, available in a laboratory of the group) 
adopted in this work, in order to investigate the metabolic impact of drugs in the biochemistry of 
OS tissues. Therefore, a deeper explanation on their modes of action is presented below. 
Cisplatin, cDDP 
Cisplatin, cis-diamminedichloroplatinum (II), is a metal-based agent widely used in 
chemotherapy of solid tumors and haematological malignancies (Tsang et al., 2009). It is 
administered to cancer patients intravenously as a saline solution (sodium chloride). Once in the 
bloodstream, it remains intact due to the relatively high concentration of chloride ions (~100 
mM). After entering the cell, either by passive diffusion or active transport (e.g. CTR1 receptor), 
cDDP molecule is hydrolysed, the chloride ligand being replaced by water (due to the much lower 
intracellular concentration of chloride ions relative to the extracellular medium), yielding an 
unstable, positively charged, species. This activated drug is prone to interact with a number of 
possible targets: DNA, RNA and sulfur-containing compounds as metallothionein and glutathione, 
the former (DNA) being cisplatin’s main pharmacological target (Figure 1.13) (Tsang et al., 2009). 
 
Figure 1.13. Mechanism of action of cisplatin (adapted from Kelland, 2007 and Pizarro and Sadler, 
2009). 
90% of all adducts
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Cisplatin coordinates to DNA mainly through the N7 atoms of the purine bases (guanine and 
adenine) within the double helix (Pizarro and Sadler, 2009). Different types of cDDP-DNA adducts 
can be formed, but the most frequent are those in which the metal coordinates to two adjacent 
purine moieties of the DNA strand (1,2-intrastrand). Although adducts involving one guanine and 
one adenine can also be found, the purine base guanine is the most frequently involved, 
accounting for around 90% of all adducts (inset of Figure 1.13), due to the formation of a 
favouring H-bond interaction between the purine carbonyl and the drug’s amine groups. These 
drug-DNA adducts (mostly 1,2-intrastrand, Figure 1.13) are responsible for disrupting of base 
pairing and base-stacking, causing the DNA helix to become kinked and affecting replication and 
transcription processes (by blocking the action of DNA polymerase), as well as mechanisms of 
DNA repair. This interferes with the normal functions of the cell and ultimately conducts to cell 
death (by apoptosis) (Gibson, 2009). 
 
Doxorubicin, DOX 
Doxorubicin is an anthracycline and is one the most potent antineoplastic agent of the 
antitumour antibiotics class (Tacar et al., 2013). Due to its mode of action, DOX shares some 
characteristic features with metal-based agents. It exerts both antimitotic and cytotoxic activities 
through several mechanisms: formation of DNA adducts via intercalation between base pairs, and 
inhibition of topoisomerase II by stabilization of the DNA-topoisomerase II complex, thus 
preventing the DNA double helix from being resealed. 
The resulting DNA damage induces cytochrome c release in mitochondria, which activates 
caspases-mediated apoptosis. In cases of acquired resistance, P-glycoprotein inhibits DOX effect 
by performing drug efflux, together with blocking of cytochrome c release by Bcl-2 and Bcl-xL and 
XIAP inhibition of the triggering of caspase pathway – Figure 1.14 (Kim et al., 2009). 
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Figure 1.14. Mechanism of action of doxorubicin (adapted from Kim et al., 2009 and Yang et al., 
2014). 
 
Methotrexate, MTX 
Methotrexate (MTX) is an antimetabolite - a folate analogue that competitively inhibits the 
enzyme dihydrofolate reductase (Tian et al., 2007). MTX enters the cells via the reduced folate 
carrier 1 (RFC1) and effluxes through the ABC B1 and ABC C1-4 proteins, members of the P-
glycoprotein family. Once inside the cell, MTX is polyglutamated (addition of multiple glutamic 
acid residues through an enzymatic process) by the enzyme folypolyglutamate synthase (FPGS). 
This enzyme, in turn, can be reversed by γ-glutamyl hydrolase (GGH) that catalyses the removal of 
the γ-linked polyglutamates, thus facilitating the MTX efflux from the cell. Polyglutamated MTX 
(MTX-PG) has several important functions: it retains MTX intracellularly; inhibits dihydrofolate 
reductase (DHFR) that reduces dihydrofolate to tetrahydrofolate; and inhibits thymidilate 
synthetase (TYMS) which converts deoxyuridylate to the deoxythymidylate in the de novo 
pyrimidine biosynthetic pathway (Figure 1.15) (Assaraf, 2007). 
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Figure 1.15. Mechanism of action of methotrexate (adapted from Nagy et al., 2010). 
 
1.4. A Palladium (II) Complex Potentially Active Against Osteosarcoma: Pd2Spm 
The use of systemic chemotherapy protocols have improved the long-term survival from 
20% to 70% for patients with localized OS disease, but this survival rate has remained essentially 
unchanged over the past 20 years (O’Day and Gorlick, 2009). In order to improve event-free and 
overall patient survival, EURAMOS 1 (presented in section 1.3.2) implemented a clinical trial for 
evaluating the benefit of adding ifosfamide plus etoposide to postoperative cDDP+DOX+MTX 
chemotherapy schemes in poor responders (>10% viable tumour), or pegylated (with attached 
polyethylene glycol polymer chains) IFN-α to the same postoperative chemotherapy regimen in 
good responders (<10% viable tumour). Nevertheless, the prognosis is still poor for patients with 
metastatic disease (O’Day and Gorlick, 2009). 
The discovery of the antitumor activity of cDDP fostered the investigation on metal-based 
anticancer agents. Over the last decades, the rational design of this type of complexes has 
involved the following metal centers: platinum (both Pt(II) and Pt(IV)), ruthenium (Ru(II) and 
Ru(III)), titanium (Ti(IV)) and gold (Au(I) and Au(III)) (Muhammad and Guo, 2014). Multinuclear 
Pt(II) chelates, in particular, have been found to display a unique, non-conventional mode of DNA 
binding through long range cross-linking interactions not occurring with classical non-multinuclear 
Pt(II) drugs (as cDDP or Carboplatin), leading to an increased cytotoxic activity as compared to 
cDDP and its analogues. Pt(IV) prodrugs, in turn, have been investigated as a promising strategy to 
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reduce drug toxicity and overcome drug resistance, as they can be activated inside tumour cells 
(by Pt(IV) to Pt(II) reduction) (Muhammad and Guo, 2014). 
The considerable similarity between the coordination chemistry of Pd(II) and Pt(II) (both 
metals being in the same group, X (ten), of the periodic table), promoted the investigation on the 
potential antitumor properties of Pd(II) complexes. The present work may add to these research 
studies on Pd(II) agents as an alternative to Pt(II) ones, with improved properties: as to selectivity, 
cytotoxic capacity and acquired resistance phenomena. 
Several Pd(II) complexes have been reported to display favorable cytotoxicity at pH 6.8 
(common pH value in tumour cells) (Ray et al., 2007). Nevertheless, these compounds are about 
105 times more reactive than Pt(II) analogues, due to the rapid hydrolysis in solution of the leaving 
group within the complex. This well known higher chemical lability typical of Pd(II) relative to Pt(II) 
compounds may prevent the complex from reaching its pharmacological target in its activated 
state (Butour et al., 1997). In order to overcome this limitation, several Pd(II)-based coordination 
compounds have been designed, using distinct ligands (usually bulky groups with a view to attain 
a slower kinetics of hydrolysis): trans-Pd(II) complexes, Pd(II) compounds containing bidentate 
nitrogen ligands, Pd(II) complexes bearing phosphine or mixed donor atom ligands and 
multinuclear Pd(II)-polyamine chelates (Abu-Sarrah et al., 2008; Marques, 2013). The latter 
include the Pd(II)-polyamine complex, Pd2Spm tested in this work (Spm spermine, 
H2N(CH2)3NH(CH2)4NH(CH2)3NH2) (Figure 1.16). 
  
Figure 1.16. Chemical structure of Pd2Spm. 
Polynuclear polyamine complexes have attracted special attention in the last twenty years, 
due to their ability to form long-distance interstrand adducts with DNA, which often circumvent 
cDDP resistance. In particular, linear aliphatic polyamines possess a high conformational freedom 
and have suitable flexibility and polidenticity that favor their interaction with metal ions through 
coordination (such as Pt(II) and Pd(II)) as well as with biological molecules (e.g. DNA) via 
hydrophobic interactions. Biogenic amines, namely the linear tetramine spermine, are 
physiological polycations, crucial for cell growth and differentiation. The dinuclear Pd2Spm chelate 
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was first synthesized and assessed as to its antitumor properties against human breast and 
leukemia cancer cells (MDA-MB-468 and HL-60, respectively) by Navarro-Ranninger and 
coworkers (Navarro-Ranninger et al., 1993). 
In ovarian cells, Pd2Spm cytotoxic ability was found to be lower than cDDP but higher than 
that of its Pt(II) analogue. Moreover, this compound was found to be more effective against a 
cDDP-resistant cell line than its Pt(II) counterpart (Tummala et al., 2010). In addition when 
comparing the activities of Pd2Spm and cDDP in human breast cancer cells, Pd2Spm showed to be 
more effective against an estrogen-independent (ER(-)) cell line, while cisplatin was more 
effective towards the estrogen-dependent (ER(+)) one (Fiuza et al., 2011). This same study 
claimed that, similarly to cDDP, the Pd(II) spermine complex triggers phosphorylation of H2AX and 
greatly influences cell morphology by severely affecting the cytoskeleton. 
Regarding the effect of a Pd(II) for Pt(II) substitution on the antitumor activity of this type of 
polyamine complexes, the Pd(II) agents showed an improved time- and dose-dependent 
cytotoxicity on HSC-3 human oral cancer when compared to their Pt(II) analogues (Soares et al., 
2007). Strong interaction with DNA was clearly evidenced by atomic force microscopy techniques, 
which detected the formation of stable adducts or aggregates between Pd2Spm and DNA 
(Corduneanu et al., 2010). 
The above described results justify the choice of Pd2Spm as a promising prospective 
anticancer agent towards OS, and fostered the present study on its metabolic impact in both 
osteoblasts and osteosarcoma human cells.  
 
1.5. Cell Metabolomics 
This section describes the concepts underlying metabolomics, as well as the analytical and 
bioinformatic tools that are generally applied to study the metabolome and pursuit the definition 
of a metabolic signature for a given perturbation. Then, the state of the art on the application of 
metabolomics to anticancer drug testing in cells is presented. 
1.5.1. Principles and General Applications 
Metabolites are low molecular weight molecules (<1 kDa) that act as carriers, substrates or 
products in cellular biochemical pathways. As final end products of biological cascades in the cells, 
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they reflect upstream alterations in genes and proteins (Figure 1.17). Moreover, given the high 
interdependence of all levels of biological organisation, perturbations in metabolism can generate 
upstream consequences. Therefore, the measurement of metabolite levels in cells, tissues or 
biofluids represents a valuable approach to understand the overall status of the organism. 
Metabolomics (or metabonomics) is an approach that enables the comprehensive detection and 
characterisation of changes in the global metabolic profiles induced by those pathophysiological 
stimuli, thus constituting a crucial complementary approach to the other “omic” sciences 
(Goodacre, 2005). 
 
Figure 1.17. Schematic representation of the organization and interactions between different levels 
within a cell (adapted from Goodacre, 2005). 
Originally, the term metabolomics has been used to express the detection and quantitation 
of metabolites comprising the metabolome of living cells, whereas metabonomics has been 
regarded as the study of dynamic metabolic changes that take place in response to a 
perturbation. Indeed, metabonomics has formally emerged in 1999, as an appealing approach to 
perform the quantitative measurement of the multivariate metabolic responses of multicellular 
systems to pathophysiological stimuli or genetic modification (Nicholson et al., 1999). Nowadays, 
the two terms are used interchangeably and as the term metabolomics is more frequently 
referred in the literature, it will be used throughout this thesis. 
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One of the most important features of metabolomic studies is that, in contrast to classical 
biochemical approaches that search for a limited and pre-defined number of compounds, they 
comprise the analysis of a large range of metabolites (frequently around hundreds). Being 
essentially untargeted, metabolomics allows the detection of unpredicted findings, offering a 
more complete overall picture of the global dynamics of cellular metabolism. 
As schematically depicted in Figure 1.18, the general strategy followed in metabolomic 
studies begins with sample collection (Figure 1.18a) and analysis by high throughput techniques 
(mainly NMR spectroscopy and hyphenated MS) (Figure 1.18b and 1.18c), alone or in combination 
(Pan and Raftery, 2007), the assignment of the obtained spectral data (Figure 1.18b and 1.18c), 
application of bioinformatic tools (particularly Multivariate Analysis, MVA) (Figure 1.18d) to 
maximize relevant information recovery from the complex datasets analysed, and ends with the 
biochemical interpretation (Figure 1.18e) of the metabolic changes detected. 
 
Figure 1.18. Typical metabolomics workflow: a) sample collection and b) analysis using one or more 
high-throughput analytical techniques, c) signals assignment, d) chemometric and bioinformatic tools and e) 
biochemical interpretation of results. 
The most frequently used analytical techniques in metabolomics are Nuclear Magnetic 
Resonance (NMR) spectroscopy and Liquid or Gas Chromatography Mass Spectrometry (LC- or 
GC-MS). Other approaches such as Fourier Transform Infra-Red (FTIR) spectroscopy and arrayed 
electrochemical detection have also been applied in some studies (Lindon et al., 2007; Jobard et 
al., 2010). 
High-resolution NMR spectroscopy, particularly of 1H nucleus (high sensitivity and natural 
abundance) (Figure 1.18b), constitutes one of the most used techniques in metabolomic studies, 
once it enables a wide range of metabolites (e.g. amino acids, sugars, lipid moieties, organic acids, 
a) b) c)
d)e)
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nucleosides) to be detected simultaneously and without any special sample preparation, in very 
distinct complex biological matrices such as biofluids, tissues and cells, in a non-destructive 
manner. The non-invasive nature of NMR gains special importance when considering the 
translation from the ex vivo or in vitro biomarkers to clinical applications. Moreover, NMR enables 
automated analysis of large sample numbers with high analytical reproducibility. Nonetheless, 
NMR has an inherent low sensitivity with typical limits of detection falling in the sub-millimolar 
range, although the advent of very high field magnets and cryoprobes has allowed these limits to 
be pushed to the micro to nanomolar range (Lindon et al., 2007). The leading role of NMR in the 
field of metabolomics has been extensively reviewed in human disease diagnosis (Emwas et al., 
2013; Duarte et al., 2014; Gebregiworgis and Powers, 2012), namely in cancer (Spratlin et al., 
2009; Serkova and Glunde, 2009) and drug discovery (Chiaradonna et al., 2012; Holzgrabe, 2010; 
Powers, 2009). 
NMR metabolomic studies have greatly benefited from the development of High Resolution 
Magic Angle Spinning (HRMAS), as it allows the direct analysis of semi-solid samples (like tissues 
and cells), thus avoiding the use of extraction procedures. This technique is based on the rapid 
sample spinning at an angle of 54.7º relative to the applied magnetic field, in order to average out 
the anisotropic effects that broaden the lines thus, improving spectral resolution. Coupled to the 
relatively high spinning rates (4-6 kHz), the provision of a deuterium (2H) lock signal (which 
compensates for variations in the magnetic field across time) yields remarkably high-resolution 
spectra, resulting in much higher and sharper peaks (Lindon et al., 2009). Thus, with HRMAS well 
resolved spectra can be obtained from reduced amounts of intact tissue or cell pellet. HRMAS has 
been widely used as tool for the metabolic characterization of cancer (Moestue et al., 2011; 
DeFeo and Cheng, 2010; Sitter et al., 2009). 
Regarding MS metabolomics, it is important to review the principles of the technique. MS is 
based on the determination of the mass-to-charge ratio (m/z) of charged compounds: molecules, 
clusters of molecules, complexes or fragments (Lei et al., 2011). Briefly, a mass spectrometer is 
composed of: an ion source, a mass analyser, a detector and a data system. After ionization, 
analytes are transferred to the high vacuum of the mass spectrometer, they are then separated 
according to m/z in the mass analyser and the ion current is measured in the detector. Finally, the 
signals are transmitted to the data system which gives a plot of ion abundance against m/z, 
corresponding to the mass spectrum of that analysed sample. Mass Spectrometry coupled to 
chromatographic separation apparatus (GC or LC) has also been largely used as a metabolic 
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profiling tool (Lei et al., 2011). Inherently more sensitive that NMR, MS is able to detect many 
compounds that escape NMR analysis. Nevertheless, chromatographically-hyphenated MS 
analysis is necessarily guided for specific classes of substances, thereby requiring different 
separation procedures. Moreover, MS methods can be quite challenging in term of reproducibility 
and metabolite identification. Despite these difficulties, GC- and LC-MS have been increasingly 
used in mammalian metabolomic studies: disease diagnosis (Buzatto et al., 2014; Gowda et al., 
2008), cancer research (Liesenfeld et al., 2013) and drug discovery (Buck et al., 2014; Drexler et 
al., 2011). The complementarity between NMR and MS relies on the fact that the untargeted 
analysis performed by the former can be used to more efficiently target (in terms of families of 
compounds of interest) the MS analysis more sensitive (Johnson and Gonzalez, 2012). 
Obtained whether by NMR or MS methods, metabolomic analysis encompasses highly 
complex datasets that require subsequent multivariate analysis (as described in section 2.3.2), to 
maximize information recovery and, eventually, biomarker identification (Trygg et al., 2007). 
 
1.5.2. Anticancer Drug Testing in Cells through Metabolomics: State of the Art 
In vitro models allow experimental variables to be simplified in order to study biochemical 
disorders that occur in specific tissues or organs under well-controlled and easily assessed 
conditions. Moreover, cell culture applications are free from additional confounding factors that 
typically affect animal models and, especially, human subjects (e.g. age, gender, global health and 
environmental exposure), potentially providing more readily interpretable results (Cuperlovic-Culf 
et al., 2010). On the other hand, cell culture systems may be over-simplistic and lead to 
misleading results, as when individual cell types are cultured in vitro, the crosstalk between 
multiple tissue cells is absent, and the information on the dynamic processes that modulate in 
vivo biochemistry may be lost. In spite of these limitations, cell culture studies are an 
indispensable tool in several areas of research, like drug testing, playing a crucial role in verifying 
hypothesis about biochemical processes or mechanisms of action at the molecular level 
(Astashkina et al., 2012). In regard to cell metabolomics, there are many possible valuable 
applications like: analysis of cellular phenotype, which enables molecular comparison of disease 
subtypes and identification of potential disease markers of therapeutic targets; systems biology, 
whereby metabolic networks can be accessed through metabolomics alone or in combination 
with other omics data; time-course assessment of metabolic pathways; toxicology and drug 
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testing studies, to understand both the metabolism of the drug (pharmacokinetics) and the 
consequences of drug administration on the models organism or cells (pharmacodynamics) 
(Cuperlovic-Culf et al., 2010). The alterations to the metabolic profile of cells have been studied in 
samples of different natures: cell extracts (Martineau et al., 2011) obtained with different 
extraction solvents like trichloroacetic acid (Lane et al., 2007; Fan et al., 2005), perchloric acid 
(Moreno et al., 1998; Santini et al., 2004; Santini et al., 2006) and methanol and/or chloroform 
(Teng et al., 2009); cell suspensions (Ferreti et al., 2002; Santini et al., 2001; Rosi et al., 2004); 
intact or lysed cell pellets analysed by HRMAS (Morvan et al., 2013; Pan et al., 2013; Borel et al., 
2007). 
In the field of oncological research, cell metabolomics has been increasingly used to study 
the metabolic singularities of cancer cell lines from different origins, knowledge that is often used 
as basis for the development of novel drugs (Halama, 2014). As shown in Figure 1.19 NMR in 
particular has been largely applied to study the pharmacodynamic behaviour of both conventional 
and emerging drugs and to get further insights into their modes of action, perturbed biochemical 
pathways and resistance phenomena (Merz and Serkova, 2009; Powers, 2009; Rodriguez et al., 
2008; Garcia-Alvarez et al., 2011). 
 
Figure 1.19. Number of studies on NMR metabolomics of cultured mammalian cells for anticancer 
drug testing (source www.webofknowledge.com, until 20th November 2014). 
The following section will briefly review the state of the art on anticancer drug testing 
performed by NMR metabolomics of cultured cells, the approach employed in this thesis. Table 
1.2 lists the studies performed on cultured cell by NMR metabolomics, according to the families 
defined above (section 1.2) in this chapter. Given the high number of such studies, the 
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subsequent discussion focuses only on a selection of more recent and/or complete NMR studies. 
In the following section, a brief review of MS metabolomics cell studies will be presented. 
Table 1.2. Overview of literature on NMR metabolomics of cultured mammalian cells for anticancer 
drug testing. 
Class Type Agent Tested cells Reference 
Alkylating Agents Nitrosourea CENU Melanoma: B16 Morvan et al., 2003 
 
  Melanoma: B16 
Lung cancer: 3LL 
Morvan et al., 2007 
 
  Osteosarcoma: 143B 
Hepatocarcinoma: HepG2 
Loiseau et al., 2009 
  Lomustine Glioma: 18 cell lines El-Deredy et al., 1997 
  Temozolomide Brain cancer: SF188 Mancuso et al., 2005 
 
 Fotemustine Hepatocarcinoma: HepG2 
Osteosarcoma: 143B 
Bayet-Robert et al., 2010 
 Chloroethyl-urea ICEU Colon cancer: CT-26 Borel et al., 2007 
Metal-based Metal salt Cisplatin Lung cancer: A549 Huang et al., 2003 
 Neuroblastoma: SH-SY5Y, 
SK-N-BE (2), SK-N-FI, SK-N-
AS, IMR-32 
Lindskog et al., 2004 
 Osteosarcoma: MG-63 Duarte et al., 2010 
 Glioma: BT4C Mirbahai et al., 2011 
 Brain cancer: BT4C, U87-MG, 
DAOY, PFSK-1, ST-PNET 
Pan et al., 2011 
 Lung cancer: A549 Duarte et al., 2013 
 Neuroectodermal tumor: 
DAYO, PESK-1 
Pan et al., 2013 
 Pluripotent stem cells Stechow et al., 2013 
 Normal liver: L02 Liu et al., 2014 
 Osteosarcoma: MG-63 Lamego et al., 2014 
Antimetabolites Pyrimidine 
analogs 
5-Fluoruracil 
Breast cancer: DU4475 Cooper et al., 2001 
Antifolate Methotrexate Breast cancer: MB231, 
MB435, MCF-7 
Sterin et al., 2001 
Osteosarcoma: MG-63 Lamego et al., 2014 
Nucleoside 
analog 
Gencitabine 
Pancreatic cancer: PK9 Ohmine et al., 2012 
Antitumor 
antibiotics 
 Doxorucibin Leukemia: K562 Le Moyec et al., 1996 
 Leukemia: Jurkat T cell Blankenberg et al., 1997 
 
Leukemia: L1210 
Colorectal cancer: SW620 
Ronen et al., 1999 
 Leukemia: K562 Le Moyec et al., 2000 
 
Breast cancer: MCF-7 
Colorectal cancer: LoVo 
Santini et al., 2001 
 
Breast cancer: MB231, 
MB435, MCF-7 
Sterin et al., 2001 
 Leukemia: HL60 Rainaldi et al., 2008 
 Melanoma: B16 Triba et al., 2010 
 Osteosarcoma: MG-63 Lamego et al., 2014 
Mitotic inhibitors 
 
Paclitaxel Leukemia: K562 Le Moyec et al., 1996 
Breast cancer: MCF-7, MDA-
MB-231, MDA-MB-435 
Sterin et al., 2001 
Leukemia: K562 
Brisdelli et al., 2003 
Knijn et al., 2005 
Breast cancer: MCF-7, BT-20 Musacchio et al., 2009 
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Table 1.2 (cont.). Overview of literature on NMR metabolomics of cultured mammalian cells for 
anticancer drug testing. 
Class Type Agent Tested cells Reference 
Mitotic inhibitors 
 
Docetaxel Breast cancer: MCF-7, MDA-
MB-231 
Morse et al., 2007 
Breast cancer: MCF-7 Bayet-Robert et al., 2010 
Breast cancer: MCF-7, MDA-
MB-231 
Bayet-Robert et al., 2013 
Vinblastine Renal cell carcinoma: KTCTL-
26, KTCTL-2 
Lutz et al., 2005 
Hormonal agents Corticosteroid Dexamethasone Thymoma cells: WEHI7.2 Lutz et al., 2002 
Adenocarcinoma: HeLa 
Tiziani et al., 2011 Leukemia: CCRF-CEM 
Ovarian carcinoma: SKOV-3 
Estrogen 
antagonist 
Tamoxifen 
Endometrial cells: Ishikawa  Griffin et al., 2003 
Inhibitors of 
Topoisomerase  
Irinotecan Neuroblastoma: SH-SY5Y, 
SK-N-BE (2), SK-N-FI, SK-N-
AS, IMR-32 
Lindskog et al., 2004 Etoposide 
Molecularly 
targeted 
HIF1 inhibitors PX-478 Colon cancer: HT29 Jordan et al., 2005 
Tyrosine kinase 
inhibitors 
Imatinib Leukemia: BCR-ABL(+), BCR-
ABL(-) 
Gottschalk et al., 2004 
Leukemia: CML Boros et al., 2005 
Leukemia: BCR-ABL(+),K562 Klawitter et al., 2009 
Leukemia: LAMA-84, K562 
Klawitter et al., 2009 
Kominsky et al., 2009 
Leukemia: Myl Dewar et al., 2010 
PD166866 Fibroblasts: 3T6 Piccioni et al., 2007 
AG957 Leukemia: K562 Knijn et al., 2005 
Ras inhibitors U0126 Breast cancer: MDA-MB-
231, MCF-7, Hs578T 
Colon carcinoma: HCT116 
Beloueche-Babari et 
al.,2005 
HSP90 inhibitors 17AAG Colorectal cancer: HCT116, 
HT29, SW620 
Chung et al., 2003 
Prostate cancer: PC3, LNCaP Lodi et al., 2011 
Lodi et al., 2011 Breast cancer: MCF-7 
HDAC inhibitors Phenylacetate 
Prostate cancer: DU145  
  
Milkevitch et al., 2005 
Phenylbutyrate Milkevitch et al., 2005 
Milkevitch et al., 2007 
LAQ824 
Colorectal cancer: HT29 Chung et al., 2008 
SAHA 
Trichostatin Primary hepatocytes Ellis et al., 2010 
Lung cancer: H460 Amoêdo et al., 2011 
PI3K inhibitors LY24002 Breast cancer: MDA-MB-
231, MCF-7, Hs578T 
Beloueche-Babari et al., 
2006 
Prostate cancer: PC3, LNCaP Lodi et al., 2011a 
Lodi et al., 2011b Breast cancer: MCF-7 
Choline kinase 
inhibitors 
MN58b Breast cancer: MDA-MB-231 
Colon cancer: HT29 
Al-Saffar et al., 2006 
PPARγ inhibitors Thiazolidenedio
ne 
Liposarcoma: 3T3F442A Chen et al., 2002 
Hexokinase 
inhibitor 
Lonidamine Breast cancer: MDA-MB-
231, MDA-MB-245, MCF-7 
Mardor et al., 2000 
2,5-
lipoxygenases 
inhibitor 
MT30, CAPE 
Glioblastoma: A172, Hs683, 
U373 
Morin et al., 2013 
 
Introduction 
 
_________________________________________________________________________________ 
 _________________________________________________________________________________ 
 
60 
 
Table 1.2 (cont.). Overview of literature on NMR metabolomics of cultured mammalian cells for 
anticancer drug testing. 
Class Type Agent Tested cells Reference 
 
Pyruvate 
dehydrogenase 
kinase 
Dichloroacetate 
Breast cancer: MDA-MB-
231, MCF-7 
Lefort et al., 2014 
Xanthine 
dehydrogenase 
inhibitor 
Allopurinol 
Breast cancer: MDA-MB-
231, MCF-7 
Lefort et al., 2014 
Calcium channel 
blockers 
Diltiazem Renal carcinoma: KTCTL-2, 
KTCTL-26 
Lutz et al., 2005 
Other agents 
 
BEZ Leukemia: HL-60, KG1a and 
K562 
Tiziani et al., 2009 
MPA Leukemia: HL-60, KG1a and 
K562 
Tiziani et al., 2009 
Silica 
nanoparticles 
Adenocarcinoma: HeLa Feng et al., 2013 
Ascididemin Breast cancer: MCF-7 Morvan et al., 2013 
Gold Nanorods Lung cancer: A549 Zhang et al., 2013 
Metformin Breast Cancer: MCF-7, MDA-
MB-231, BT-474 
Corominas-Faja et al., 
2012 
Methyltrienolon
e 
Prostate cancer: LnCAP MacKinnon et al., 2012 
2-deoxyglucose Breast cancer: MCF-7 Kaplan et al., 1991 
Resveratrol Hepatoblastoma: HepG2 Massimi et al., 2012 
Sodium butyrate 
and Trichostatin 
Lung cancer: H460 Amoêdo et al., 2011 
2,3,7,8-
tetrachlorodiben
zo-p-dioxin 
Hepatoblastoma: HepG2 
Jennen et al., 2011 
Ruiz-Aracama et al., 2011 
Bezielle Breast cancer: SKBR3, BT474 Klawitter et al., 2011 
Marine natural 
products 
Breast cancer: MCF-7 Bayet-Robert et al., 2010 
CENU: chloroethyl nitrosourea, ICEU: N-(4-iodophenyl)-N’-(2-chloroethyl) urea, SAHA: suberoylanilide 
hydroxamic acid, BEZ: bezafibrate, MPA: medroxyprogesterone acetate. 
Alkylating Agents 
Chloroethyl nitrosourea, CENU, used in the treatment of melanoma and glioma, is among 
the alkylating agents whose effects have been studied by NMR metabolic profiling, both in vitro, 
using cultured cells, and ex vivo using animal models. In particular, this drug has been found to 
induce significant alterations in phospholipids metabolism in different cell types, as viewed by 1H 
HRMAS NMR of intact cell pellets. In B16 melanoma cells (Morvan et al., 2003), CENU treatment 
induced a down-regulation of phosphocholine (PC), attributed to altered CDP-Cho pathway and 
increased phospholipase A activity, and a dramatic rise in phosphoethanolamine (PE) contents. 
Comparison between B16 melanoma and 3LL pulmonary carcinoma animal models (Morvan et al., 
2007) confirmed the previous phosphoethanolamine (PE) results and clarified that, although some 
differences were observed in the metabolic profile of the untreated tumour types, the most 
significant metabolic features of CENU-treatment were common to both. Additional results 
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witnessed the activation of pathways implicated in energy production and down-regulation of 
nucleotide de novo synthesis. 
Human glioma cells treated with temozolomide and analysed by 31P NMR spectroscopy 
showed decreased PC levels in relation to those of GPC and diphosphodiester (Mancuso et al., 
2005). Treated cells also exhibited a marked reduction in aerobic metabolism and TCA cycle and 
were associated with mitochondrial dysfunction-mediated apoptosis. 
Together with other complementary methods, NMR also revealed the effects of CENU on 
the bioenergetic metabolism of two cell lines differing in their oxidative phosphorylation 
(OXPHOS) background, the most differentiated one (with the least impaired OXPHOS background) 
being able to escape drug-induced death (Loiseau et al., 2009). This survival advantage of 
differentiated cells resulted in high lactate/pyruvate ratios (biochemical markers of respiratory 
chain deficiencies) although no significant lactate variations were measured. Thus, mitochondrial 
OXPHOX background seems to play a crucial role in cells response to chemotherapy. 
HRMAS NMR was also used to evaluate the metabolic impact of fotemustine (an alkylating 
agent that damages DNA) in hepatocarcinoma and osteosarcoma cells (Bayet-Robert et al., 2010). 
An increase in PC levels was measured in both cell lines upon treatment, what was associated 
with the activation of choline-kinase or the stimulation of ATP biosynthesis (since ATP is required 
as cofactor of the previous reaction). However, several metabolites were found to vary differently 
between the tested cell lines: Glu increased in osteosarcoma cells and decreased in 
hepatocarcinoma and lipids, which accumulate in treated osteosarcoma cells, didn’t change in 
hepatocarcinoma cells. This study highlighted the potential of HRMAS NMR metabolomics in 
unveiling specificities of the metabolic response of different cell lines to treatment, by bringing 
insights into drugs mode of action and tumour cell adaptation to treatment (Bayet-Robert et al., 
2010). 
Metal-Based Anticancer Agents 
The first study in which NMR metabolomics was used to evaluate the metabolic response of 
cancer cells to cDDP dates of 2003 (Huang et al., 2003). In this study, an increase in the mean 
chain length of fatty acids (given by CH2/CH3) was detected in lung cancer cells treated with cDDP, 
as well as a decrease of the choline compounds/CH3 and ethanolamine/creatine. Moreover, 
31P 
NMR showed a decrease of phosphomonoesters and ATP levels with treatment. These cDDP-
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induced alterations were associated with perturbations in the composition and properties of the 
membrane phospholipids, giving rise to changes in the plasma membrane fluidity. This study 
(Huang et al., 2003) also evaluated the response of cDDP-resistant lung cancer cells, which 
changes were found to be opposite from those refered above.  
The metabolic response of MG-63 cells to cDDP-treatment was evaluated by NMR, in a 
work of our own and part of this thesis (Duarte et al, 2010; Lamego et al., 2014). The results 
revealed significant changes in lipids, choline and choline-containing compounds, what was 
associated with the occurrence of apoptosis and perturbations in the lipid metabolism regulation. 
Decreases in Glu and Tau were measured upon cDDP-exposure, possibly reflecting oxidative stress 
and activation of DNA-related defense mechanisms, respectively. The cDDP-induced decreases in 
m- and s-Inositol were interpreted as indicators of cellular stress response mechanisms activation 
and the decreases in Ino/Ado were seen as reflecting reduced DNA synthesis. This work (Duarte et 
al, 2010) resulted of this thesis and will be presented in detail in subsequent chapters. 
Recent studies have evaluated the effects of cDDP over neuroectodermal tumour cells (Pan 
et al., 2013). Results from HRMAS analysis showed increases in saturated and unsaturated lipids 
that were associated with accumulation of lipid droplets prior to DNA fragmentation and 
apoptosis. Analysis of lipidic extracts revealed that the main responsible for the elevation of 
unsaturated lipid moieties was mainly due to oleic and linoneic acids accumulation. In lung cancer 
cells (Duarte et al., 2013), increased lipid contents (particularly unsaturated triglycerides) as well 
as increased nucleotide sugars (particularly UDP-GlcNAc) were pointed as markers of cDDP 
exposure, together with an increase of sorbitol and decreased niacinamide and several amino 
acids (Gln, Ala, Lys, Met, Phe, Tyr and citrulline). Similarly, cDDP treatment of brain tumour cells 
induced augments of UDP-GlcNAc but also of UDP-GalNAc together with higher levels of lipids, 
both associated with evolving cell death (Pan et al., 2011). 
Antimetabolites 
As shown by 1H NMR of mammary carcinoma cell suspensions, treatment with 5-Fu is 
associated with a global increase of mobile lipids (ML) (Cooper et al., 2001). Cells respond to 
treatment increasing mobile lipid acyl chains levels and glycerol contents as well as raising choline 
and decreasing PC levels. Since naturally involved in the regulation of the above metabolites, 
phospholipase A1 and A2 activities are thought to be potentiated by 5-Fu exposure inducing an 
accumulation of ML that in turn seems to be a general response to cytotoxic insults. 
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Global changes in phospholipids were also detected by in vivo and ex vivo (extracts) analysis 
of a mouse mammary carcinoma model treated with 5-Fu (Street et al., 1997). 31P NMR metabolic 
profile data indicated a drop in PC levels after exposure to the drug that was reflected in a 
consistent increase of PME/PC ratio. The later is even pointed in the literature as good indicator 
of tumour response to this particular therapy. But other choline compounds seem to be altered 
after 5-Fu treatment, namely GPC, and also PE and GPE. In what concerns to tumour 
bioenergetics, exposure to 5-Fu induces considerable changes in important energy charge indices 
as NTP/Pi and PCr/Pi ratios, results that in vivo reflected improved tumour flow on cancerous 
tissues after treatment. 
Recently, a 1H HRMAS NMR study evaluated the response of MG-63 osteosarcoma cells to 
MTX-treatment (Lamego et al., 2014). This work is part of this thesis and will be explored in detail 
in chapter 5. In short, decreased PC levels were the most significant change upon MTX-exposure, 
which, together with the absence of alterations in lipids, was tentatively interpreted as evidencing 
no membrane degradation, decreased phosphatidylcholine (PTC) synthesis and inhibition of de 
novo synthesis of lipids. 
Antitumor Antibiotics 
Due to its mode of action, doxorubicin shares some characteristics with alkylating agents as 
shown by comparison of 31P NMR data of colorectal carcinoma cells treated with doxorubicin or 
with one alkylating agent (Ronen et al., 1999). The overall results were not drug specific, showing 
increased glycolytic intermediates independently on the DNA damaging agent used, what 
foresees an inhibition of the glycolytic pathway by the two agents. 
The overall pathways involved in doxorubicin induced apoptosis seem to relate with lipids 
metabolism, namely with membrane lipids according to the 1H NMR data of treated T-Jurkat cells 
suspensions, which revealed a reduction of Cho/CH3 and an increase in CH2/CH3 that positively 
relates with the fraction of the apoptotic cells (Blankenberg et al., 1997). Moreover, CH3 moieties 
were not significantly altered with doxorubicin treatment what, on one hand means that this 
particular portion of fatty acid chains does not seem to be greatly affected by exposure to this 
drug and, on the other hand, that the dynamic changes of the membrane may be largely 
attributed to loss of choline compounds by the lipid bilayer. 
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1H NMR of leukemia cells treated with doxorubicin revealed a drop in GSH levels, what can 
be attributed to cells response mechanism of doxorubicin to generate free oxygen radicals. 
Another important decrease that was supposed to relate with oxidative stress, occurred in Tau 
that among others has antioxidant properties. Interestingly, Tau levels increased in cells that were 
submitted to a necrotic stimulus what, keeping in mind that the necrotic phenomenon is 
characterized by swelling of cells, point Tau – important in osmoregulatory processes – as possible 
biomarker to distinguish between the two types of cell death (Rainaldi et al., 2008). 
In a recent study, part of the work presented in this thesis, the metabolic response of MG-
63 osteosarcoma cells to DOX exposure was investigated (Lamego et al., 2014). In summary, the 
results suggested significant membrane degradation, decreased membrane synthesis and 
apparent inhibition of de novo lipid synthesis in treated cells. Moreover, a link between UDP-
GlcNAc and the active pathways of membrane degradation and energy metabolism was found in 
the metabolic information recovered from DOX-treated cells.  
Doxorubicin chemotherapy treatments also face the problem of resistance. Some 1H NMR 
evidences show that resistance may be associated with membrane lipids metabolism and the 
capacity to adapt to oxidative stress. The comparison between K562 human leukemia cells and 
their resistant counterparts (both treated with doxorubicin) revealed higher Cho/CH3 ratios and 
loss of fatty acid signals (lower CH2/CH3). Measurements on Gln levels showed a drop for this 
metabolite that was associated with a higher turnover of it through Gln-Glu-GSH, supporting the 
hypothesis that cells capacity to face oxidative stress represents a survival advantage and may 
underlie a mechanism that contributes to resistance (Moyec et al., 1996).  
Mitotic Inhibitors 
Used for the treatment of mammary and ovary carcinoma and Kaposi sarcoma, Paclitaxel 
acts by blocking the microtubules dynamics, inducing a 2 step formation of 1H NMR visible mobile 
lipids along with ongoing apoptosis (Brisdelli et al., 2003). Besides mobile lipids formation, this 
drug seems to induce early accumulation of PC that may be attributed to alterations in 
phospholipids metabolism. Once no significant changes in GSH or m-Inositol are known, no 
important alterations in oxidative mechanisms or osmoregulation processes are supposed to be 
associated with Taxol treatment (Knijn et al., 2005).  
Docetaxel is approved for the treatment of breast and prostate cancers as well as small-cell 
carcinoma of the lung (Morse et al., 2007). This drug has increased affinity for tubulin and higher 
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antitumour activity than that of Paclitaxel. 31P MRS of extracts of breast cancer cell lines treated 
with docetaxel revealed important changes in choline compounds (Morse et al., 2007). The 
detected drop in PC and rise in GPC were also confirmed through in vivo and ex vivo analysis and 
are coincident with mitotic catastrophe. Complementary in vitro NMR tests with cell lines with 
different grades of differentiation show that this drug-induced changes in Cho metabolites get 
more pronounced as cancer get more aggressive. Breast cancer cells were tested in their response 
to the mitotic inhibitor docetaxel (Bayet-Robert et al., 2010). HRMAS results revealed that after 
48 hours drug-treatment, cells decreased GSH and taurine levels possibly as a consequence of 
activation of drug efflux detoxification processes. The decrease of PC together with increments of 
cytidine diphosphocholine (CTP) in response to treatment suggested activation of PC:CTP 
cytidylyltransferase, which activity is closely related to cell cycle and cytoskeletal organization. 
Drug-induced increase of poli-unsaturated fatty acids (PUFA), was interpreted as reflecting 
decreased β-oxidation or lower rates of membrane formation. 
Vinblastine, a Vinca alkaloid, was used to unveil metabolic changes induced by treatment 
that could be associated with mitotic inhibitors resistance (Lutz et al., 2005). 1H and 31P MRS data 
of human renal cell carcinoma (RCC) line and its vinblastine resistant variant were acquired and 
the comparison of the results revealed significant changes in phosphate metabolites and in cells’ 
energetic state (. Results showed that increased GPC and also GPC/PC ratios in response to VBL 
treatment. Contrarily to KTCTL-2 cells were no alterations were detected, resistant cells also 
suffered a drop in Pi concentration and an increase of PCr levels that together, indicate increased 
energy requirements by these cells, what was attributed to P-170 glycoprotein activity. 
Hormonal Agents 
Tamoxifen is currently used for the treatment of both early and advanced ER(+)breast 
cancer in pre- and post-menopausal women (Griffin et al., 2003). Acting as an antagonist in breast 
tissue, tamoxifen also acts as a partial agonist on the endometrium, what has been linked to the 
occurrence of endometrial carcinoma in some women. The 1H HRMAS NMR metabolic 
characterisation of endometrial adenocarcinoma cells response to tamoxifen, demonstrated that 
this agent induces significant and time-dependent increases in nucleotides levels (namely uridine 
and adenosine), suggesting that tamoxifen affects RNA transcription and also interferes with the 
intracellular contents of Ethanolamine and m-Inositol, constituents of cellular membranes, what 
may reflect phosphoglyceride mobilisation and cell membrane synthesis (Griffin et al., 2003).  
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Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, 
which presents anti-inflammatory and immunosuppressant properties (Lutz et al., 2002). 
Glucocorticoids have been used for more than 2 decades to treat leukemia and lymphoma 
however, a considerable number of patients that suffer from these pathologies are resistant to 
glucocorticoids. Some evidences show that increased antioxidant defence contributes to cells 
increased resistance to dexamethasone. The 31P NMR analysis of extracts of dexamethasone-
treated thymoma cells, which present increasing antioxidant capacity, revealed significant 
alterations in phosphate metabolism (Lutz et al., 2002). The ratio of Cho containing phospholipids 
to ethanolamine containing phospholipids was generally reduced in steroid-resistant cells. PE and 
its derivatives contained higher amounts of PUFA than the Cho containing analogs. Considering 
that PUFA are readily oxidized by reactive oxygen species, this increased amount of PE can lead to 
higher antioxidant defences and may thus contribute to the steroid resistance in this cells. 
Resistance to steroids therapy also seem to have to do with decreased ATP and energetic status 
and increased concentrations of hexose and triose phosphates. 
Inhibitors of Topoisomerase 
Etoposide and irinotecan are topoisomerase I and II inhibitors, respectively. The metabolic 
effects of these two agents were investigated on neuroblastoma cell lines with various drug 
sensitivities (Lindskog et al., 2004). The global 1H MRS metabolic changes induced by treatment 
showed, for both drugs, important changes in lipids metabolism. After chemotherapy, 
neuroblastoma cells showed time-dependent changes in response to irinotecan treatment 
particularly in Cho and CH2 resonances. A positive correlation was found between CH2/Cho ratio 
and the extent of cell death after cytotoxic treatment (Lindskog et al., 2004).  
Molecularly Targeted 
PX-478 is an HIF inhibitor whose effects on metabolic profile of HT-29 cell line were 
decreased glucose consumption and lactate production (Jordan et al., 2005). 1H and 31P MRS 
studies on an animal model of the same cells, gave further information on metabolic changes 
induced by this agent. Decreased PC and GPC were responsible for a drop of the total choline 
resonance and PE and glycerophosphoethanolamine (GPE) were also proved to decrease with 
treatment. Beyond membrane lipids alterations a significant decrease was also observed in m-
inositol levels. Thus, these metabolites may have potential as 1H or 31P MRS-visible biomarkers of 
drug response in vivo or ex vivo markers of response (Jordan et al., 2005). 
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Imatinib is an anticancer drug used in the treatment of chronic myelogenous leukemia 
(CML), gastrointestinal stromal tumours and some other diseases. NMR has been used to 
elucidate about the metabolic changes induced by imatinib treatment on leukemia cells. Once 
again, the main observed changes linked to glycolytic activity and lipids metabolism (Kominsky et 
al., 2009; Klawitter et al., 2009; Gottschalk et al., 2004). Imatinib treatment seems to induce a 
decrease in glucose uptake and metabolism and the use of labelled glucose in the media helped 
the detection of a decreased lactate production also. Some evidences also suggest an increase on 
Glu production after exposure, and the analysis of labelled experiments point glucose as one of its 
precursors. Lipids and specially membrane lipids seem to be greatly affected by imatinib 
treatment. Decreases in PC and phosphatidylcholine (PTC) and increments on GPC levels result in 
an overall decline of phosphomonoesters/phosphodiesters ratio and are thought to be due to 
inhibition of cell proliferation and differentiation processes, as well as cellular membrane 
dysfunctions related to apoptotic events. Increased PUFA and CH2/CH3 resonances after imatinib 
treatment were associated with ongoing cell death and together with the alterations on Cho 
compounds, probably result from either activated PTC catabolism or inactivated PTC anabolism 
(Kominsky et al., 2009; Klawitter et al., 2009; Gottschalk et al., 2004). 
1H and 31P NMR of prostatic carcinoma cells showed a very significant time course 
accumulation of lipids in phenylacetate- (PA) or phenylbutyrate-treated (PB) cells (Milkevitch et 
al., 2005). Besides the observed general lipids accumulation, total choline, whose levels did not 
change significantly in controls, suffered important increases in treated cells. Although no 
significant changes were seen in phosphomonoesters, GPC contents increased markedly in 
exposed cells. These total choline and GPC increments after PA or PB exposure were attributed to 
the activation of phospholipase A2, since fatty acids and GPC are released by the consecutive 
action of this enzyme and lysophospholipase on phospholipids (Milkevitch et al., 2005).  
31P NMR spectroscopy was used to unveil some of the metabolic markers of breast cancer 
cell lines response to PIK3 inhibitors: LY294002 and wortmannin (Beloueche-Babari et al., 2006). 
The results from LY294002-treatment showed a consistent drop of PC, accompanied by a 
decrease of PC/GPC in all tested breast cancer cells, whether intact or extracts. Treatment with 
wortmannin resulted in a reduction of PC contents and changes of GPC and GPE levels (although 
not statistically relevant). The consistent drop of PC observed for both treatments suggest PC as a 
common metabolic marker of PI3K inhibition, what in turn relates PC production with a common 
metabolic target of these two inhibitors of PI3K pathway. 
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The use of MS metabolomics of cultured mammalian cells for anticancer drug testing has 
gained importance in the last few years (Figure 1.20) although a lower number of papers have 
been published compared to NMR metabolomics. This possibly relates to the more complex 
sample preparation for MS analysis, which implies extraction procedures and requires a more 
complex and time consuming optimisation of experimental acquisition parameters. Additionally, 
MS has usually been employed in a targeted manner, thus comprising very few untargeted 
studies, due to the additional complexity of the resulting data and, hence, its interpretation. 
 
Figure 1.20. Number of studies on MS metabolomics of cultured mammalian cells for anticancer 
drug testing (source www.webofknowledge.com, until 20th November 2014). 
A list of the available MS metabolomics studies of cultured mammalian cells for anticancer 
drug testing, divided according to the different classes of chemotherapy agents is presented in 
Table 1.3. Since the emphasis of this thesis is on NMR, an overview of the knowledge produced in 
this area through MS metabolomics will be presented only for studies in which either cell lines 
(MG-63) or drugs (cDDP, DOX or MTX) tested in this thesis were investigated. 
Table 1.3. Overview of literature on MS metabolomics of cultured mammalian cells for anticancer 
drug testing. 
Class Type Agent Tested cells Reference 
Metal-based Metal salt Cisplatin Pluripotent stem cells Stechow et al., 2013 
Antimetabolites Pyrimidine 
analogs 
5-Fluoruracil Colorectal cancer: HCT116 Uehara et al., 2009 
Leukemia: Jurkat Miura et al., 2010 
Hepatoblastoma: HepG2 
Halama et al., 2013 
Embryonic kidney: HEK293 
Gastric cancer: MNK45 Sasada et al., 2013 
Gemcitabine Colorectal cancer: HCT116 Uehara et al., 2009 
Antifolate Methotrexate Melanoma: Hela Myint et al., 2009 
Colorectal cancer: HTC116 Uehara et al., 2009 
Leukemia: Jurkat Miura et al., 2010 
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Table 1.3 (cont.). Overview of literature on MS metabolomics of cultured mammalian cells for 
anticancer drug testing. 
Class Type Agent Tested cells Reference 
Antitumor 
antibiotics 
 Doxorubicin Breast cancer: MCF-7 Cao et al., 2013 
 Hypopharyngeal tumor: 
FaDu 
Kotze et al., 2013 
Hormonal agents 
Androgen 
agonist 
R1881 Prostate cancer: RWPE, PC3, 
DU145, VCaP, LNCaP 
Putluri et al., 2011 
Steroid hormone Dehydroepiandr
osterone 
Hepatoblastoma: SK-Hep-1 Cheng et al., 2011 
Inhibitors of 
Topoisomerase 
 Etoposide Hepatoblastoma: HepG2 
Halama et al., 2013 
 Embryonic kidney: HEK293 
 ARQ501 Primary hepatocytes Miao et al., 2009 
Molecularly 
targeted 
Tyrosine kinase 
inhibitors 
Imatinib 
Leukemia: CML Boros et al., 2005 
Protease 
inhibitors 
Indinavir 
Cervical cancer: C33A Kim et al., 2014 
Lopinavir 
HSP90 inhibitors Celasterol Adenocarcinoma: HeLa Hu et al., 2013 
PI3K inhibitors LY24002 Glioblastoma: U87MG Pandher et al., 2009 
PAF inhibitor Gossypol Ovarian cancer: SKOV-3 Wang et al., 2013 
Other agents 
 
PNU-91325, 
rosiglitazone, 
pioglitazone 
Hepatoblastoma: HepG2 Harrigan et al., 2006 
 Lovastatin 
Breast cancer: MDA-MB-
231, MDA-MB-468 
Klawitter et al., 2010 
 
Dehydroepiandr
osterone 
Hepatoblastoma: SK-Hep-1 Cheng et al., 2011 
 
Docosahaexanoi
c acid 
Pancreatic cancer: PaCa-44 D’Alessandro et al., 2011 
 Bezielle Breast cancer: SKBR3, BT474 Klawitter et al., 2011 
 GdCl3 Adenocarcinoma: HeLa Long et al., 2011 
 2,3,7,8-
tetrachlorodiben
zo-p-dioxin 
Hepatoblastoma: HepG2 
Jennen et al., 2011 
 Ruiz-Aracama et al., 2011 
 
Metformin Breast cancer: MCF-7, BT-
474, MDA-MB-231 
Corominas-Fajas et al., 
2012 
 
Phenolic 
compounds 
Colorectal cancer: HT29, 
SW480 
Fernández-Arroyo et al., 
2012 
 Colorectal cancer: HT29 Ibañez et al., 2012 
 Leukemia: K562 Valdes et al., 2012 
 
Perfluorooctanoi
c acid 
Normal liver: L02 Peng et al., 2013 
 EPA  Lung cancer: A549, H596 Pirman et al., 2013 
 
Flavonoid 
derivative 
Hepatoblastoma: HepG2 Gao et al., 2014 
YNB, Yunnan Baiyao, EPA: eicosapentaenoic acid. 
 
The metabolic response of pluripotent stem cells to cDDP treatment was investigated by 
integrated MS metabolomics and transcriptomics (Stechow et al., 2013). The results revealed 
changes in metabolites involved in Met degradation pathways, polyamine synthesis and 
catabolism, urea cycle, Pro and Arg metabolism as well as nucleotide metabolism in cDDP-treated 
cells. 
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Concerning the metabolic effects of antimetabolites administration, LC/MS analysis of 
colorectal cells treated with MTX revealed a decrease of dTDP and increases in 
5’phosphoribosylglycinamide (GAR), 5’phosphorobosyl-5-amino-4-imidazolecarboxamide (AICAR) 
and dUMP (substrates or products of the enzymes that catalyse purine and thymidine 
biosynthesis, inhibited by MTX) (Uehara et al., 2009). 5’-phosphoribosyl-4-(N-
succinocarboxamide)-5-aminoimidazole (SAICAR) was also found to increase with MTX as well as 
UTP (Myint et al., 2009). When administered to leukemia cells, MTX was also found to down-
regulate UDP-GlcNAc biosynthesis (Miura et al., 2010). 
Recent work investigated the metabolic consequences of the antitumor antibiotics DOX on 
breast cancer cells by MS metabolomics (Cao et al., 2013). The results showed that DOX promoted 
a down-regulation of proteins biosynthesis, purines, pyrimidines and glutathione as well as a 
decreased rate of glycolysis, which in turn enhanced glycerol metabolism (Cao et al., 2013). This 
increased glycerol metabolism and decreased glutathione biosynthesis suggested a drug-induced 
generation of reactive oxygen species (ROS) and a weakened ability of treated cells to balance 
ROS, respectively. In hypopharyngeal tumour cells (Kotze et al., 2013), cholesterol and 
diacylglycerols were pointed as drug-response markers and when high dose DOX is administered 
Gln alterations also became relevant. 
 
1.6. Aims and Outline of this Work 
The general aim of this thesis was to characterize, interpret and compare the metabolic 
response of osteosarcoma cells to selected conventional anticancer drugs and to a new palladium 
complex, in order to achieve a better understanding of the drugs mechanisms of action and, 
subsequently, effects arising from drug combination protocols. In this line, the specific aims were: 
−  To optimize cell culturing and sampling conditions for NMR spectroscopy and to evaluate 
the influence of different experimental procedures on the cell’s spectral profiles. 
−  To characterize in detail the metabolome (inventory of endogenous metabolites involved 
in cells biochemical pathways) of human osteosarcoma MG-63 cells and to characterise their 
metabolic response to three drugs conventionally used in the treatment of OS: cisplatin, 
doxorubicin and methotrexate. 
−  To characterise the metabolic profile of human osteoblast (HOb) cells and establish the 
differences in relation to that of previously characterized MG-63 OS cells metabolome. 
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−  To evaluate the metabolic response of MG-63 cells to Pd2Spm, potentially active against 
OS, in relation to the metabolic perturbation induced by cisplatin and to comprehensively 
understand the metabolic impact of each of these two drugs in HOb cells, concluding about the 
possible advantages of using the new Pd(II) agent. 
− To understand the metabolic impact of conventionally used drug combination regimens 
(cisplatin, doxorubicin, methotrexate) on MG-63 OS cells in relation to that induced by 
combination regimens including Pd(II) drug (Pd2Spm, doxorubicin, methotrexate). 
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2. Analytical Methods 
2.1. Biological Assays 
2.1.1. Trypan Blue, Sulforhodamine B (SRB) and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) Assays 
Trypan blue, SRB and MTT assays were used throughout this work to evaluate cell integrity 
and density (Trypan Blue and SRB) and cell viability (MTT). The principles and methodologies of 
each of these methods are described below. 
 
The Trypan Blue Assay 
The Trypan blue dye (chemical structure shown in Figure 2.1) exclusion colorimetric test is a 
standard cellular biology method for quantifying living (morphologically intact) cells. This method 
is based on a simple principle: living cells possess intact cell membranes that exclude the Trypan 
blue dye (the same principle applying to Eosin and propidium iodide dyes, mostly used to stain 
proteins and DNA, respectively), whereas the cells with a compromised/damaged membrane 
appear blue-coloured under the light microscope (Strober, 2001). This assay was applied to assess 
the extent of cell death at each time point of the experiments performed for NMR, allowing plots 
of number of cells as a function of time to be built. Additionally, this quantification, performed 
prior to NMR data acquisition, was used to confirm that the samples analysed had indeed been 
exposed to the chosen drug concentration since, at the time point for which IC50 was determined, 
a reduction of 50% in the number of living cells was expected (excluding possible experimental 
errors). 
 
Figure 2.1. Chemical structure of Trypan blue dye. 
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The SRB Assay 
The SRB dye (sulforhodamine B, chemical structure shown in Figure 2.2) assay was first 
described by Skehan and co-workers in 1989 (Skehan et al., 1989), in the course of an anticancer 
drug discovery program carried out by the National Cancer Institute, USA. This assay is based on 
the capacity of the sulforhodamine B dye to bind electrostatically (depending on pH) to protein 
basic amino acid residues. SRB links to proteins of trichloroacetic (TCA)-fixed cells under mild 
acidic conditions and can be solubilised by weak bases as Tris (tris-hydroxymethyl-
aminomethane), prior to optical density measurement (Voigt et al., 2005). A very important 
advantage of this method is the fact that the colorimetric end point is non-destructive and 
indefinitely stable, which allows samples to be analysed, by spectrophotometry at 540 nm, days 
after the experiment. 
 
Figure 2.2. Chemical structure of SRB fluorescent dye. 
Compared to the MTT assay, the SRB method shows a better linearity with cell number, 
higher sensitivity and the corresponding staining is cell-line independent. Furthermore, as 
opposed to MTT, SRB has been successfully used in freshly lysed cells (hence, easily stained) 
preserving cell debris unstained, thus providing a reliable way of measuring sensitivity to drugs 
(Keepers et al., 1991). 
In the present work, the SRB assay was used for IC50 determination of the effect of Pd2Spm 
on MG-63 cells, as well as for obtaining the 12 days growth curve of osteoblasts. 
 
The MTT Assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, chemical structure 
shown in Figure 2.4) assay, established by Mossmann in 1983, (Mossmann, 1983) is based on the 
reduction of the water soluble yellow tetrazolium salt (MTT) to insoluble violet formazan crystals 
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via cleavage of the tetrazolium ring by mitochondrial NADH-dependent dehydrogenases of 
metabolically active cells (Figure 2.3). This process can be followed spectrophotometrically, as 
formazan is a coloured product (maximum absorbance at 570 nm), that accumulates inside the 
viable cells, since cell membranes are impermeable to it. The amount of formazan produced is 
assumed to be directly proportional to the number of viable cells (Berridge et al., 1993). 
 
Figure 2.3. Reduction of MTT to formazan crystals by mitochondrial NADH-dependent 
dehydrogenases of metabolically active cells. 
The MTT assay is generally accepted as a reliable, rapid and inexpensive method to assess 
cell viability (Kepp et al., 2011). In this work, this method was used to determine IC50 values for 
each of the tested drugs, with the exception of Pd2Spm. 
 
2.1.2. Fluorescein Isothiocyanate (FITC) Annexin V/Propidium Iodide (PI) Assay for 
Apoptosis Detection 
Apoptosis is a normal physiological process, crucial for the maintenance of tissue 
homeostasis. This process relates to programmed cell death and is characterised by a number of 
morphological features including disassembling of cytoskeleton and nuclear envelope, 
fragmentation of nuclear DNA and alteration of cell surface, so that dying cells shrink and 
condense, becoming rapidly phagocytosed (Alberts et al., 2002). Cellular events involving the 
plasmatic membrane constitute the earliest features of the process. In apoptotic cells, the 
membrane phospholipid phosphatidylserine (PS) is translocated from the inner to the outer 
membrane layer, thus exposing PS to the external cellular environment (Kerr et al., 1972). 
Annexin V is a 36 kDa Ca2+-dependent phospholipid-binding protein with high affinity for PS, 
thus binding to it in apoptotic cells (Vermes et al., 1995). Annexin can also be conjugated to the 
fluorochrome FITC (fluorescein isothiocyanate) while keeping its affinity for PS, therefore being 
MTT (yellow)
Mitochondrial
reductases
Formazan (violet)
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very useful as a sensitive fluorescent probe for flow cytometry analysis of cell cultures. Since PS 
externalisation is one of the first events of apoptosis, FITC-Annexin V staining identifies cells in 
early apoptotic stages. In addition, experiments based on nuclear changes (such as DNA 
fragmentation and loss of nuclear membrane integrity) can be used as markers of late apoptosis 
or necrotic processes. Hence, staining with FITC-Annexin V is commonly used in combination with 
a vital dye such as propidium iodide (PI) to allow different stages of apoptosis to be identified 
simultaneously: viable cells with intact cell membranes exclude PI, whereas cells with damaged 
membranes are permeable to it. Consequently, viable cells appear negative for both FITC-Annexin 
V and PI, cells in early apoptosis are positive for FITC Annexin V and negative for PI, and cells 
already undergoing late apoptosis are both FITC-Annexin V and PI positive (Figure 2.4). 
 
Figure 2.4. Schematic representation of the information obtained with the FITC-Annexin V/PI 
apoptosis detection method. 
Cells in the R1 quadrant display no apoptosis-related damaged cell membranes (FITC-
Annexin V(-)/PI (+)) with PI labelling arising from cells mechanically damaged during the assay; 
cells in the R2 quadrant are undergoing late apoptosis (FITC-Annexin V(+)/PI (+)); cells in the R3 
quadrant are viable (FITC-Annexin V (-)/PI (-)) and, finally, cells allocated to the R4 quadrant are 
undergoing initial apoptosis (FITC-Annexin V (+)/PI (-)). 
 
2.2. Nuclear Magnetic Resonance (NMR) Spectroscopy 
2.2.1. Principles of NMR Spectroscopy 
NMR spectroscopy has emerged in the early 1940s (Becker, 1993) and since then, this 
technique has suffered tremendous improvements, having nowadays a leading role in most 
scientific fields.  
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Atomic nuclei have characteristic proton/neutron compositions which, in some nuclei, 
induce the property known as spin, perceived as a rotational motion of the nucleus. The nuclear 
spin generates a magnetic dipole along the nucleus rotation axis, corresponding to a magnetic 
moment, µ, associated to the spin angular moment, P, and the spin quantum number I. Only the 
nuclei with non-zero values of I (I assuming either integer or half-integer values) are detectable by 
NMR, e.g.: 1H, 9F, 13C, 15N and 31P with I=1/2; 2H, 14N with I=1 and 17O with I=5/2.  For nuclei with 
I≠0, I and µ relate to each other by the expression µ = γ.I, where γ is the gyromagnetic ratio, which 
relates to the sensitivity of each particular nucleus (γ=2.675 x 10-8 rad.T-1s-1, for 1H). For nuclei 
with I=1/2, the presence of an external magnetic field B0 induces two possible spin orientations 
that correspond to different energy levels. The number of possible spin orientations is given by 
the magnetic quantum number ml described by the equation ml=2I+1. For a nucleus with I=1/2, 
spin orientations may be either parallel (lower energy, α) or antiparallel (higher energy, β) and the 
energy difference (UE) between α and β states is given by UE=γ.ħ.B0, where ħ is the Planck’s 
constant (h) divided by 2π. The external magnetic field B0 induces a torque (momentum that 
causes rotation about an axis) on the nuclei, leading the spins to precess around the direction of 
the applied B0 (Figure 2.5a). This is called Larmor precession and it occurs at a frequency named 
Larmor frequency, expressed as linear or angular frequencies: ν0 (ν0=-γ.B0/2π in Hz) or ω0 (ω0=- 
γ.B0 in rad.s
-1) (Lindon et al., 2000). 
 
Figure 2.5. a) Precession of an individual magnetic moment µ around the external magnetic field B0, 
b) precession of magnetic moments in the α and β spin states and c) resulting magnetic moment M0 
reflecting the excess of spin population in the α state (adapted from Claridge, 1999). 
The Boltzmann equation (Eq. 2.1) describes the distribution of the spins by the two energy 
levels (considering, for instance, the case of protons), in which N refers to the number of spins in 
each spin state, UE is the difference between the energetic states, k is the Boltzmann constant 
and T the absolute temperature. Accordingly, in the presence of B0 and at thermal equilibrium, 
µ
α-state
β-state
M0
b) c)a)
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there will be an excess of spins in the α state, thus creating a bulk magnetization M0, parallel to B0 
(Reynolds, 2000). 
 
 α
 β
  
  
        |Eq. 2.1| 
 
 
Figure 2.6. a) scheme of the magnetization vector M0 precessing on the x’-y’ plane around the z axis, 
cutting the receiver coil aligned with the same plane, b) time domain signal or free induction decay (FID) 
and c) frequency domain signal of the FID after applying the Fourier transformation (FT) (adapted from 
Keller, 1988 and Keeler, 2002). 
The detection of the NMR signal (Figure 2.6) involves the application of a radiofrequency 
(RF) pulse for a established period of time, commonly of the order of µs (Keller, 1988). The RF is 
then transmitted through a coil that surrounds the sample, which induces a magnetic field B1 in 
the transverse plain, perpendicular to B0, and made to oscillate at the Larmor frequency. To 
facilitate the visualisation of the rotating fields and precessing vectors, a reference rotating frame 
(x’, y’, z’=z) spinning at the Larmor frequency around z is used, rather than the static laboratory 
frame (x, y, z). The applied RF pulse (usually corresponding to a 90˚ radiation pulse) causes the net 
magnetization M0 to flip from the z axis to the x’-y’ plane. After the pulse, the magnetization 
vector is reestablished, in a way that the transverse magnetization gradually disappears towards 
z, ending at its starting M0 value, through a process called relaxation. To detect the NMR signal, 
the receiver reads the signal in the x’-y’ plane which is crossed by the magnetization vector M0, 
thus originating a current that is amplified and recorded, known as Free Induction Decay (FID). 
This is a time domain signal (f(t)), subsequently transformed into a frequency domain (f(w)), i.e. 
the NMR spectrum, by applying a Fourier transformation (FT, Eq. 2.2). 
                
          |Eq. 2.2| 
 
Receiver
coil
Time domain Frequency domain
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Relaxation 
The relaxation process occurs through two main mechanisms, named spin-lattice and spin-
spin relaxation, also known as longitudinal and transverse relaxation, respectively. These 
processes are characterized by time constants named relaxation times T1 and T2, respectively. T1 
describes the exponential decay of the net magnetization in the z axis whereas T2 accounts for the 
relaxation process in the x’-y’ plane. The spin-lattice relaxation refers to the exchange of 
magnetization with the surroundings and the z component of magnetization (Mz) is expressed in 
terms of T1 according to Eq. 2.3. The spin-spin relaxation relates to a spin-spin exchange process, 
resulting from differences in magnetic field that are experienced by the spins, due to sample 
heterogeneities or intra- and inter-molecular interactions. Described in terms of T2 by Equations 
2.4 and 2.5, these differences cause the spanning out of the magnetization component in the x’-y’ 
plane, so that ultimately no net magnetization exists in this plane (Jacobsen et al., 2007). 
                         |Eq. 2.3| 
                               |Eq. 2.4| 
                               |Eq. 2.5| 
 
Finally, it is important to note that T2 relates to the width at half height of the NMR signals 
(Uν1/2), according to a relationship of proportionality between Uν1/2, and 1/π.T2* (Claridge et al., 
1999). Therefore, large and slowly diffusing molecules are characterized by short T2 values and 
thus, give rise to broad NMR resonances. Indeed, both T1 and T2 values are related to molecular 
mobility, as illustrated in Figure 2.6. For nonviscous liquids, containing fast diffusing molecules, 
therefore with short correlation time, τC, T1 and T2 are identical (initial phase of curve shown in 
Figure 2.7) (Harris et al., 1987). As mobility decreases (τC increases), T1 goes through a minimum 
(at τC
2=ν0
-1, where ν0 is the resonance frequency) determined by field strength (see different red 
lines in Figure 2.7) from which it increases, while T2 continues to decrease (Figure 2.7). T2 
eventually reaches a minimum limiting value when the sample is in the solid state. 
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Figure 2.7. Schematic representation of the dependence of T1 and T2 on the molecular tumbling 
rates, expressed by the correlation time, τC (adapted from Harris, 1987). 
 
Chemical Shift and Scalar Coupling 
Each nucleus is surrounded by electrons that create a local magnetic field, that either 
opposes or reinforces the applied magnetic field (B0). The local field may act as a shield and 
causes each nucleus to experience different effective magnetic fields (Beff) (Lindon et al., 2000). 
Thus, the effective magnetic field experienced by the nucleus results from the addition of B0 and 
the local magnetic field produced by the surrounding electrons (Eq. 2.6, where σ is the shielding 
constant, which may adopt either positive or negative values). 
                       |Eq. 2.6| 
The chemical environment that surrounds the nucleus (determined by the neighboring 
atoms and chemical bonds) determines the frequency (ν) at which each nucleus resonates, 
resulting in absorption peaks at singular positions in the NMR spectrum. The position of each 
NMR resonance is measured by its resonance frequency, which is proportional to the magnetic 
field strength and depends directly on the operating frequency of the spectrometer (νref). The 
resultant dimensionless value is called chemical shift (δ) and is expressed in parts per million 
Fast
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Intermediate 
motion
Slow
motion
Chapter 2 
 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
81 
 
(ppm) (Eq.2.7). This results in a chemical shift scale that is independent of the frequency of the 
NMR spectrometer used (Lindon et al., 2000; Jacobsen, 2007). 
                            |Eq. 2.7| 
The frequencies of the methyl groups bound to the silicon atom of chemically stable 
compounds such as dimethylsilapentanesulfonic acids (DSS), tetramethylsilane (TMS) or 
trimethylsilyl propionate (TSP) are usually used as reference for 1H and 13C ppm calibration 
(Santini et al., 2001). Nevertheless, TSP has been found to be sensitive to intermolecular 
interactions in cellular samples (and, in general, in complex mixtures) and for that reason, in this 
work chemical shifts were internally referenced to alanine signal at δ 1.48 (Duarte et al., 2010; 
Duarte et al., 2013). Typical ranges of chemical shift values for 1H and 13C nuclei in common 
functional groups are listed in table 2.1. 
Table 2.1. 1H and 13C chemical shifts of common functional groups (adapted from Fan et al., 1996). 
1H chemical shifts 13C chemical shifts 
Chemical group δ (ppm) Chemical group δ (ppm) 
C-CH3 0.7-1.1 -CH3 (methyl) 8-30 
=C-CH3 1.5-1.8 -CH2 (methylene) 14-55 
COCH3 (acetyl) 2.0-2.5 -CH- (methane) 22-60 
N-CH3 2.5-3.3 -C- (quaternary) 30-40 
O-CH3 3.3-4.3 CH2=C-R 100-150 
CO-CH2-C 1.3-2.5 C=C-C=C-R 110-150 
O-CH2-C 4.0-5.0 Heteroaromatic ring 100-165 
C-CH-OH 3.3-4.0 C-OH (alcohol) 44-85 
C-CH-O-ester 4.2-5.3 C-O-C (ester) 55-85 
=CH-C (olefinic) 5.5-8.5 R-COOH (saturated) 165-188 
Aromatic ring 6.0-9.0 R-C=C-COOH 158-174 
-CHO (aldehyde) 9.0-10.2 R-COOR’ (saturated) 158-178 
-COOH 10.5-13.5 R-C=C-COOR’ 152-172 
C-OH (alcohol) 1.5-6.0 R-CHO (saturated) 196-220 
C-OH (phenol) 6.5-18.5 R-C=C-CHO 176-195 
Primary amines 1.1-1.8 Saturated ketones 195-220 
Secondary amines 1.2-2.1 C-N-R2 20-70 
CO-NH 5.0-6.5 R-CO-NH2 150-178 
 
 Nuclei interact with their neighboring nuclei through a mechanism known as spin-spin 
coupling, scalar coupling or J-coupling, which occurs via electrons of the chemical bonds (Harris, 
1987). The interaction between neighboring spins of nuclei A and X induces a shift in their energy 
levels that is dependent on their quantum numbers mA and mX and their coupling constant JAX 
(parameter that reflects the strength of the interaction). This through-bond nuclear interaction 
results in the splitting of the NMR signal into a multiplicity given by 2nI+1, where n corresponds to 
the number of neighbor equivalent nuclei (Lindon et al., 2000; Jacobsen, 2007). 
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Quantitation in NMR 
In 1H NMR spectra, the area under a signal is directly proportional to the number of nuclei 
giving rise to it. NMR spectroscopy is, therefore, a quantitative technique, as long as spectral 
acquisition is performed under quantitative conditions. Such conditions are fulfilled if inter-scan 
delays are at least 5 times the longest T1, thus ensuring near complete relaxation of all spins 
(Jacobsen et al., 2007). In such conditions, the concentration of a given compound may be 
calculated using Eq. 2.8 which expresses that the concentration of a certain compound B (CB) may 
be determined given the concentration of a reference compound A (CA), the integral of the 
reference signal (AA) and that of the compound signal to be quantified (AB), as well as considering 
the number of protons giving rise to the reference peak (nA) and to the signal to be quantified 
(nB). 
      
  
  
                |Eq. 2.8| 
However, the quantitative analysis in complex mixtures, such as cell samples or other 
biological samples, is often hampered by the broadening of resonances which may result from 
interactions within sample components and between these and the reference compound. This 
effect will compromise area assessment as faithfully reflecting concentrations. In order to 
overcome these limitations, alternative approaches have been considered in complex misture 
analysis (mostly in a metabolomics context). The Electronic Reference To acess In vivo 
Concentrations (ERETIC) method  (Barantin et al., 1997) is able to create a reference signal that 
can be either generated during acquisition or synthetically produced in the postprocessing and 
has been used to determine absolute concentrations on biological samples analysed by liquid 
state NMR (Akoka et al., 1999) or HRMAS (Albers et al., 2009). Other possibility is the use of the 
PULCON principle (PUlse length based CONcentrations determination), which requires no 
particular hardware or software (Wider and Dreier 2006) and has very recently been used for 
quantification of phosphorilated compounds in breast tumor tissue samples by 31P HRMAS 
(Esmaeili et al., 2014). PULCON consists of the determination of the concentration of metabolites 
present in the samples using as external reference, the spectrum of a standard compound with 
known concentration, obtained under identical experimental conditions (Esmaeili et al., 2014). 
 
 
Chapter 2 
 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
83 
 
2.2.2. One-Dimensional (1D) and Two-Dimensional (2D) NMR Spectroscopy 
1H is the most extensively used nucleus in metabolomic studies, due to its high sensitivity 
and natural abundance. The assignment of 1H NMR spectra of complex mixtures is a lengthy but 
necessary procedure, which usually requires several 1D and 2D NMR methods. In 1D NMR, 
experiments usually require a preparation step in which spins reach equilibrium (during a 
relaxation delay d1) and the application of an RF pulse, followed by signal acquisition. Three types 
of 1D 1H NMR experiments are commonly used for the study of complex mixtures: the standard 
NMR experiments (e.g. using the noesypr1d pulse sequence, Bruker library), that consist of a 
preparation step with water presaturation, followed by a 90˚ pulse, and are used to detect signals 
from all type of molecules, and other two experiments which intend to selectively detect signals 
from small or macromolecules, respectively. These are named Carr-Purcell-Meiboom-Gill (CPMG) 
or T2-edited experiments and diffusion-edited experiments, respectively, and the corresponding 
pulse programs are shown in Figure 2.8. CPMG experiments (e.g. using the cpmgpr1d pulse 
program, Bruker library) improve the visibility of narrow signals arising from small molecules, 
making use of a spin echo sequence followed by a delay during which the magnetization 
decreases exponentially with the ratio between τ/T2. This means that the magnetization from 
macromolecules (with lower T2 relaxation times) decreases faster than small molecules (higher T2 
relaxation times), thus the inclusion of an inter-pulse delay period τ (refered as to d20 in Figure 
2.8b) results in the attenuation of the broad signals. On the other hand, diffusion-edited 
experiments (e.g. using the ledbpgp2s1dpr pulse program, Bruker library) are performed to more 
accurately detect signals arising from large and slowly diffusing macromolecules with low T2 
values. In this experiment, after an initial 90˚pulse magnetization is diphased through the 
application of gradients. Then, a new gradient is applied to allow the molecules to diffuse and, 
once diffusion depends on the size of the molecule, the position of larger molecules will remain 
almost unaffected in contrast to small ones. At this time, a new gradient (opposite to the initial) is 
applied, to refocus the magnetization of macromolecules and attenuate the resonances from 
smaller ones (Lindon et al., 2004; Duarte et al., 2009). 
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Figure 2.8. Pulse sequences of typical 1D experiments: a) standard 1D, b) CPMG and c) diffusion-
edited (adapted from the Bruker Avance 1D/2D manual, Bruker 2003). 
The initial steps in the signal assignment process rely on the comparison between chemical 
shifts, signal multiplicity and coupling constants measured in the 1D spectra and similar data 
available in the literature (Ulrich et al., 2008; Wishart et al., 2013), as well as with spectra of 
reference compounds. The 1D spectra of complex mixtures typically comprise hundreds of well 
resolved signals, which correspond to a wide range of low molecular weight molecules, often 
superimposed with broad resonances arising from larger molecules, such as lipids and proteins. 
2D NMR methods are a valuable tool to deal with this sample complexity and enable the 
construction of a significantly more complete list of assigned metabolites. All 2D NMR 
experiments possess the same generic format, consisting in four steps: preparation, evolution (t1) 
mixing and detection (t2) periods. Briefly, the preparation step encompasses a relaxation time 
that allows spins to reach equilibrium, followed by a 90˚ pulse that brings the magnetization to 
the x’-y’ plane. During the evolution step, a series of pulses is applied to force the energy transfer 
between nuclei, thus establishing the second dimension. According to the specificities of the pulse 
sequence chosen, additional pulses may be applied prior to signal detection (Claridge, 1999). 
Relying on inter-nuclei interactions, two types of 2D experiments are usually used in the 
context of mixture analysis: homonuclear and heteronuclear correlation experiments. In the 
context of metabolomic studies, correlation spectroscopy (COSY) and total correlation 
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spectroscopy (TOCSY) are two possible experiments of homonuclear proton correlation, that give 
rise to spectra where peaks that are seen outside the diagonal line, represent 1H-1H spin coupling 
connectivities, facilitating the assignment of different spin systems and compounds. Another 
valuable 2D experiment, also a 1H-1H experiment is J-resolved (J-res), that attenuates peaks from 
macromolecules and yields information on the multiplicity and coupling patterns of resonances. 
Heteronuclear single quantum coherence (HSQC) is a heteronuclear experiment which usually 
correlates the proton and the 13C (Lindon et al., 2004; Duarte et al., 2009). Regarding 
homonuclear experiments, 2D COSY gives coupling information over two or three bonds while 
TOCSY spectra provide information on coupled protons that belong to the same spin-system, 
which can be up to five bonds apart. Therefore, TOCSY experiment enables the identification of all 
resonances within a spin-system, assuming a crucial importance for metabolite assignment. In the 
TOCSY experiment, the evolution step is followed by a spin-lock sequence during the mixing time 
(Malcolm Levitt-17 sequence, MLEV-17) which allows the coherence transfer between all coupled 
nuclei from a spin-system. The general scheme of the TOCSY sequence is shown in Figure 2.9. 
 
Figure 2.9. a) COSY and b) TOCSY pulse sequence (adapted from the Bruker Avance 1D/2D manual, 
Bruker 2003). 
The heteronuclear correlation HSQC experiments give information on the chemical shift of 
13C scalar coupled with 1H chemical shift of the directly connected proton. As shown in Figure 
2.10, this experiment starts with a 90˚ pulse for proton magnetization, then an insensitive nuclei 
enhanced by polarization transfer sequence (INEPT) transfers the magnetization from the 1H to 
the bounded 13C, recovering the magnetization from 13C to the 1H. 
a)
b)
90˚
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Figure 2.10. HSQC pulse sequence (adapted from Keeler, 2002). 
In J-res experiments, information about multiplicity is contained in the F1 dimension and 
scalar couplings are shown in F2 dimension. This aids in the identification of non-overlapped 
multiplets, allowing the coupling constants (J) to be determined. The pulse sequence starts with a 
90˚ pulse to create magnetization, followed by a 180˚ pulse by the midpoint of the evolution time 
to refocus the proton shifts (but not scalar couplings) that appear in the F1 dimension (Figure 
2.11a). At this time, the interpretation of the spectra is more complicated, since F2 contains 
information about both chemical shift and coupling constants. To make spectral interpretation 
easier by only retaining chemical shift information in F2, a “tilting” of the multiplets through a 45˚ 
angle is performed (Figure 2.11b). 
 
Figure 2.11. J-res pulse sequence. (adapted from Claridge, 1999) 
In more recent years, cryogenic probes have contributed to the improvement of spectral 
resolution and sensitivity (Lindon et al., 2007). These probes possess a way of cooling down the 
a)
b)
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detector coil and preamplifier (and not the sample) to around 20K, which leads to an 
improvement in spectral signal to noise ratio of more than five times, thanks to a reduction in the 
electronics’ thermal noise of the spectrometer; this in turn leads to a reduction in spectral 
acquisition times (of about 25 times) (Lindon et al., 2007). 
 
2.2.3. High Resolution Magic Angle Spinning (HRMAS) NMR Spectroscopy 
For a nucleus with spin I, the nuclear energy state is dominated by the Zeeman interaction 
with the external magnetic field B0 (described by an Hamiltonian term Ĥz), the chemical shift 
interaction (ĤCS) and the scalar spin-spin interaction (ĤSC), which result in a total Hamiltonian 
expression defined by these three Hamiltonian operators (Ĥ). Due to the rapid tumbling of the 
molecules in liquid state, these interactions are isotropic, thus resulting in discrete average values 
for chemical shifts and coupling constants. In solid state NMR, additional mechanisms have to be 
taken into consideration, namely, the anisotropy of the chemical shift interaction (ĤCS), dipole-
dipole interactions (ĤD) and quadrupolar interactions (ĤQ), the later occurring only in nuclei with 
spin I>1/2, due to the interaction of the nuclear electric quadrupole moment with the non 
spherically symmetrical electric field around the nucleus. Therefore, the interactions felt by a 
nucleus in solid state are described by the Hamiltonian expression that comprises these 
operators, as well as those referred above for liquid state NMR. These solid state anisotropic 
interactions are due to the restricted motion of the molecules and lead to the broadening of 
spectral lines (Fyfe, 1983).  
The NMR spectra of semi-solid samples such as tissues or cells are also influenced by line 
broadening caused by anisotropic interactions (mainly chemical shift anisotropy and dipolar 
interactions) and sample heterogeneity. This limitation has been largely overcome through high-
resolution magic angle spinning (HRMAS) NMR, which enables the acquisition of well resolved 
spectra of small amounts of semi-solid samples (Claridge, 1999). Figure 2.12a shows the zirconia 
rotors in which samples are packed for analysis in a HRMAS probe (Figure 2.12b). This technique is 
based on the rapid spinning of the sample (usually around 4-6 kHz), at an angle of 54.7˚ relative to 
the applied magnetic field B0 (Figure 2.12c), in order to average out the anisotropic effects that 
broaden the lines, thus improving spectral resolution. This happens because the dipolar couplings 
are proportional to the factor r-3(3cos2θ-1) (where r is the internuclear separation) which becomes 
zero for θ = 54.7˚ (Claridge, 1999). Therefore, the effect of sample rotation is to average out the 
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effect of chemical shift anisotropy and anisotropy of dipolar interactions, and provided that the 
spinning rate is high enough, single values of chemical shifts are obtained, mimicking the isotropic 
values observed in solution state. 
 
Figure 2.12. HRMAS NMR related apparatus: (a) representation of a zirconia 4 mm rotor, (b) the 
sample compartment of a 4 mm HRMAS NMR probe, showing a gradient coil at the magic angle, c) 
representation of sample rotation at the magic angle (adapted from Lindon et al., 2009 and Claridge, 1999). 
Figure 2.13 clearly demonstrates the spectral improvements produced by Magic Angle 
Spinning (MAS) in a 1H NMR spectra of an intact piece of liver tissue. 
 
Figure 2.13. 600 MHz CPMG 1H NMR spectra of control liver acquired either a) in static conditions 
and b) at a spinning rate of 6.2 kHz (adapted from Bollard et al., 2000). 
a) b) c)
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Coupled to relatively high spinning rates, the use of a deuterium (2H) lock signal (which 
compensates for variations in the magnetic field across time) yields remarkable high-resolution 
spectra, resulting in much higher and sharper peaks (Lindon et al., 2009). Moreover, HRMAS 
probes are configured with a Z-gradient aligned along the magic angle, enabling the access of a 
wide variety of NMR experimental techniques including gradient enhanced solvent suppression 
and artifact free 2D homonuclear and heteronuclear experiments. Disposable rotor inserts are 
available for easy sample preparation and/or safety issues, namely when dealing with toxic 
samples (e.g. samples exposed to toxic agents), as drug-exposed samples used in some of the 
studies described ahead in this thesis. 
 
2.3. Data Pre-Processing and Analysis 
The metabolomic analysis of biologic samples (cells, tissues or biofluids) encompasses the 
manipulation of complex datasets, usually with several hundreds of variables. In order to extract 
meaningful biological information from the NMR spectra of complex mixtures, appropriate data 
pre-processing procedures and statistical/multivariate methods must be applied. Prior to 
statistical or multivariate analysis, important pre-processing steps include alignment, 
normalization and scaling procedures. Conventional univariate statistical methods such as 
Student’s t-test, Wilcoxon, Mann-Whitney test or ANOVA, which perform the analysis of one 
variable at a time, are unpractical as a first approach to extract this kind of information from such 
complex datasets. On the other hand, Multivariate Analysis (MVA) has the ability of dealing with 
all the variables in one single analysis with the additional advantage of allowing the construction 
of predictive models. Thus, MVA is a method of excellence to extract relevant information from 
the whole data set, and is usually complemented by univariate analysis to extract statistical 
meaning of those suggested variations. Finally, the validation of the MVA results is of paramount 
importance to ensure the reliability of MVA models (Kjeldahl and Bro, 2010). In the following 
sections these steps are described in detail. 
 
2.3.1. Data Pre-Processing 
Metabolomics data is usually translated into two-dimensional matrices of intensities, where 
each line corresponds to a different observation or object (sample, time point, etc.) and each 
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column represents a variable which in the case of NMR metabolomics, corresponds to a chemical 
shift. 
The alignment or bucketing of shifted signals is usually a first pre-processing procedure, 
particularly in samples like urine, which may vary significantly in terms of pH or ionic strengh. 
Indeed, changes in NMR peak chemical shifts are frequently found in sample spectra due to slight 
changes in pH, temperature or salt concentration, constituting one of the first issues to be tackled 
in order to be able to adequately compare different spectra. In the case of cellular samples, minor 
variations in peaks position are detected (lower than 0.5Hz or 0.001 ppm) with the exception of 
peaks of the amino acid histidine (due to ionization of its NH group of the imidazole ring with a 
pKa close to 6, leading to the instability of the bonds of the ring and the formation of tautomeric 
species). In order to correct these minor chemical shift deviations between samples, spectral 
alignment may be performed, as in this work, using the algorithm recursive segment-wise peak 
alignment (RSPA) (Veselkov et al., 2009). Other alignment algorithms are available such as interval 
correlated shifting (icoshift) (Savorani et al., 2010), fast iterative warping algorithm (Alm et al., 
2009) and hierarchical cluster-based peak alignment (CluPA) (Vu et al., 2011). Spectral bucketing, 
also known as binning, can also be applied to tackle chemical shift variations in peaks (Lindon et 
al., 2007; Smolinska et al., 2012). This procedure consists of dividing de spectrum in fixed or 
variable widths, which can vary from 0.005 to 0.04 ppm. Despite being helpful in eliminating 
differences in peak positions, with a consequent reduction in the complexity of the matrix, 
bucketing entails some loss of spectral resolution. 
Normalization is required in order to account for differences in concentration or total 
amount of different samples. Normalization of the data is, thus, a crucial pre-processing step in 
metabolomic studies since it aims to reduce these differences so that all samples become 
comparable in terms of absolute intensities, and only profile changes or relative intensity ones are 
detected. This step assumes particular relevance in cell culture studies where drugs cytotoxicity is 
evaluated since, for increased times of exposure, the number of cells in treated groups is half or 
less than that of control groups. Normalization is applied to each spectrum (corresponding to a 
row in the data matrix) typically by dividing each point by a constant, which can be determined in 
several different manners. A commonly used way of determining this normalization factor is to 
divide each variable by the total integrated intensity (total area) of its spectrum (Veselkov et al., 
2011). However the metabolic profile of MG-63 cells is dominated by broad and intense 
resonances attributed to lipid fatty acid acyl chains which gain even more importance when cells 
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are exposed to certain drugs. In this and other similar cases, the normalization to total area 
particularly affects the normalization of low intensity signals: the richer the spectrum in lipid 
signals, the higher is the total area and so, the less importance is attributed to small resonances 
after normalization. Therefore, to overcome this, an alternative normalization method was 
applied throughout this work: probabilistic quotient normalization (PQN) (Dieterle et al., 2006). 
This method uses a spectrum or set of spectra (for instance, the spectra of control samples when 
studying drug-induced effects) as reference to calculate the most probable dilution coefficient of 
the whole set of samples, thus reducing the contribution of exceptionally concentrated 
compounds. For that, the method calculates the quotient between each variable (point) of each 
spectrum and the median value of the given control group. Then, the median value of all 
quotients – also referred as the most probable quotient – is chosen and used as normalization 
factor for each sample (Dieterle et al., 2006). 
Data scaling constitutes another important pre-processing step, where each variable is 
divided by a scaling factor. In projection based methods, compounds present in higher 
concentrations are given higher importance and can dominate the projections, hindering 
potentially valuable changes in metabolites present in lower concentrations (Smolinska et al., 
2012; Xia et al., 2013). There are several ways in which data scaling may be performed (Ebbels et 
al., 2011; Craig et al., 2006; van den Berg et al., 2006; Worley et al., 2013; Smolinska et al., 2012; 
van der Berg et al., 2006), the main comprising: 1) mean centering, that compensates for 
differences between low- and high-concentrated compounds, by converting all values to vary 
around zero instead of around the mean of the compound level; 2) Unit Variance, also known as 
auto-scaling, which applies mean centering (subtraction of sample mean value) and divides each 
variable by its standard deviation; 3) Pareto scaling, with which after mean centering each 
variable is divided by the square root of its standard variation; 4) range scaling, in which mean 
centered data are divided by the difference between the minimal and the maximal concentration 
of a metabolite (influenced by outliers); 5) Vast (VAriable STability) scaling, consisting of an auto-
scaling divided by the coefficient of variation of that variable; and 6) level scaling which addresses 
relative responses by using the mean as scaling factor. In this thesis, mean centering, Unit 
Variance and Pareto scaling were applied to the spectral data. Unit Variance was the scaling 
method chosen as it attributes equal importance to all metabolites, independently of their 
concentrations, thus enabling low concentrated compounds to be identified as varying 
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importantly with drug exposure. Nevertheless, mean centering was also occasionally used to 
unveil time course trajectories of samples. 
 
2.3.2. Multivariate Analysis (MVA) Methods 
In order to handle the complex data obtained in metabolomic studies and obtain reliable 
models that may successfully classify each sample and identify relevant profile differences 
between sample groups, multivariate statistical methods (chemometrics) are needed. Indeed, 
MVA is an indispensable tool in metabolomics, since it enables the observation and analysis of 
several statistical variables at a time, searching for consistent patterns of variation that may 
account for samples’ grouping and biomarker identification (Madsen et al., 2010). MVA 
comprehends both unsupervised and supervised approaches, differing in the quantity and type of 
information that is provided about the samples. In unsupervised methods, computations are 
performed without any information on sample classes, for instance control vs drug-treated, 
maximizing the main sources of variations and enabling a blind identification of outliers, trends 
(for instance, temporal ones) or grouping tendencies. Principal Component Analysis (PCA) is the 
most extensively used unsupervised method in metabolomic studies and will be described in 
detail below. There are many other unsupervised methods available such as Hierarchical Cluster 
Analysis (HCA), K-means, Self-Organizing Maps (SOM) and Non-Linear Mapping (NLM) (Lindon et 
al., 2007; Smolinska et al., 2012). On the other hand, supervised methods require a priori 
information on samples grouping, computing models with the objective of maximizing differences 
between the established classes. Thus, they are crucial in metabolomic studies since enable, 
besides classification, sample prediction. Partial Least Squares-Discriminant Analysis (PLS-DA) and 
its orthogonal variation (OPLS-DA) are some of the most used supervised methods and will be 
described in detail in this chapter. Nonetheless, other supervised methods exist such as Soft 
Independent Modeling of Class Analogy (SIMCA), Artificial Neural Networks (ANN) or canonical 
correlation. (Lindon et al., 2007; Smolinska et al., 2012) 
 
2.3.2.1. Principal Components Analysis (PCA) 
PCA calculates linear combinations of the original variables producing much fewer and 
more informative factors called Principal Components (PCs), which describe decreasing amounts 
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of data variance (Trygg et al., 2007). PCs are orthogonal to each other and are linear combinations 
of the variables contained in the original matrix X according to Equation 2.9, where the matrix of 
projections of X is designated by T, corresponding to the scores, P is the loadings matrix and E is 
the residual matrix. 
      X = TPT + E     |Eq. 2.9| 
The projection of observations/samples into this low-dimension model plane formed by the 
PCs is visualized as a scores plot, where each point corresponds to a sample spectrum, enabling 
the identification of groups, trends and outliers through the analysis of their relative position in 
the plot – similar observations appear close in the scores plane. Figure 2.14 shows a global 
scheme of the general computation of a PCA model from the original dataset is shown. As can be 
seen, the multidimensional matrix X is projected into a two-dimensional space in which the main 
variation of the matrix is contained is the two first calculated components (or PCs). The scores 
plot, by means of relative position of the observations, translates the most relevant original 
information into similarities or differences between samples and finally, the loadings plot explains 
which variables are responsible for those similarities/differences between the observations (Trygg 
et al., 2007). 
 
Figure 2.14. Scheme of the construction of a projection-based PCA model (adapted from Trygg et al., 
2007). 
The loadings plot describes the influence of the variables (e.g. chemical shift, intensity) in 
that model plane, and the relation among them. The direction of the distribution of the 
PC1
PC2
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observations in the scores plot corresponds to that of the loadings plot, and vice versa (Trygg et 
al., 2007; Lindon et al., 2007). 
 
2.3.2.2. Partial Least Squares and Orthogonal Partial Least Squares – Discriminant 
Analysis (PLS-DA and OPLS-DA) 
Once the overall tendencies are revealed by unsupervised approaches, supervised methods 
may be applied to the data in order to maximize grouping, thus optimizing the recovery of 
information that explains it. Supervised methods make use of a priori knowledge to find out 
patterns and rules that enable the prediction of new data. PLS and OPLS are examples of 
supervised methods commonly used in metabolomics studies and can be used Discriminant 
Analysis (DA) with the objective of establishing an optimal position to trace a discriminant surface 
that best separates classes. (Trygg et al., 2007; Wiklund et al., 2008) PLS-DA is a regression 
method which intends to find out the relationship between two data matrices referred to as X 
(e.g. NMR data) and Y (information about sample membership, i.e. controls vs drug-treated). Like 
PCA, PLS-DA is a projection-based approach that assumes that data variations can be reduced in 
low dimension spaces called latent variables (LVs), which constitute linear combinations of the 
original variables. The first calculated LV in a PLS-DA contains the highest amount of variation 
between classes which, in turn, may not correspond to the highest source of variation within the 
dataset. (Trygg et al., 2007; Lindon et al., 2007; Smolinska et al., 2012) The model can then be 
expressed in terms of X and Y, as given in Equations 2.9 and 2.10, where T represents the scores 
common  to X and Y matrices, respectively, P and C the respective loading matrices and E and F 
the respective residual information in the two matrices. 
      Y = TCT + F     |Eq. 2.10| 
The PLS-DA model can also be given by Eq. 2.11, in which Y matrix is expressed in terms of 
X, where b represents the regression coefficients of each variable and r the residual information 
of the matrix. 
      Y = Xb + r     |Eq. 2.11| 
The orthogonal transformation of PLS-DA, OPLS-DA, intends to separate the systematic 
variation of X matrix into two parts: one linearly related to Y and one orthogonal (unrelated) to Y. 
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This division of X matrix facilitates the model interpretation. The OPLS-DA model contains two 
modeled variations: the response-orthogonal (ToP
T
o) and the response-predictive (TpP
T
p), as given 
by Eq. 2.12. For the modeling of Y, only the Y-predictive variation (UpQ’p) is considered (Eq. 2.13) 
(Lindon et al., 2007; Smolinska et al., 2012). 
     Model of X: X= ToP
T
o + TpP
T
p+ E     |Eq. 2.12| 
     Model of Y: Y= TpC
T
p + F     |Eq. 2.13| 
For comparable number of LVs, OPLS-DA and PLS-DA possess comparable predictive 
powers. OPLS has advantages over PLS-DA in what refers to interpretability, since orthogonal 
modelling filters out irrelevant variations; nevertheless it does not replace PLS-DA (Smolinska et 
al., 2012). 
 
2.3.2.3. Statistical Total Correlation Spectroscopy (STOCSY) 
Statistical Total Correlation Spectroscopy (STOCSY) is a very useful approach for peak 
assignment and determination of metabolic correlations (Cloarec et al., 2005). In this work this 
method was used to achieve both objectives. STOCSY is based on correlation properties inside the 
matrix C (correlations between peak intensities), enabling the identification of positive 
correlations between peaks that arise from a particular spin system. STOCSY has also been used 
to identify molecules involved in the same metabolic pathways, based on their biological 
covariance, resulting in different colorations for positive and negative correlated molecules, 
corresponding to variations in the same and opposite directions respectively. STOCSY 
computations are based on Eq. 2.14, where X1 and X2 refer to the autoscaled data matrices 
(Cloarec et al., 2005). 
              
        |Eq. 2.14| 
STOCSY was developed to increase the information recovery from complex 1D NMR 
spectra, but can also be applied to 2D data and to homo or heteronuclear comparisons within the 
spectral data. Recent developments combine STOCSY and HCA in an approach designated by 
CLASSY (Cluster Analysis Statistical Spectroscopy), with some advantages over conventional 
STOCSY, namely increased accuracy with which the correlations between peaks of the same 
molecule are determined. Correlations between datasets acquired through two different 
Analytical Methods 
 
________________________________________________________________________________ 
 
________________________________________________________________________________ 
 
96 
 
experimental techniques (e.g. NMR and MS) can also be determined by heterospectroscopic 
STOCSY (Smolinska et al., 2012). 
 
2.3.2.4. Validation of MVA Models 
The study of biological samples through metabolomics implies the existence of many more 
variables (e.g. chemical shift in NMR or m/z in MS) than samples, which increase the possibility of 
finding a model that fits the data showing an apparently good separation of sample groups in the 
multivariate space. Although the apparent geometrical grouping obtained in supervised models’ 
scores plots, these can fail to extract differences between groups (Westerhuis et al., 2008). For 
this reason, validation emerges as one of the most valuable tools in metabolomics studies, since it 
enables the determination of robustness of the model and its predictive ability. In typical 
metabolomic studies which analyse for instance control vs drug-treated cells, the whole dataset 
must be divided into a training dataset, that will be used to develop and test the model and a 
second validation dataset, in which model accuracy will be tested, i.e., check if the model 
classifies a new sample in the correct group. This is called external validation, which is now 
considered as the best means to establish a reliable predictive performance of the model 
(Smolinska et al., 2012). 
The reduced number of biological samples commonly available forces the use of the whole 
sample groups as training set and, in these cases, Cross Validation (CV) can be used to prove how 
well a model works for the prediction of new samples. CV is thus a reliable approach to evaluate 
the model predictive power, which consists of an initial division of the data into a number of 
groups with which training models are built, leaving just one group to be used for the prediction 
test (Westerhuis et al., 2008). Permutation tests constitute another way of performing model 
validation, through which is tested if a given model is significantly different from a null hypothesis 
model (randomly obtained). Permutation tests imply that sample grouping information is 
randomly permuted as model is recomputed. This enables the robustness of the model to be 
determined (Westerhuis et al., 2008). The robustness of a model can also be evaluated through 
parameters obtained through confusion matrices: classification rate (CR), sensitivity and 
specificity. Confusion matrices are composed by false positives (FP), false negatives (FN), true 
positives (TP) and true negatives (TN) as shown in Figure 2.15a. The CR refers to the percentage of 
samples that were correctly classified in the model, sensitivity (also referred to as true positive 
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rate, TPR) indicates the number of true positives as a percentage of all positives, 1-specificity (or 
false positive rate, FPR) refers to the number of false positives as a percentage of all negatives, 
calculated according Eq. 2.14 to 2.17, respectively. 
                         |Eq. 2.14| 
                              |Eq. 2.15| 
                                |Eq. 2.16| 
The plot of sensitivity (TPR) vs 1-specificity (FPR) results in the Receiver Operating 
Characteristic (ROC) plot. In this work, ROC plots were built from sensitivity and specificity of the 
PLS-DA model and calculated through Monte Carlo Cross Validation (MCCV). To perform MCCV, 
the original dataset is divided into a training and a prediction set, in which the latter is used for 
class membership prediction. An important feature of MCCV is that it is usually performs at least 
500 iterations, and for each the Q2 value and confusion matrix are determined. Moreover, MCCV 
can be repeated for permuted classes and if the model is robust enough, a complete separation 
between true and permuted classes in observed in the ROC plot, as shown is Figure 2.15c (Xu and 
Liang, 2001; Xia et al., 2013). 
 
Figure 2.15. Examples of a) confusion matrix obtained for two classes, b) Q2 distribution of true and 
permuted models and c) MCCV-obtained representations of ROC space plot (adapted from Diaz, 2014).  
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PLS-DA computations also provide a parameter that evaluates the discriminant power of 
the model, called predictive power and given by a Q2 parameter. For robust models this 
parameter is closer to 1, meaning that predictive classification almost always matches real 
classification. Due to variation inherent to each sample (even within the same class) it is very 
difficult to achieve the ideal Q2 value of 1. By comparing the Q2 distribution of the permuted 
models with original ones, evaluation of the predictive power of the model can be made: minimal 
overlapping between the Q2 of true (original) and permuted models indicates a model with an 
interesting predictive power (Figure 2.15b) (Westerhuis et al., 2008). 
 
2.3.3. Statistical Methods 
Univariate analysis presents some advantages over multivariate analysis, such as ease of 
application, ease of interpretation and ease of communication of the results. Nevertheless, single 
variables and markers do not provide the comprehensive knowledge that metabolomic studies 
intend to achieve. The analysis of biological phenomena by metabolomics implies a 
comprehensive characterization of the biological processes, which is translated in a metabolic 
picture that simultaneously correlate several compounds from the sample under study, what can 
only be achieved with multivariate analysis. Still, an increasing number of metabolomic studies 
apply both univariate and multivariate statistical methods. This can be explained by the 
complementary information that the two approaches provide: on the one hand, MVA looks for 
the metabolic relationships reflected in metabolites correlation and variation and univariate 
methods compares individual variations, independently on the whole profile. This means that a 
particular metabolite variation can be found relevant through MVA and not show individual 
statistical significant when analysed apart from the rest of the profile, and vice-versa. This may be 
explained by the high complexity of the dataset, with a considerable number of non relevant 
variables that mask important information (Saccenti et al., 2014). 
Univariate methods can be parametric or non-parametric, for data that follows a normal 
distribution or not, respectively. In this work, univariate analysis was used to compare groups of 
three (sometimes only two) samples and, since no reliable determination can be made on data 
normality in such a reduced sample group, unpaired t-test (parametric) was used for p-value 
calculations. 
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3. Experimental Procedures 
The present chapter describes the experimental procedures carried out throughout this 
work, therefore comprising cell culturing, sample preparation for analysis, NMR data acquisition 
and data analysis. 
 
3.1. Cell Lines and Biological Assays 
This section describes the cell growth and drug exposed protocols performed in biological 
assays with the osteosarcoma MG-63 and osteoblast HOb cell lines. 
3.1.1. Cell Lines 
Two human (adherent) cell lines were tested throughout this work: the MG-63 cancer cell 
line and a healthy osteoblast cell line (the HOb cell line). Figure 3.1 shows the microscopic 
appearance of the corresponding cells in terms of cell size and morphology. 
 
Figure 3.1. Optical microscope photographs (x 200) of the human a) MG-63 and b) HOb cell lines. 
A study by Pautke and co-workers (Pautke et al., 2004) offers a characterization of three 
osteosarcoma cell lines (MG-63, Saos-2 and U-2 OS), in comparison to human osteoblasts. 
Regarding morphology, such results evidenced that the mean size of attached osteosarcoma cells 
is around 1/6 that of osteoblasts (as clearly evidenced in Figure 3.1) and, unlike osteoblasts, the 
size of the cancer cells does not vary according to their degree of confluence. Moreover, strictly 
referring to MG-63 vs HOb cells, the former have an oval to spindle-shape, without branching-cell 
processes while healthy cells are less consistent in shape (although still having a characteristic 
a) b)
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morphology, illustrated in Figure 3.1) displaying several elongated and prominent cell branching 
processes. 
The human MG-63 osteosarcoma cells are morphologically classified as fibroblasts (due to 
their elongated shape) and were established from an osteosarcoma of a 14 year old Caucasian 
male (Billiau et al., 1977; Heremans et al., 1978). This cell line has a population doubling time of 
approximately 24 hours and can be propagated for several tens of passages, with preservation of 
morphological characteristics and doubling times. These properties explain the common choise of 
this cells line for model studies in different research contexts. Human osteoblasts have the ability 
to synthesize bone matrix. The HOb cells used here were isolated from normal adult human bone, 
cryopreserved at their second passage and may be propagated for at least 10 population 
doublings (according to the information of the supplier and our own experience). 
 
3.1.2. Cell Culture 
The human MG-63 OS cells (kindly provided by the Associate Laboratory IBMC/INEB, 
Portugal) are adherent and grow in monolayers. Cells were grown in Minimum Essential Medium 
(MEM, Sigma-Aldrich), supplemented with 10% heat-inactivated fetal bovine serum (FBS, 
Alfagene), 1 mM sodium pyruvate (Sigma-Aldrich), 1 mM non-essential amino acids (Sigma-
Aldrich) and antibiotics (penicillin-streptomycin, Sigma-Aldrich) and maintained under humidified 
atmosphere, at 5% CO2 and 37˚C (MCO-19A Incubator, SanyoElectric Co., Ltd.). Due to the high 
number of cells needed for the NMR experiments (ca.10 x 106 per sample), cells were grown in 
150 cm2 cultures flasks. When a confluence of ca 90% was reached, the cells were washed with 
phosphate buffered saline (PBS, pH 7.4, Sigma-Aldrich) and harvested with the addition of a 
0.05% trypsin/ethylenedieminetetraacetic acid (EDTA, Sigma-Aldrich) solution. After detachment 
of the cells, trypsin was immediately neutralized by adding twice volume of complete MEM. Cell 
suspensions were then centrifuged at 1100 rpm for 5 minutes, at 21˚C (MPW-350 Centrifuge), and 
resuspended in a known volume of MEM, from which 100 µL were taken for cell counting through 
the Trypan blue assay (either to continue growth or to proceed for drug exposure experiments). 
Human osteoblasts (HOb, 406-05a, Sigma-Aldrich), similarly to MG-63, are adherent cells 
that grow in monolayers. In this work, these cells were cultured in Osteoblast Basal Medium 
(Sigma-Aldrich) supplemented with Osteoblast Growth Supplement and were maintained under a 
humidified atmosphere, at 5% CO2 and 37˚C. Although of larger dimensions than the MG-63 cells, 
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a good NMR signal-to-noise ratio still required ca. 1 x 106 cells per sample, and for this reason 
HOb cells were grown in 150 cm2 cultures flasks. According to the supplier’s instructions, cells 
were seeded at a 10000 cell/cm2 density and subdivided at ca. 80% confluence. The cells were 
then washed with Hank’s Balanced Salt Solution (HBSS, Sigma-Aldrich) and harvested by addition 
of a 0.05% trypsin/EDTA solution (just enough to cover the bottom of the flask). Due to the 
increased sensitivity of these cells, compared to the tumour OS cell line, as soon as cells became 
round (i.e. detached) a trypsin neutralizing solution (5% FBS in HBSS) was added to stop trypsin 
action. Cells were then centrifuged at 1200 rpm, at 21˚C for 5 minutes and resuspended in a 
known volume of Osteoblast Growth Medium, from which 100 µL were taken for cell counting by 
Trypan blue assay, either to continue growth or to proceed for drug exposure experiments. 
 
3.1.3. Cytotoxic Evaluation 
3.1.3.1. Drug Exposure and IC50 Determination 
Single Drug Exposure 
For single drug exposure experiments, 5x106 MG-63 cells were plated in 100 mm diameter 
Petri dishes, corresponding to a density of approximately 80 000 cells/cm2, in order to provide 
sufficiently high cell number for NMR analysis. After waiting for 24 hours for cells to adhere, the 
assays were initiated (t = 0h) by adding a volume of stock solution of each drug to be tested at its 
IC50 concentration in the Petri dish containing 12 mL of MEM culture medium. All cells were used 
after 21-30 passages, if not referred otherwise. At each time point, cells were harvested by 
trypsinisation, washed with PBS pH 7.4 and centrifuged (6 minutes, 1000 rpm, 21˚C). Cells were 
then added the deuterated solutions for NMR analysis (section 3.2.1.1.) prior to storage at -80˚C 
until spectroscopic analysis. For each drug, three independent assays were carried out, with 
duplicates for each condition (time point and drug dosage). cDDP was obtained from Sigma-
Aldrich, DOX and MTX from Fisher Scientific and Pd2Spm was kindly provided by Molecular 
Physical-Chemistry (QFM) I&D Unit, Faculty of Science and Technology, University of Coimbra. The 
different single drug exposure studies performed with MG-63 cells are listed in Table 3.1. 
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Table 3.1: Solutions and time course conditions used in single drug assays in MG-63 cells. 
Drug Solvent Drug concentration Time points (h) Controls group 
cDDP (study 1) PBS 
30 µM 
0, 12, 18, 24, 48 PBS (120 µL) 
50 µM 
DOX Mili Q water 3 µM 0, 12, 24, 36, 48 Mili Q water (12 µL) 
MTX DMSO 3 µM 0, 12, 24, 36, 48 DMSO (12 µL) 
Pd2Spm
a DMSO (6%) in PBS 12 µM 0, 12, 24, 36, 48 PBS (120 µL) 
cDDP (study 2)a, 
b 
PBS 30 µM 0, 12, 24, 36, 48 PBS (120 µL) 
a Only two independent assays were considered for analysis. 
b Performed in parallel with Pd2Spm assays, as a drug exposure reference. 
HOb cells were used for NMR experiments upon exposure to cDDP and Pd2Spm. In these 
assays, 1x106 cells were seeded in 100 mm diameter Petri dishes (corresponding to a density of 
approximately 15 000 cells/cm2) and, after waiting 24 hours for cells to adhere, experiments were 
initiated (t = 0h) by adding the appropriate volumes of cDDP or Pd2Spm stock solutions that led to 
an IC50 concentrations as previously determined for MG-63 cells (Table 3.1). Due to the high costs 
of the cell culture medium and considering the time-consuming task of growing large numbers of 
HOb cells due to their long doubling time, experiments with these cells were confined to the time 
points 0 and 24 hours. After exposure to each drug, cells were harvested by trypsinisation, 
washed with HBSS and centrifuged at 1200 rpm, at 21˚C for 5 minutes. Cells were then prepared 
for NMR analysis (section 3.2.1.1.) and stored at -80˚C until spectroscopic acquisition. Two 
independent assays were carried out, with duplicates for each condition (time point and drug 
dosage). All cells were used in passages numbers from 4 to 10. 
Drug Combination Exposure 
Regarding assays of MG-63 cells exposure to drug combinations (drug cocktails), a similar 
protocol was followed, although dosages had to be adjusted in order to enable a sufficiently high 
percentage of living cells to be obtained for NMR analysis. In this line and according to the drug 
concentrations used in clinic (described in the EURAMOS protocol, http://212.219.75.232/ 
euramos /euramos_i_trial.asp), the IC50 concentration of DOX (3 µM) was used as a reference to 
determine the dosages of cDDP or Pd2Spm (4.8 µM) and MTX (480 µM) to use in these assays. 
Regarding the MTX concentration, preliminary tests revealed that a decrease of up to 100 times in 
concentration, resulted in a similar decrease in proliferation rates of MG-63 cells, thus 4.8 µM was 
selected to be used in these assays. As a matter of simplicity and due to cell culture limitations, 
the weeks scale in the EURAMOS protocol was converted into a days scale in cell experiments, 
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and a single dose of methotrexate was administered to cells. Solutions and time course conditions 
used are listed in Table 3.2. 
Table 3.2: Solutions and time course conditions used in drug combination assays in MG-63 cells. 
Drug/ 
Drug combination 
Solvent Drug concentration Time points (h) Controls group 
DOX 
+ 
cDDP 
Mili Q water 3 µM 
24, 48, 72, 96 PBS 
PBS 4.8 µM 
DOX 
+ 
Pd2Spm 
Mili Q water 3 µM 
24, 48, 72, 96 PBS 
PBS 4.8 µM 
MTX DMSO 4.8 µM 24* PBS 
* after 72h treatment with DOX+cDDP or DOX+Pd2Spm. 
MG-63 cells were seeded at 5x106 cells per dish and after waiting 24h for cells to adhere the 
experiment was initiated by adding cDDP+DOX or Pd2Spm+DOX. Then, at 24, 48 and 72 hours 
duplicates of each condition were collected and handled as previously described. At 72 hours, 
MTX was added to either cDDP+DOX or Pd2Spm+DOX exposed cells and after an additional 24 
hours period these samples were also collected, so that changes attributed just to MTX action 
(and not the whole cocktail) could be assessed. Figure 3.2 schematically presents the entire 
process of drug administration and sample collection.  
 
Figure 3.2. Schematic representation of assays of cells exposure to drug combinations. 
0h
•Addition of DOX/cDDP or DOX/Pd2Spm
24h
•Collection of 24h DOX/cDDP- and DOX/Pd2Spm-exposed samples and respective controls
48h
•Collection of 48h DOX/cDDP- and DOX/Pd2Spm-exposed samples and respective controls
72h
•Collection of 72h DOX/cDDP- and DOX/Pd2Spm-exposed samples and respective controls
•Addition of MTX
96h
•Collection of 96h DOX/cDDP- and DOX/Pd2Spm-exposed samples and respective controls
•Collection of DOX/cDDP/MTX- and DOX/Pd2Spm/MTX-exposed samples
Timeline Addition of drugs and sample collection
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Duplicates were obtained for each condition (mixed together whenever required to ensure 
a good signal-to-noise ratio) and 3 independent assays were performed. Similarly to single drug 
assays, cells were then lysed and stored at -80˚C until NMR analysis. 
 
3.1.3.2. Trypan Blue Assay 
The Trypan blue colorimetric assay (Strober, 2001) was used to assess the number of 
morphologically intact cells (cells with undamaged cell membranes), either for seeding purposes 
or to determine the extent of cell death at each established time point of drug exposure. For this 
purpose, after the washing steps, the cells were incubated with a solution of Trypan blue dye (0.4 
% (w/v) in PBS, Sigma-Aldrich) and then counted by observation under the optical microscope 
using a Neubauer-counting chamber (Boeco). As a result, the number of cells with intact 
membranes and, therefore, dye excluding was expressed in terms of mean ± standard deviation. 
 
3.1.3.3. MTT Assay 
The MTT assay (Mosmann, 1983) was used to estimate the IC50 concentration for cDDP, 
DOX and MTX. MG-63 cells were plated on 24-well plates at 100000 cells per well. Cells were 
enabled to adhere for 24 hours, treated with different concentrations of each drug (cDDP: 10, 30 
and 50 µM; DOX: 0.1, 1, 3 and 6 µM; MTX: 0.1, 0.5, 1, 3 and 5 µM) and incubated in a humidified 
atmosphere at 37˚C, 5% CO2. After 24 hours of drug exposure, cells were washed with 1 mL of 
PBS, 250 µL of MTT solution (0.5 mg/mL in PBS, Sigma-Aldrich) was added to each well and plates 
were incubated for 3 hours. The violet MTT formazan precipitate was then solubilised by adding 
500 µL of dimethylsulfoxide (DMSO, Sigma-Aldrich) to each well and absorbance was measured at 
570 nm on a microplate reader (Biotek µQuant MQX200 UV-Visible Spectrophotometer, Gen5 
software, Biotek). Experiments were performed in triplicate and each of 3 independent assays. 
Absorbance of control cells was taken as 100% and the values of treated cells were calculated as a 
percentage of the control. Accordingly, IC50 values of 30, 3 and 3 µM were determined for cDDP, 
DOX and MTX, respectively, at 24 hours of drug exposure. 
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3.1.3.4. Reversibility Assays 
Reversibility assays were performed with a view to understand if cDDP- and Pd2Spm-
induced effects are reverted after drug removal. Upon a 24 hours treatment with either cDDP or 
Pd2Spm in the same conditions as previously described for Single Drug Exposure (see section 
3.1.3.1), the culture medium from control and treated Petri dishes was removed, MG-63 cells 
were washed with PBS and 12 mL of fresh, drug-free medium was added. After a 3 days recovery 
period, MG-63 cells were collected and prepared for NMR analysis as described in section 3.2.1.1. 
 
Figure 3.3. Schematic representation of the reversibility assays. PBS: phosphate buffered saline. 
Reversibility assays were also performed with HOb cells, following the protocol described 
for MG-63 cells with HOb cell culture specificities (culture medium, saline solution, cell’s seeding 
density). 
 
3.1.4. Antiproliferative Activity Evaluation: SRB Assay 
The colorimetric SRB assay (Skehan et al., 1989) was used to determine the IC50 
concentration for Pd2Spm of MG-63 cells, to obtain the growth curves of the HOb cells and to 
evaluate the influence of drug combination treatment in these cells. 
For IC50 determination, MG-63 cells were seeded on 24-well plates at 100 000 cells per well. 
After adhering, cells were treated with increasing doses of Pd2Spm (1, 3, 5, 10, 15, 20 and 30 µM) 
and incubated in a humidified atmosphere at 37˚C, 5% CO2. After 12, 24, 36, 48 and 72 hours of 
drug exposure, cells were washed twice with PBS and once with miliQ water (to remove the salt). 
Drug-free 
medium
Adherent cells
PBS
cDDP and 
Pd2Spm
Controls
cDDP-treated
Pd2Spm-treated
Controls
cDDP Reversibility
Pd2Spm 
Reversibility
24 hours 3 days
Sa
m
pl
e 
co
lle
ct
io
n
Experimental Procedures 
 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
106 
 
After water removal in the incubator for 10 minutes, the cells were fixed overnight with 2 mL/well 
of 1% acetic acid in methanol, at -20˚C. The solvent excess was then discarded and the plate was 
left to dry at room temperature. The same repeated was performed for each plate (corresponding 
to a different exposure period), after which 1mL of SRB (Sigma-Aldrich) 0.5% in acetic acid (g/v) 
was added to each well and plate was incubated in the dark for 1 hour, at 37˚C. MG-63 cells were 
washed with 1% acetic acid solution to remove non-bonded SRB and dried overnight, at room 
temperature. The amount of SRB bounded to protein of cells was dissolved by adding 2 mL of a 10 
mM Tris solution at pH 10, and absorbance was read at 540 nm (Tris solution was used as blank). 
Cell density was expressed in %, according to Eq 3.1. 
                                                         |Eq. 3.1| 
Regarding the growth curves, after an initial replication of the HOb cells in Osteoblast 
Growth Medium, osteoblasts growth was also tested in another culture media also commonly 
used for establishing and growing osteoblast primary cells and/or other osteoblast-like cells. 
Actually, besides the Osteoblast Growth Medium recommend by the cell’s supplier, HOb cells can 
also be cultured in DME/F12 (1:1 mixture of Dulbecco’s Modified Eagle’s Medium – DMEM – and 
Ham’s F-12 Nutrient Mixture) (Piva et al., 2011) or McCoy’s medium (Ma et al., 2011) (with or 
without the addition of ascorbic acid, at 30 µg/mL). 10x103 HOb cells/well were seeded in 12-well 
plates, in triplicate. Due to the marked difference in growth rates in relation to other tested 
media, Osteoblast Growth Medium was chosen to culture HOb cells. For 12 consecutive days, at 
each 24 hours, one plate of cells was collected and prepared for the SRB assay, as described 
above for MG-63 cells (saline solution used for HOb cells washing steps was HBSS). As an example, 
the growth curve of HOb cells in Osteoblast Growth Medium is shown in Figure 3.4. 
  
Figure 3.4. Growth curve of HOb cell line, determined by SRB assay during 12 days. 
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In exponential growth, HOb cells were shown to have a doubling time of around 72 hours (3 
days), which is three times longer than that of MG-63 cells (around 24 hours). 
 
3.1.5. Apoptosis Detection Using FITC Annexin V/Propidium Iodide 
MG-63 cells were cultured in 6-wells plates and after appropriate growth conditions and 
exposure to IC50 concentrations of either cDDP or Pd2Spm, each well was washed with 2 mL of 
PBS. Cells were then detached by the addition of 500 µL trypsin/EDTA solution, after which 1 mL 
of MEM medium was added to inactivate trypsin.  Cells were harvested and counted by the 
Trypan blue assay. Cell suspensions were centrifuged at 2250 rpm, for 5 minutes at 4˚C, 
supernatant discarded and 1 mL of PBS added without pellet resuspension. After a second 
centrifugation, the supernatant was discarded and each pellet was resuspended in 1X Annexin 
Binding buffer to a suspension of 1x106 cells/mL. 100 µL of each cell suspension was transferred 
to a 5 mL tube to which 5 µL of FITC Annexin V and 5 µL of Propidium Iodide (PI) were added. 
After 15 minutes incubation in the dark, at room temperature, 400 µL of 1X Annexin Binding 
Buffer was added to each tube. The refered buffers and solutions were part of the FITC Annexin V 
apoptosis detection kit (BD Pharmingen). Samples were then analysed by flow cytometry within 1 
hour (maximum). At last 10000 events per sample were acquired and the percentage of cells in 
each quadrant was estimated according to Eq. 3.2. Three independent assays were performed in 
triplicate. 
                                                                                 |Eq. 3.2| 
 
3.2. Analysis by NMR Spectroscopy 
3.2.1. Cell Sample Preparation for NMR Analysis 
3.2.1.1. Preparation of Cells and Cell Extracts 
After cell growth and drug exposure procedures, cells were washed with PBS (or with HBSS, 
for HOb cells), suspended in 1mL PBS/D2O (0.14 M NaCl, 0.0027 M KCl, 0.0015 M KH2PO4, 0.0081 
M Na2HPO4 in deuterated water, pH 7.4), centrifuged (1000 rpm, 6 min, 21˚C) and resuspended in 
35 µL PBS/D2O, to which 5 µL PBS/D2O containing TSP 0.25% (for chemical shift referencing) were 
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added. Whenever needed, in order to have a good signal-to-noise relation in NMR data, 
duplicates of the same condition were mixed. This procedure was based on that described in 
(Duarte et al., 2009). D2O was acquired from Cortecnet Europe and D2O containing 0.75% TSP was 
obtained from Sigma-Aldrich. 
Cell Lysis 
To obtain a suspension of lysed cells (both MG-63 and HOb), a three-fold cycle of liquid 
nitrogen dipping and sonication was applied to the frozen samples prepared previously. Finally, 
and for the sake of safety, all samples from single drug exposure assays were transferred to a 
sealed NMR disposable insert (ca 35 µL) and stored at -80˚C (Duarte et al., 2009). Samples from 
other experimental sets were stored in eppendorfs and transferred at the moment of analysis to 
the HRMAS rotors. 
Trichloroacetic Acid (TCA) Extraction 
TCA extractions followed a previously reported procedure (Huang et al., 2003) and was 
applied to samples treated for 48 hours with sole drugs cDDP, DOX, MTX and Pd2Spm and drug 
combinations cDDP+DOX and Pd2Spm+DOX. The control samples collected at 48 hours from cDDP 
exposure and combination assays were also extracted. This was a meticulous procedure that 
involved the recovery of the samples already analysed by HRMAS (around 30 µL of pellet), which 
resulted in some sample loss and precluded the recovery of the entire set of replicates. Table 3.3 
lists the samples that were successfully recovered and extracted. 
Table 3.3: TCA samples for 1H NMR analysis. 
Sample (year) Time point Number of Replicates 
Control (2009) 
48 hours 
1 
30 µM cDDP (2009) 2 
3 µM DOX (2011) 3 
3 µM MTX (2011) 3 
12 µM Pd2Spm (2012) 2 
Control (2013) 3 
4.8 μM cDDP+3 μM DOX 3 
4.8 μM Pd2Spm+3 μM DOX 3 
 
In order to perform this extraction, 200 µL of TCA 6% (prepared from a commercial solution 
of TCA 20% (w/v), Fisher Scientific) in distilled water was added to the cell pellet (around 70-100 
µL), followed by vigorous shaking in a vortex for 20 seconds and placement in an ice bath for 10 
minutes. After this period a new 20 seconds vortex cycle was performed just before a 10 min 
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centrifugation at 13000 rpm, at room temperature. Proteins were precipitated and the acidic 
extract was transferred to an eppendorf, an equal volume of distilled water being added. The 
sample was vortexed again for 60 seconds. After this extraction procedure, samples were dried by 
evaporation under vacuum and were stored at -80˚C until NMR analysis. Dried TCA extracts were 
solved in 550 µL of sodium buffer prepared in 100% D2O, vortexed and 500 µL of each sample was 
transferred to a NMR tube at the moment of analysis. 
 
3.2.1.2. Study of the Influence of Several Factors on the Spectral Quality 
Cells Integrity: Intact vs Lysed Cells 
After applying the cell growth protocol described in section 3.1.2., different manipulation 
and storage procedures were employed, in order to evaluate their consequences on cell integrity 
and 1H HRMAS NMR spectra. This different handling and storage procedures to which MG-63 cells 
were submitted are schematically represented in Figure 3.5. 
 
 Figure 3.5. Schematic representation of the protocols followed for preparation of cell samples 
(adapted from Duarte et al., 2009). Dashed boxes indicate solution state NMR. 
Sample A is constituted of MG-63 cells that, upon washing with PBS and PBS/D2O, were 
analysed by HRMAS within 2 – 3 hours after harvesting (period during which they were kept 
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analysis 
A: Not frozen 
(freshly 
harvested) 
Asuspension: Pellet 
from sample A 
(after spinning) 
Asupernatant: 
Supernatant 
from sample A 
(after spinning) 
B: Gradually 
frozen with 
FBS/DMSO, 
stored at -80˚C 
C: Gradually 
frozen without 
FBS/DMSO, 
stored at -80˚C 
D: Not frozen 
and 
mechanically 
lysed 
E: Gradually 
frozen without 
FBS/DMSO, 
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at -80˚C 
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(after spinning) 
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refrigerated at 4˚C), without any freezing process.  Samples Asuspension and Asupernatant represent the 
cell pellet and sample supernatant from A, respectively, that were collected after spinning of the 
sample (HRMAS analysis) and were analysed by solution state 1H NMR. Sample B was obtained by 
suspending the cells in a cryoprotective solution (FBS with 10% DMSO), gradually freezing and 
storage at -80˚C for ca. 1 month (prior to NMR analysis the sample was washed with PBS to 
remove the cryoprotective agent). Sample C resulted from gradually freezing the cell pellets 
without adding the cryoprotective agent and storing at -80˚C for ca. 1 month (cells were thawing 
immediately prior to analysis). Sample D was obtained by mechanical lysis of freshly harvested 
cells (refrigerated for up to 3 hours) through sonication and dipping into liquid nitrogen. Sample E 
corresponded to cells gradually frozen and kept frozen at -80˚C for ca. 1 month, after which lysis 
protocol was performed. Samples Esuspension and Esupernatant represent the cell pellet and sample 
supernatant from E, respectively, that were collected after spinning of the sample (HRMAS 
analysis) and were analysed by solution state 1H NMR. 
Reproducibility Assays 
To evaluate the reproducibility of the cells culture and harvesting procedures, 5x106 MG-63 
cells were plated in 100 mm diameter Petri dishes. After waiting 24 hours for cells to adhere, the 
experiment was initiated (t = 0h). At 12, 18, 24 and 48 hours of growth, cells were collected in 
triplicate, washed with PBS, centrifuged (6 minutes, 1000 rpm, 21˚C), prepared for NMR analysis 
(as described in section 3.2.1.1.) and stored at -80˚C until HRMAS NMR acquisition. Three 
independent assays were performed, yielding a total of 9 samples per time point. 
Cell Passage Number 
In order to understand the influence of the number of cell passages on the metabolic 
profile of the MG-63 cells, these were continually cultured and divided. When reaching passages 
25, 35 and 45, 5x106 cells were seeded in 100 mm diameter Petri dishes and harvested 24 hours 
later. Cells were then prepared for NMR analysis (as described in section 3.2.1.1.) and stored at -
80˚C until data acquisition. Only one sample for each chosen passage number was collected, 
without any further replicates. 
The influence of the number of cell passages was also evaluated for MG-63 cells treated 
with IC50 concentrations of cDDP. Accordingly, MG-63 cells with increasing number of passages 
(#25, #35 and #45) were exposed to 30 µM of CDDP for 24 hours. Only one sample at each chosen 
passage number was collected (without any further replicates). 
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Sample Stability During Storage 
MG-63 cells at passage number 23 were grown in T-75 cm2 culture flasks. Once confluence 
was reached, cells from 10 flasks were harvested, mixed together, washed with PBS and divided 
into 12 equivalent pools, each of them containing around 8 million cells (determined by the 
Trypan blue assay). Each cellular pool was prepared for HRMAS NMR analysis and stored at -80˚C 
until acquisition. The 1st pool was analysed within the next 2 weeks and, whenever possible, a 
new sample was evaluated every 2 months, the last one being analysed upon 27 months of 
storage. Problems associated with shimming optimisation during NMR acquisition led to the 
exclusion of the sample at 20 months of storage. 
 
3.2.2. Glutathione/Drug Competition Assays 
Glutathione/drug competition assays were performed with the aim of understand 
complexation reactions between reduced glutathione (GSH) and metal ions of drugs used in 
biological assays, Pt(II) and Pd(II) present in cDDP and Pd2Spm respectively. With this purpose, 
fresh solutions of GSH (reduced glutathione) and of cDDP or Pd2Spm in PBS/D2O(100%) were 
prepared and mixed: GSH fresh solution was mixed with each of the 2 drug solutions and reaction 
kinetics was followed for 3 hours by 1D 1H NMR,  with one spectrum being registered every 15 
minutes. Solutions of GSSG (oxidized form of glutathione) and Pd2Spm were also prepared and 
analysed alone by NMR to aid signal assignment.  In Table 3.4 the solutions prepared and their 
purpose are listed. 
Table 3.4: Information on solutions prepared for GSH competition assays. 
Solution Concentration Solvent Purpose of study 
GSH (fresh) 1 mM 
PBS in 100% D2O 
Assignment 
GSSG (fresh) 1 mM Assignment 
GSH/cDDP 1 mM/0.5 mM Kinetics 
GSH/Pd2Spm 1 mM/0.5 mM Kinetics 
Pd2Spm 0.5 mM Assignment 
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3.2.3. NMR Data Acquisition and Processing 
3.2.3.1. NMR Equipment 
The facilities and NMR spectrometers on which NMR experiments were carried out are 
listed in Table 3.5. All samples (including those contained in rotor inserts) were kept frozen until a 
few minutes (ca. 10 minutes) prior to analysis, just long enough to ensure they were completely 
thawed when inserted into the probe. Due to time constraints in the NMR spectrometer of 
University of Aveiro, NMR analysis had to be performed outside, namely at CRMN (Lyon, France) 
and CERMAX (Oeiras, Portugal), the latter being accessed within the Portuguese NMR network. 
Table 3.5: Facilities and equipment used to perform the NMR experiments. 
NMR facility Spectrometer and equipment Assay (year) 
CRMN – Centre de RMN à 
Très Hauts Champs, 
CNRS/ENS Lyon, France 
• SB Bruker Avance II, 700 MHz 
• 4mm HRMAS probe 
• T = 277K 
cDDP (2009) 
CERMAX – Centro de 
Ressonância Magnética 
António Xavier – ITQB, 
Oeiras, Portugala 
• Bruker Avance II +, 500 MHz 
• 4mm HRMAS probe 
• Room temperature 
Reproducibility (2010) 
• Bruker Avance II +, 800 MHz 
• 4mm HRMAS probe 
• T = 277K 
DOX and MTX (2011) 
Pd2Spm and cDDP (2012) 
Departamento de 
Química, Universidade de 
Aveiro, Portugal 
• Bruker Avance DRX,  500 MHz 
• 4mm HRMAS probe 
• T = 277K 
Influence of cell integrity (2009) 
Influence of cell passage no. (2012) 
Stability during storage (2010-2012) 
Influence of acquisition parameters (2011) 
Drug combination assays (2013) 
• Bruker Avance DRX,  500 MHz 
• TXI probe 
• T = 277 and 310K 
GSH competition assays (2013) 
• Bruker Avance DRX,  500 MHz 
• 5mm BBI probe 
• TXI probe 
• T = 298K 
TCA extracts (2013) 
a Accessed within the Portuguese NMR network (PT NMR). 
 
3.2.3.2. Spectral Acquisition (1D and 2D 1H Experiments) 
1H HRMAS NMR experiments employed, as a starting point, the cell analysis acquisition 
parameters obtained from literature (Santini et al., 2004). These were then optimized for the 
samples to be studied, in order to obtain a good signal-to-noise ratio with short acquisition times 
(typically around 30 min). A total of 128 scans were acquired for each standard 1D 1H NMR 
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experiment (noesypr1d, Bruker library) with suppression of the water signal by presaturation 
(power level for presaturation, PL9, 55 dB) during the relaxation delay (D1, 4 s) and mixing time 
(D8, 100 ms). Experiments were acquired with a spectral window (SW) of 6510.42 Hz and 32 k 
data points (TD). Receiver gain (RG) was set to 256. The rotor containing the sample was spun at 
the magic angle (54.7˚ relative to the magnetic field) at a 4 kHz spinning rate. A Bruker cooling 
unit was used to cool down the bearing air flowing into the probe, in order to enable acquisitions 
to be performed at the temperature of 277 K. 
T2-edited (Carr-Purcell-Meiboom-Gill, CPMG, cpmgpr1d, Bruker library) and diffusion-edited 
(ledbpgp2s1dpr from Bruker library) experiments were also recorded. Details on the 1D pulse 
programs from Bruker pulse program library can be found in Chapter 2 (for the 1H nucleus) and 
acquisition parameters are listed in Table 3.6. 
Table 3.6: Acquisition parameters used for 1D 1H HRMAS NMR spectra of lysed cells suspension. 
Acquisition parameters – 500 MHz (Aveiro) 
Standard 
(noesypr1d) 
CPMG 
(cpmgpr1d) 
Diffusion-edited 
(ledbpgp2s1dpr) 
NS: 256 
D1: 4s 
D8: 100ms 
SW: 6510.42Hz 
TD: 32k points 
RG: 256 
PL9: 55dB 
 
NS: 256 
D1: 4s 
τ: 300 µs 
n: 150 
SW: 6510.42Hz 
TD: 32k points 
RG: 1024 
PL9: 55dB 
NS: 256 
D1: 4s 
δ: 2ms 
U: 100ms 
SW: 6510.42Hz 
TD: 32k points 
RG: 256 
PL9: 55dB 
Acquisition parameters – 500 
MHz (CERMAX) 
Acquisition parameters – 700 
MHz (Lyon) 
Acquisition parameters – 800 
MHz (CERMAX, MG/HOb)  
Standard 
(noesypr1d) 
Standard 
(noesypr1d) 
Standard 
(noesypr1d) 
NS: 256 
D1: 4s 
D8: 100ms 
SW: 6510.42Hz 
TD: 32k points 
RG: 128 
PL9: 60dB 
NS: 256 
D1: 2s 
D8: 100ms 
SW: 9803.922Hz 
TD: 32k points 
RG: 512 
PL9: 50dB 
NS: 256/512 
D1: 4s/2s 
D8: 100ms 
SW: 9803.922Hz 
TD: 32k points 
RG: 256/256 
PL9: 50dB 
NS: number of scans, D1: relaxation delay, D8: mixing time, SW: size of spectral window, TD: number of 
data points, RG: receiver gain, PL9: power level for presaturation, τ: echo time, n: number of (τ-180˚-τ) 
loops, 2nτ: total spin-spin relaxation time, U: diffusion time,  δ: gradient duration. 
The NMR spectra of TCA extracts were acquired at 298 K, using either a BBI or a TXI probe. 
A total of 512 scans were acquired for each standard 1D 1H NMR experiment (noesypr1d from 
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Bruker library) with water signal suppression by presaturation (power level for presaturation, PL9, 
52 or 45 dB) during the relaxation delay (D1, 4 s) and mixing time (D8, 100 ms). Experiments were 
acquired with a size of the spectral window (SW) of 6510.42 Hz and 32 k data points (TD). 
Receiver gain (RG) was set to 256 or 203. 
 
2D total correlation spectroscopy (TOCSY) and heteronuclear single quantum coherence 
(HSQC) spectra were registered for selected samples to aid spectral assignment. Bruker Avance 
spectrometers operating at 500 and 800 MHz for 1H observation were used to record the 2D 
spectra. The acquisition parameters were based on previous studies on cells (Santini et al., 2004) 
and submitted to further optimization to these particular type of samples. Typically, TOCSY 
spectra were acquired in phase-sensitive mode using States-TPPI (time proportional phase 
incrementation) detection using the MLEV-17 pulse sequence (mlevgsst19 and dipsi2pphpr pulse 
programs from Bruker library) and 1H-13C phase-sensitive (echo/antiecho) HSQC was recorded 
with inverse detection and carbon decoupling during acquisition (hsqcetgppr and invietgpsi pulse 
programs from Bruker library). Both 2D experiments were recorded with a minimum of 56 scans 
and a relaxation delay time (D1) of 2 s was used. For both TOCSY and HSQC spectra, 2 or 4 k data 
points were used in the F1 dimension and a minimum of 220 points in the F2 dimension. 
 
3.2.3.3. Spectral Processing and Assignment 
All spectra were processed using the Bruker TopSpin 3.2 software (from Bruker BioSpin, 
Reinstetten, Germany). Standard 1D spectra were Fourier transformed (FT), processed with a line 
broadening (LB) of 0.3 Hz (or 0.5 Hz for diffusion-edited experiments) and a zero filling factor of 2 
(to 64k points), manually phased and baseline corrected. Chemical shifts were referenced 
internally to the alanine signal at δ 1.48. 3-(trimethylsilyl)propionate sodium salt (TSP) was not 
used as chemical shift reference once it was found to suffer interactions with sample constituents 
(proteins for instance) resulting in a line-broadening of its signal. Nevertheless, and once it was 
added in a known concentration which allowed well resolved signal to be obtained with only few 
scans (TSP at 0.025% in the sample), TSP was particularly useful for shimming optimization 
purposes. 2D spectra were Fourier transformed (FT), processed with a line broadening (LB) of 0.3 
Hz, manually phased and baseline corrected. Chemical shifts were also referenced to the alanine 
signal. 
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In order to aid peak assignment, CPMG and diffusion-edited 1H NMR spectra were acquired 
as well as 2D experiments (TOCSY and HSQC). Spectral assignments were also aided by the use of 
several NMR spectra of known standards obtained through Metabolic Profiling Database, 
Biorefcode (courtesy of NMR Applications, NMR division, Bruker BioSpin, Rheinsteten, Germany), 
the Human Metabolome Database (HMDB, Wishart et al., 2013) and the Biological Magnetic 
Resonance Data Bank (BMRB, Ulrich et al., 2008). Statistical total correlation spectroscopy 
(STOCSY) analysis was used for assignment purposes as well (properly indicated in assignment 
tables), with the objective of unveiling whole spin systems. 
 
3.2.3.4. Proton Relaxation Times Measurement 
The 1H relaxation times constants T1 and T2 were measured for lysed MG-63 cell samples 
under HRMAS conditions. 
For measuring 1H T1 values a standard inversion-recovery pulse sequence was used, while 
for the determination of 1H T2, the CPMG pulse sequence was used. Table 3.7 lists the main 
acquisition and processing parameters used in these experiments. 
Table 3.7: Acquisition and processing parameters used for T1 and T2 measurements in lysed MG-63 cells. 
T1 measurement 
( t1irpr ) 
T2 measurement 
 ( t2zgpr ) 
NS: 40 
D1: 10s 
TD[F1]: 26 points 
TD[F2]: 16384 points 
SW[F1]: 1.9995 ppm 
SW[F2]: 13.0174 ppm 
Range of delays: 0.01-20.00 
NS: 40 
D1: 10s 
TD[F1]: 30 points 
TD[F2]:  16384 points 
SW[F1]: 1.9995 ppm 
SW[F2]: 13.0174 ppm 
Range of loops: 5-8000 
Processing parameters 
SI [F1]: 16384 points 
SI [F2]: 26 points 
LB: 0.3 Hz 
SI [F1]: 16384 points 
SI [F2]: 30 points 
LB: 0.3 Hz 
NS: number of scans, D1: relaxation delay, SW: size of spectral window, TD: number of data points. 
The determination of 1H T1 and T2 values was performed with T1/T2 calculation routine of 
Topspin 3.1, through the construction of exponential graphics, in which each point corresponds to 
one 1D spectrum, resulting in curves with rates 1/T1 and -1/T2, described by Equations 3.3 and 
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3.4, respectively, where y is the integral area of the peak, t is the delay (Eq. 3.3) or total echo time 
(Eq. 3.4) used, A is a constant representing the amplitude of the decay. 
                
 
  
 
    |Eq. 3.3| 
           
 
        |Eq. 3.4| 
 
3.3. Multivariate and Statistical Analysis of the NMR Data 
3.3.1. Data Pre-Processing 
1D spectra were aligned using a recursive segment-wise peak alignment (RSPA) algorithm 
(Veselkov et al., 2009) and normalized to probabilistic peak alignment (PQN, Diertle et al., 2006) 
to account for dilution-independent effects on spectral area (MATLAB version 7.12.0, The 
MathWorks Inc.). Data were then scaled and, although mean centering and Pareto scaling were 
sometimes used to detect temporal trajectories of samples with treatment, unit variance (UV) 
was the most used scaling method to extract information on metabolic changes with drug-
exposure. 
 
3.3.2. PCA, PLS-DA and STOCSY 
PCA, PLS-DA and OPLS-DA were applied to the data in which samples were classified as 
Control or Drug-treated, using SIMCA –P 11.5 (Umetrics, Sweden) employing a default seven-fold 
internal cross validation, from which Q2 (predictive ability) and R2 (explained variance) were 
extracted. Relevant drug-induced metabolic changes were assigned from the weight loadings 
plots obtained from PLS-DA models. The loadings plots of UV-scaled models were coloured 
according to the Variable Importance in the Projection (VIP) parameters list automatically 
calculated by SIMCA-P program for the respective PLS-DA model. All presented MVA models were 
validated through MCCV (Wiklund et al., 2007; Westerhuis et al., 2008), using an in-house 
software developed by Professor António Barros. STOSCY analysis was performed to aid 
assignment (properly indicated in assignment tables) and to unveil metabolic correlations 
between metabolites (conveniently indicated throughout the text whenever used). Since reduced 
numbers of replicates per sample were available, metabolic correlations were investigated 
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considering data from both Control and Drug-treated groups. In fact, STOCSY analysis performed 
only with the data of one group of samples (either control or drug-treated) frequently resulted in 
strong correlations with noise regions and, on the other hand, when considering data from the 
two groups this issue was eliminated. The inclusion of the data of controls does not alter either 
the recovery of information from drug-induced metabolic correlations or the comparison 
between different drugs, since the information of Controls is very similar regardless of the drug 
tested and, thus, only drug-induced correlations are obtained. 
The magnitude of variation of NMR peaks pointed by MVA as possibly relevant for group 
separation was evaluated by performing signal integration, using the Amix-Viewer software 
(Bruker, version 3.9.11). Signal deconvolution was also used for choline region, particularly for 
GPC and PC peaks, which frequently presented a considerable degree of superimposition. 
 
3.3.3. Statistical Analysis 
For each metabolite, the statistical significance of the difference between the means of the 
two groups (control and drug-treated) were assessed using the two sample t-test. A p-value < 
0.05, with a confidence level of 95%, was considered statistically significant. Integration results 
were used to construct time course graphs. Integration values were also used to determine 
percentages (%) of variation of compounds in drug-treated samples relative to controls and Effect 
Size (ES) was also calculated with a correction factor for reduced number of samples, according to 
Eq. 3.5 to 3.9 (Berben et al., 2012), where smd is the standardized mean difference, spooled the 
pooled standard deviation, df the degrees of freedom, SE the standard error, J the correction 
factor for reduced number of samples, Mean the mean of integrals, n the number of samples and 
SD the standard deviation. By measuring fold change relative to controls, ES values were 
performed in complement to % of variation to corroborate (or not) previous t-test statistical 
validation (due to the fragility of performing such statistical validation with just 3 samples per 
group). ES calculations were used to build heatmaps with MATLAB program (version 7.12.0, The 
MathWorks Inc.) which enabled the comparison of changes (in relation to control group) along 
exposure periods and/or among different drugs, helping to unveil common and/or opposite 
changes through a colourmap, where positive changes appear yellow-red coloured and negative 
ones are green-blue coloured. 
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 ESgsmd=JxESsmd     |Eq. 3.5| 
 J=1-(3/(4df-1))     |Eq. 3.6| 
     ESsmd=(MeanCTR-MeanDrug)/spooled   |Eq. 3.7| 
 spooled=√[((nCTR-1)SD
2
CTR+(nDrug-1)SD
2
Drug)/df]   |Eq. 3.8| 
 df=nCTR+nDrug-2, SEgsmd=√[J
2x((nCTR+nDrug)/(nCTRxnDrug)+(ES
2
smd/2(nCTR+nDrug)))]  |Eq. 3.9| 
 
A global scheme of the entire process of multivariate and statistical analysis of the NMR 
data is presented in Figure 3.6. 
 
Figure 3.6. Schematic representation of pre-processing and analysis of the 1H HRMAS NMR data. 
RSPA: recursive segment-wise peak alignment, PQN: probabilistic quotient normalisation, UV: unit variance, 
CV: cross-validation, MCCV: Monte Carlo cross/validation. 
The peak assignment step, which appears at the final stages of the process of multivariate 
and statistical analysis of the NMR data (indicated in Figure 3.6) was actually performed 
throughout the entire process of data analysis, since the first analysis of the data is obtained by 
visual inspection of the spectra and frequently, metabolite variations are newly revealed by 
multivariate analysis raising the need for additional assignment work. 
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4. Spectral Assignment and Assessment of Analytical 
and Biological Reproducibility of the Metabolic 
Profile of MG-63 Cells: a HRMAS NMR Study 
The establishment of Standard Operating Procedures (SOPs) is of crucial importance to 
produce cell samples that can be replicated in subsequent assays with satisfactory reproducibility, 
thus enabling robust metabolomics conclusions to be drawn. SOPs are particularly important in 
cell HRMAS NMR studies, in comparison to liquid state NMR, due to the relative complexity of cell 
samples handling and NMR acquisition procedures. The present chapter begins by comparing the 
spectral profiles of intact and lysed cells, prepared by different protocols, in order to define the 
best sample presentation for more informative spectra to be obtained. This is followed by 
detailed peak assignment of the 1H HRMAS NMR spectral profile of MG-63 cells. Next, the 
influence of certain acquisition conditions (spinning rate, sample temperature, acquisition time) 
and sample relaxation properties on spectral profile is described. Finally, a reproducibility check is 
performed and the influence of storage conditions evaluated, in order to assess the conditions for 
best sample quality and spectral reproducibility. 
 
4.1. Spectral Profile of Intact and Lysed MG-63 Cells 
Given the value of HRMAS in aiding a global picture of the metabolome of a whole sample 
to be obtained (enabling both hydrophilic and hydrophobic compounds to be detected in one 
single experiment) it is important to understand in which state, intact or lysed, would cell samples 
provide the best quality HRMAS spectra. The results hereby presented are part of our own work 
published in Duarte et al., 2009. 
Determination of the number of cells by the Trypan blue assay indicated that protective 
freezing in FBS/DMSO is as efficient in preserving cell integrity as using freshly harvested cells, 
kept briefly under refrigeration until analysis. For procedures A and B most cells remained intact, 
samples obtained through protective freezing presenting the advantage of easiness of storage 
over longer periods. Samples C, D, and E give information, respectively, on unintentional cell lysis 
by unprotected freezing and storage at -80 °C, the extent of mechanical lysis using a snap-
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freezing/sonication procedure, and the cumulative effects of freezing, storage at -80 °C and 
mechanical lysis. All of these procedures (C, D and E) produced cells which showed total staining 
with Trypan blue, indicating total membrane disruption, thus meaning that freezing process is, by 
itself, enough to promote cell lysis. According to these results, cells cannot be considered intact 
when analysed after being frozen without a cryoprotective solution. 
Figure 4.1 shows the 1H HRMAS NMR spectra of MG-63 cells submitted to different 
handling conditions. Spectral analysis reveals that although all spectral profiles are dominated by 
broad lipid resonances, the spectra corresponding to fully lysed cells, samples D and E (Figure 4.1d 
and 4.1e), show many additional sharp signals arising from metabolites released from the 
intracellular shell. The spectral profiles of samples A and B (Figure 4.1a and 4.1b), which comprise 
mainly intact cells, are generally similar, revealing a dominance of lipids content (probably 
comprising contributions from both membrane/or intracellular lipids), and a lesser number of 
sharp peaks arising from small cellular metabolites, namely some amino acids. However, the 
intensities of N(CH3)3
+ resonances of choline-containing compounds change between samples A 
and B (Figure 4.1a and 4.1b) with a considerable lower level of PC+GPC (Figure 4.2) in the sample 
prepared according to protocol B (gradually frozen with cryoprotectant). PC and GPC are 
membrane breakdown products and their higher contents in samples A (freshly harvested cells 
suggest higher membrane degradation, compared to sample B. In sample A, this may arise 
because of the activity of degrading enzymes during the 2-3 hours refrigeration period between 
harvesting and NMR analysis. Interestingly, choline content is similar for samples A and B. In 
addition, PTC integrals remain high for samples A and B, reflecting the maintenance of cell 
integrity for the majority of cells (since PTC integrals were measured in diffusion-edited spectra, 
not acquired for every sample, PTC integral for sample B is missing). These results show that, 
despite equivalent results given by the Trypan blue assay of these samples (ca. 70-80%), the NMR 
lipid profiles indicate that cell membranes are less degraded in the case of samples cryoprotected 
with FBS/DMSO after harvesting (sample B), compared to fresh samples (sample A). 
The study of samples C (gradually frozen without cryoprotectant) gives insight on the effect 
of cell freezing without the use of a cryoprotective agent. The results given by the Trypan blue 
exclusion assay have shown that cells are cleaved in the process, similarly to samples D and E for 
which a cell lysis method was intentionally applied. MG-63 cells show a marked increase in 
choline (Figure 4.2) as a consequence of cell lysis.  
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 Figure 4.1. 500 MHz 1H HRMAS NMR spectra of MG-63 cells submitted to different conditions: a) 
sample A, b) sample B, c) sample C, d) sample D and e) sample E. Main assignments are noted.  
Moreover, the PC+GPC increase (Figure 4.2) in lysed cells is only noted relative to samples B 
(suggested to be the less degraded of all), with similar values to those found for sample A. The 
decrease in PTC is also confirmed. Thus, it seems plausible to suggest that choline and/or PC+GPC 
to PTC ratios may be used as general indicators of the extension of cell physical breakage. Taking 
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choline as the final end-product of cell choline-containing lipids, comparison between samples 
suggests, therefore, that unprotected freezing (sample C) may have a more disruptive effect than 
intentional mechanical lysis (sample D), with the cumulative effects (sample E) giving the highest 
cell breakage extension. As noted above, in fresh cells (sample A), where cell breakage occurs to a 
much lesser extent, and possibly in parallel with membrane enzymatic degradation, GPC and PC 
contents seem to be better degradation indicators. 
 
 Figure 4.2. Integral values obtained for selected choline-containing compounds (Cho δ 3.20, PC δ 
3.22, GPC δ 3.23 and PTC δ 3.26) relative to total spectral area in the standard 1D spectra of MG-63 cells 
(adapted from Duarte et al., 2009). Since PTC integrals were measured in diffusion-edited spectra, which 
were not acquired for every sample, PTC integral is missing for sample B. 
In an attempt to compare HRMAS and solution-state NMR, which is still generally more 
readily available than the former, the information provided by both methods on the metabolic 
profile of intact cells was compared. The spectra of sample A of MG-63 cells by 1H HRMAS and by 
solution-state 1H NMR of both the cell suspension (Asuspension) and the supernatant removed after 
deposition of the cells (Asupernatant) were obtained (not shown). Spectral analysis shows that, as 
expected, the lipid profile is improved by the HRMAS technique, compared to the cell suspension 
spectrum. The lower signal-to-noise ratio of the latter spectrum is due to the enhanced dilution of 
the sample, being expected to degrade overtime because of cell deposition in the tube. 
Interestingly, the spectrum obtained for the supernatant of sample A (fresh cells) is very similar to 
that of the corresponding suspension, indicating that metabolites leaked from the small 
percentage of broken cells, thus showing that significant metabolite loss may occur when 
supposedly intact cells pellets are washed and their metabolome analysed. 
A
re
a 
(a
.u
.)
A B C D E
Protocol of sample preparation
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As shown above, whenever cell metabolome characterization is intended at a fixed point in 
time, the use of fully lysed cells is recommended since enhanced metabolic information is 
obtained (with particular improvements in lipids and choline compounds). Moreover, the use of 
different NMR methods has shown that the corresponding spectra of fully lysed cells (samples E, 
Esuspension and Esupernatant) are significantly similar, both in terms of resolution and of the metabolic 
profiles detected, the main difference being that, as expected, lipid signals are enhanced in the 
HRMAS spectrum (E) and hardly detected in the supernatant measured by solution-state NMR 
(Esupernatant). A lipid profile is also observed for the cellular suspension (Esuspension), but the gradual 
deposition with time renders this option inadequate for lipid characterization. 
These results show that, when dealing with fully lysed samples, particularly in metabolomic 
studies, great care must be paid to the profile of small metabolites and choline compounds since 
they are highly sensitive to the sample handling conditions (namely the extent of cell lysis), in 
order to ensure suitable reproducibility of samples and spectra. 
 
4.2. Spectral Assignment of 1H HRMAS NMR Spectrum of Lysed MG-63 Cells 
The typical 1H HRMAS NMR spectrum of lysed MG-63 cells contains several tens of signals 
arising from numerous metabolites. As shown in Figure 4.3a and listed in Table 4.1, several 
metabolites have been identified by 1D and 2D NMR, with the assistance of several databases, 
namely the Human Metabolome Database (HMDB) (Wishart et al., 2013), Biological Magnetic 
Resonance Data Bank (BMRB) (http://www.bmrb.wisc.edu/) and Bruker Biorefcode 2.0.0 
(courtesy of Bruker BioSpin Rheinsteten, Germany) as well as comparison with previous reports 
(Santini et al., 2004; Santini et al., 2006a; Santini et al., 2006b; Santini et al., 2006c; Duarte et al., 
2010). Metabolites identified comprised organic acids (formate and lactate), polyalcohols (m- and 
s-inositols), several amino acids (Ala, Arg, Asp/Asn, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, 
Tau, Thr, Tyr, Val), choline and choline-containing compounds (GPC and PC) and 
phosphoethanolamine (PE), nucleotides and derivatives (Ino/Ado, uridine, UXP, cytidine and 
several other compounds (N-acetyl moieties, creatine, reduced glutathione (GSH) and 
hypoxanthine). As shown in Figure 4.3b and 4.3c in CPMG and diffusion-edited experiments 
(explained in section 2.2.2), respectively, sharp and broad peaks are selected, the latter arising 
from slowly diffusing molecules like proteins and fatty acyl lipid moieties (lipid fatty acyl moieties, 
L f.a. CH3, (CH2)n, CH2CH2CO, CH2COO, =CHCH2CH= and CH=CH). Since both sharp and main broad 
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resonances could be successfully assigned in the standard 1D spectrum (Figure 4.3a), only 
standard 1D noesy experiments were routinely acquired subsequently. 
 
 Figure 4.3. Typical 500 MHz 1D 1H HRMAS NMR spectra of MG-63 cells: a) standard 1D, b) CPMG 
and c) diffusion-edited experiments Insets show expansions of choline compounds (3.2-3.3 ppm) and 
aromatic (5.2-8.5 ppm) regions. Main assignments are noted. 
To aid peak assignment, TOCSY and HSQC experiments were acquired and expansions of the 
respective spectra are shown in Figure 4.4 TOCSY (Figure 4.4a) experiments are crucial to assign 
complete spin systems, particularly low intensity signals, not rarely overlapped with other 
resonances. On the other hand, the assignment of singlet resonances (without scalar correlations 
that can be assigned through TOCSY experiments) is assisted by HSQC spectra (Figure 4.4b). 
a) Standard 1D (noesy)
b) CPMG
c) Diffusion-edited
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 Figure 4.4. Expansions of 0.5-4.5 ppm region of the 500 MHz 2D HRMAS NMR spectra of MG-63 
cells: a) TOCSY and b) HSQC experiments. 1: Ala, 2: Ala (bonded), 3: Arg, 4: Asn/Asp, 5: choline, 6: creatine, 
7: cytidine, 8: L f.a., 9: formate, 10: fumarate, 11: glucose, 12: GSH, 13: Glu, 14: Gln, 15: glycerol, 16: GPC, 
17: Gly, 18: His, 19: hypoxanthine, 20: Ino/Ado, 21: Ile, 22: lactate, 23: Leu, 24: Lys, 25: Met, 26: m-Inositol, 
27: niacinamide, 28: Phe, 29: PTC, 30: PC, 31: PE, 32: Pro, 33: Ser, 34: Tau, 35: Thr, 36: Thr (bonded), 37: Tyr, 
38: uracil, 39: uridine, 40: Val. 
In addition, STOCSY analysis enabled the identification of full spin systems, within the 
resonances not readily assigned by 1D and 2D NMR. The STOCSY recorded in Figure 4.5 showed, 
for instance, that the triplet at δ 2.30 is strongly and positively correlated with peaks at δ 1.91 
(multiplet) and at δ 3.00 (triplet) (r > 0.8), thus enabling the assignment of the complete spin 
system of GABA. Besides being useful for assignment purposes, STOCSY analysis can also be used 
to identify metabolic relationships between metabolites and thus, when used for assignment, 
STOCSY results must be carefully analysed by comparison with existing information from 
literature and databases. All the metabolites assigned through STOCSY are identified in Table 4.1. 
 
Overall, 47 metabolites were identified in the 1H HRMAS NMR spectra of lysed MG-63 cells, 
most of which having been previously identified in these cells (Santini et al., 2004; Santini et al., 
2006a; Santini et al., 2006b; Santini et al., 2006c; Duarte et al., 2009; Duarte et al., 2010). The 
UDP-GNAc derivatives (UDP-GlcNAc and UDP-GalNAc) are here newly assigned. 
a) b)
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 Figure 4.5. STOCSY for the assignment of γ-aminobutyric acid (GABA). 
 
Table 4.1: List of metabolite assignments in 1H/13C HRMAS NMR spectra of lysed MG-63 cells. 
Legend: s singlet, d doublet, t triplet, q quartet, dd double of doublets, m multiplet. 
Compound Assignment δ 1H ppm (multiplicity )/ δ 13C ppm 
Acetate βCH3 1.92 (s) 
Alanine βCH3 
αCH 
1.48 (d)/ 18.76 
3.78 (q)/ 53.18 
Arginine γCH2 
βCH2 
δCH2 
αCH 
1.69 (m) 
1.92 (m) 
3.25 (t) 
3.77 (t) 
Aspartate βCH3 
β’CH3 
αCH 
2.69 (dd)/ 39.12 
2.83 (dd)/ 39.12 
3.89 (dd)/ 54.51 
Cholesterol C18 0.72 
Choline N(CH3)3 
CH2(NH) 
CH2(OH) 
3.21 (s)/ 56.42 
3.54 
4.08 
Creatine CH3 
CH2 
3.03 (s)/ 41.75 
3.94 (s)/ 59.20 
Cytidine  5.91 
6.06 (d) 
7.83 (d) 
Ethanol βCH3 
αCH2 
1.19 (t)/ 17.10 
3.65 (q)/ 57.03 
Ethanolamine CH2(NH2) 
CH2(OH) 
3.13 (t) 
3.82 (t) 
 
αCH2
βCH2
γCH2
δ2.30, t
α CH2δ3.00, t
γCH2
δ1.91, m
βCH2
correlationco
va
ria
nc
e
chemicalshift (ppm)
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Table 4.1 (cont.): List of metabolite assignments in 1H/13C HRMAS NMR spectra of lysed MG-63 cells. 
Legend: s singlet, d doublet, t triplet, q quartet, dd double of doublets, m multiplet. 
Compound Assignment δ 1H ppm (multiplicity )/ δ 13C ppm 
Fatty acyl (F.A.) chain peaks CH3 
(CH2)n 
CH2CH2CO 
CH=CHCH2 
CH2CO 
=CHCH2CH= 
CH=CH 
0.88-0.95/17.07 
1.31/25.32,32.48,34.91 
1.59/27.63 
2.04/26.91 
2.26/36.10 
2.83/41.17 
5.33/132.17 
Formate CH 8.46 (s)/ 172.68 
γ-Aminobutyric acida βCH2 
αCH2 
γCH2 
1.91 (m) 
2.30 (t) 
3.00 (t) 
Glutamate ββ’CH3 
γCH2 
αCH 
2.09/29.64 
2.35/35.95 
3.78 (dd)/ 53.20 
Glutamine βCH2 
γCH2 
αCH 
2.13/29.58 
2.45/33.70 
3.76/57.04 
Glutathione (reduced)a βCH2 Glu 
γCH Glu 
αCH2 Cys 
αCH Glu 
γCH2 Cys 
2.17/29.34 
2.56/36.02 
2.96/26.76 
3.77/46.52,57.08 
4.17/57.51 
Glycerol C1H2 
C3H2 
C2H 
3.57/65.11 
3.64/65.11 
3.78/72.52 
Glycerol (in lipids) C1H2 
C3H2 
C2H 
4.09 
4.30 
5.23 
Glycerophospho 
choline (GPC) 
N(CH3)3 
γCH2 
βCH/β’CH2(N) 
αCH2 
 
αCH2(P) 
3.24 (s)/ 56.54 
3.65/65.02 
3.87/69.16 
3.91/73.08 
3.94/69.10 
4.33/64.49 
Glycine αCH2 3.56 (s)/ 43.84 
Histidine C4H, ring 7.27 (s) 
Hypoxanthine C2H 
C8H 
8.19 (s)/ 147.76 
8.21 (s)/ 144.37 
Inosine / Adenosine C4’H, ribose 
C3’H, ribose 
C2’H, ribose 
C1’H, ribose 
C2H, ring 
C8H, ring 
4.29/88.28 
4.44/72.95 
4.78 (t)/ 76.69 
6.11 (d)/ 90.92 
8.23 (s)/ 148.59 
8.36 (s)/ 142.98 
Isoleucine δCH3 
β’CH3 
βCH 
αCH 
0.94 (t)/ 17.06 
1.01 (d)/ 20.17 
1.99 
3.65 
Lactate βCH3 
αCH 
1.33 (d)/ 22.73 
4.13 (q)/ 70.92 
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Table 4.1 (cont.): List of metabolite assignments in 1H/13C HRMAS NMR spectra of lysed MG-63 cells. 
Legend: s singlet, d doublet, t triplet, q quartet, dd double of doublets, m multiplet. 
Compound Assignment δ 1H ppm (multiplicity )/ δ 13C ppm 
Leucine δCH3 
δ’CH3 
γCH/βCH2 
αCH 
0.95 (d)/ 25.31 
0.97 (d)/ 23.64 
1.72/26.88 
3.76 (t)/ 57.06 
Lysine γCH2 
δCH2 
βCH2 
εCH2 
αCH 
1.47/25.39 
1.73/28.88 
1.92/32.41 
3.02 (t)/ 41.69 
3.76 (t)/ 57.07 
Methionine εCH3/ βCH2 
γCH2 
αCH 
2.13 (s)/ 16.89 
2.64 (t)/ 29.17 
3.87 (t)/ 54.40 
myo-Inositol C5H 
C1H, C3H 
C4H, C6H 
C2H 
3.27 (t)/ 74.63 
3.54 (dd)/ 74.03 
3.62 (t)/ 74.73 
4.05 (t)/ 74.52 
Niacinamide N5, ring 
N6, ring 
N2, ring 
7.59 
8.71 
8.94 
Phenylalanine βCH 
β’CH 
αCH 
C2H, C6H, ring 
C4H, ring 
C3H, C5H, ring 
3.15 
3.29 
3.99 (dd)/ 58.83 
7.32/131.83 
7.37/129.63 
7.42/131.78 
Phosphatidyl cholines (PTC) N(CH3)3 3.27 (s)/ 56.62 
Phosphocholine (PC) N(CH3)3 
N-CH2 
PO3-CH2 
3.23 (s)/ 56.53 
3.61 (s)/ 65.03 
4.19/62.22 
Phosphoethanol amine (PE) N-CH2 
PO3-CH2 
3.25/42.55 
3.97/62.81 
Proline γCH2 
βCH 
β’CH 
δCH 
δ’CH 
αCH 
2.01/26.89 
2.07/27.07 
2.35/31.98 
3.33 (t)/ 48.54 
3.41 (t)/ 48.54 
4.12 (t)/ 64.48 
Scyllo-Inositol CH 3.34 (s)/ 76.64 
Serine αCH 
ββ’CH 
3.84/59.13 
3.97 (dd)/ 62.78 
Succinate α, βCH2 2.41 (s) 
Taurine S-CH2 
N-CH2 
3.25 (t)/ 38.37 
3.42 (t)/ 48.68 
Threonine γCH3 
αCH 
βCH 
1.32 (d)/ 22.73 
3.58 (d)/ 65.12 
4.26/71.71 
Tyrosine ββ’CH 
αCH 
C3H, C5H, ring 
C2H, C6H, ring 
3.05/3.18 
3.95/59.20 
6.89 (d)/ 118.39 
7.19 (d)/ 133.39 
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Table 4.1 (cont.): List of metabolite assignments in 1H/13C HRMAS NMR spectra of lysed MG-63 cells. 
Legend: s singlet, d doublet, t triplet, q quartet, dd double of doublets, m multiplet. 
Compound Assignment δ 1H ppm (multiplicity )/ δ 13C ppm 
UDP/UTPa C1’H, ribose 
C6H, ring 
5.98 
7.98 
UDP-GalNAca  
C1H, Glc 
2.08 
5.52 
UDP-GlcNAca  
C1H, Gal 
2.09 
5.62 
Uracil C5H, ring 
C6H, ring 
5.80 (d) 
7.53 (d) 
Uridine C4’H, ribose 
C3’H, ribose 
C2’H, ribose 
C1’H, ribose 
C5H, ring 
C6H, ring 
4.12/70.93 
4.22 (dd)/ 71.66 
4.34 (dd)/ 76.57 
5.89 (d)/ 91.95 
5.92 (d)/ 91.77 
7.87 (d)/ 144.32 
Valine γCH3 
γ’CH3 
βCH 
αCH 
0.99 (d)/ 17.06 
1.05 (d)/ 16.98 
2.28/27.87 
3.63 (d)/ 64.98 
a Metabolites assigned through STOCSY. 
 
4.3. Influence of Acquisition Conditions on the Cell Metabolic Profile 
Sample spinning in HRMAS NMR experiments implies a set of direct or indirect 
consequences on the nature and dynamics of the sample: phase separation inside the rotor that, 
in turn, induces alterations in metabolites mobility (thus, visibility also) and sample heating that 
induces also alterations in metabolites’ mobility and chemical shift variations, as well as increased 
enzymatic and chemical activity within the sample. Since some of these effects may irreversibly 
alter the sample, they must be considered when defining the best experimental conditions. With 
this in mind, the following studies intended to determine the influence of spinning rate (SR), 
sample temperature and acquisition time duration on sample and spectral quality. In addition, 
sample relaxation properties, namely described by T1 and T2 relaxation times, were characterised 
and their impact on spectral characteristics described. The results allowed the best value for each 
of the referred conditions to be chosen, giving insight into a field with very few reports on 
literature (Griffin et al., 2002; Griffin et al., 2003; Duarte et al., 2009; Martin-Sitjar et al., 2012). 
4.3.1. Spinning Rate (SR) 
In order to evaluate the influence of spinning rate on the 1H HRMAS NMR spectra of fully 
lysed MG-63 cells, a range of rates from 3 to 7 kHz was tested (stable spinning rates were not 
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achieved for lower SR values) (Figure 4.6). As expected, a considerable increase in signals intensity 
is observed at higher spinning rates, with the most significant improvement being observed from 
3 to 4 kHz. This is particularly seen for peaks arising from amino acids, whose signal intensities 
suffer a marked increase from 3 to 4 kHz, with very slight increases at higher SR. Besides the 
effects of higher SR in reducing the dipolar couplings and chemical shift anisotropy, it is also 
possible that a contribution of some sample heating and possible partial phase separation, leaving 
polar metabolites such as amino acids in a more liquid-like environment, thus increasing their 
visibility. A similar tendency was detected for creatine and m- and s-inositols. 
Resonances arising from choline and PC show a considerable increase from 3 to 4 kHz, 
remaining essentially stable at higher spinning rates in parallel with a slight deviation for lower 
chemical shifts, probably due to sample heating promoted by spinning. For PC, these results are in 
partial agreement with those obtained in Martin-Sitjar work (Martin-Sitjar et al., 2012), in which 
the intensity of PC was found to increase up to 6 kHz. 
 
 Figure 4.6. 500 MHz 1H HRMAS NMR spectra of MG-63 cells with spinning rates ranging from 3 to 7 
kHz (see colour legend in top left of figure). Insets show the main variations and direction of change. 
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Regarding Ino/Ado and Tyr, increases in signal intensities were detected up to 6 kHz. 
Finally, increasing SR (from 3 to 7 kHz) induced an increase in the intensity of resonances 
from lipids. These results are in agreement with those reported in similar measurements in C6 
glioma cells (Martin-Sitjar et al., 2012). Similar determinations in glioma tissue (Griffin et al., 2003) 
found no alterations in the line width and intensity of lipid signals for SR ranging from 1 to 9 kHz, 
showing the distinct behaviour of different types of samples.  
In order to test the reversibility of the above described changes, a last spectrum was 
acquired at a spinning rate of 4 kHz. Minor increases of Met, Lys, Gly, Phe and Tyr and decreases 
of Ino/Ado were observed, with no further variations in other metabolites. This finding shows that 
sample alterations induced by high SR are not completely reversible, drawing attention for the 
persistence of phase separation inside the rotor and for eventually occurring enzymatic activity 
(even after submitting samples to very low storage temperatures). This is not in complete 
agreement with a literature report on glioma cells (Martin-Sitjar et al., 2012), in which the authors 
concluded that the metabolite changes induced by increasing spinning rates were essentially 
reversible. 
The effect of sample spinning rate and spectral acquisition duration on the integrity of MG-
63 cells, as well as of other two cellular lines were also evaluated (Duarte et al., 2009). Trypan 
blue results showed that the behaviour of cells spun at 4 kHz for 2 hours is greatly dependent on 
cell type and, in the particular case of MG-63 cells, this procedure does not affect greatly their 
integrity. Additionally, the results of HRMAS analysis of neuronal and glial cells revealed that 
spinning rates ranging from 1 to 6 kHz exerted little effect on either shape or intensity of detected 
resonances and claim that at the end of experiment (around 40 minutes) cells that stained with 
Trypan blue increased just 3% (Griffin et al., 2002). These results once again highlight the 
importance of evaluating the influence of spinning rate for each particular type of cell sample. 
According to these results, a spinning rate of 4 kHz was chosen for HRMAS analysis. 
 
4.3.2. Sample Temperature 
The following study intended to determine how sample temperature during acquisition 
influences the global profile of the 1H HRMAS NMR spectra. With that purpose, spectra were 
recorded at temperatures ranging from 4 to 25˚C (Figure 4.7). 
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 Figure 4.7. 500 MHz 1H HRMAS NMR spectra of MG-63 cells acquired at different temperatures: 4, 
10, 15, 20 and 25˚C (see colour legend in top left of figure). Insets show the main changes. 
These results show a more marked increase in the resonances of CH3 and (CH2)n of lipids, 
compared to the results recorded as a function of spinning rate (Figure 4.6). This reflects the large 
sensitivity of lipids to temperature and their resulting increased molecular mobility. Visual 
inspection of the spectra in Figure 4.7 reveals no relevant additional changes in metabolites 
intensity. Therefore, considering the increases in signal intensity previously observed for several 
metabolites as a function of spinning rate (Figure 4.6), it may be concluded that such changes are 
mainly due to some sample separation (allocation of polar small molecules to the liquid phase 
and, hence, more mobile environment), rather than due to sample heating. In addition, for the 
majority of metabolites, chemical shifts suffer some deviation with temperature, again more 
markedly than for the spinning-induced effect, for which only choline compound peaks were seen 
to change in position (Figure 4.6). 
Some of the above presented results confirmed earlier HRMAS studies of neuronal and glial 
cells (Griffin et al., 2002), in which authors concluded that an increase in temperature (ranging 
from 4 to 27˚C) caused an increases in the intensity of CH3 and (CH2)n signals from lipids (no 
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further changes in other lipid resonances), while relative intensities for Ala and lactate remained 
constant. On the other hand, studies of glioma tissue (Griffin et al., 2003), referred no alterations 
of the lipid signals between 4 and 20˚C, once again highlighting the different dynamic behaviour 
of lipids in distinct cellular matrixes.  
The reversibility of the changes observed with temperature (Figure 4.7) was also evaluated 
by comparison with a spectrum subsequently acquired back at 4˚C, ca. 1h30min after the first 
spectral acquisition (Figure 4.8). Such comparison evaluates both the effect of sample heating and 
sample spinning for over one hour. 
 
 Figure 4.8. 500 MHz 1H HRMAS NMR spectra of MG-63 cells acquired at 4˚C at the beginning (green) 
and the end (black) of temperature increase assays. Insets show the main changes. 
As shown in Figure 4.8, lasting metabolic changes induced by temperature increases are 
revealed to be tenuous. Only discrete increases of some amino acids (Val, Leu, Ile, Lys, Met, Gly, 
Tyr and Phe), lactate and (CH2)n of lipids are noted in the last spectrum acquired at 4˚C, in 
comparison to the first spectrum recorded at 4˚C. Increases in choline and hypoxanthine as well 
as decreases in inosine constitute slightly more pronounced changes. The alterations measured 
for these compounds probably relate both to phase separation of sample components inside the 
rotor and alterations to sample composition eventually promoted by some enzymatic activity. 
imd_MG_sr3_1_1
7.50 5.00 2.50 ppm
imd_MG_sr4_1_1
imd_MG_sr5_1_1
imd_MG_sr6_1_1
imd_MG_sr7_1_1
4˚C initial
4˚C final
imd_MG_4graus_1_1
8.00 7.00 6.00 5.00 4.00 3.00 2.00 1.00 ppm
imd_MG_4graus_final_1_1
imd_MG_4graus_1_1
1.30 1.20 1.10 1.00 0.90 0.80 ppm
imd_MG_4graus_final_1_1
imd_MG_4graus_1_1
1.30 1.20 1.10 1.00 0.90 0.80 ppm
imd_MG_4graus_final_1_1
Lf.a.
CH3
Val, Leu. Ile
Lf.a.
(CH2)n
lactate
imd_MG_4graus_1_1
3.300 3.250 3.200 3.150 3.100 ppm
imd_MG_4graus_final_1_1
Cho
PC
m-inositol
imd_MG_4graus_1_1
8.40 8.30 8.20 8.10 8.00 7.90 ppm
imd_MG_4graus_final_1_1
His
Ino/Ado Hypoxanthine
Spectral Assignment and Assessment of Analytical and Biological Reproducibility of the Metabolic  
Profile of MG-63 Cells: a HRMAS NMR Study 
________________________________________________________________________________ 
 
________________________________________________________________________________ 
 
134 
 
Interestingly, the latter is supported by the fact that an irreversible change seems to occur in the 
chemical shift of His, shifted for higher ppm values characteristic of lower pH values. 
In line with the above presented results, 4˚C was chosen as the most appropriate 
temperature for HRMAS analysis of cell samples. 
 
4.3.3. Acquisition Duration 
Mechanical and sample heating effects have already been demonstrated to be important in 
determining the exact spectral profile of cell samples. Therefore, the duration of spectral 
acquisition is a clear important factor to be studied too. In this work, this was evaluated by 
considering overnight (ca. 10 hours) runs, at both 4 and at 22˚C. 
Visual comparison of the first and the last spectra of a 10 hours acquisition of MG-63 cells 
at 4˚C is shown in Figure 4.9. 
 
 Figure 4.9. 500 MHz 1H HRMAS NMR spectra of MG-63 cells at the beginning (black) and end (blue) 
of a 10 hours acquisition at 4˚C. Insets show the main changes. 
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Visual inspection of the spectra in Figure 4.9 shows that 4˚C ensures a high stability of the 
sample metabolite composition, over the period of 10 hours, with maximum global variations of 
10% relatively to the first acquired spectrum. The most significant fluctuations were registered for 
uridine, hypoxanthine, Phe and Tyr. These are less resolved signals, with lower signal-to-noise 
ratios, what might contribute to an increased error in signal integration and thus, to the apparent 
more significant fluctuations registered for those metabolites. 
Figure 4.10 shows de initial and final spectra of fully lysed MG-63 cells, during a 10 hours 
acquisition at 22˚C. A global increase of the intensity of the peaks of amino acids is clearly 
detected through visual inspection, as well as of uridine, hypoxanthine and choline compounds.  
 
 Figure 4.10. 500 MHz 1H HRMAS NMR spectra of MG-63 cells at the beginning (black) and end (red) 
of a 10 hours acquisition at 22˚C. Insets show the main changes. 
When compared to the results of previous section (4.3.2), in which increments of sample 
temperature were found to increase the intensities of the lipid signals, long term spinning at 22˚C 
induces distinct metabolic alterations. After ca. 10 hours spinning at 22˚C, the sample suffers a 
marked decrease of lipids, probably associated with their biochemical alteration in the sample 
since, after long term spinning at 4˚C lipid signals showed to be very stable, thus excluding the 
mechanical action in the sample, induced by spinning, as responsible for this lipids decrease. 
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Additionally, dramatic changes in the choline compounds region, as well as clear variations seen 
in amino acid levels were exclusive of long term spinning at high temperature (22˚C), thus 
highlighting the danger that spectral acquisition under such conditions represents for sample 
stability. The strong suggestion of a pH shift upon consecutive increases of sample temperature 
(section 4.3.2) is once again present. The proton of the NH group of His was also found to shift for 
higher ppm values, and more pronounced shifts were detected when long term spectral 
acquisition was performed at 22˚C, showing that temperature induces a crucial influence on 
sample pH, eventually due to potentiation of enzymatic activity.  
PCA of the spectra registered during 10 hours at 4 and 22˚C (Figure 4.11) shows a clear 
clustering of the spectra acquired at 4˚C, reflecting the high stability of the sample at low 
temperatures, even for an acquisition of 10 hours (the shifted point refers to the spectrum 
acquired after 1 hour of experiment, which has slightly broader signals) . On the other hand, at 
22˚C samples describe a clear time course trajectory along PC2, reflecting a greater magnitude of 
metabolites variation when compared to lower acquisition temperatures. 
 
 Figure 4.11. PCA scores plot 1H HRMAS NMR spectra of MG-63 cells at 4˚C (blue) and at 22˚C (red), 
during a 10 hours acquisition time (Ctr scaling, R2X=0.997 and Q2=0.992). Arrow indicates time course of 
samples acquired at 22˚C. 
Signal integration of varying peaks was used to construct time course plots corresponding 
to the 10 hours acquisitions at 4 and 22˚C. The intensity of lipids signals decrease at both 
temperatures, although more dramatically at the higher temperature (Figure 4.12a). This confirms 
the opposite effect compared to short-term sample spinning, even at a relative high temperature 
(25˚C, see Figure 4.7), a possible indication of degradation processes. In what concerns choline 
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compounds (Figure 4.12b), for acquisitions at 4˚C fluctuations did not reach 10% whereas, at 22˚C, 
and dispite the small variations of PC, dramatic increases were registered in choline (ca. 100%) 
and GPC (ca. 40%). These increases in choline and GPC are most probably associated with their 
increased mobility as a consequence of the decreased viscosity, which can occur as a 
consequence of the high temperatures of acquisition (if so, such increasing tendency would have 
been observed in Figure 4.7) or mechanical action due to long term effect. 
 
 Figure 4.12. Time course variation (in %) of a) lipids and b) choline compounds, during acquisition at 
4˚C (blue) and at 22˚C (red) for 10 hours. 
The time course of several amino acids is presented in Figure 4.13. As can be seen, both 
temperatures induce an increase of amino acids with time of acquisition, however, at 22˚C, the 
changes nearly doubled those measured at 4˚C. Since this increase with time happens for the two 
tested temperatures, the observed variation is not attributable to a biochemical phenomenon but 
to an increased visibility of these compounds induced by concomitant phase separation 
(consequence of sample spinning) and some sample heating. Gly is the amino acid that shows the 
highest variation (ca. 110%), probably due to its small size. Glu levels revealed to be very stable 
with time, for both temperatures of acquisition. 
 
 Figure 4.13. Time course variation (in %) of amino acids, during acquisition at 4˚C (blue) and at 22˚C 
(red) for 10 hours. 
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Decreases of around 30% were measured for UXP (Figure 4.14a) after 10 hours acquisition 
at 4˚C however it was not possible to identify this compound in the spectrum acquired at 22˚C. 
Increases at 4˚C are probably associated with the fact that with sample spinning this compound 
stays in a more mobile phase thus improving its NMR detection, while for higher temperatures, 
some biochemical alteration phenomenon must account for its non detection. Regarding Ino/Ado 
(Figure 4.14a), which revealed to be very stable at 4˚C, a considerable decrease is seen when data 
acquisition was performed at 22˚C, also suggesting the occurrence of biochemical alteration 
processes. Uridine (Figure 4.14a) shows considerable increases already at 4˚C, that in turn 
increase in magnitude when measurements were performed at 22˚C, suggesting that 
improvements in the mobility are the most important effects accounting for its variations. 
 
 Figure 4.14. Time course variation (in %) of a) nucleotides and derivatives and b) other compounds, 
during acquisition at 4˚C (blue) and at 22˚C (red) for 10 hours. 
Time course variation of other compounds (Figure 4.14b) shows that at both 4 and 22˚C 
variations in N-acetyl, creatine, m- and s-inositol do not go beyond 10%, reflecting their relative 
stability. A similar trend is observed for GSH, but it is interesting to note that, at 22˚C, it decreases 
more markedly than at 4˚C, possibly suggesting its degradation as consequence of increased 
stress conditions of samples at higher temperatures (Yamamoto and Ishihara, 1994). 
As shown above, an increased stability of sample metabolites is achieved at 4˚C, what 
fostered its choice for further cell sample analysis. 
 
4.3.4. Sample Relaxation Properties 
If metabolite quantitation is intended, then the relation between relation time T1 
properties with the relaxation delay time (D1) needs to be considered. In this case, it is crucial to 
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guarantee that the time between consecutive scans is long enough to ensure complete relaxation 
of all nuclei so that quantitative intensities are achieved. This condition is accomplished when a 
period of, at least, 5 times the longest T1 (Bharti and Roy, 2012) measured in the sample is 
respected between scans. In order to determine in which conditions the 1H HRMAS NMR spectra 
of lysed MG-63 cells may be considered quantitative, a set of experiments were performed with 
different D1 times, ranging from 2 to 6 seconds (Figure 4.15). 
 
 Figure 4.15. 500 MHz 1H HRMAS NMR spectra of MG-63 cells with increasing relaxation delay times, 
ranging from 2 to 6 s (see colour legend in top left of figure). Insets show the main changes. 
Results show no considerable spectral variations with D1 ranging from 2 to 6 seconds for 
the majority of the detected signals. Only for (CH2)n of lipids, choline, m-Inositol and amino acids 
Gly, Met, Thr and Phe a slight increase of signal intensity was detected for increasing D1 times, 
specially until a relaxation delay of 4 seconds. 
Table 4.2, shows the set of T1 values obtained for all integrable signals. Indeed, these 
results indicate that a D1 of 4 seconds (as chosen for the spectra in this work) will not allow for 
the absolute quantitation of choline, some amino acids (Gly, Phe, Tau, Thr and Tyr), Ino/Ado, 
creatine and m- and s-Inositol, while providing quantitative measurements for PC, ethanol, lactate 
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and some amino acids (Ala, Glu, Ser and Val). Regarding lipid resonances (CH3, (CH2)n and CH=CH), 
the apparent short T1 values (Table 4.2) suggest that these moieties may be quantified with a D1 
of 4 seconds, however it is possible that the relaxation times measured correspond to a faster-
relaxing sub-population, a second slower-relaxing sub-population justifying the visual dependence 
of lipid peak intensities on the D1 delay. Gly is the metabolite with the highest T1, 2.9 seconds, in 
sample. Since a D1 of 4 seconds is not long enough to ensure complete relaxation of all 1H nuclei, 
only semi-quantitative information can be extracted from spectral data. To our knowledge, there 
are no studies in the literature in which T1 relaxation times are determined in cell samples and, in 
particular in lysed cell samples. 
Table 4.2. Proton longitudinal relaxation times (T1) measured for peaks identified in 500 MHz 
1H 
HRMAS NMR spectra of lysed MG-63 cells. 
Family of compounds Metabolite (δ, ppm) T1 (s) Standard Deviation 
Lipids Lipids –CH3 (δ 0.91)* 0.258 2.037E-02 
Lipids –(CH2)n (δ 1.31)* 0.415 4.412E-02 
Lipids –CH=CH- (δ 5.33)* 0.315 3.469E-02 
Choline compounds Choline (δ 3.21)** 1.380 3.189E-02 
Phosphocholine (δ 3.23) 0.541 2.238E-02 
Amino Acids Alanine (δ 1.48) 0.442 3.349E-02 
Glutamate (δ 2.35) 0.698 1.800E-02 
Glycine (δ 3.56)** 2.916 1.451E-02 
Phenylalanine (δ 7.32)** 1.157 7.690E-03 
Serine (δ 3.97) 0.605 1.495E-02 
Taurine (δ 3.42)** 1.350 1.899E-02 
Threonine (δ 3.58)** 1.209 1.834E-02 
Tyrosine (δ 6.89)** 0.989 8.267E-03 
Valine (δ 1.04) 0.249 2.247E-02 
Nuc. and Deriv. Inosine/Adenosine (δ 8.36)** 1.483 8.024E-03 
Other Metabolites Acetate(s) (δ 2.02) 0.541 3.147E-02 
Creatine (δ 3.94)** 1.371 2.949E-02 
Ethanol (δ 1.19) 0.551 6.106E-02 
Lactate (δ 4.13) 0.422 3.577E-02 
m-Inositol (δ 4.05)** 1.143 2.487E-02 
s-Inositol (δ 3.34)** 1.317 1.654E-02 
* Compounds partially quantifiable with a D1 of 4 seconds. ** Compounds not absolutely quantifiable with 
a D1 of 4 seconds.  
The choice of the appropriate D1 value to be used is performed based on a compromise 
between two factors: best possible signal intensities of all resonances and the total acquisition 
time of the spectrum. For maximum intensities of all peaks and, hence, full quantitative 
conditions, a D1 of ca. 15 seconds would have to be considered, thus involving considerably 
longer acquisition times, compromising sample integrity during acquisition. Therefore, the value 
of 4 seconds was chosen, with the knowledge that absolute quantitation may only be considered 
for a subset of compounds, while allowing for relative intensity analysis for all compounds. In 
metabolomics, the intention is normally to detect profile changes, that is, corresponding relative 
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intensity changes. Hence, semi-quantitative conditions are usually employed and completely 
acceptable, whenever absolute quantitation is not specifically aimed for. 
In addition to T1 measurements, transverse relaxation times (T2) help to evaluate the 
relative overall molecular mobility of different metabolites in the sample, information which may 
be valuable in distinguishing different dynamic environments for instance regarding free and 
macromolecule-bound metabolites. The results of T2 measurements for all integrable resonances 
are listed in Table 4.3. 
Table 4.3. Proton transverse relaxation times (T2) measured for peaks identified in 500 MHz 
1H HRMAS 
NMR spectra of lysed MG-63 cells. 
Family of compounds Metabolite (δ, ppm) T2 (ms) Standard Deviation 
Lipids 
Lipids –CH3 (δ 0.91) 35.16 2.061E-02 
Lipids –(CH2)n (δ 1.31) 373.8 1.101E-01 
Choline compounds 
Choline (δ 3.21) 587.5 2.069E-02 
Phosphocholine (δ 3.23) 242.6 1.942E-02 
Amino Acids 
Alanine (δ 1.48) 306.8 7.379E-02 
Glutamate (δ 2.35) 322.0 3.250E-02 
Glycine (δ 3.56) 419.8 5.129E-02 
Phenylalanine (δ 7.32) 343.7 4.098E-02 
Serine (δ 3.97) 301.4 5.814E-02 
Taurine (δ 3.42) 597.8 4.934E-02 
Threonine (δ 3.58) 331.5 4.673E-02 
Tyrosine (δ 6.89) 349.2 7.454E-02 
Valine (δ 1.04) 182.3 7.050E-02 
Nuc. and Deriv. Inosine/Adenosine (δ 8.36) 553.9 5.354E-02 
Other Metabolites 
Acetate(s) (δ 2.02) 179.2 7.662E-02 
Creatine (δ 3.94) 382.6 3.010E-02 
Ethanol (δ 1.19) 924.7 1.223E-01 
Lactate (δ 4.13) 226.0 9.499E-02 
m-Inositol (δ 4.05) 450.2 8.555E-03 
s-Inositol (δ 3.34) 342.1 2.592E-02 
 
T2 values range from 35 ms for CH3 of lipids to 925 ms for ethanol. For CH3 of lipids the 
determined T2 is of the order of tens while for all other measured metabolites, including for (CH2)n 
of lipids it is of the order of hundreds, suggesting a lower mobility for the lipid chain terminals, 
which is difficult to explain, at this stage. Again, the possible multi-exponential behaviour of lipid 
resonances should be tested for a more complete dynamic characterisation of these compounds. 
Among the small compounds, Val, acetate and lactate exhibit relatively low T2 times, showing that 
these compounds may be possibly adsorbed to macromolecules. The very distinct values found 
for choline (587 ms) and PC (242 ms) may also reflect different dynamic environments and inter-
compound interactions affecting each of these compounds. 
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4.4. Spectral Profile Reproducibility Check and Influence of Sample Storage 
4.4.1. Spectral Profile Reproducibility Check 
The reproducibility of the 1H HRMAS NMR profile of lysed MG-63 cells was assessed in 
order to establish the impact of the practical protocols of cell culture, harvesting and mechanical 
lysis on the spectral profile of these cells. This knowledge is useful in two ways: firstly, it helps to 
determine the minimal level of spectral variability inherent to sample preparation above which 
meaningful variations (e.g. due to drug exposure) may be detected; secondly, it enables the 
identification of the compounds which are more sensitive to experimental protocol and for which 
over interpretation of variations should be avoided. Figures 4.16 and 4.17 show the 1H HRMAS 
NMR spectra of triplicates of each of three independent assays, for lysed MG-63 cells collected at 
0 and 48 hours, respectively. 
 
  Figure 4.16. 500 MHz 1H HRMAS NMR spectra of lysed MG-63 cells collected at 0 hours, at 22˚C. 
Different colours correspond to distinct assays (see top left of figure). 
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All these spectra were recorded at 22˚C, despite the previous choice of 4˚C as the adequate 
temperature of acquisition. This was so due to lack of refrigerating capability of the instrument 
used (500 MHz in CERMAX, ITQB, Oeiras, Portugal). This should not, however, hinder any 
conclusions to be drawn, since all time intervals included in protocol (during which sample 
degradation may occur), were similar. 
 
 Figure 4.17. 500 MHz 1H HRMAS NMR spectra of lysed MG-63 cells collected at 48 hours, at 22˚C. 
Different colours correspond to distinct assays (see top left of figure). 
Regarding intra-assay comparison of spectra, the highest degree of dispersion between 
replicates occurred at 0 hours (Figure 4.16) in assay 1, with one replica showing lower lipids 
signals and a different profile in choline compounds, and at 48 hours (Figure 4.17) in assay 2, with 
one replica showing lower lipid signals. In relation to inter-assay comparison, spectra show a low 
dispersion between assays at 0 hours (Figure 4.16, with the already refered exception of one 
replica) and a low dispersion between assays 1 and 3 at 48 hours (Figure 4.17). At 48 hours, 
differences are noted in assay 2, namely a global decrease of amino acids, m- and s-Inositol, 
creatine, uridine and Ino/Ado, together with a dramatically different profile of the choline 
compounds region. Regarding other time points (12, 18 and 24 hours), similar changes were 
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observed in some of the spectra replica. It is difficult to advance a specific explanation for the 
changes noted, since the same experimental procedures were in principle followed for all 3 
assays, but this study shows that small differences may occur and have some impact on the 
measured cell profile, namely in relation to lipids and choline compounds (eventually due to 
nuances in the lysis protocol (as shown in section 4.1). 
The PCA scores plot of PC1 vs PC3 coloured as function of assay (Figure 4.18) enables 
general differences between spectra to be visualised (similar tendencies were observed in the 
PCA scores plot of PC1 vs PC2, with a slightly higher dispersion between samples). This result 
shows no clustering of samples according to assay, which indicates a general agreement between 
assays, with exception of assay 1 (in black in Figure 4.18) for which a large dispersion (not related 
to time course) is confirmed graphically. In assay 2 (in red in Figure 4.18), samples at 48 hours are 
separated from the rest of the samples, as again already inferred by visual inspection, this having 
been attributed to a global decrease of amino acids, m- and s-Inositol, creatine, uridine and 
inosine and a singular profile of the choline compounds region. Samples of assay 3 (in green in 
Figure 4.18) are those with lower dispersion, and for which no clear time course tendency was 
found. 
 
 
 Figure 4.18. PCA scores plot of PC1 vs PC3 of reproducibility assays. Ctr scaled model, 5 
components, R2X=0.869 and Q2=0.740. Different colours correspond to distinct assays. 
The analysis of the same PCA scores plot coloured per assay, but comparing PC2 vs PC3 
(Figure 4.19) shows that even though there are variations between assays, their time course is 
similar and describable along PC3. This result indicates the advantage of comparing time course 
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trajectories instead of single points in time. Figure 4.19 also shows that experimentally-induced 
dispersion leads to shifts along the PC2 axis. In order to get further insight into these differences 
between samples from assay to assay, several spectral signals were integrated and p-values 
determined. 
 
 Figure 4.19. PCA scores plot of the PC2 vs PC3 of reproducibility assays. Ctr scaled model, 5 
components, R2X=0.869 and Q2=0.740. Different colours correspond to distinct assays. 
 
Differences in lipid resonances were found to be small but statistically relevant only at 18 
and at 48 hours (Figure 4.20) possibly as a consequence of slightly different sample spinning 
durations due to the sample-dependent need to optimize NMR acquisition (namely for sample 
shimming). This is consistent with observations previously described in section 4.3.3. Also, since 
these experiments were performed at room temperature (22˚C), possible slight variations in the 
time required for complete defrosting and temperature homogenisation within the sample may 
contribute to the above described changes in lipid resonances. Regarding choline compounds, 
choline levels (Figure 4.20d) revealed to be very stable from assay to assay, with just one 
statistically relevant difference at 48 hours between assay 1 and 2. PC and GPC (Figure 4.20e) 
showed a considerable number of statistically relevant differences. These results once again show 
how choline compounds (particularly PC and GPC) reflect unintentional differences in the lysis 
protocol and for this reason, special care have to be given when considering drug-induced 
changes in this type of compounds.  
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 Figure 4.20. Time course integrals of selected lipids and choline compounds signals. (Error bars 
reflect n=9. Assay 1 (), assay 2 () and assay 3 (); *p<0.05) 
 
Amino acid analysis (Figure 4.21) reveals significant variations (magnitudes varying from 
amino acid to amino acid) between assays for Phe, Gly, Leu, Lys, Met, Tyr, Pro and Val. These 
differences were more frequent at 48 hours but for Gly and Pro additional significant differences 
were also found for other time points. This probably relates once again to slight differences in the 
time necessary to optimise spectral acquisition and the temperature of acquisition (which, as 
shown in section 4.3.2, interferes with amino acids levels).  
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 Figure 4.21. Time course integrals of selected amino acids. (Error bars reflect n=9. Assay 1 (), assay 
2 () and assay 3 (); *p<0.05) 
 
For Ino/Ado and uridine (Figure 4.22), statistically relevant differences between assays 
were measured possibly due to biochemical alterations related to slight differences in 
temperature and time of spectral acquisition, the latter implying also differences in samples 
spinning periods (and respective consequences in metabolites visibility by NMR). 
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 Figure 4.22. Time course integrals of nucleotides and derivatives. (Error bars reflect n=9. Assay 1 
(), assay 2 () and assay 3 (); *p<0.05) 
 
As shown in Figure 4.23, significant differences were also detected for creatine (0 and 48 
hours), m- and s-inositol (18, 24 and 48 hours). Interestingly, despite the global decrease over 
time, no statistically relevant differences were found in GSH levels between assays (Figure 4.23). 
 
 Figure 4.23. Time course integrals of other compounds. (Error bars reflect n=9. Assay 1 (), assay 2 
() and assay 3 (); *p<0.05) 
 
These results show that the whole cell handling procedure results in intra and inter-assay 
differences between samples that must be taken into consideration when searching for drug- or 
other perturbation-induced changes. 
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4.4.2. Cell Passage Number 
The influence of cell passage number (designated by #) on the metabolic profile of MG-63 
cells is here presented at a very exploratory level (only one replica per condition) and, to our 
knowledge, for the first time. Figure 4.24 shows the 1H HR MAS NMR spectra of lysed MG-63 cells 
with increasing number of cell passages. 
 
 Figure 4.24. 500 MHz 1H HRMAS NMR spectra of MG-63 cells with passage numbers 25, 35 and 45. 
Different colours correspond to distinct assays (see top left of figure). 
Minor changes are addressed when comparing the spectra of MG-63 cells at #25 and at 
#45. However, when comparing these with the spectrum of MG-63 cells at #35, a considerable 
number of differences were identified: cells at #35 showed a global increase of the amino acids 
Val, Leu, Ile, Ala, Lys, Gly and Phe and decrease of Glu and Tau. Slightly decreased (CH2)n and 
CH=CH resonances of lipids and lower creatine, m- and s-inositol were also seen in #35 cells 
together with changes in choline:PC ratio. Since very similar profiles were found for cells at #25 
and #45 and due to the lack of replicates, it seems apparent that the effect of passage numbers in 
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not significant (at least in the range considered), the differences seen in the #35 sample being 
possibly due to effects of the handling protocol (culture, harvesting, mechanical lysis) of those 
cells. 
Besides trying to understand if the number of cell passages influences the profile of control 
cells, this experiment also searched for differences in the drug-response profile of MG-63 cells 
with increasing number of passages since, hypothetically, the minor changes detected between 
cells at #25 and #45 might be determinant in response to drug, resulting in different profiles of 
treated-cells. Figure 4.25 compares the metabolic profile of MG-63 cells with increasing number 
of passages exposed to 30 µM cDDP for 24 hours. 
 
 Figure 4.25. 500 MHz 1H HRMAS NMR spectra of cDDP-treated MG-63 cells with passage numbers 
25, 35 and 45. Different colours correspond to distinct assays (see top left of figure). 
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Visual inspection reveals, once again, marked differences in the profile of #35 cells, when 
compared to #25 and #45, what cannot be dissociated from the different metabolic profile of the 
respective control cells (already mentioned). However, when comparing the response profile of 
cells at #25 with that of #45, whose controls were found to be very similar, a considerable number 
of changes were detected in cells with higher number of passages: increased Glu, Tau, creatine 
and m-inositol together with slight decreased lipids signals and a change in the global profile of 
the choline-compounds region (induced by a decrease in GPC). 
Signals of both control and treated spectra were also integrated and, since some 
differences were already noted in control conditions, the results expressed as treated:control 
ratios (not shown), in order to aid interpretation. Since this was an exploratory experiment, only 
one sample per condition was obtained (no error bars) thus, when analyzing the calculated ratios, 
only those showing consistent increasing/decreasing tendencies with number of passages were 
considered relevant. Slight increasing tendencies were found for PC, Glu, Thr, Tau, m-Inositol and 
creatine while a decreasing tendency for GPC was detected in response to cDDP as the number of 
cell passages increases. 
Despite exploratory, this experiment suggests that the metabolic response of MG-63 cells 
which differ by several number of passages might be slightly different namely affecting some 
choline compounds (PC and GPC), amino acids (Glu, Thr and Tau), m-Inositol and creatine, and 
therefore must be considered for cell studies. Further studies would be needed confirm the 
magnitude of these changes. 
 
4.4.3. Sample Stability During Storage at -80˚C 
Beyond the frequent impossibility of immediate analysis, biological samples are often too 
valuable to be discarded after spectral acquisition. In this line, it is important to know how long 
cell samples can be stored and still ensure accurate metabolic profile information. To evaluate 
this, a total of 11 samples were considered for analysis of stability during a 27 months period of 
storage at -80˚C. Visual comparison of the spectra acquired at increasing times of storage is 
shown in Figures 4.26 (0.5-4.1 ppm) and 4.27 (5.2-8.5 ppm). 
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 Figure 4.26. 500 MHz 1H HRMAS NMR spectra of MG-63 cells with increasing times of storage, 
ranging from 1 week to 27 months. 0.5-4.1 ppm region is shown. (Arrow indicates Un. at δ 2.73). 
Analysis of the 0.5-4.1 ppm region (Figure 4.26) does not show any clear time course 
variation of metabolites (either amino acids, lipids or other compounds like m-Inositol, creatine or 
GSH) during the 27 months of storage at -80˚C.  Interestingly, a singlet at δ 2.73 is observed 
occasionally in the spectra of frozen samples, at 7, 9 and 16 months of storage. Since it was not 
possible to assign the corresponding metabolite and the respective variations do not describe a 
consistent change over time, it is not possible to advance an interpretation for such signal.  Visual 
inspection of Figure 4.27 (5.2-8.5 ppm region), suggests a slight change in uridine and UXP levels 
together with random chemical shift fluctuations of the His resonances, thus suggesting slight pH 
variations of samples in time. No further changes in other metabolites were noted, thus 
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suggesting that storage at -80˚C is able to preserve cell samples for long periods of storage with 
minor metabolic consequences. 
 
 Figure 4.27. 500 MHz 1H HRMAS NMR spectra of MG-63 cells with increasing times of storage, 
ranging from 1 week to 27 months. 5.2-8.5 ppm region is shown. (Arrow indicates His resonance). 
Peak integration was performed to identify small quantitative changes as a consequence of 
storage. Regarding lipids (Figure 4.28a), CH3 is the most stable resonance during the tested period 
of storage at -80˚C. (CH2)n of lipids registered increases of around 10% and -CH=CH- changed very 
considerably, with a percentage of variation at the end of the 27 months of around 50%. 
However, during the 2 months of storage all the three lipid resonances (CH3, (CH2)n and CH=CH) 
suffer only a negligible variation.  For choline-compounds (Figure 4.28b) fluctuations around -10 
to 10% were measured. 
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 Figure 4.28. Time course (in %) of a) lipids and b) choline compounds during storage at -80˚C. 
The analysis of the time course of amino acids (Figure 4.29) shows maximum negative 
fluctuations of around 20% for most amino acids and a slightly higher variation (around 30% 
negative) for Tyr, while Glu and Lys presented variations that were less than 10%. 
 
 Figure 4.29. Time course (in %) of amino acids during storage at -80˚C. 
Negligible changes were detected for Ino/Ado but uridine changed of around 40% 
(negative) after 26 months of storage (Figure 4.30a). GSH, m- and s-Inositol (Figure 4.30b) and 
creatine levels oscillated during the period of the test of around 10%. 
 
 Figure 4.30. Time course (in %) of a) nucleotides and derivatives and b) other compounds during 
storage at -80˚C. 
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The low magnitude variations in the majority of metabolites found in these results, seem to 
suggest that lysed MG-63 cell samples have a high stability to storage at -80˚C for long periods of 
time, although these results do not enable the establishment of a window time during which 
spectra can be recorded with an acceptable stability of the metabolites in the sample. Further 
studies with replicates would be necessary to infer on the magnitude of the error associated with 
these measurements. Nevertheless, since most variations were around 10% (both positive or 
negative), this was tentatively assumed as the uncertainty dimension of the fluctuations here 
shown. Although some of the metabolites achieve slightly high percentages of variation over time 
(in relation to the first recorded spectrum), such variations were quite random in time and do not 
enable a clear tendency (of increase or decrease) to be established. Additionally, and recalling the 
value of these type of samples, studies of freeze-thaw cycles would also retrieve valuable 
information on the number of times that these samples can be analysed without significantly 
altering their global metabolic profile. 
Variations in more intense resonances are assumed to be more reliable than those of low 
intensity peaks (with low S/N). Thus, variations in more reliable signals as choline compounds and 
lipids (exception for CH=CH, with low S/N) show increased stability over the entire period, what 
strongly suggests a high stability of lysed cell samples over the 27 months of storage at -80˚C. 
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5. Metabolic Impact of Conventional Drugs on 
Osteosarcoma MG-63 Cells 
Administration of cisplatin (cDDP), doxorubicin (DOX) and methotrexate (MTX), often 
together with ifosfamide, constitute one of the most frequently adopted preoperative 
chemotherapy protocol for the treatment of osteosarcoma (Ta et al., 2009). Despite the already 
existing knowledge on the mechanism of action of these drugs, there is still little understanding 
on the metabolic adaptations that tumour cells undergo when exposed to them. Such knowledge 
may pave the way to the identification of possible metabolic markers of therapeutic efficacy. 
Accordingly, this chapter deals with the metabolic effects of cDDP, DOX and MTX, in sole 
administration, on the human osteosarcoma MG-63 cell line. 
5.1. Cytotoxicity Assay Results 
Dealing with different drugs, with distinct cytotoxic activities, requires preliminary assays to 
determine, for each drug, the concentration capable of inducing a certain extension of cell 
damage, either cell death (cytotoxic activity) or growth inhibition (cytostatic effect). These studies 
enable to determine the so called inhibitory concentration (IC), namely the IC50 values, that 
represent the drug dosage that results in 50 % of cell death (for a certain period of drug 
exposure). In the present work, IC50 at 24 hours was the concentration used for each drug in the 
cell culture experiments, in order to follow the metabolic consequences of treatment as a 
function of time, for a total of 48 hours. 
Figure 5.1 shows the results of the Trypan blue tests performed for the human 
osteosarcoma cells that were harvested for HRMAS NMR analysis. This test was performed in 
order to assess the number of intact cells in each sample and ensuring that a suitable number of 
cells (5 to 10 million) is obtained for NMR analysis. For cDDP in the MG-63 cells, the IC50 value at 
24 hours was found to be 30 µM. As shown in Figure 5.1a, the cytotoxic effect of cisplatin is 
already visible at 12 hours, becoming more pronounced, as expected, for increasing exposure 
times, with a clear reduction in the number of living cells up to 48 hours. Moreover, 30 and 50 µM 
of the drug have very similar effects on drug-induced cell death. Regarding DOX, the IC50 value at 
24 hours was determined to be 3 µM and a clear decrease in the number of living cells occurs for 
increasing incubation periods with the drug (Figure 5.1b). As for MTX, the IC50 value is 3 µM at 24 
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hours but, interestingly, no clear decrease on the number of living cells is detected for higher 
periods of drug exposure, as opposed to the results obtained for cDDP and DOX (Figure 5.1c). This 
result indicates that the mechanism of action of MTX is somehow less effective in the longer term 
on MG-63 cells than cDDP or DOX. 
 
Figure 5.1. Dose- and time-response plots of the cytotoxic effect of a) cDDP, b) DOX and c) MTX, in 
sole administration, to MG-63 cells. Cell proliferation was evaluated by Trypan blue assay (as described in 
Chapter 3). Control (); a) 30 µM () and 50 µM () cDDP; b) 3 µM DOX (); c) 3 µM MTX (). The data 
represent the average ± mean standard deviation from n=3 experiments, carried out in duplicate (n=6).  
Hence, the IC50 concentration determined for cDDP is ten times higher than that obtained 
for DOX and MTX (30 vs 3 µM). Additionally, this concentration was found to induce an increased 
cell death over time (up to 48 hours) for both cDDP and DOX, while for MTX no significant 
cytotoxic effect was observed beyond 24 hours of drug exposure (Figure 5.1). 
The IC50 values determined for cDDP and DOX are in agreement with those obtained in MG-
63 cells, at 24 hours of drug-exposure, by Naruse and coworkers (Naruse et al., 2007), of 28.6 and 
3.4 µM, respectively. In relation to MTX, the determined IC50 value  (3 µM) is more than fifteen 
times higher than that obtained by Diddens (Diddens et al., 1983): 0.17 µM in MG-63 cells at 24 
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hours of MTX-treatment. Other three references refer quite distinct IC50 values for 72 hours of 
MG-63 treatment with MTX: 0.03 µM (Palmero et al., 2006; Bodmer et al., 2007) and 3.8 nM (Cole 
et al., 2002). In the present work, the results obtained were considered reliable since they were 
reproduced for all three independent experiments, each carried out in duplicate (section 3.1.3.1). 
 
5.2. 1H HRMAS NMR Analysis 
In order to assess and interpret the metabolic changes induced by each of the above 
refered three drugs in sole administration, 1H HRMAS NMR experiments were carried out as 
discussed below. 
5.2.1. Cisplatin (cDDP) 
The metabolic changes that occur in MG-63 cells exposed to cDDP are hereby analysed by 
1H HRMAS. These results were reported for the first time by us in Duarte et al., 2010 and are here 
presented with improved reprocessing of the NMR data, as described in a recent publication of 
our own (Lamego et al., 2014). At the time of the first report, the NMR spectra had been 
normalised to total area in order to account for differences in sample quantities, which became 
particularly significant when comparing controls with drug-treated samples (the latter containing 
much fewer cell numbers). However, with this type of data normalization, important variation in 
very intense and/or broad resonances markedly determine the normalization factor, eventually 
hiding changes in low intensity resonances. By defining one or a set of reference spectra, 
probabilistic quotient normalization (PQN) normalization finds the most probable normalisation 
factor for each sample spectrum (see Chapter 2) this better accommodating alterations of low 
intensity signals. Together with peak alignment, this data reprocessing should result in a more 
accurate assessment of spectral changes. 
In order to compare the mean behavior of the drug-treated samples, visual inspection was 
performed by comparing the average 1H HRMAS NMR spectra of the three samples collected at 
each condition (time point and drug concentration). Prior to the analysis of the cDDP-induced 
effects, it is important to evaluate how the metabolic profile of MG-63 cells changes with time, as 
a consequence of cell basal metabolism (controls). As depicted in Figure 5.2, 48 hours of cell 
growth result in a slight decrease of the unsaturation degree of lipids (δ 5.33) and of creatine, Glu, 
GSH and UXP compounds, suggesting a certain degree of stress affecting the cells, probably due 
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to their increased confluence in culture. Increases in m-Inositol levels may relate to the 
osmoregulatory function of this metabolite. 
 
Figure 5.2. Average 700 MHz 1H HRMAS NMR spectra of control MG-63 cells at: a) 0 hours and b) 48 
hours. Insets show expansions of choline compounds (3.2-3.3 ppm) and aromatic (5.2-8.5 ppm) regions. 
Main assignments are noted and visible spectral changes due to time course are marked by arrows. 
Visual inspection of the 1H HRMAS NMR spectra of MG-63 cells exposed to cDDP, showed 
that, in general, drug-induced metabolic changes become more relevant as exposure time 
increases (not shown) as will be discussed further ahead in this section. Firstly, the metabolic 
impact of different concentrations of cDDP (30 and 50 µM) on MG-63 cells after 48 hours of 
treatment (Figure 5.3) is discussed. 
As it is shown by the arrows in Figure 5.3b and 5.3c, the metabolic alterations induced by a 
48 hours treatment with 30 and 50 µM of cDDP are essentially the same, generally more 
pronounced in the latter case. These changes comprise a marked increase of all detectable lipid 
resonances, together with increased choline (δ 3.21) and GPC (δ 3.24) levels, increased UXP (δ 
5.99 and δ 7.98) and UDP-GNAc (δ 5.52) derivatives and decreased Ino/Ado (δ 8.36) contents. In 
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order to confirm visual findings and unveil the most relevant drug-induced metabolic changes, 
multivariate analysis was applied to the 1H HRMAS spectra of controls and cDDP-treated cells. 
 
Figure 5.3. Average 700 MHz 1H HRMAS NMR spectra of MG-63 cells, at 48 hours: a) under control 
conditions, b) exposed to 30 µM cDDP and c) exposed to 50 µM cDDP. Insets show expansions of choline 
compounds (3.2-3.3 ppm) and aromatic (5.2-8.5 ppm) regions. Main assignments are noted and visible 
spectral changes due to drug exposure are marked with arrows. 
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Due to the similarity between the results of the two tested cDDP concentrations, for the 
sake of simplicity, only the results from 30 µM treatment (IC50 concentration) are shown here 
(Figure 5.4). 
 
Figure 5.4. Multivariate analysis of controls (z) and 30 µM cDDP-treated (c) cells: (a) PCA scores 
plot, UV scaled data (b) PLS-DA scores plot, UV scaled model with 2 components calculated with R2X = 
0.306, R2Y = 0.888 and Q2 = 0.745. MCCV results of PLS-DA model in b): c) Q2 distributions and d) ROC plots 
of true and permuted models. TPR: true positive rate, FPR: false positive rate, Sens.: sensitivity, Spec.: 
specificity, CR: classification rate. 
PCA analysis (Figure 5.4a) shows that no significant discrimination occurs between controls 
and cDDP-treated cells along PC1 until 24 hours of treatment, but a clear discrimination is 
observed for cells treated for  48 hours (negative PC1 and PC2). No evident time course tendency 
can be seen for either control or treated samples. The corresponding PLS-DA scores plot (Figure 
5.4b) shows good separation (Q2 0.745) between controls and cDDP-treated samples along LV1, 
although time course tendencies are again not completely consistent, while a progression 
tendency is suggested from negative to positive LV2 for controls and for lower negative LV1 in the 
case of treated samples. The robustness of group discrimination is reflected in a very low Q2 
a) b)
LV=2  Q2=0.745
Sens 72.8%  Spec 93.4%  CR 84.6%
c) d)
0%
5%
10%
15%
20%
25%
30%
35%
Fr
eq
ue
nc
y
Q2 values
True classes Permuted classes
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0.0 0.5 1.0
TP
R
 (s
en
si
ti
vi
ty
)
FPR (1-specificity)
True classes Permuted classes
-250
-200
-150
-100
-50
0
50
100
150
200
-400 -200 0 200 400
PC
2 
(1
3.
9%
)
PC1 (22.2%)
-150
-100
-50
0
50
100
150
200
-300 -200 -100 0 100 200
LV
2 
(1
1.
0%
)
LV1 (19.5%)
48h
0h
48h
0h
48h
48h
48h
Chapter 5 
 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
163 
 
distribution overlap (Figure 5.4c) and reasonable MCCV results: 72.8% sensitivity, 93.4% specificity 
and 84.6% classification rate (Figure 5.4d). 
The loadings plot coloured according to Variable Importance for Projection (VIP) values is a 
valuable tool to identify the signals that underlie class separation in PLS-DA models. The colour 
scale reflects the statistical relevance of the signals variation, with hot colours indicating more 
relevant changes. Accordingly, signals in the positive side of the VIP loadings plot for LV1 
correspond to signals increased in samples located in the LV1 positive of the corresponding scores 
plot, a similar reasoning applying to negative peaks and samples located in negative LV1 
quadrants in the scores plot. Figure 5.5 presents the VIP loadings plot of the model shown in 
Figure 5.4b. Variations in some metabolites are pin pointed as responsible for group separation 
upon cDDP exposure: increased lipid signals as well as of choline (δ 3.21) and GPC (δ 3.24), 
increased UXP (δ 5.99 and δ 7.98) and UDP-GlcNAc (δ 5.52) derivative, along with marked 
decreased m- and s-Inositol (δ 4.05 and δ 3.34), inosine/adenosine (δ 8.36) and phenylalanine (δ 
7.32). Hence, visual observations were confirmed and complemented by this analysis. 
 
Figure 5.5. Loadings plot coloured according to VIP values of UV scaled PLD-DA model of controls and 30 
µM cDDP-treated cells. 
Following this analysis, signal integration and univariate statistical evaluation of the 
changes identified the relevant metabolites variations at 48 hours were computed (Table 5.1) and 
are shown as time course plots in Figure 5.6. 
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Figure 5.6. Time course changes of metabolites varying with cDDP (30 µM) treatment (dashed -{-) in 
relation to control (full _z_): a) main compound variations and b) compound ratio variations. *p < 0.05 and 
*p < 0.01. 
As mentioned in the beginning of this section, the cDDP exposure results presently 
considered (and published in Lamego et al., 2014) were obtained through an improved processing 
of the data (peak alignment and PQN normalization), as compared to an initial report (Duarte et 
al., 2010). In spite some of the changes then reported having been shown presently to be not 
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significantly, namely regarding creatine, PC, succinate and taurine,  most  changes reported earlier 
were confirmed, while some were newly unveiled, namely for Pro, Thr, PE, UDP-GlcNAc and UXP 
(marked with § in Table 5.1). These correspond to low intensity resonances with a significant 
interference of noise and/or signals in which a considerable dispersion between replicates occurs, 
thereby more susceptible to be improved by the PQN normalization procedure used. 
The cDDP-induced adaptations of the MG-63 cells metabolome comprise: marked increases 
in all detected lipids resonances, reflected in increased (CH2)n/CH3 and –CH=CH-/CH3 ratios which 
respectively represent average chain length and unsaturation degree (Blankerberg et al., 1997) 
(Figure 5.6 and Table 5.1 and 5.2); increases in choline and GPC and no change in PC, leading to 
decreased PC/Cho and PC/GPC ratios (Figure 5.5 and Table 5.2), while PE decreases; large number 
of treatment-sensitive amino acids show a general decreasing tendency (exception for Val and 
Ile); changes in UXP and glucosylated derivatives (UDP-GNAc); strong decreases in m- and s-
Inositols in addition to an increase in acetate(s) (Figure 5.6 and Table 5.1). 
Table 5.1. Metabolite variations in MG-63 cells exposed to 30 µM cisplatin (cDDP), 3 µM doxorubicin 
(DOX) or 3 µM methotrexate (MTX) for 48 hours, compared to control cells. 
Metabolite 
Signal 
(δ/ 
ppm)a 
cDDP DOX MTX 
% var.b Effect size c %var.b Effect size c % var.b Effect size c 
Lipids 
-CH3 0.91 42.2±3.0** 8.88±2.46 _ _ _ _ 
-(CH2)n 1.30 115.6±2.4** 20.0±5.40 _ _ _ _ 
-CH2CH2CO 1.60  47.1±4.1** 7.24±2.04 _ _ _ _ 
-CH2COO 2.25  41.8±3.4** 6.98±1.97 _ _ _ _ 
=CHCH2CH= 2.83  61.1±12.6 2.88±1.00 53.4±10.5* 2.63±1.00 8.20±3.30 1.59±0.83 
-CH=CH- 5.33  228.1±9.6** 9.14±2.52 (+) (+) _ _ 
Choline and phospholipids 
Choline 3.21, s 32.7±6.4** 2.88±1.00 178±15.4* 3.94±1.31 41.1±16.0 1.26±0.78 
GPC 3.24, s 213±55.3 1.55±0.76 266±39.0 1.91 ± 0.86 (+) (+) 
PC 3.23, s _ _ -28.6±12.3 -1.77±0.83 -56.4±17.2 -3.91±1.40 
PE 3.25, s -19.0±5.5* -2.67±0.96§ (+) (+) (+) (+) 
Amino acids 
Alanine  1.40, d -8.40±1.90** -2.91±1.01 _ _ _ _ 
Glutamate  2.34, m -27.7±6.2** -2.79±0.98 _ _ -21.6±9.8 -1.54±0.82 
Glycine  3.56, s -35.6±9.0** -2.73±0.97 -28.0±13.6 -1.57±0.80 24.4±6.9 1.60±0.84 
Histidine 8.18, s (+) (+) _ _ (+) (+) 
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Table 5.1 (cont.). Metabolite variations in MG-63 cells exposed to 30 µM cisplatin (cDDP), 3 µM 
doxorubicin (DOX) or 3 µM methotrexate (MTX) for 48 hours, compared to control cells. 
Metabolite 
Signal (δ/ 
ppm)a 
cDDP DOX MTX 
% var.b Effect size c % var.b Effect size c % var.b Effect size c 
Isoleucine  1.02, d 12.3±5.1 1.75±0.80 _ _ _ _ 
Leucine  -10.0±2.9* -2.10±0.85 _ _ _ _ 
Lysine  1.72, m -12.6± 3.9* -2.04±0.84 (-) (-) _ _ 
Phenylalanine 7.32, d -23.0±4.1** -3.91±1.23 _ _ 17.6±4.2* 2.05±0.93 
Proline 4.12, t -10.1±5.8 -1.12±0.71§ _ _ _ _ 
Taurine 3.42, t (-) (-) (-) (-) -12.5±4.1 -1.76±0.87 
Threonine 3.58, d (-) (-)§ (-) (-) _ _ 
Tyrosine 6.89, d -19.9±7.1* -1.99±0.83 27.2±8.8 1.78±0.83 26.6±5.7 2.06±0.93 
Valine 1.05, d 12.0±5.3 1.59±0.77 _ _ (+) (+) 
Nucleotides and derivatives 
Ado/Ino 8.36, s -38.2±8.1** -3.41±1.12 _ _ _ _ 
UDP-GlcNAc 5.52, m 66.4±28.9 1.13±0.73§ 166±32.6  1.36±0.80 _ _ 
UXP  5.99, m 155±40.1 1.63±0.78§ _ _ (-) (-) 
 7.98, m 77.3±21.3* 1.72±0.79 (+) (+) _ _ 
Uridine 5.89, d _ _ (+) (+) 165.4±54.5 0.94±0.73 
Other compounds 
Acetate (s) 2.02, s 27.5±4.7** 3.17±1.06 _ _ _ _ 
Creatine 3.93, s _ _ 13.7±6.1 1.37±0.76 -10.7±3.7 -2.28±0.98 
GSH 2.56, m _ _ -20.3±7.6 -1.94±0.86 (-) (-) 
m-Inositol 4.05, t -60.7±13.9** -3.30±1.09 -53.0±10.9* -4.34±1.41 _ _ 
s-Inositol 3.34, s -37.8±8.9** -2.84±1.00 -22.1±8.3* -1.96±0.86 _ _ 
a Resonance chosen for signal integration, b % variation and c effect size in relation to control cells. * p < 
0.05,  ** p < 0.01, _ : no significant variation. (+) and (-) indicate consistent positive and negative variations, 
respectively, without statistical meaning. 
In the analysis of the values listed in Tables 5.1 and 5.2, variations were generally accepted 
as relevant when the corresponding errors did not exceed 50% of the variation (or ES) value. In 
some cases, however, variations affected by larger errors were also considered when carrying a 
known biochemical meaning. This is the case, for example, of UDP-GlcNAc variations (Table 5.1), 
noted before in other similar studies (Duarte et al., 2013; Pan et al., 2011). 
The information listed in Table 5.1 and the plots in Figure 5.6 show that treatment with 
cDDP for 48 hours induces severe changes in the metabolome of MG-63 cells, for instance note 
the dramatic increases of lipid moieties with statistical relevant variation (except for 
polyunsaturated fatty acid, PUFA) ranging from ca. 40% (-CH2COO- at 48 h) to around 230% (-
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CH=CH- at 48 h), together with high ES, ranging from almost 3 to 20. Furthermore, than 19% 
variations are noted in choline and phospholipids with corresponding ES values in the 1.5-2.9 
range and several amino acids statistically vary with cDDP-treatment (Ala, Glu, Gly, Leu, Lys, Phe 
and Tyr) with ES values ranging from 2 to almost 3 in relation to control conditions. Some 
nucleotides and derivatives (Ino/Ado and UXP) also show statistical relevant percentages of 
variation of 40-77% and ES values ranging from 1.7 to 3.34 (in magnitude) and variations in other 
compounds (acetate(s), m- and s-Ino) were also statistical relevant with significant ES values of ca. 
3. Table 5.2 and Figure 5.6b show that the above refered cDDP-induced alterations in lipids, 
choline and phospholipids are also reflected in statistical relevant alterations in some compound 
ratios, namely CH2/CH3, CH=CH/CH3 and PC/GPC. 
Table 5.2. Mean ratios for lipids and choline compounds in MG-63 cells exposed to 30 µM cisplatin 
(cDDP), 3 µM doxorubicin (DOX) or 3 µM methotrexate (MTX) for 48 hours, compared to control cells.  
Ratio  cDDP DOX MTX 
Controls cDDP  Controls DOX Controls MTX 
Lipid ratios 
CH2/CH3 1.96 ± 0.08 2.97 ± 0.12** 2.59±0.24 2.36±0.12 2.58±0.28 2.05 ± 0.21 
CH=CH/CH3 0.11 ± 0.01 0.26 ± 0.02** 0.19±0.02 0.29±0.04* 0.20±0.04 0.16 ± 0.02 
=CHCH2CH=/ CH3 0.20 ± 0.01 0.22 ± 0.02 0.20±0.06 0.31±0.01 0.18 ± 0.04 0.25 ± 0.02 
Choline compound ratios 
PC/Cho 2.17±0.60 1.72±0.29 2.18±0.64 0.56±0.15 2.68±0.46 0.83±0.08 
GPC/Cho 0.38±0.04 0.91±0.44 1.17±0.22 1.55±0.42 0.92±0.02 0.86±0.19 
PC/GPC 5.63±1.45 1.90±0.99* 1.86±0.52 0.36±0.18* 2.92±0.56 0.97±0.16 
Abbreviations as defined in Table 5.1. * p < 0.05,  ** p < 0.01. 
Accordingly, significant increases in the mean chain length (given by CH2/CH3) and 
unsaturation degree (CH=CH/CH3) of lipid fatty acids are depicted upon 48 hours treatment with 
cDDP. Additionally, a significant decrease in PC/GPC registered in MG-63 cells treated with cDDP 
for 48 hours suggest a drug-induced alteration in choline compounds, namely concerning its 
breakdown and storage pathways. 
 
5.2.2. Doxorubicin (DOX) 
The average 1H HRMAS spectra of control and DOX-treated MG-63 cells, at 48 hours, are 
shown in Figure 5.7a and b, respectively. Visual inspection highlights relevant changes in the 
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choline-compounds region (relative increases in choline and GPC), a relative decrease in m-
Inositol and some changes above 5 ppm, namely in UXP (δ 5.99 and δ 7.98) and UDP-GNAc 
derivatives (δ 5.52). 
 
Figure 5.7. Average 800 MHz 1H HRMAS NMR spectra of MG-63 cells, at 48 hours: a) under control 
conditions and b) exposed to 3 µM DOX. Insets show expansions of choline compounds (3.2-3.3 ppm) and 
aromatic (5.2-8.5 ppm) regions. Main assignments are noted and visible spectral changes due to drug 
exposure are marked with arrows. 
 
PCA of the 1H HRMAS spectra resulted in a clear separation between DOX-treated samples 
and controls, towards negative PC1 and positive PC2 (Figure 5.8a). Despite the suggestion of a 
time course tendency for control samples in PCA, such was only faintly observed for DOX-treated 
cells. The corresponding PLS-DA scores plot (Figure 5.8b) showed good separation between 
groups (Q2 0.665), although time course trajectories were again unclear. The robustness of group 
discrimination was reflected in a low Q2 distribution overlap and reasonable MCCV results (82.7% 
sensitivity, 90.2% specificity and 86.9% classification rate, Figure 5.8c and d). Despite these 
a) Control cells at 48 hours
b) DOX-treated cells at 48 hours
8.00 7.00 6.00 5.00 4.00 3.00 2.00 1.00 ppm
3.400 3.350 3.300 3.250 3.200 3.150 3.100 ppm
8.00 7.50 7.00 6.50 6.00 5.50 ppm
8.00 7.00 6.00 5.00 4.00 3.00 2.00 1.00 ppm
3.400 3.350 3.300 3.250 3.200 3.150 3.100 ppm
8.00 7.50 7.00 6.50 6.00 5.50 ppm
Lf.a. CH3,
Val, Ile, Leu
Lf.a. (CH2)n,
Thr, Lac
Lf.a.
CH=CH
Phe
Tyr Cho
Glu, Gln, GSH, 
N-acetyl
Ala
PC
GPC
GSH
Lys
m-Inositolm-Inositol
Creatine
Ino/Ado
Ino/Ado
UXP
Urd
Urd
UXP
s-Inositol
Tau
Creatine
GSH
x8
x8
UDP-GNAc
8.00 7.00 6.00 5.00 4.00 3.00 2.00 1.00 ppm
Chapter 5 
 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
169 
 
results, some dispersion within the true classes samples is seen in Figure 5.8d, but it is noted that 
only 5 samples are dispersed from the whole rest of samples that cluster together. 
 
Figure 5.8. Multivariate analysis of controls (z) and DOX-treated (c) cells: (a) PCA scores plot, 
centered scaled data (b) PLS-DA scores plot , UV scaled model with 2 components calculated with R2X = 
0.243, R2Y = 0.918 and Q2 = 0.665. MCCV results of PLS-DA model obtained in b): c) Q2 distributions and d) 
ROC plots of true and permuted models. TPR: true positive rate, FPR: false positive rate, Sens.: sensitivity, 
Spec.: specificity, CR: classification rate. 
 
The VIP-coloured loadings (Figure 5.9) indicates decreases of m-Inositol (δ 4.05) and N-
acetyl (δ 2.01) moieties in contrast with increases of Ala (δ 1.48), creatine (δ 3.03), choline (δ 
3.21), GPC (δ 3.24) as well as of UXP (δ 5.99 and δ 7.98) and UDP-GlcNAc (δ 5.52). 
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Figure 5.9. Loadings plot coloured according to VIP values of UV scaled PLD-DA model of controls 
and 3 µM DOX-treated cells. 
 
Subsequently to signal integration, statistical calculations identified the most relevant 
compound variations (Table 5.1) and some compound ratios (Table 5.2) for 48 hours and shown 
as time course plots in Figure 5.10. These results show that the metabolic response of MG-63 cells 
to DOX exposure is described by residual changes in lipids with small increases in =CHCH2CH= and 
–CH=CH- resonances at 48 hours (around 53% with an ES value of 2.6), also expressed by modest 
changes in =CHCH2CH=/CH3 and –CH=CH-/CH3 lipid ratios (Figure 5.10b and Table 5.2). A marked 
increase in choline and GPC (of 178% and 266%, corresponding to ES values of around 4 and 2, 
respectively, at 48 hours), in tandem with PC decrease (negative variations of 29%, with ES value 
of -1.8) is seen, resulting in significant decreases in PC/Cho and PC/GPC ratios (Figure 5.10b and 
Table 5.2). Moreover, strong decreases in Gly (-28% with an ES value of -1.6) and Tyr increase 
(which, despite being positive, is identical in % and ES value to that of Gly) is detected, together 
with slight decreasing tendencies in other amino acids (Table 5.1). A large increase in UDP-GlcNAc 
at 24 and 48 hours (of around 166% and ES of 1.4) is observed, as well as small increases in UXP 
and uridine (Table 5.1). Creatine significantly increases (14% with an ES value of 1.4) whereas a 
decrease in seen for GSH (-20% and -1.9) and m- and s-Inositols (with -53% to -22% variation, to 
which correspond ES values ranging from -4.3 to -2). 
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Figure 5.10. Time course of metabolites varying with DOX treatment (dashed -{-) in relation to 
control (full _z_): a) main compound variations and b) compound ratio variations. *p < 0.05 and *p < 0.01. 
In general, the above refered DOX-induced changes in the metabolome of MG-63 cells were 
both reduced in number and magnitude when compared to those induced by cDDP. Interestingly, 
the only observed change in lipids occurs in PUFA moieties (δ 5.33), and its 53% of variation was 
found to be statistically relevant, corresponding to a significant ES value of 2.6, this being similar 
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to that obtained by cDDP-treatment (which in turn, did not correspond to a significant percentage 
of variation). This result shows that the two drugs display different modes of action, despite their 
common target (DNA), leading to markedly different metabolism of lipids. Similarly to cDDP, DOX-
treatment also triggers statistically relevant changes in choline, to which a significantly high value 
of ES of almost 4 was calculated, i.e. even more marked than the change observed with cDDP. In 
relation to amino acids, no statistically relevant changes were found, despite the relatively high ES 
values (around 1.6 and 1.8 in magnitude). A marked but not statistically significant increase of 
UDP-GlcNAc (δ 5.52) of 166% was noted, contrasting with the significant 53% and 22% decreases 
in m- and s-Inositol, for which ES values ranging from 2 to more than 4, similarly to that measured 
in cDDP-treatment). 
 
5.2.3. Methotrexate (MTX) 
The average 1H HRMAS spectra of control and 48 hours MTX-treated MG-63 cells are shown 
in Figure 5.11a and b, respectively.  
 
Figure 5.11. Average 800 MHz 1H HRMAS NMR spectra of MG-63 cells, at 48 hours: a) under control 
conditions and b) exposed to 3 µM MTX. Insets show expansions of choline compounds (3.2-3.3 ppm) and 
aromatic (5.2-8.5 ppm) regions. Main assignments are noted and visible spectral changes due to drug 
exposure are marked with arrows. 
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Visual inspection suggests that the treatment with MTX slightly affects lipid contents, alters 
the relative proportion of choline compounds (decrease in PC, δ 3.23, and possible increase in 
choline, δ 3.21), changes levels of UXP (either UDP/UTP at δ 5.99 and δ 7.98 and UDP-GNAc 
species, δ 5.52), uridine (δ 5.89) and Ino/Ado (δ 8.36). 
Multivariate analysis of the spectra of controls and MTX-treated samples show that group 
separation is not clear in the PCA scores plot (Figure 5.12a) but becomes obvious in the 
corresponding PLS-DA scores plot (Figure 5.12b). 
 
Figure 5.12. Multivariate analysis of controls (z) and MTX-treated (c) cells: (a) PCA scores plot, UV 
scaled data (b) PLS-DA scores plot , UV scaled model with 2 components calculated with R2X = 0.262, R2Y = 
0.902 and Q2 = 0.622. MCCV results of PLS-DA model in b): c) Q2 distributions and d) ROC plots of true and 
permuted models. TPR: true positive rate, FPR: false positive rate, Sens.: sensitivity, Spec.: specificity, CR: 
classification rate. 
MCCV results (Figure 5.12c and d) reflect a slightly lowered performance of the model (Q2 
0.622, 84.2% sensitivity, 89.3% specificity and 87.0% classification rate) when compared to cDDP 
exposure, suggesting an overall lesser impact of MTX on the cell metabolome compared to this 
LV=2  Q2=0.622
Sens. 84.2%  Spec. 89.3%  CR 87.0%
a) b)
c) d)
-250
0
250
-300 -200 -100 0 100 200
PC
2 
(1
6.
7%
)
PC1 (20.2%)
0-12h
-150
-100
-50
0
50
100
150
200
-200 -100 0 100 200
LV
2 
(9
.9
%
)
LV1 (16.4%)
48h
0-12h
36h48h
24h
24h
48h24h
48h
12h
36h
36h
12h
36h
24h
12h
0%
5%
10%
15%
20%
25%
30%
Fr
eq
ue
nc
y
Q2 values
True classes Permuted classes
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0.0 0.5 1.0
TP
R
 (s
en
si
ti
vi
ty
)
FPR (1-specificity)
True classes Permuted classes
Metabolic Impact of Conventional Drugs on Osteosarcoma MG-63 Cells 
 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
174 
 
drug. Similarly to what was seen for DOX, MCCV results seem to be affected by a reduction in 
sensitivity and specificity of a few samples, evidenced in Figure 5.12d by their slight dispersion in 
relation to the remaining samples. 
The VIP-coloured loadings plot (Figure 5.13) point to a distinct drug response profile, 
namely in choline compounds and nucleotide bases regions. Changes in lipids also seem to 
account for relevant differences between control and MTX-treated samples with decreases being 
suggested for CH3 (δ 0.91) and (CH2)n (δ 1.30) in treated samples. Decreases in PC (δ 3.23), N-
acetyl moiety (δ 2.02), GSH (δ 2.56), Glu (δ 2.34) and Ino/Ado (δ 8.36) as well as an increase of 
uridine (δ 5.89) were also pointed by PLS-DA as metabolic consequences of MTX-exposure. 
 
Figure 5.13. Loadings plot coloured according to VIP values of UV scaled PLD-DA model of controls 
and 3 µM MTX-treated cells.  
Following the previously established procedure of data analysis, signal integration and 
statistical evaluation of changes were performed and are shown as time course graphs for each 
measured metabolite and listed in Table 5.1 (for 48 hours only). This confirms the following 
adaptations as induced by MTX: nearly absent lipid changes (Figure 5.14 and Table 5.1 and 5.2), 
showing that the VIP-loadings results were strongly influenced by the considerable dispersion 
between replicates in what concerns lipid signals. Additionally, almost no changes in choline and 
GPC (exception for small increases at 48 hours) and a marked increase in PC are detected (Figure 
5.14a and Table 5.1), thus resulting in a strongly decreased PC/Cho and PC/GPC ratios (Figure 
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5.14b and Table 5.2). Furthermore, the amino acids Gly, Phe and Tyr increase and decreases in 
Glu and Tau are seen (Figure 14a and Table 5.1). MTX-treatment also seems to induce important 
increases in uridine (although with a large uncertainty in effect size value) and small decreases in 
creatine, as well as a modest decrease of GSH. For the first time (considering metabolic responses 
to cDDP and DOX) no changes in inositols are observed. 
 
Figure 5.14. Time course of metabolites varying with MTX treatment (dashed -{-) in relation to 
control (full _z_): a) main compound variations and b) compound ratio variations. *p < 0.05. 
The number of statistically relevant changes in MG-63 cells induced by MTX-treatment is 
lower than that determined for both DOX and cDDP (even more pronounced), reflecting the 
modest metabolic impact of this antifolate agent on these cells. 
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5.3. 1H NMR Analysis of TCA Extracts of cDDP-, DOX- and MTX-Treated Cells 
Acidic extraction with trichloroacetic acid (TCA) denatures and precipitates proteins and 
other macromolecules, and enables elimination of the volatile TCA by lyophilisation (McQueen, 
2010). TCA extracts of mammalian cells have succeeded in revealing several nucleotide 
derivatives (AXP, UTP and NAD+) signals (Lane et al., 2007; Fan et al., 2008). In this section, TCA 
extracts from controls and drug-treated samples at 48 hours (previously analysed by HRMAS) are 
compared. Since some of the tested drugs target DNA (cDDP and DOX), the analysis of TCA 
extracts aimed at extracting information on possible drug-induced changes in nucleotides and 
their derivatives. Below, a first comparison between the information retrieved by HRMAS and TCA 
extracts spectra is presented. 
  
Figure 5.15. Average 500 MHz 1H NMR spectra of MG-63 cells, at 48 hours: a) HRMAS and b) TCA 
extract. Expansion of the aromatic (5.0-9.5 ppm) region is shown. Main assignments are noted and those 
indicated in b) reflect those newly detected through analysis of extracts. 
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Figure 5.15 compares the metabolic profile of control cells at 48 hours when analysed by 
HRMAS (Figure 5.15a) and their respective TCA extracts (Figure 5.15b). Both HRMAS and TCA 
extracts yielded 1H NMR spectra with very similar resolutions (width at half height, ν½, of 1.8 Hz 
for inosine at δ8.36 for the two spectra). Additionally, the NMR spectra of TCA extracts improve 
the information on nucleotide derivatives since ADP, ATP, UMP, UDP and ATP signals are only 
visible upon TCA extraction of samples. Moreover, the resonances of NAD+, only slightly visible in 
the HRMAS spectra, are clearly identified in the spectra of TCA extracts. Glucose, which is also not 
visible in the HRMAS spectra of cells, probably due to low intracellular amounts and binding to 
other molecules, is clearly detected in the spectra of TCA extracts. On the other hand, resonances 
from lipids (δ 0.90, δ 1.31) and from other macromolecules that show broad signals in the HRMAS 
spectra (e.g. δ 7.37) are lost in the spectra of TCA extracts as expected. The 2D TOCSY spectrum of 
a control extract sample (not shown) also indicates that oxidation of glutathione takes place 
during TCA extraction: when assigning the glutathione spin system, the typical GSH resonance at δ 
4.58 (present in the spectra of samples analysed by HRMAS) disappears and the GSSG typical 
resonance at δ 4.78 clearly emerges. This highlights the additional issue of oxidation arising from 
this type of sample manipulation, which must be taken into consideration when choosing 
between the two types of sample analysis. 
Cell exposure to chemotherapy drugs may induce metabolic changes in nucleotides and 
derivatives, especially when considering metal-based agents that target DNA (as cDDP). 
Therefore, in order to detect more detailed alterations in these compounds, analysis of the 
aromatic region of TCA extracts of cell samples exposed to cDDP, DOX or MTX was performed 
(Figure 5.16). The average spectra of TCA extracts of cDDP-treated cells (Figure 5.16b) shows that 
treatment with this metal-based agent induces the disappearance of ADP/ATP and NAD+ signals 
relative to the control (Figure 5.16a). Additional changes in the metabolic profile of the aromatic 
region of cDDP-treated cells are detected: Ino/Ado decreases in relation to uridine and UXP, 
which also seem to increase with treatment. When looking at the average spectrum of TCA 
extracts of DOX-treated cells (Figure 5.16c), resonances from ADP/ATP and NAD+ (as with cDDP) 
and UXP, clearly disappear. Moreover, Ino/Ado signal clearly decreases in comparison to uridine 
(that seems to increase in relation to controls) and hypoxanthine increases. Similar alterations are 
seen in TCA extracts of MTX-treated cells (Figure 5.16d). The unassigned resonance (Un.) also 
disappears after treatment with any of the three drugs.  These results suggest that DOX and MTX 
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treatments induce similar changes in nucleotide derivatives, these differing dramatically from the 
effects of cDDP exposure. 
  
Figure 5.16. Average 500 MHz 1H NMR spectra of TCA extracts of MG-63 cells, at 48 hours: a) under 
control conditions, b) exposed to 30 μM cDDP, c) exposed to 3 μM DOX and d) exposed to 3 μM MTX. 
Expansion of the aromatic (5.0-9.5 ppm) region is shown. Main assignments are noted and visible spectral 
changes due to drug exposure are marked by arrows. 
These observations are somewhat surprising when considering the different mechanisms of 
action of each drug. In fact, it would be expected that DOX-induced changes would more closely 
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resemble those induced by cDDP, since both drugs target DNA (although through a different 
mechanism). In addition, since MTX is an antifolate drug, not directly targeting DNA, no 
pronounced changes in nucleotides would be expected. Therefore, it may be concluded that the 
relation of the nucleotide profile (as viewed through TCA extracts) and the drug mechanism is not 
a straightforward one, requiring more detailed investigation.  
In terms of comparison between the information provided by HRMAS and TCA extracts, the 
information retrieved by HRMAS analysis of the same samples only revealed significant decreases 
in Ino/Ado upon cDDP treatment, while TCA extracts showed a decrease in Ino/Ado contents for 
the three treatments. HRMAS analysis showed similar variation trends in UXP levels with cDDP 
and MTX (increase and decrease, respectively) in relation to TCA extracts, but slight increases of 
UXP were suggested to occur upon DOX treatment while in TCA extracts UXP signal is not 
detected. Uridine, suggested to increase upon treatment with each of the three drugs according 
to the information contained in the spectra of the respective TCA extracts, was also increased in 
DOX- and MTX-treated samples analysed by HRMAS, whereas no significant changes were 
measured upon cDDP-exposure. These differences identified between HRMAS and TCA extracts in 
what regards to drug-induced changes in nucleotides and derivatives may relate to the high 
concentration of these compounds in extracts, possibly leading to a more accurate determination 
of compound fluctuations. 
 
5.4. Comparison of the Metabolic Impact of cDDP, DOX and MTX 
The heatmap of the effect size values shown in Figure 5.17a illustrates the most relevant 
drug-induced time course changes, hot and cold colors expressing, respectively, increased and 
decreased metabolite levels in the drug-treated samples as compared to controls. Clearly, the 
numerous yellow/orange patches seen in lipid resonances are a clear signature of cDDP response, 
whereas smaller and fewer changes in this region are noted for DOX and MTX. The increase in 
PUFA is a common feature to the three tested drugs, although more marked for DOX (even 
though total visible lipids do not increase). Regarding phospholipid related compounds, drug-
specific changes include a PE decrease for cDDP, a marked PC decrease for MTX and a mixed 
behaviour for DOX (PC reduction and rise in both Cho and GPC). The heatmap of the compound 
ratios (Figure 5.17b), in turn,  clearly evidences the time course increase in lipid chain length and 
unsaturation degree due to cDDP treatment, along with a suggestion of chain length shortening 
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for DOX and MTX, which, for the former is possibly accompanied by a some increase in lipid 
unsaturation degree, including in PUFA. Moreover, the distinct choline signatures detected in 
Figure 5.17a are highlighted when considering PC/Cho and PC/GPC ratios: cDDP affects these 
ratios to a much lesser extent than DOX or MTX, the latter leading to a clear gradual time-
dependent response in both cases. These findings allow choline ratios to be identified as 
particularly sensitive markers of MG-63 cells metabolic response to DOX and MTX. 
Regarding amino acids, a quite distinct colour distribution is obtained for the three drugs: 
for cDDP, a decrease in amino acid content (blue patches) is predominant, especially upon 48 
hours of drug effect, whereas increases (yellow patches) dominate for DOX and MTX. The 
nucleotide bases profiles also seem distinct, with some pronounced changes detected for cDDP 
(Ino/Ado decrease and an increase in UXP species), whereas DOX and MTX induce, respectively, 
small increases (yellow) and decreases (blue) in these compounds. Special emphasis should be 
paid to the uridine variation at 48 hours with MTX, which is not reflected in the heatmap due to 
the high associated effect of size uncertainty. 
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Figure 5.17. Heatmaps of effect size values of the time course response for a) several metabolites 
and b) compound ratios in MG-63 cells exposed to DOX, MTX or cDDP. The effect size values are shown in a 
colour scale from minimum (dark blue) to maximum (dark red) values. * p < 0.05 and ** p < 0.01 refer to 
the results of significance tests with integrals. 
Concerning other compounds, a concomitant decrease in m- and s-Inositols, characteristic 
of cDDP and DOX responses, is shown to be absent in MTX treatment, and distinct trends are seen 
for acetate(s), creatine and GSH (with minor increases in the presence of cDDP at 24 hours and 
also minor decreases for DOX and MTX). 
 
It is now clear that exposure to cDDP induces a much stronger metabolic response in MG-
63 cells than incubation with either DOX or MTX. The following integrated discussion about the 
results obtained for these three drugs considers the cells metabolic response to cDDP as a 
reference and compares it to the other two drugs (one anticancer antibiotic and one 
antimetabolite), discussing the impact on the metabolic pathways associated with lipids and 
choline compounds, amino acids and nucleotides, among others (such as GSH and inositols). This 
work has been recently published in Lamego et al. 2014. 
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Biochemical interpretation of the results 
Lipids and choline compounds 
Some of the main differences between MG-63 cell responses to the three tested drugs 
relate to lipids and choline compounds. The significant lipids increase observed in the presence of 
cDDP was expected from previously reported studies, not only on OS cells (Duarte 2010) but also 
on different tumour lines (Pan et al., 2011; Pan et al., 2013; Duarte et al., 2013; Huang et al., 
2003; Lindskog et al., 2004). NMR-visible lipid signals are believed to arise mainly from cytosolic 
lipid droplets (composed of mobile neutral lipids), rather than membrane components (Hakumaki 
and Kauppinen, 2000; Delikatny et al., 2011), but additional contributions have been suggested 
from membrane lipid microdomains or lipid rafts (Santini et al., 2001; Mannechez et al., 2005). An 
increase in neutral lipids have been associated with cell apoptosis (Huang et al., 2003; Rainaldi et 
al., 2008; Boren and Brindle, 2012), although some authors propose that they may also be due to 
other (still unspecified) causes (Milkevitch et al., 2005; Santini et al., 2006; Mirbahai et al., 2012). 
Specifically, it has been anticipated that apoptosis involves inhibition of mitochondrial fatty acid 
E-oxidation and divertion of fatty acids to an enhanced de novo lipid synthesis (Boren and Brindle, 
2012), thus leading to an intensification of the corresponding NMR-visible signals. Also, increased 
lipid chain length and unsaturation degree, as clearly observed in this work for MG-63 cells 
exposed to cDDP, have also been suggested as indicative of apoptosis (Huang et al., 2003; 
Zietkowski et al., 2012). The PUFA structures, detected here for the first time in cDDP-treated OS 
cells through the =CHCH2CH= resonance (60% increased upon cDDP treatment for 48 hours), have 
been specifically suggested as pre-apoptotic functional lipid mediators in the cell death pathway 
(Pan et al., 2013). Remarkably, MG-63 cells exposed to DOX or MTX failed to exhibit an increase in 
neutral lipids (resonances assigned to CH3 and (CH2)n),  faint decreases having even been 
suggested (Figure 5.17a). In turn, particularly for DOX, increases in the PUFA resonance were 
observed. Up-regulation of the levels of neutral lipids (usually taken as apoptosis signs) was 
absent in previous studies with DOX-treated melanoma (Triba et al., 2010), leukemia (Rainaldi et 
al., 2008) and breast and colon carcinomas (Santini et al., 2001), suggesting that no significant 
apoptosis is taking place in cells exposed to DOX or MTX, under the present experimental 
conditions. However, the increase in PUFA moieties (for both DOX and to a lesser extent for MTX) 
and the knowledge that both these drugs are known to ultimately induce apoptotic cell death 
(Minotti et al., 2004; Schmiegelow et al., 2009), suggests that apoptosis is perhaps at a very early 
stage at the time of sampling (contrary to cDDP-treated cells).  
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Regarding phospholipid-related compounds, the changes in choline metabolites previously 
reported for cDDP (Duarte et al., 2010) have been confirmed through the data reprocessing 
procedure presently carried out, and a relevant decrease in PE was now observed for the first 
time. cDDP is believed to induce membrane breakdown in MG-63 cells, leading to large and mild 
increases in GPC and Cho, respectively, the latter being also affected by an involvement in 
enhanced phospholipid biosynthesis through PC formation and/or PTC-cycle regulation (Duarte et 
al., 2010). The GPC peak at δ 3.24 correlated positively with the PUFA resonance (Figure 5.18), 
through STOCSY experiments, suggesting a close metabolic link to phosphatidylcholine (PTC) 
hydrolysis, which possibly releases PUFAs into the cytosol thus contributing to the NMR spectrum. 
It is important to note that STOCSY correlations between different compounds may indeed reflect 
metabolic links, but may also be simply casual, ultimate confirmation of metabolic relationships 
thus requiring additional evaluation, namely through specific pathway analysis. Regarding the 
elevated PC levels in cDDP-treated cells, as compared to controls (Figure 5.6), are proposed to be 
due to an intracellular overexpression of PE to PC conversion in order to sustain PTC synthesis, 
probably as an attempt to compensate for the concomitant membrane breakdown. Actually, 
these elevated PC levels seem specific of cDDP action (except at 48 hours), since relatively large 
PC decreases are observed for both DOX (Table 5.1, Figure 5.10) and MTX (Table 5.2, Figure 5.14), 
with no enhanced use of PE being noted (PE even experiences a slight increase, Table 5.1). 
For DOX, the variations in choline compounds differ from the reported data on other DOX-
treated cells (Sterin et al., 2001; Rainaldi et al., 2008; Triba et al., 2010), once more highlighting 
the strong dependence of drug effects on the cell type. Lower PC levels were accompanied by a 
large increase in GPC and Cho, the latter reflecting an extensive membrane breakdown through 
phospholipases action. Lowered PC levels are usually associated with reduced PTC biosynthesis, 
accompanying cell growth arrest and apoptosis (Knijn et al., 2005), but may also arise from 
enhanced catabolism to Cho (probably more active in the presence of DOX as compared to cDDP, 
given the much larger observed Cho increase for DOX). Low PC levels have also been proposed to 
evidence inhibition of de novo biosynthesis of cytosolic lipids (Ross et al., 2008), an effect possibly 
responsible for the lack of lipids increase in the DOX-treated cells. Furthermore, STOCSY analysis 
identified strong positive correlations between both GPC and Cho and the PUFA resonance 
(results not shown), once more establishing a clear relationship between membrane degradation 
and an increased polyunsaturation degree, clearly reflected in the NMR-visible lipids. Since no 
concomitant increase in lipids occurs, the proportion of cytosolic PUFA lipids should be increasing, 
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while keeping the total lipids amount unchanged, through a mechanism that still remains unclear 
at this stage. 
 
Figure 5.18. STOCSY results obtained for PUFA resonance at δ2.83, obtained for cDDP-treated cells. 
The above described changes translate into a clear decrease in the PC/GPC and PC/Cho 
ratios (Figure 5.17b), the former having been related to cell growth arrest prior to apoptosis 
(Mirbahai et al., 2011). The distinctly different signature observed for MTX comprises a more 
marked decrease in PC than for DOX, reflecting a further decrease in PTC synthesis, and no 
meaningful changes in GPC or Cho (no significant membrane breakdown) were detected, in 
accordance with reports on MTX-treated breast cancer cells (Sterin et al., 2001) and imatinib-
treated leukemia cells (Klawitter et al., 2009). These changes originate steadier decreases for 
PC/GPC and PC/Cho, which establish a clear signature for MTX reflecting, as for DOX, lower PTC 
synthesis not leading to the expected lipids accumulation. 
Amino acids 
The previously reported large impact of cDDP on the amino acid metabolism in MG-63 cells 
(Duarte et al., 2010) was confirmed after the present data reprocessing, with much less significant 
effects observed for DOX- and MTX-treated cells. For cDDP, the residually lower Tau levels (and 
the absence of measurable GSH changes) suggested a low level of oxidative stress (similarly to 
cDDP-treated lung cancer cells (Duarte et al., 2013), which probably justifies the efficiently 
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levelled GSH contents. Since Glu and Gly are GSH precursors (through the J-glutamyl cycle 
(Macnicol et al., 1987), the concomitant decreases in both amino acids could also evidence some 
degree of activation of antioxidant protection mechanisms, which are often associated with cell 
cycle arrest and apoptosis (Santini et al., 2006; Garcia-Alvarez et al., 2011; Mirbahai et al., 2011; 
Santini et al., 2001; Triba et al., 2010). However, together with an Ala decrease (also observed in 
this work, for cDDP-treated cells), Gln/Glu reduction may also be indicative of enhanced Krebs 
cycle and oxidative phosphorylation activities, in order to produce more ATP to sustain apoptosis 
(Triba et al., 2010). In the OS cell line currently tested, this was not corroborated by variations in 
lactate or Krebs cycle intermediates (Mirbahai et al., 2011; Klawitter et al., 2009), but the 
decrease in Gly, Leu, Lys, Phe, Pro and Tyr may arise from their enhanced catabolism via an 
activated Krebs cycle, while acetate(s) may indicate a higher mithochondrial lipids E-oxidation 
activity. Finally, Val and Ile, not previously evaluated in cDDP-treated MG-63 cells, evolve against 
the general trend of amino acids decrease. STOCSY analysis (data not shown) revealed positive 
correlations of these branched chain amino acids with a typical lipidic profile, possibly due to the 
fact their catabolism crosses with the biosynthesis of branched chain fatty acids.  
In DOX-treated cells, no relevant amino acid indicators of oxidative stress (decrease in 
Gln/Glu or Tau) were noted, although DOX induces a relevant decrease in intracellular GSH 
(reported by Cao et al., 2013 and Rainaldi et al., 2008). The absence of a consistent depletion of 
cellular amino acids (with even a positive variation detected for Tyr), suggests no Krebs cycle 
activation, although some kind of bioenergetic disturbance is noted through the increase in 
creatine, also reported to change in MG-63 spheroids exposed to radiation (Santini et al., 2006). 
On the other hand, in MTX-treated cells, Tau and Glu are clearly diminished, while GSH is slightly 
decreased, thus suggesting an oxidative stress enhancement. Furthermore, the observed increase 
in Gly, Tyr and Phe (in contrast to cDDP) may stem from their underuse as anaplerotic agents in 
the TCA cycle, possibly indicating a slowing down of the energy metabolism, in agreement with 
the observed creatine depletion (opposite to DOX-treated cells). 
Nucleotide bases and other compounds 
The nucleotide base signatures are quite distinct between the three tested drugs, showing 
an increase in UXP and UDP-GlcNAc species having been observed for cDDP- and DOX-treated 
cells, and a marked Ado/Ino decrease for cDDP (apparently specific for this drug). The rise in UXP 
and UDP-GlcNAc may relate to the fact that both cDDP and DOX exert their activity through 
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interaction with DNA (covalent binding or intercalation, respectively) and subsequent DNA 
conformational changes, and the distinct overall nucleotide profiles may relate to the different 
specific mechanisms (pharmacodynamics) involved. For MTX, the general absence of relevant 
changes (including for uridine, despite the apparent increase at 48 hours) or the decreasing 
tendencies for Ado/Ino and UXP are consistent with MTX (an antifolate) being known to hamper 
de novo purine synthesis, probably keeping nucleotide levels low or unchanged, including those of 
pyrimidine bases (such as uridine and UXP). 
Specifically regarding UDP-GlcNAc, a donor in the glycosylation processes of post-
translational proteins (Pan et al., 2011; Grande et al., 2011) its increase was newly noted in this 
work in cDDP- and DOX-treated OS cells (remaining unchanged for MTX). This compound was 
previously seen to increase, along with UDP-GalNAc, in cDDP-treated brain tumour (Pan et al., 
2011) and lung cancer cells (Duarte et al., 2013), having been correlated to mobile lipids 
associated to apoptotic cell death. However, STOCSY analysis of the data (Figure 5.19a) failed to 
reveal any correlation to lipid resonances in cDDP-treated OS cells, showing positive correlations 
with GPC, Cho and PC (membrane degradation metabolism), and creatine and GSH (antioxidative 
process), with negative correlations with Lys, uridine and Ado/Ino (the latter proposed to vary 
relative to cDDP-induced DNA damage). 
 
a)
UXP
UXP
Ino/Ado Ino/Ado
UrdUrd
UDP-GlcNAc
UDP-GNAc
(δ2.08, δ2.09)
GSH
Creatine
Creatine
GSH
GSH
Lys
Cho
PC
GPC
m-Inositol
Chapter 5 
 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
187 
 
 
Figure 5.19. STOCSY results obtained for UDP-GlcNAc resonance at δ5.52, obtained for a) cDDP-
treated and b) DOX-treated cells. 
In DOX-treated cells (Figure 5.19b), UDP-GlcNAc (much increased relatively to cDDP) again 
correlates positively with the main membrane degradation products (GPC and Cho) and creatine 
but notably, not to GSH thus suggesting that in DOX-treated cells, the main metabolic origin of 
UDP-GlcNAc does not relate to antioxidative mechanisms as opposed to cDDP-incubated cells. In 
addition, for DOX, UDP-GlcNAc actually correlates negatively with lipids, in agreement with the 
slight decrease seen for CH3 and (CH2)n resonances (Figure 5.17) once more contradicting a direct 
relationship with a neutral lipids increase. Overall, the above observations suggest a general 
connection of UDP-GlcNAc with the active and preferential pathways of membrane degradation 
and energy metabolism (through creatine), while in cDDP an additional link to cellular oxidative 
state seems to exist.  
Finally, some considerations are due regarding the marked decrease in m- and s-inositols 
(mainly for the former), detected for both cDDP- and DOX-treated cells. In turn, these compounds 
were unchanged in MTX-treated cells. Depletion in m-inositol has been previously reported 
(Griffin et al., 2003; Knijn et al., 2005; Triba et al., 2010) several explanations having been put 
forward: disturbance in its osmolytic function through drug-induced partial inhibition of the 
Na+/m-inositol co-transporter (SMIT) (Knijn et al., 2005); diminished inhibition of the mitogen-
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activated protein kinase (MAPK) signal transduction pathway, thus leading to stimulation of cells 
into apoptosis (Knijn et al., 2005); effect on the biosynthesis and turnover of some phospholipids 
(Ferreti et al., 2002); or activation of cell detoxification processes. 
With a view to clarify the role of inositols in treated MG-63 cells (particularly with cDDP and 
DOX), STOCSY analysis of the inositol resonances (not shown) revealed that in the presence of 
cDDP m-inositol decreases concomitantly with Tau, Glu/Gln and creatine (besides s-inositol), 
whereas in DOX-treated cells m-inositol is reduced together with Glu/Gln and GSH (and s-inositol). 
These observations allowed a significant inositol decrease to be identified as preferentially related 
with an ongoing antioxidative mechanism, although the corresponding metabolite signatures 
seem distinct: i) for cDDP, it is apparent that Tau, Glu/Gln, inositols and ( possibly) creatine help to 
regulate GSH levels efficiently (since such levels are unchanged upon drug treatment); ii) for DOX, 
Glu/Gln and inositols alone seem to be insufficient to avoid a concomitant GSH use in the cellular 
response to oxidative stress (negative variation, Table 5.1). For MTX, the resonances due to 
inositols, although unchanged upon drug treatment, were found to also correlate weakly to 
Glu/Gln, GSH and, possibly, creatine, confirming the proposed link to an antioxidative response. 
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6. Metabolic Impact of Pd2Spm on Osteosarcoma 
MG-63 Cells and Comparison with Osteoblast HOb 
Cells 
This chapter describes the application of the methodology used in the previous chapter to a 
similar study regarding a palladium complex with the biogenic polyamine spermine (Spm), 
Pd2Spm, which has been reported  to display significant antineoplastic activity (Fiuza et al., 2011). 
Platinum and palladium belong to the same group (X, ten) of the periodic table, thus 
presenting similar coordination chemistry. Palladium (II) has lately attracted considerable interest 
as a potential metal ion center in drug formulations capable of effectively interacting with DNA 
while circumventing undesired toxicity and resistance phenomena usually associated with 
platinum agents (e.g. cDDP) (Marques, 2013; Silva et al., 2014; Silva et al., 2013; Fiuza et al., 2011; 
Tummala et al., 2010; Corduneanu et al., 2010). Pd2Spm in particular, has shown very promising 
results towards a human breast cancer cell line, MDA-MB-231 (Fiuza et al., 2011), showing 
improved cytotoxic action coupled to less deleterious side-effects (damages in DNA and impact 
over cytoskeleton) when compared to cDDP. This chapter evaluates the metabolic response of 
MG-63 cells to Pd2Spm, compared to that of cDDP. Moreover, a human osteoblast cell line (HOb) 
was analysed by HRMAS NMR in the presence of either cDDP or Pd2Spm, this constituting the first 
reported study of the metabolic consequences of treatment in healthy cells, to our knowledge. 
Besides providing a more comprehensive knowledge of the impact of chemotherapy in both 
tumour and healthy cells, these results can help understand which of the two drugs is preferable 
by considering their potential to induce death in cancer cells and the least possible damage to 
healthy cells. Although this type of approach would have been extremely valuable as a 
complement of the drug exposure assays presented in Chapter 5, it was not possible to pursue it, 
due to time and economical constraints (mainly associated with HOb cells’ very slow growth and 
expensive culture conditions). 
6.1. Antiproliferative Activity and Cytotoxic Assay Results 
Since no IC50 value was available in the literature for the Pd2Spm complex towards MG-63 
cells, the drug concentrations to be tested were chosen in the light of the experiments previously 
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reported for this Pd(II) agent in other cell lines, namely breast (Fiuza et al., 2011), tongue (Soares 
et al., 2007) and ovarian (Tummala et al., 2010) cancer cell lines (Table 6.1). 
Table 6.1. Cell line studies of IC50 determination with the Pd2Spm complex. 
Cell Line IC50 at 24 hours Reference 
MCF-7 (breast cancer) 10.9 µM Fiuza et al., 2011 
MDA-MB-231 (breast cancer) 4.7 µM Fiuza et al., 2011 
HSC-3 (tongue cancer) 19 µM Soares et al., 2007 
 IC50 at 72 hours  
A2780 (ovarian cancer) 1.25 µM Tummala et al., 2010 
 
Figure 6.1 shows the results of the first evaluation of antiproliferative activity of Pd2Spm in 
MG-63 cells, using the SRB assay. In this preliminary study, a concentration of 12.06 µM of 
Pd2Spm was found to inhibit 50 % of MG-63 cell growth (as shown in inset of Figure 6.1). Two 
additional determinations were performed and yielded the IC50 values of 9.32 and 9.01 µM (not 
shown), hence indicating an average IC50 value of 10.13 PM. However, due to timings of NMR 
spectrometer availability, all NMR experiments were performed using the first value measured 
(12 µM). This value is in broad agreement with those reported in literature for breast and tongue 
cancer cell lines (Table 6.1). 
 
Figure 6.1. SRB evaluation of antiproliferative activity of Pd2Spm against MG-63 cells. Inset shows the 
logaritmic determination of IC50 concentration upon 24 hours drug exposure. 
Figure 6.2 represents the time- and dose-response plot of the cytotoxicity assays (using the 
Trypan blue assay) of the two considered assays for HRMAS NMR analysis. The results validated 
the previously value of IC50 of 12 PM determined by SRB. 
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Figure 6.2. Time-dependent plot of the cytotoxic effect of cDDP and Pd2Spm, in sole administration, 
towards the MG-63 cell line. Cell proliferation was evaluated by the Trypan blue assay (as described in the 
Experimental Procedures, Chapter 3). Control (), 30 µM cDDP () and 12 µM Pd2Spm (). The data 
represent the average ± mean standard deviation from n=2 experiments, carried out in duplicate. 
As previously determined for a 24 hours drug exposure, ca. 50% of MG-63 cells death is 
achieved for 30 and 12 µM concentrations of cDDP and Pd2Spm, respectively. This indicates, 
therefore, that at this time point Pd2Spm displays a growth-inhibiting effect about twice as high as 
that of cDDP. However, the results are less promising for higher exposure periods (36 and 48 
hours), when cDDP-treated cells show a steady decrease in cell proliferation while some recovery 
is observed for Pd2Spm-treated cultures. Recalling the results obtained for DOX and MTX 
(presented in Chapter 5), the former showed a long term effect on cell survival similar to that of 
cDDP, while the cytotoxic effect of MTX that resulted in the absence of a clear decrease on living 
cells from 24 hours more closely resembles that here obtained for Pd2Spm. 
Only two studies are to be found in the literature comparing the antineoplastic activity of 
cDDP and Pd2Spm: one in human ovarian carcinoma cells (Tummala et al., 2010) and another in 
two different breast cancer cell lines, estrogen-dependent (ER(+)) and estrogen-independent (ER(-
)) (Fiuza et al., 2011). The studies from Tummala et al., 2010 showed that cDDP has a higher 
cytotoxic potency than Pd2Spm towards ovarian carcinoma, although against the homologous 
cDDP-resistant cell line the degree of resistance was found to be much lower for Pd2Spm. 
According to the same study, the most important mechanistic difference between these two 
compounds appears to be their potential to affect the biogenic polyamine pathway, this being 
much more pronounced for the spermine complex. According to Fiuza (Fiuza et al., 2011), Pd2Spm 
is more effective against the ER(-) breast cancer cells, while cDDP displays a higher efficacy 
towards the ER(+) line. Also, the Pd(II) complex was verified to trigger phosphorylation of H2AX, a 
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human histone (similarly to cDDP but to a higher extent), evidencing that it induces DNA 
conformational changes and cytoskeleton damage, with a greater impact on cell morphology than 
cDDP. 
Another study (Soares et al., 2007), assessed the effect of the metal center (either Pt(II) or 
Pd(II)) in two analogous dinuclear spermine chelates on their anticancer activity towards human 
tongue epithelioma  (HSC-3 cells). The results evidenced an improved cytotoxicity for the Pd(II) 
complex as compared to its Pt(II) counterpart. A similar test performed by Tummala et al., 2010, 
allowed to unveil an identical behaviour, as a Pd(II) complex also showed an increased cytotoxic 
capacity than its Pt(II) analogue against human ovarian carcinoma cells. Furthermore, Fiuza and 
co-workers (Fiuza et al., 2006) evaluated the antiproliferative effect of two homologous Pd(II) and 
Pt(II) complexes with a different polyamine ligand – the biogenic triamine spermidine (Spd) as 
opposed to the tetramine spermine (Spm). Once again, the Pd(II) agent displayed a higher effect 
towards the tested cancer cells (HSC-3) than its Pt(II) analogue. 
Within the work of this thesis, a Pd(II) complex with Spd (Pd3Spd2) was assessed towards 
the MG-63 cells for a 24 hours exposure time (using the SRB method) and an IC50 value of 10.6 µM 
was obtained, which is identical to the one obtained for the spermine chelate Pd2Spm. In the light 
of these similar results, experiments for the metabolic profiling proceeded with the Spm agent, 
due to its highly promising results towards human ER(-) breast cancer cells (Fiuza et al., 2011). 
 
6.2. 1H HRMAS NMR Analysis of Pd2Spm-Induced Metabolic Changes in MG-63 Cells and 
Comparison to cDDP 
The metabolic alterations that underlie the cytotoxic effect of Pd2Spm over the MG-63 cells 
are hereby investigated and compared with those induced by cDDP-treatment. The results hereby 
presented were obtained from only two independent assays (see Experimental Section, Chapter 
3), and for this reason they are affected by some degree of uncertainty, when compared to the 
rest of the data, based on three independent assays. 
Visual inspection of the average spectra of controls vs Pd2Spm-treated MG-63 cells (Figure 
6.3) shows that, after 24 hours treatment with Pd2Spm (Figure 6.3c), MG-63 cells exhibit slight 
increases in Val, Leu, Ile and Tyr and decreases in Glu, Tau and Pro resonances. Additional 
observations comprise decreased (CH2)n of lipids and GPC and increased PC. Moreover, N-acetyl, 
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creatine, m- and s-Inositol, UXP and hypoxanthine signals also decreased with treatment and an 
increase of GSH was detected. 
  
Figure 6.3. Average 800 MHz 1H HRMAS NMR spectra of MG-63 cells, at 24 hours: a) under control 
conditions, b) exposed to 30 µM cDDP and c) exposed to 12 µM Pd2Spm. Insets show expansions of choline 
compounds (3.2-3.3 ppm) and aromatic (5.2-8.5 ppm) regions. Main assignments are noted and visible 
spectral changes due to drug exposure are marked by arrows. 
When compared to the global metabolic alterations induced by cDDP-treatment, Pd2Spm 
clearly behaves differently in what concerns lipids and choline compounds biochemistry. The 
typical cDDP pattern of increased lipid resonances is not observed upon Pd2Spm-treatment, 
instead, a slight decrease of the (CH2)n peaks (δ 1.30) is suggested by visual inspection (Figure 
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6.3c). Moreover, upon 24 hours treatment, the alterations seen in choline compounds upon 
Pd2Spm-exposure are less dramatic than those induced by cDDP, for instance, Pd2Spm does not 
alter the profile of the three main choline compounds, with PC (δ 3.23) remaining the most 
abundant and GPC (δ 3.24) the less abundant choline compound. The different modes of action of 
the two drugs are also suggested by differences in the levels of Ino/Ado, since a decrease is 
detected already at 24 hours treatment with cDDP while no considerable alterations to this 
nucleoside are detected upon Pd2Spm exposure. Nevertheless, the two drugs share a common 
decreasing effect over m-Inositol. 
Following the established data analysis workflow, multivariate analysis was applied to the 
1H HRMAS NMR spectra in order to confirm visual findings and unveil the most relevant drug-
induced metabolic changes. Multivariate analysis (Figure 6.4) suggested that changes compared 
to controls are much more pronounced upon cDDP than Pd2Spm treatment.  As shown by the PCA 
analysis (Figure 6.4a), controls and Pd2Spm-treated cell cluster together, while cDDP-treated cells 
are clearly separated from the other two groups in the scores plot, in a time-dependent trajectory 
(in negative PC1). The corresponding PLS-DA scores plot (Figure 6.4b) shows good separation 
between the 3 groups of samples (Q2 0.815): cDDP from Pd2Spm and controls along LV1 and 
Pd2Spm from controls along LV2 (positive and negative, respectively). In these results, a time-
dependent disposition of samples in scores space is only clearly identified for cDDP-treated 
samples, since samples exposed to the drug for higher periods move to lower LV1. PLS-DA of 
controls vs cDDP-treated samples (Figure 6.4c) shows a clustering of the control samples while 
cDDP-treated ones dispose themselves in the scores plot in a time dependent manner (in 
agreement to what was suggested by PCA, Figure 6.4a), suggesting that metabolic changes that 
account for time course adaptations in controls are less marked than those induced by treatment 
with cDDP (in agreement to what is reported in Chapter 5 for cDDP-induced effects). In line to 
what is reported in Chapter 5 for cDDP, the robustness of the group discrimination is reflected in 
a very low Q2 distribution overlap (Figure 6.5a) and good MCCV results: 79.9% sensitivity, 100% 
specificity and 91.1% classification rate (Figure 6.5b).  PLS-DA of controls vs Pd2Spm (Figure 6.4d) 
enables the discrimination of the two groups of samples along LV1, but no evident time course 
tendency can be drawn for neither control or treated samples, with the 48 hour samples differing 
considerably in lipids and m-inositol contents. In fact, in addition to the satisfactory Q2 value 
(0.607) obtained for the model, some overlap of Q2 distributions is visible (Figure 6.5c) along with 
poor MCCV results: 77.0% sensitivity, 60.8% specificity and 68.0% classification rate (Figure 6.5d). 
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This indicates that the metabolic impact of Pd2Spm, at IC50, is much weaker than that of cDDP. The 
increase of the number of samples per condition (time point) might probably improve the quality 
of this particular model by lowering the level of uncertainty, since, as has been suggested by 
results, Pd2Spm-induced changes are globally tenuous thus being more affected by variation 
within duplicates. 
 
Figure 6.4. Multivariate analysis of controls (z), 30 µM cDDP- (c) and 12 µM Pd2Spm-treated (c) cells: 
a) PCA scores plot for all samples, UV, 4 components, R2X = 0.462 and Q2 = 0.087, b) PLS-DA scores plot for 
all samples, UV, 6 components, R2X = 0.502, R2Y = 0.993 and Q2 = 0.815, c) PLS-DA scores plot for cDDP 
assay, UV, 2 components, R2X = 0.327, R2Y = 0.977 and Q2 = 0.822, d) PLS-DA scores plot for Pd2Spm assay, 
UV, 3 components, R2X = 0.329, R2Y = 0.991 and Q2 = 0.607 and e) loadings plot of the PLS-DA model shown 
in d). 
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The loadings plot corresponding to the PLS-DA model of controls vs Pd2Spm-treated 
samples (Figure 6.4d) is shown in Figure 6.4e, helping to unveil the signals that underlie class 
separation. Amino acids Val (δ 1.05), Leu (δ 0.97) and Ile (δ 1.02) are suggested to be increased in 
Pd2Spm-treated samples as well as γ-aminobutyric acid (GABA, δ 1.91, δ 2.30, δ 3.00). Important 
decreases of UXP (δ 5.99 and δ 7.98) and less marked decreases of m-inositol, Pro and N-acetyl 
moieties (δ 2.02) also seem to account for metabolic alterations induced by cells treatment with 
the Pd agent. Figure 6.4e also suggests that Pd2Spm-treatment may induce a decrease of (CH2)n 
resonances of lipids but, as stated above, the intensity of this particular resonance is considerable 
different within 48 hours replica, fact that can be erroneously influencing this result. 
  
Figure 6.5. Monte Carlo Cross-Validation (MCCV) results of PLS-DA model obtained for MG-63 cells 
exposed to 30 µM cDDP (a and b) or 12 µM Pd2Spm (c and d) , vs control cells: a) and c) Q
2 distributions, c) 
and d) ROC plots of true and permuted models. TPR: true positive rate, FPR: false positive rate, Sens.: 
sensitivity, Spec.: specificity, CR: classification rate. 
a) b)
LV=3 Q2=0.607
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Subsequent signal integration and univariate statistical analysis identified the relevant 
variations in metabolites over time and their time course plots are shown in Figures 6.6 and 6.7 
and compiled in Tables 6.2 and 6.3 for 24 and 48 hours. 
 
 Figure 6.6. Time course variation  of lipids (L f.a.) and choline compounds with cDDP (30 µM) and 
Pd2Spm (12 µM) treatment. Controls (z), cDDP-treated ({) and Pd2Spm ({) (controls are indicated with 
full lines and drug-treated with dashed lines).*p < 0.05. 
Results show that the metabolic adaptations experienced by MG-63 cells upon exposure to 
Pd2Spm comprise decreases in the amino acids Pro, Gly and Thr (with % of variation in the range -
20 to -30 and ES of -1.4 to -3.5) and slight increases in Ser, Tyr and Phe (mainly detected at early 
periods of exposure). Moreover, decreases in Cho and increases in PC are detected, leading to 
slight increased PC/Cho and PC/GPC ratios. Pd2Spm treatment also resulted in fluctuations in 
UDP-GlcNAc, slight increased Ino/Ado (only at 48 hours, with around 73% variation in relation 
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controls) and important decreases in UXP (with around -29 to -35% variation in relation to 
controls, to which ES values range from -2.4 to -1.5. Decreases in N-acetyl moieties, GSH (only at 
12 hours) and m-Inositol (24 and 36 hours) are also seen in Pd2Spm-treated MG-63 cells. 
In what concerns to cDDP-treatment, the marked increases detected in L f.a. and respective 
ratios as well as global variations in choline compounds and choline compounds ratios (Figure 6.6) 
are generally in agreement with previous findings reported in Chapter 5. The compound 
variations shown in Figure 6.7, also confirm previous findings reported in Chapter 5, for cDDP-
treated cells: decreased Glu and Phe, decreased Ino/Ado and m-Ino and slight increased UDP-
GlcNAc. The error associated with variations in UXP ad N-acetyl moieties difficult similar 
comparisons. The variations in GABA, here detected for the first time, were also absent in 
previous assays of MG-63 cells exposure to cDDP. 
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Figure 6.7. Time course variation of several compounds with cDDP (30 µM) and Pd2Spm (12 µM) 
treatment. Controls (z), cDDP-treated ({) and Pd2Spm ({) (controls are indicated with full lines and drug-
treated with dashed lines).*p < 0.05, *p < 0.01. 
 
The heatmap of the effect size values shown is Figure 6.8a highlights the most relevant time 
course changes induced by each of the two tested drugs. Pd2Spm-induced alterations in amino 
acids occur mostly at initial times of exposure and are mainly positive, while for cDDP treatment 
most changes are negative and occur from 24 hours onwards, suggesting that Pd2Spm has a slight 
higher and mostly transitory impact at initial periods of exposure while cDDP has a more 
sustained effect over time. Some similarities were found between cDDP and Pd2Spm treated cells 
namely regarding increases in Phe and Val and the drug-induced decreases in Pro. 
One of the most relevant differences between the two drugs concerns lipids, since no 
significant changes were noted with Pd2Spm treatment while clear increases were confirmed 
again in cells treated with cDDP (consistently with Chapter 5). Regarding lipid ratios, a global 
increase in all calculated ratios was detected upon cDDP exposure, pointing to a drug-induced 
increase in mean chain length ((CH2)n/CH3), mono (CH=CH/CH3) and polyunsaturation degrees 
(=CHCH2CH=/CH3). On the other hand, Pd2Spm, which induced no alterations in lipids, was found 
to promote a decrease in mean chain length of lipid fatty acids at 24 hours (cancelled at higher 
exposure periods) and an increase in the polyunsaturation degree after 48 hours treatment. 
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 Table 6.2. M
etabolite variations in M
G
-63 cells exposed to 30 µM
 cD
D
P or 12 µM
 Pd
2 Spm
 for 24 and 48 hours and after the 3 days reversibility period, com
pared to 
control cells 
M
etabolite 
Signal 
(δ,ppm
) a 
cD
D
P (30 µM
) 
Pd
2 Spm
 (12 µM
) 
24h 
48h 
Reversibility 
24h 
48h 
Reversibility 
%
 var b 
Effect size
c 
%
 var b 
Effect size
c 
%
 var b 
Effect size
c 
%
 var b 
Effect size
c 
%
 var b 
Effect size
c 
%
 var b 
Effect size
c 
A
m
ino acids 
Alanine 
1.48, d 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
G
lutam
ate 
2.34, m
 
-49.0±4.8* 
-7.76±2.80 
-48.5±17.2 
-2.13±0.94 
-70.1±7.60* 
-8.09±2.92 
- 
- 
- 
- 
- 
- 
G
lycine 
3.56, s 
(-) 
(-) 
-26.2±6.8* 
-2.52±1.06 
-58.6±10.1 
-4.68±1.75 
- 
- 
-27.9±5.3 
-3.46±1.35 
- 
- 
Isoleucine 
1.02, d 
nv 
nv 
(+) 
(+) 
- 
- 
7.00±3.20 
(+) 
- 
- 
- 
- 
Lysine 
1.72, m
 
-4.70±2.20 
(-) 
-14.4±2.9 
-3.02±1.21 
-33.7±10.6 
2.19±0.96 
- 
- 
-7.1±2.7 
-1.56±0.80 
- 
- 
Phenylalanine 
7.32, d 
- 
- 
-19.5±9.7 
(-) 
-35.1±17.0 
-1.43±0.76 
- 
- 
- 
- 
- 
- 
Proline 
4.12, t 
-40.2±6.90 
-4.15±1.58 
(-) 
(-) 
-58.1±18.6 
-2.52±1.06 
-29.8±7.60 
-2.64±1.09 
- 
- 
- 
- 
Serine 
3.84, d 
-13.6±4.8 
-1.72±0.83 
-19.8±9.4 
(-) 
-49.4±11.1 
-3.38±1.32 
- 
- 
- 
- 
- 
- 
Taurine 
3.42, t 
-68.6±4.7* 
-12.59±4.49 
(-) 
(-) 
-68.4±10.2** 
-5.82±2.14 
(-) 
(-) 
- 
- 
- 
- 
Threonine 
3.58, d 
-24.8±10.0 
-1.61±0.81 
-34.3±6.2* 
-3.82±1.47 
-41.8±17.1 
-1.76±0.85 
- 
- 
-18.4±8.6 
-1.35±0.74 
- 
- 
Tyrosine 
6.89, d 
- 
- 
-14±1.3** 
-6.62±2.41 
-33.2±15.0 
-1.52±0.78 
- 
- 
6.7±2.5 
1.51±0.78 
- 
- 
Valine 
1.05, d 
- 
- 
- 
- 
- 
- 
8.20±3.10 
1.42±0.76 
- 
- 
- 
- 
Lipids 
-CH
3  
0.91 
(+) 
- 
68.5±18.7 
1.56±0.79 
83.2±27.3 
(+) 
- 
- 
- 
- 
- 
- 
-(CH
2 )n  
1.30 
- 
- 
95.4±41.0 
- 
135.8±38.0 
(+) 
- 
- 
- 
- 
- 
- 
-CH
2 CH
2 CO
 
1.60 
- 
- 
87.2±23.1 
1.50±0.78 
91.1±30.4 
(+) 
- 
- 
- 
- 
- 
- 
-CH
2 CO
O
 
2.25 
- 
- 
73.0±22.4 
1.37±0.75 
68.8±30.3 
(+) 
- 
- 
- 
- 
- 
- 
=CH
CH
2 CH
= 
2.83 
25.8±11.6 
(+) 
146.8±24.2 
2.00±0.91 
170.8±30.2 
(+) 
- 
- 
- 
- 
- 
- 
-CH
=CH
- 
5.33 
68.4±33.2 
- 
287.7±46.6 
1.45±0.77 
364.6±34.8 
(+) 
- 
- 
- 
- 
- 
- 
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 Table 6.2 (cont.). M
etabolite variations in M
G
-63 cells exposed to 30 µM
 cD
D
P or 12 µM
 Pd
2 Spm
 for 24 and 48 hours and after the 3 days reversibility period, com
pared 
to control cells. 
M
etabolite 
Signal 
(δ,ppm
) a 
cD
D
P (30 µM
) 
Pd
2 Spm
 (12 µM
) 
24h 
48h 
Reversibility 
24h 
48h 
Reversibility 
%
 var b 
Effect size
c 
%
 var b 
Effect size
c 
%
 var b 
Effect size
c 
%
 var b 
Effect size
c 
%
 var b 
Effect size
c 
%
 var b 
Effect size
c 
Choline com
pounds 
Choline 
3.21, s 
37.9±4.90 
3.70±1.43 
-54.4±8.9* 
-4.81±1.79 
-70.2±34.5 
-1.79±0.85 
- 
- 
-22.3±3.0* 
-4.76±1.78 
- 
- 
G
PC 
3.24, s 
- 
- 
- 
- 
-34.4±8.10 
-2.94±1.18 
-13.3±6.20 
(-) 
- 
- 
- 
- 
PC 
3.23, s 
-10.9±5.00 
(-) 
-38.4±4.70 
-5.76±2.12 
-65.3±7.80* 
-7.12±2.58 
- 
- 
67.1±4.2** 
6.87±2.50 
- 
- 
PE 
3.25, s 
- 
- 
- 
- 
-43.0±15.6 
-2.01±0.91 
- 
- 
- 
- 
- 
- 
N
ucleotides and D
erivatives 
Inosine 
8.36, s 
- 
(-) 
-45.6±14.2 
-2.37±1.01 
- 
- 
- 
- 
73.4±36.4 
- 
12.7±4.90 
1.39±0.75 
U
D
P-G
lcN
A
c 
5.52, m
 
87.9±16.5 
2.12±0.94 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
U
XP 
5.99, d 
- 
- 
-52.1±17.7 
-2.27±0.98 
- 
- 
-28.6±8.00 
-2.38±1.02 
-35.3±16.3 
-1.51±0.78 
- 
- 
U
ridine 
5.89, d 
- 
- 
90.8±26.3 
(+) 
- 
- 
- 
- 
- 
- 
- 
- 
O
ther Com
pounds 
Creatine 
3.93, s 
-50.6±13.5 
-2.87±1.16 
-64.3±18.1 
-3.00±1.20 
-74.6±5.5** 
-12.3±4.40 
- 
- 
- 
- 
- 
- 
Ethanolam
ine 
 
- 
- 
42.3±5.60 
3.55±1.38 
80.3±8.20 
3.99±1.52 
- 
- 
- 
- 
14.7±5.40 
(+) 
G
SH
 
2.56, m
 
- 
- 
-37.6±8.4 
-3.14±1.25 
-61.4±2.2** 
-23.52±8.33 
27.0±12.7 
(+) 
14.3±2.80 
2.75±1.13 
- 
- 
H
ypoxanthine 
8.18, s 
-26.6±13.0 
(-) 
(-) 
(-) 
- 
- 
- 
- 
- 
- 
- 
- 
m
-Inositol 
4.05, t 
-45.0±8.00 
-4.16±1.58 
(-) 
(-) 
-81.8±0.90** 
-92.8±32.8 
-25.4±7.40 
-2.26±0.98 
- 
- 
- 
- 
s-Inositol 
3.34, s 
-36.4±5.50 
-4.61±1.73 
-66.5±37.9 
-1.50±0.78 
- 
- 
-18.2±4.80 
-2.37±1.01 
- 
- 
- 
- 
N
-acetyl 
2.02, s 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
a Resonance chosen for signal integration, b %
 variation and c effect size in relation to control cells. * p < 0.05,  ** p < 0.01, _ : no significant variation. (+) and (-) indicate 
consistent positive and negative variations, respectively, w
ithout statistical m
eaning. 
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 Table 6.3. M
ean ratios for lipids and choline com
pounds in M
G
-63 cells exposed to either 30 µM
 cD
D
P or 12 µM
 Pd
2 Spm
, for 24 and 48 hours and after a 3 days 
reversibility period. 
M
etabolite 
cD
D
P (30 µM
) 
Pd
2 Spm
 (12 µM
) 
24h 
48h 
Reversibility 
24h 
48h 
Reversibility 
Controls 
cD
D
P 
Controls 
cD
D
P 
Controls 
cD
D
P 
Controls 
Pd
2 Spm
 
Controls 
Pd
2 Spm
 
Controls 
Pd
2 Spm
 
Lipid ratios 
(CH
2 )n /CH
3  
3.34±0.09 
2.98±0.26 
2.73±0.61 
3.16±0.40 
2.73±0.29 
3.52±0.19 
3.34±0.09 
2.69±0.29 
2.73±0.61 
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Figure 6.8. Heatmaps of effect size values of the time course response for a) several metabolites and 
b) compound ratios in MG-63 cells exposed to cDDP or Pd2Spm. The effect size values are shown in a colour 
scale from minimum (dark blue) to maximum (dark red) values. * p < 0.05 and ** p < 0.01 refer to the 
results of significance tests with integrals. Column indicated as REV, refers to cells exposed to the drug for 
24 hours, followed by a recovery period of 3 days in drug free medium. 
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In what concerns to choline compounds, significant choline decreases are measured at 48 
hours for both drugs, a transitory increase in GPC (36 hours) is induced by Pd2Spm drug and 
opposite variations are seen in PC at 48 hours (decreases with cDDP and a marked increase of 
around 67% with Pd2Spm, to which correspond an ES value close to 7). The results of choline 
compound ratios were also found to be drug-specific: cDDP induced a decrease of PC/Cho while 
Pd2Spm promoted its increase; significant increases in GPC/Cho were detected upon 48 hours 
exposure to cDDP, while no alterations were detected with Pd2Spm treatment; changes in PC/GPC 
were opposite (down-regulated upon cDDP exposure and up-regulated upon treatment with 
Pd2Spm) and specific in time. 
Concerning the impact on nucleotides and their derivatives, Pd2Spm only influences the 
levels of UXP (which decrease at initial times of exposure) while the same tendency is only 
achieved upon 48 hours exposure to cDDP. In what refers to changes in other metabolites, 
alterations in creatine (decrease) are exclusive from cDDP treatment, while none of the drugs 
altered the levels of ethanolamine along the 48 hours exposure period. Interestingly, cDDP and 
Pd2Spm differently affect the time course of GSH: upon 48 hours treatment, Pd2Spm induces its 
increase (upon a slight decrease at 12 hours) while a decrease is registered in cDDP-treated 
samples. Hypoxanthine, also seems to be affected only by cDDP treatment, since exposure to the 
Pt(II) drug induced its increase at 36 hours. M- and s-Ino decrease upon exposure to each of the 
two drugs, but effects are slightly more pronounced with cDDP. Negative variation of N-acetyl 
moiety was only detected in Pd2Spm-treated cells. 
Some of these Pd2Spm-induced alterations may be a consequence of the known effect of 
this complex on histone H2AX, the cytoskeleton and the expression of genes in the polyamine 
pathway, as already suggested in literature as being a consequence of Pd2Spm treatment 
(Tummala et al., 2010; Fiuza et al., 2011). However, this hypothesis would need further 
investigations, namely beginning by a targeted search for DNA and cytoskeleton alterations in 
Pd2Spm-treated MG-63 cells. Despite the novelty of the use of Pd2Spm in metabolomic studies, 
interpretation of some of its drug-induced effects could be tentatively advanced by comparison 
with the cDDP-induced effects, most widely explored. One of the most marked differences 
between Pd2Spm and cDDP treatments, was the absence of changes in lipids in the former, while 
marked increases were found to be characteristic of cDDP treatment in osteosarcoma (Duarte et 
al., 2010; Lamego et al., 2014) and other cancer cell lines (Huang et al., 2003; Lindskog et al., 
2004; Pan et al., 2011; Pan et al., 2013; Duarte et al., 2013). Since the increase in lipids has been 
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associated with cell apoptosis (Rainaldi et al., 2008; Boren and Brindle et al., 2012), the absence 
of changes with Pd2Spm suggests that the decreases in the number of living MG-63 cells are not 
due to cell death. 
Regarding the variations in choline compounds, similar variations were found in choline 
while opposite changes were detected in PC levels upon treatment with either cDDP or Pd2Spm, 
what may point to distinct PTC-cycle regulation (Knijn et al., 2005; Duarte et al., 2010) by the two 
drugs. These differences translated into increases in the PC/GPC and PC/Cho for Pd2Spm-treated 
cells, while decreases in both ratios were detected in cDDP-treated cells. This result once again 
reinforces the idea that Pd2Spm-treated MG-63 cells are not undergoing apoptosis (differently 
from cDDP-treated ones), since cell growth arrest prior apoptosis has been associated with 
variations in PC/GPC opposite from those now observed with the Pd(II) agent (Mirbahai et al., 
2011). 
Quite distinct amino acid signatures characterise the MG-63 cells response to either of the 
two drugs, suggesting that cDDP and Pd2Spm differently affect the Krebs cycle. Additionally, and 
although non significant, distinct nucleotide variations are registered for cDDP and Pd2Spm, 
strongly suggesting that, despite their interaction with DNA, different downstream effects 
account for the mode of action of each drug. 
 
6.3. 1H NMR Analysis of TCA Extracts of cDDP- and Pd2Spm-Treated MG-63 Cells 
By measuring the drug-induced alterations in nucleotides and derivatives, the extent to 
which cDDP and Pd2Spm affect DNA can be indirectly assessed. TCA extraction was applied to the 
samples analysed by HRMAS, with the aim of assessing such alterations in nucleotides and 
derivatives, namely AXP and UXP derivatives, Ino/Ado and NAD+. Comparison between the 
average spectra of controls and cDDP- and Pd2Spm-treated cells (Figure 6.9) shows considerable 
drug-induced changes in the aromatic region. Treatment with cDDP (Figure 6.9b) induces 
increases in uridine, UXP, UDP/UTP and hypoxanthine, while decreases occur for ADP/ATP and 
NAD+. Upon exposure to Pd2Spm (Figure 6.9c), cells experience slight increases in uridine and 
hypoxanthine (like cDDP) while UXP, Ino/Ado, ADP/ATP (like cDDP) and NAD+ (like cDDP) levels 
decrease. Pd2Spm-induced changes in UXP and Ino/Ado resemble those induced by DOX and MTX 
treatment, eventually pinpointing similar influences of these drugs over pathways involving these 
compounds. 
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Beyond the metabolites newly detected in extracts compared to HRMAS (ADP/ATP, 
UDP/UTP and NAD+), alterations in some metabolites already detected by HRMAS slightly differ 
from TCA analysis. Regarding cDDP-treatment, slight increases in uridine were also measured by 
HRMAS but the hypoxanthine, which showed no alteration with this drug, now reveals to be 
increased and opposite variations were detected for UXP. The HRMAS results from Pd2Spm-
treated cells also pointed for decreases (slight) in UXP but uridine and hypoxanthine showed no 
variations and opposite variations in relation to TCA analysis were detected in Ino/Ado contents, 
upon cells’ treatment with Pd2Spm. 
  
Figure 6.9. Expansion of aromatic (5.0-9.5 ppm) regions of average 500 MHz 1H NMR spectra of TCA 
extracts of MG-63 cells, at 48 hours: a) under control conditions, b) exposed to 30 μM cDDP and c) exposed 
to 12 μM Pd2Spm. Main assignments are noted and visible spectral changes due to drug exposure are 
marked by arrows. 
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6.4. 1H HRMAS NMR Analysis of Pd2Spm-Induced Metabolic Changes in HOb Cells and 
Comparison to cDDP 
In this section, the metabolic alterations in HOb cells induced by exposure to either Pd2Spm 
or cDDP are presented. Since the HRMAS NMR analysis of HOb cells is performed for the first 
time, a general characterization of the metabolic profile of these non-neoplastic cells is presented 
and a comparison with the metabolic profile of MG-63 cells is discussed. 
6.4.1. Metabolic Profile of Osteoblast HOb Cells: Comparison to MG-63 Cells 
  
Figure 6.10. Average 800 MHz 1H HRMAS NMR spectra of HOb cells at a) 0 and b) 24 hours and of c) 
MG-63 cells at 24 hours, in control conditions. Insets show expansions of choline compounds (3.2-3.3 ppm) 
and aromatic (5.2-8.5) regions. Arrows in b) indicate main changes from a); arrows in c) indicate main 
changes from b). 
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b) Control HOb cells at 24 hours
c) Control MG-63 cells at 24 hours
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The 1D 1H HRMAS NMR metabolic profile of HOb cells is presented in Figure 6.10 (a, b) and 
2D HRMAS NMR spectra are shown in Figure 6.11. A total of 43 metabolites were assigned in the 
spectrum of lysed HOb cells and other 3 remain unassigned, as compiled in Table 6.4. To our 
knowledge, there are no reports in the literature about metabolomic studies, either by HRMAS 
NMR or MS, on osteoblasts (either using whole cells or cell extracts). This may be explained by the 
high costs involved in HOb cells culture, their long doubling time compared to OS cells (around 3 
days, as compared to 24 hours for MG-63 cells) and the high number of cells needed for 
metabolomic studies. 
  
Figure 6.11. Expansions of 0.5-4.5 ppm region of the 800 MHz 2D HRMAS NMR spectra of HOb cells: 
a) TOCSY and b) HSQC.  
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Table 6.4: List of metabolite assignments in HRMAS NMR spectra of lysed HOb cells. Legend: s 
singlet, d doublet, t triplet, q quartet, dd double of doublets, m multiplet. 
Compound Assignment δ 1H ppm (multiplicity )/ δ 13C ppm 
Acetate βCH3 1.92 (s) 
Alanine βCH3 
αCH 
1.48 (d)/ 18.79 
3.78 (q) 
Arginine γCH2 
βCH2 
δCH2 
αCH 
1.69 (m) 
1.92 (m)/ 30.20 
3.25 (t) 
3.77 (t) 
Asparagine βCH3 
β’CH3 
αCH 
2.87 (dd) 
2.95 (dd) 
4.01 (dd) 
Aspartate βCH3 
β’CH3 
αCH 
2.69 (dd) 
2.82 (dd) 
3.90 (dd) 
Choline N(CH3)3 
CH2(NH) 
CH2(OH) 
3.22 (s)/ 56.49 
3.54/ 75.10 
4.07 
Creatine CH3 
CH2 
3.03 (s) 
3.94 (s) 
Dihydroxyacetone αCH2 4.42 (s) 
Ethanol βCH3 
αCH2 
1.19 (t) 
3.65 (q) 
Ethanolamine CH2(NH2) 
CH2(OH) 
3.13 (t) 
3.82 (t) 
Fatty acyl (L f.a.) chain CH3 
(CH2)n 
CH2CO 
CH=CH 
0.88/16.50 
1.31 
2.28 
5.33 
β-Glucose C1H 4.65 (d) 
Glutamate ββ’CH3 
γCH2 
αCH 
2.09/29.70 
2.35/36.03 
3.75 (dd)/ 57.18 
Glutamine βCH2 
γCH2 
αCH 
2.13/29.66 
2.45/33.70 
3.78/53.02 
GSHa βCH2 Glu 
γCH Glu 
αCH2 Cys 
αCH Glu 
γCH2 Cys 
βCH2 Cys 
2.17 
2.56 
2.95 
3.77 
4.17 
4.58 
Glycerol C1H2 
C3H2 
C2H 
3.57 
3.64 
3.78 
Glycerol (in lipids) C3H2 
C2H 
4.30 
5.23 
Glycerophosphocholine (GPC) N(CH3)3 
γCH2 
βCH/β’CH2(N) 
αCH2 
αCH2(P) 
3.24 (s)/ 56.50 
3.65 
3.87/3.91 
3.94 
4.33 
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Table 6.4 (cont.): List of metabolite assignments in HRMAS NMR spectra of lysed HOb cells. Legend: s 
singlet, d doublet, t triplet, q quartet, dd double of doublets, m multiplet. 
Compound Assignment δ 1H ppm (multiplicity )/ δ 13C ppm 
Glycine αCH2 3.56 (s)/ 43.97 
Histidine C4H, ring 7.10 (s) 
Hypotaurine βCH2 
αCH2 
2.67 (t) 
3.34 (t) 
Hypoxanthine C2H 
C8H 
8.19 (s) 
8.21 (s) 
Inosine / Adenosine C2’H, ribose 
C1’H, ribose 
C2H, ring 
C8H, ring 
4.78 (t) 
6.11 (d)/ 94.30 
8.24 (s) 
8.36 (s) 
Isoleucine δCH3 
β’CH3 
βCH 
αCH 
0.94 (t) 
1.01 (d) 
1.99 
3.65 
Lactate βCH3 
αCH 
1.33 (d)/ 22.70 
4.14 (q) 
Leucine δCH3 
δ’CH3 
γCH/βCH2 
αCH 
0.96 (d) 
0.97 (d)/ 23.49 
1.71 
3.76 (t) 
Lysine γCH2 
δCH2 
βCH2 
εCH2 
αCH 
1.47 
1.73/26.40 
1.92/32.50 
3.02 (t)/ 41.73 
3.76 (t) 
Methanol CH3 3.35 (s)/51.22 
Methionine εCH3/ βCH2 
γCH2 
αCH 
2.14 (s) 
2.64 (t) 
3.88 (t) 
m-Inositola C5H 
C1H, C3H 
C4H, C6H 
C2H 
3.27 (t) 
3.54 (dd)/ 73.86 
3.62 (t)/ 75.03 
4.05 (t)/ 74.97 
NMN+  8.99 (d) 
9.32 
9.62 
Phenylalanine βCH 
β’CH 
αCH 
C2H, C6H, ring 
C4H, ring 
C3H, C5H, ring 
3.12 
3.29 
3.99 (dd)/ 58.66 
7.32/127.20 
7.37 
7.42 
Phosphatidylcholines (PTC) N(CH3)3 3.26 (s)/ 56.68 
Phosphocholine (PC) N(CH3)3 
N-CH2 
3.23 (s)/ 56.50 
3.61 (s) 
Phosphoethanolamine (PE) N-CH2 
PO3-CH2 
3.25/43.04 
3.97 
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Table 6.4 (cont.): List of metabolite assignments in HRMAS NMR spectra of lysed HOb cells. Legend: s 
singlet, d doublet, t triplet, q quartet, dd double of doublets, m multiplet. 
Compound Assignment δ 1H ppm (multiplicity )/ δ 13C ppm 
Proline γCH2 
βCH 
β’CH 
δCH 
δ’CH 
αCH 
2.01 
2.07 
2.35 
3.33 (t) 
3.41 (t) 
4.12 (t)/ 63.75 
s-Inositol CH 3.34 (s) 
Serine αCH 
ββ’CH 
3.84/59.10 
3.97 (dd)/ 62.82 
Taurine S-CH2 
N-CH2 
3.28 (t) 
3.42 (t)/ 37.95 
Threonine γCH3 
αCH 
βCH 
1.32 (d)/ 22.70 
3.58 (d)/ 63.07 
4.26/68.71 
Tyrosine ββ’CH 
αCH 
C3H, C5H, ring 
C2H, C6H, ring 
3.05/3.18 
3.95 
6.89 (d)/ 118.8 
7.19 (d) 
UN 1  4.46 (s) 
UN 2  4.48 (s) 
UN 3  4.68 (d) 
Uridine C4’H, ribose 
 
C3’H, ribose 
C2’H, ribose 
C1’H, ribose 
C5H, ring 
C6H, ring 
3.81 (dd) 
3.92 (dd) 
4.23 (t) 
4.36 (t)/ 76.40 
5.89 (d)/ 104.9 
5.93 (d)/ 92.00 
7.91 (d) 
Valine γCH3 
γ’CH3 
βCH 
αCH 
0.99 (d)/ 24.78 
1.05 (d) 
2.28 
3.61 (d)/ 63.00 
a Metabolites assigned through STOCSY. 
Comparison between the average spectra corresponding to 0 and 24 hours growth (Figure 
6.10a and 6.10b, respectively) shows that during their basal growth, HOb cells exhibit a slight 
decrease in several amino acids (Val, Leu, Ile, Glu, Gln and Met) and discrete increases in Phe and 
Tyr.  Additionally, decreases of Cho (δ 3.21) and PC (δ 3.23) are seen at 24 hours growth, as well 
as a slight decrease in m-Inositol (δ 3.27). 
Comparison between the metabolic profiles of HOb and MG-63 cells in comparable 
conditions of 24 hours growth (Figure 6.10b and 6.10c), enables the identification of relevant 
differences. One of the most evident differences relates to lipid resonances, much more intense in 
MG-63 cells with only CH3, (CH2)n and CH=CH being unequivocally identified in the spectra of HOb 
cells, due to their low intensity. This could, at least in part, be due to the longer size of the non-
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neoplastic cells in relation to cancer ones (6500 µm2 and 1200 µm2 respectively, a difference of 
about 6 times according to Pautke et al., 2004), resulting in a decreased proportion of membrane 
lipids in relation to the rest of the detected metabolites. Examples of compounds significantly 
more abundant in MG-63 cells, compared to HOb cells, comprise m-Ino, Ino/Ado and UXP 
derivatives (δ 5.99 and δ 7.98, absent in the spectra of HOb cells).  
Through comparison of the relative intensities of choline compounds in HOb cells spectra, it 
can be advanced that free choline (δ 3.21) is the most abundant choline compound followed by 
PC; on the other hand, PC is the dominant choline-compound resonance in MG-63 cells. In both 
cell lines, GPC and PE are the less abundant choline-compounds. It is interesting to note the 
different ratios of Ala/lactate in the spectra of MG-63 and HOb cells. The HOb cells spectra also 
show a decrease in the relative proportion of creatine (δ 3.03 and δ 3.93) (for example in relation 
to lysine) and increased glycine intensity (δ 3.56). 
 
6.4.2. Pd2Spm- vs cDDP-Induced Metabolic Changes in HOb Cells 
In order to understand how Pd2Spm compares with cDDP in affecting non-malignant cells, 
the effects of these drugs were also tested in non-neoplastic HOb cells. The drugs were 
administered at concentrations corresponding to their IC50 values to the MG-63 cell line. Only two 
time points (0 and 24 hours) were considered due to cell culture constrains associated with HOb 
cells). It was found that the integrity of the cellular membrane is not significantly compromised 
upon 24 hours treatment with either cDDP or Pd2Spm (Figure 6.12). 
  
Figure 6.12. Plot of the cytotoxic effect of cDDP and Pd2Spm, in sole administration, towards the 
HOb cell line. Cell proliferation was evaluated by Trypan blue assay (as described in the Experimental 
Procedures, Chapter 3). Control (), 30 µM cDDP () and 12 µM Pd2Spm (). The data represent the 
average ± mean standard deviation from n=2 experiments, carried out in duplicate. 
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Nevertheless, it is suggested that the Pd complex induces a slightly higher damage to the 
HOb cellular membrane than cDDP. However, this absence of a significant influence of these two 
drugs on the HOb cellular membrane may be partly due to the much larger doubling time of these 
cells (ca. three days, Chapter 3) relative to MG-63 (24 hours) and the drug concentrations used in 
the experiments (equal to their IC50 values towards MG-63 cell at 24 hours). The drug-induced 
effects in HOb cells may thus be underestimated. It is also worth noting the large error bars in 
HOb measurements, which is probably associated with the extra care that is needed at the time of 
cells recovery, since non-neoplastic cells are more sensitive to trypsin exposure, possibly leading 
to considerable differences in efficiency of cells recovery between replicas. 
Comparison between the cytotoxic effects of Pd2Spm and cDDP in human fibrobasts (BJ cell 
line) was performed by Fiuza et al. (Fiuza et al., 2011). In this study both compounds behaved 
similarly and BJ cells showed to be more resistant to both Pd2Spm and cDDP than the two tested 
breast cancer cell lines. These are very promising results, since they reflect a certain degree of 
tissue-selectivity of the Pd2Spm complex, a very important feature for an anticancer agent. 
 
The average 1H HRMAS spectra of HOb cells under control conditions and upon 24 hours 
treatment with either cDDP (30 µM) or Pd2Spm (12 µM) are shown in Figure 6.13. Visual 
inspection suggests that cDDP-treatment (Figure 6.12b) induces a considerable increase in 
acetate(s) (δ 1.92), increases the Cho (δ 3.21) and GPC (δ 3.24) levels as well as the uridine 
contents and possibly alters the levels of m-inositol (δ 3.27). Pd2Spm-treatment seems to induce a 
slight decrease of several amino acids (Val, Ala, Lys, Arg and Gly) and increase of acetate(s) (δ 
1.92), altering the relative proportion of choline compounds (decreases Cho, δ 3.21, and increases 
GPC, δ 3.24) and possibly changing m-inositol (δ 3.27) and CH=CH of L f.a. (δ 5.33) contents. 
Next, signal integration and statistical evaluation of changes were performed and are 
compiled in Table 6.5. As refered previously for MG-63 results, the statistical evaluation was 
performed with just two replicas per condition, meaning that the determined degree of statistical 
meaning is low. For this reason, particular attention was paid to the determined effect size values. 
The only amino acid affected by 24 hours treatment of HOb cells with cDDP was Glu, which levels 
decreased (-14.2% and an ES of -2.4). cDDP treatment didn’t induce any considerable alteration in 
lipids or choline compounds in HOb cells. 
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exposure (26.4% and 10.9% and ES of 1.5 and 2.1, respectively) together with a decrease in m-Ino 
contents (-17.7% and ES of -1.8) in HOb cells. 
 
  
Figure 6.13. Average 800 MHz 1H HRMAS NMR spectra of HOb cells, at 24 hours: a) under control 
conditions, b) exposed to 30 µM cDDP and c) exposed to 12 µM Pd2Spm. Insets show expansions of choline 
compounds (3.2-3.3 ppm) and aromatic (5.2-8.5 ppm) regions. Main assignments are noted and visible 
spectral changes due to drug exposure are marked by arrows. 
 
a) Control HOb cells at 24 hours
b) cDDP-treated HOb cells at 24 hours
c) Pd2Spm-treated HOb cells at 24 hours
8.00 7.00 6.00 5.00 4.00 3.00 2.00 1.00 ppm
8.00 7.00 6.00 5.00 4.00 3.00 2.00 1.00 ppm
8.00 7.50 7.00 6.50 6.00 5.50 ppm
3.400 3.300 3.200 ppm
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 Table 6.5 M
etabolite and choline com
pounds variations in H
O
b cells exposed to 30 µM
 cD
D
P or 12 µM
 Pd
2 Spm
, for 24 hours and after a 3 days reversibility period. 
M
etabolite 
Signal 
(δ,ppm
) a 
cD
D
P (30 µM
) 
Pd
2 Spm
 (12 µM
) 
24h 
Reversibility 
24h 
Reversibility 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
A
m
ino acids 
Alanine 
1.48, d 
- 
- 
- 
- 
-21.2±5.30 
-2.57±1.07 
-37.8±17.7 
-1.51±0.78 
Arginine 
1.65, m
 
- 
- 
- 
- 
-4.40±1.20 
-2.09±0.93 
- 
- 
G
lutam
ate 
2.34, m
 
-14.2±3.60 
-2.43±1.03 
-30.5±11.0 
-1.87±0.87 
-22.5±4.70 
-3.06±1.22 
-53.2±12.2 
-3.38±1.33 
G
lutam
ine 
2.45, m
 
- 
- 
- 
- 
- 
- 
- 
- 
G
lycine 
3.56, s 
- 
- 
-23.2±4.60 
-3.24±1.28 
-18.8±4.30 
-2.78±1.14 
-35.3±12.0 
-2.04±0.92 
Isoleucine 
1.02, d 
- 
- 
- 
- 
-5.40±2.10 
-1.51±0.78 
- 
- 
Lysine 
1.72, m
 
- 
- 
- 
- 
-14.0±3.50 
-2.48±1.05 
- 
- 
M
ethionine 
2.64, s 
- 
- 
9.40±4.50 
(+) 
-9.40±4.00 
-1.41±0.76 
- 
- 
Phenylalanine 
7.32, d 
- 
- 
-6.70±2.70 
-1.47±0.77 
- 
- 
- 
- 
Proline 
4.12, t 
- 
- 
-8.60±4.1 
(-) 
-9.50±3.60 
-1.57±0.80 
-28.3±13.0 
-1.44±0.77 
Serine 
3.98, d 
- 
- 
19.8±1.4* 
7.25±2.63 
- 
(-) 
-17.7±4.50 
-2.46±1.04 
Threonine 
3.58, d 
- 
- 
-2.1±0.5 
-2.19±0.96 
- 
- 
- 
- 
Tyrosine 
6.89, d 
- 
- 
- 
- 
- 
- 
- 
- 
Valine 
1.05, d 
- 
- 
- 
- 
-13.8±4.50 
-1.88±0.88 
- 
- 
Lipids 
-(CH
2 )n  
1.30 
- 
- 
- 
- 
24.1±10.1 
(+) 
- 
- 
Choline and phospholipids 
Choline 
3.21, s 
- 
- 
- 
- 
- 
- 
-49.6±7.60* 
-4.93±1.84 
G
PC 
3.24, s 
- 
- 
15.3±4.70 
1.75±0.84 
99.8±31.4 
(+) 
- 
- 
PC 
3.23, s 
- 
- 
57.0±2.50** 
10.29±3.68 
- 
- 
- 
- 
M
etabolic Im
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2 Spm
on O
steosarcom
a M
G
-63 Cells and Com
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 Table 6.5 (cont.). M
etabolite and choline com
pounds variations in H
O
b cells exposed to either 30 µM
 cD
D
P or 12 µM
 Pd
2 Spm
, for 24 hours and after a 3 days 
reversibility period. 
M
etabolite 
Signal 
(δ,ppm
) a 
cD
D
P (30 µM
) 
Pd
2 Spm
 (12 µM
) 
24h 
Reversibility 
24h 
Reversibility 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
PE 
3.25, s 
- 
- 
- 
- 
- 
- 
- 
- 
N
ucleotides and D
erivatives 
Inosine 
8.36, s 
- 
- 
- 
- 
- 
- 
41.1±5.2* 
3.72±1.43 
U
ridine 
5.89, d 
26.4±8.7 
1.54±0.79 
- 
- 
(+) 
(+) 
8.3±1.6 
2.88±1.17 
O
ther Com
pounds 
Creatine 
3.93, s 
- 
- 
- 
- 
- 
- 
-34.2±9.70 
-2.44±1.04 
D
ihydroxyacetone 
4.42, s 
- 
- 
- 
- 
- 
- 
-24.9±8.40 
-1.94±0.89 
Ethanolam
ine 
3.13, t 
- 
- 
- 
- 
- 
- 
49.4±18.3 
(+) 
G
SH
 
2.56, m
 
10.9±2.80 
2.12±0.94 
21.3±5.50 
2.00±0.91 
- 
- 
- 
- 
H
ypoxanthine 
8.18, s 
- 
- 
-19.0±8.30 
-1.45±0.77 
- 
- 
- 
- 
Lactate 
1.33, d 
- 
- 
- 
- 
- 
- 
- 
- 
m
-Inositol 
4.05, t 
-17.7±6.10 
-1.83±0.86 
-41.5±13.6 
-2.21±0.97 
-28.6±5.90 
-3.25±1.28 
-50.4±14.6 
-2.64±1.09 
s-Inositol 
3.34, s 
- 
- 
- 
- 
- 
- 
- 
- 
Ratios 
Controls 
cD
D
P 
Controls 
cD
D
P 
Controls 
Pd
2 Spm
 
Controls 
Pd
2 Spm
 
Choline com
pound ratios 
PC/Cho 
0.89±0.01 
0.56±0.07 
0.56±0.02 
0.93±0.02** 
0.89±0.01 
0.68±0.28 
0.56±0.02 
1.03±0.14 
G
PC/Cho 
0.98±013 
0.64±0.21 
0.58±0.03 
0.71±0.03 
0.98±013 
1.44±0.67 
0.58±0.03 
1.48±0.12 
PC/G
PC 
0.92±0.17 
0.89±0.17 
0.96±0.01 
1.31±0.03* 
0.92±0.17 
0.47±0.03 
0.96±0.01 
0.70±0.15 
a Resonance chosen for signal integration, b %
 variation and c effect size in relation to control cells. * p < 0.05,  ** p < 0.01, _ : no significant variation. (+) and (-) indicate 
consistent positive and negative variations, respectively, w
ithout statistical m
eaning. 
Chapter 6 
 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
 
217 
 
The drug-response profile of HOb cells treated with Pd2Spm for 24 hours is globally distinct 
from that of cDDP-treated cells. Several amino acids were found to decrease after Pd2Spm, from 
which Ala, Glu (similarly to what was seen for cDDP) and Gly registered the most marked changes 
(with % of variation of around -20 and ES values around -3). Pd2Spm was also suggested to 
induced a slight increase of L f.a. (CH2)n and GPC. Similarly to what was seen for cDDP treatment, a 
decrease in m-Ino (-28.6% and ES of -3.2) was also measured as consequence of HOb cells 
exposure to Pd2Spm. With the exception of PC/GPC, for which a ca. 50% decrease was 
determined in HOb cells treated with Pd2Spm for 24 hours, no relevant changes were measured 
for choline compound ratios upon a 24 hours treatment with either cDDP or Pd2Spm. 
Graphical comparison between the metabolic impact of cDDP and Pd2Spm on the HOb cell 
line is shown in Figure 6.13. Upon 24 hours of treatment, Pd2Spm was found to induce a more 
significant change in their metabolic profile than cDDP. Regarding amino acids, negative variations 
were detected for Ala, Arg, Gly, Lys, Pro and Val, in Pd2Spm-treated HOb cells compared to the 
controls, Glu being decreased for both drugs. Recent results from cDDP administration to rats 
(Ozaki et al., 2013) indicated that the drug caused a marked decrease in the activity of the 
mitochondrial enzyme aspartate aminotransferase, by binding to it. Since this enzyme catalyses 
the conversion of Asp and α-ketoglutarate to oxaloacetate and Glu, its reduced activity may 
underlie the observed decrease in Glu upon cDDP exposure. 
Regarding lipid signatures, and despite the reduced expression of these compounds in the 
metabolic profile of HOb cells, there are no evidences of disturbance upon 24 hours 
administration of any of the two compounds, eventually proving that a reduced cell death rate is 
taking place at this time, as suggested in Figure 6.12. Likewise, no variations were detected in the 
choline compounds upon either cDDP or Pd2Spm treatment. Since several studies (Ridgway et al., 
2013; Blankenberg et al., 2013; Wright et al., 2004) refer to alterations in lipids and choline 
compounds as fingerprints of programmed cell death, the absence of such changes may indicate 
that for this period of drug exposure (24 hours) there are still no clear metabolic evidences of 
apoptosis. In relation to compound ratios, due to the low intensity of the lipid resonances only the 
(CH2)n moiety was integrated, thus not disabling the determination of lipid ratios. Still, the choline 
compound ratios (Figure 6.14b) show that, despite showing no relevant change in each of the two 
compounds when considered separately (Figure 6.14a), the ratio between PC and GPC was found 
to be decreased in HOb cells treated with Pd2Spm for 24 hours, evidencing that, in opposition to 
cDDP, Pd2Spm appears to affect the dynamics of the choline compounds. 
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Figure 6.14. Heatmaps of effect size values of the time course response for a) several metabolites 
and b) choline compound ratios in HOb cells exposed to cDDP or Pd2Spm. The effect size values are shown 
in a colour scale from minimum (dark blue) to maximum (dark red) values. * p < 0.05 and ** p < 0.01 refer 
to the results of significance tests with integrals. Column indicated as REV, refers to cells exposed to the 
drug for 24 hours, followed by a recovery period of 3 days in drug free medium. 
Uridine, the most abundant nucleotide derivative found in the metabolic NMR profile of 
osteoblasts, was the only compound showing changes at 24 hours incubation with cDDP. 
Accumulation of uridine, one of the basic components of RNA, may suggest altered RNA synthesis 
as a consequence of treatment. 
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Regarding drug-induced changes in other metabolites, GSH was found to be upregulated in 
HOb cells exposed to cDDP while no alterations were detected upon Pd2Spm treatment. 
Interestingly, exactly the opposite was found in MG-63 cells, where Pd2Spm induced an increase 
of GSH at 24 hours while no alterations were measured upon the same period of treatment with 
cDDP. These results suggest that each one of these drugs display a particular influence on the 
redox system of either non-neoplastic or cancer cells, which can be an advantage in a treatment 
regimen where these two agents are administered in combination. 
The levels of m-Inositol are decreased in HOb cells exposed to both cDDP and Pd2Spm, 
what, together with the drug-induced decreased Glu, may be indicative that both drugs share, in 
their mechanism of action, common metabolic pathways at least with respect to those involving 
these two metabolites. This hypothesis could not be confirmed through STOCSY analysis, since 
strong correlations with the chosen signals were found even for noise regions, probably as a 
consequence of the reduced number of samples per group. The decreases in m-Inositol registered 
for both drugs, may reflect perturbations in the metabolism of phospholipids and/or inositol 
phosphate as well as in the osmotic homeostasis, since m-Inositol is implicated in all of these 
biofunctions. The decreased m-Inositol levels in both the cDDP- and Pd2Spm-treated HOb cells is 
similar to that measured for the MG-63 cell line upon the same drug-exposure conditions. Apart 
from their osmolytic functions, inositol and other polyols are known to play an important role in 
cellular detoxification processes, and its decrease due to chemotherapy treatment may reflect a 
lower turnover of phosphoinositides, a class of signaling phospholipids implicated in the control of 
cell proliferation (Triba et al., 2010) Thus, inositol can act as an indicator of membrane 
phospholipid turnover, and its reduction suggests an inhibition of cell proliferation. 
 
6.5. Assessment of Biological and Metabolic Reversibility of Effects of cDDP and Pd2Spm 
After assessing the metabolic consequences of a continuous cell exposure to either cDDP or 
Pd2Spm, the reversibility of the drug-induced alterations are were measured. As explained in the 
Experimental Section (Chapter 3), reversibility assays involved the analysis of cells that were 
exposed to IC50 concentrations of either cDDP or Pd2Spm for 24 hours and then allowed to grow in 
drug-free medium for 3 additional days. 
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6.5.1. Osteosarcoma MG-63 Cells 
As previously shown (Figure 6.2), no considerable changes in cell growth inhibition were 
detected at 36 and 48 hours of Pd2Spm-exposure relative to the 24 hours levels. A different 
behavior, however, was observed upon cDDP-treatment, since increasing treatment periods 
always led to a decreased cell proliferation. Figure 6.15 shows the time-dependent effect of cDDP 
and Pd2Spm on the MG-63 cells, for a 24 hours drug-exposure followed by a recovery period of 3 
days. It is clearly seen that in the presence of 30 µM cDDP the MG-63 cells are already committed 
to death since, even after a recovery period of 3 days (in the absence of the drug), the percentage 
of living cells is close to zero. On the contrary, for Pd2Spm drug removal for 3 days ensures a 
partial recovery of MG-63 cell growth, up to 65%, proving that, contrary to cDDP, Pd2Spm action 
can be reverted by cells when drug is removed from the growth medium. 
  
Figure 6.15. Cytotoxic effect of cDDP and Pd2Spm, in sole administration, towards the MG-63 cell 
line, upon 24 hours and a 3 days recovery period. Cell proliferation was evaluated by Trypan blue assay (as 
described in the Experimental Procedures, Chapter 3). Control (), 30 µM cDDP () and 12 µM Pd2Spm 
(). The data represent the average ± mean standard deviation from n=2 experiments, carried out in 
duplicate. 
Figure 6.14 reveals that the metabolism of MG-63 cells reacts differently to the removal of 
cDDP or Pd2Spm. For cDDP, the alterations detected in nine metabolites at 24 hours increased to 
fifteen after the 3 days growth in drug-free medium with a higher number of alterations being 
detected in amino acids, lipids, choline compounds and other miscellaneous metabolites, most of 
them being new ones or resulting from the intensification of the alteration measured at 24 hours, 
showing that cDDP-induced effects are not reversible. Interestingly enough, since DNA is one of 
the preferred targets of cDDP, no changes are detected in nucleotides and derivatives upon the 
recovery period, and even the slight increase of UDP-GlcNAc (δ 5.52) registered at 24 hours 
disappears. On the other hand, the reduced number of changes, five, detected upon 24 hours 
exposure to Pd2Spm are all reverted upon the reversibility period, with only two new increases in 
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Ino/Ado and ethanolamine. Increases of Ino/Ado probably reflect perturbations at the DNA level 
and changes of ethanolamine, a component of glycerophospholipids metabolism, point to altered 
phospholipid dynamics despite the absence of changes in choline compounds.   
Regarding reversibility to either cDDP- or Pd2Spm-treatment, no such studies have been 
found for MG-63 cells. The reversibility of the drug effect is highly dependent on the type of 
cancer cell line, which is confirmed by the results reported by Soares et al (Soares et al., 2007) on 
the Pd2Spm activity towards human tongue epitelioma HSC-3 cells, which showed to be almost 
irreversible upon a 3 days recovery period without the drug, as opposed to the results obtained 
here for the MG-63 cell line. 
 
6.5.2. Osteoblast HOb Cells 
Figure 6.16 shows the time-dependent effect of cDDP and Pd2Spm on the HOb cells, for a 
24 hours drug-exposure followed by a recovery period of 3 days. As it can be seen, the negligible 
alterations in the percentage of living cells (cells with intact cell membrane) upon 24 hours 
exposure to each of the two drugs gain relevance after 3 days of growth in drug-free medium: a 
reduced percentage of Trypan blue excluding cells was determined for both treatments with cell 
density being ca 50% or 30% relative to the control for cDDP and Pd2Spm, respectively. Moreover, 
and despite the considerable dimension of both error bars, these results suggest that, even after a 
3 days growth in drug-free medium, Pd2Spm possess a higher cytotoxic power over HOb cells than 
cDDP. 
 
Figure 6.16. Cytotoxic effect of cDDP and Pd2Spm, in sole administration, towards the HOb cell line, 
upon 24 hours and a 3 days recovery period. Cell proliferation was evaluated by Trypan blue assay (as 
described in the Experimental Procedures, Chapter 3). Control (), 30 µM cDDP () and 12 µM Pd2Spm 
(). The data represent the average ± mean standard deviation from n=2 experiments, carried out in 
duplicate. 
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In fact, PCA analysis (Figure 6.17a) also reveals that control and cDDP-treated HOb cells are 
much closer in the scores plot than control and Pd2Spm-treated cells, meaning that HOb cells are 
less affected by cDDP than by Pd2Spm. The PLS-DA analysis of the three groups (Figure 6.17b) 
shows a clear separation between the three sample groups but, interestingly, while all cDDP-
treated samples (24 hours and reversibility) remain globally equidistant in the scores space from 
controls, the Pd2Spm-reversibility samples become more distant in LV1 from both controls and 
samples treated with Pd2Spm for 24 hours, once again suggesting that a larger set of differences 
distinguishes controls from Pd2Spm-treated samples. PLS-DA analysis of both control vs cDDP-
treated (Figure 6.17c) and control vs Pd2Spm-treated samples (Figure 6.17d) show a clear 
discrimination between control and drug-treated groups, however more consistent/pronounced 
differences between groups probably underlie the higher Q2 value obtained for the Pd2Spm model 
in relation  to cDDP (0.787 and 0.509, respectively). 
  
Figure 6.17. Multivariate analysis of controls (z), 30 µM cDDP- (c) and 12 µM Pd2Spm-treated (c) HOb 
cells. a) PCA scores plot for all samples, UV, 3 components, R2X = 0.552 and Q2 = -0.129, b) PLS-DA scores 
plot for all samples, UV, 2 components, R2X = 0.382, R2Y = 0.780 and Q2 = 0.298, c) PLS-DA scores plot for 
cDDP assay, UV, 2 components, R2X = 0.286, R2Y = 0.990 and Q2 = 0.509 and d) PLS-DA scores plot for 
Pd2Spm assay, UV, 3 components, R
2X = 0.572, R2Y = 0.993 and Q2 = 0.787. 
The loading plots of the models presented in Figures 6.17c and 6.17d, resulted in 
representations in which noise was significantly coloured, thus eventually masking real and 
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important metabolic changes. For this reason, this information was not considered relevant and 
data analysis proceeded with the integration of as many signals as possible, based on 
observations made by visual inspection. The results from signal integration are summarised in 
Table 6.5 and the information contained therein is expressed as heatmap in Figure 6.14. 
As shown in Figure 6.14a, the low number of alterations induced by 24 hours treatment 
with cDDP (Glu, Urd, GSH and m-inositol) are still present upon the recovery period (with 
exception of Urd, which level seems to normalise), in addition to five new amino acid changes 
(Gly, Ser and Thr) and choline compounds (GPC and PC). This shows that cDDP has a long term 
effect over HOb cells. The higher number of metabolic alterations induced upon 24 hours 
treatment with Pd2Spm (mainly in amino acids) are globally reverted upon cells growth for 3 days 
in drug-free medium, excluding changes in Glu and Gln that persist. Reversibility results from 
Pd2Spm-treatment reveal alterations in Ser levels as well as in choline, Ino/Ado and Urd (both 
increase), creatine and dihydroxyacetone (DHA, δ 4.42). The long term decrease of choline 
induced by Pd2Spm immediately suggests a perturbation of the metabolism of membrane 
phospholipids (as most choline is found in phospholipids). However, and since this alteration is 
not accompanied by a change of either GPC or PC, other pathways involving the use of choline 
may underlie this variation, namely its oxidation to form betaine which may be used as an 
antioxidant. Nevertheless, the typical resonances of betaine, at δ 3.25 and δ 3.89, could not be 
identified in either 1D or 2D spectra, eventually due to the its low concentration. Changes in 
Ino/Ado and Urd probably reflect perturbations in DNA synthesis and metabolism, induced by 
Pd2Spm-treatment. DHA is a component of glycerophospholipid and inositol metabolism and can 
also be used as energy source. Thus, its decrease in HOb cells once again reinforce the idea of 
altered phospholipid metabolism as a consequence of cells treatment with Pd2Spm. Decreases in 
m-inositol and Glu persist upon the recovery period, similarly to what was seen for cDDP, 
eventually pointing to a common metabolic pathway shared by the two drugs. In relation to 
choline compound ratios, all registered increases upon the recovery period with exception for 
PC/GPC in Pd2Spm which recovered after the decrease upon treatment for 24 hours. Despite the 
similar trends observed for the two drugs, statistically significant increases were only registered in 
PC/Cho and PC/GPC of HOb cells treated with cDDP. 
In the light of these results, it becomes apparent that Pd2Spm induces more dramatic 
alterations in HOb cells than cDDP, such alterations being also more pronounced compared to 
those noted in osteosarcoma MG-63 cells. 
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6.6. Evaluation of Apoptosis in MG-63 Cells Exposed to cDDP or Pd2Spm: FITC Annexin V/PI 
Assays 
The above discussed results showed that, despite the established IC50 concentration 
determined at 24 hours for the drugs under study, the consequences in terms of cell survival and 
metabolic profile that result from cDDP or Pd2Spm exposure are clearly distinct. Regarding MG-63 
cells, cDDP treatment induced the highest decrease in the number of living cells (even after drug 
removal) and their metabolic profile revealed a marked increase of the lipid content, an important 
marker of apoptosis. 
As to Pd2Spm-treated MG-63 cells, the number of living cells after 24 hours of exposure was 
kept stable and the metabolic profile did not reveal a perturbation of the lipid moieties which 
raised the question of whether these cells are indeed dying or if drug is somehow only inducing a 
time lag in their normal growth and division processes. Accordingly, a FITC Annexin V/PI apoptosis 
detection experiment was performed with a view to determine and compare apoptosis in MG-63 
cells treated with either cDDP or Pd2Spm (at IC50 concentrations - 30 and 12 µM, respectively) 
over a period of 48 hours (Figure 6.18). 
  
Figure 6.18. Global results of FITC Annexin V/PI assays of control (), 30 µM cDDP- () and 12 µM 
Pd2Spm-treated () MG-63 cells. The data represent the average ± mean standard deviation from n=3 
experiments, carried out in duplicate. 
The results presented in Figure 6.18 show that at 48 hours, and as expected, the great 
majority of the control cells are viable (around 86%) and only a small percentage is undergoing 
apoptosis, as can be seen in more detail in Figure 6.19a. On the other hand, after 48 hours of 
exposure to cDDP, only 26% of the cells remain viable, while around 22% are undergoing initial 
apoptosis and 51% are already in late stage apoptosis (Figure 6.19b). Interestingly enough, 
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analysis of the results for the Pd2Spm-treated samples (Figure 6.19c) revealed a significant 
similarity to controls, both for viable and apoptotic cells, which means that Pd2Spm-treatment 
does not compromise their overall viability. 
 
 
Figure 6.19. Global results of FITC Annexin V/PI assays, at 48 hours, of a) control, b) cDDP- and c) 
Pd2Spm-treated MG-63 cells. Values represent the average from n=3 experiments, carried out in duplicate. 
These assays were accompanied by a parallel Trypan blue assay that ensured that for each 
of the two drug treatments, at 24 hours, only 50% of cells remain alive, i.e. the drug concentration 
to which cells were exposed was in agreement with the previously determined IC50.  
According to these results it becomes clear that cDDP-exposed MG-63 cells were 
undergoing extensive apoptosis, in agreement with reported studies for this drug (Kinoshita et al., 
2000; Koyama et al., 2004; Tsai et al., 2014). Regarding Pd2Spm, the results suggest that the 
reduction in the number of cells when treated with this agent might be due to a lag effect of the 
drug over their normal growth and division times, instead of relating to a cell death induced 
mechanism, since neither apoptosis nor necrosis were found to take place. 
The data by Fiuza (Fiuza et al., 2011) for human breast cancer cells have shown that the 
activity of Pd2Spm on the cytoskeleton, and its expected impact on cell morphology, is much 
greater than for cDDP, although no experiments on apoptosis detection were reported at that 
time. Taken together, these results suggest that both Pd2Spm and cDDP impair cell proliferation 
via distinct cellular targets. 
 
6.7. Glutathione Competition Assays 
Due to the high affinity of soft metals such as Pt(II) and Pd(II) for the sulphur atom (a soft 
ligand), glutathione is a key component in the pharmacokinetic pathway of Pt- and Pd-containing 
a) b) c)
1.0% 8.5% 0.7% 50.9% 1.3% 6.9%
86.0% 4.5% 26.5% 21.9% 87.6% 4.2%
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agents, being known to affect their intracellular bioavailability and to be responsible for 
mechanisms associated to acquired resistance to Pt(II) agents such as cDDP (Marques, 2013; 
Wang et al., 2007; Zhang et al., 1998). Glutathione, a tripeptide comprising Gly, Glu and Cys, is the 
most abundant non-protein thiol in the cell and acts as a fundamental antioxidant preventing the 
oxidative damage of intracellular components (mainly by reactive oxygen species, ROS, such as 
peroxides and free radicals). Glutathione exists predominantly in the reduced form (GSH), at 
intracellular concentrations in the range of 0.5-10 mM and can be readily oxidised to the stable 
disulfide species (GSSG) (Lushchak et al., 2012). The liquid state 1H NMR spectra of both reduced 
and oxidised glutathione solutions are shown in Figures 6.20a and 6.20b, respectively. 
 
Figure 6.20. 500 MHz 1H NMR spectra of aqueous solutions of a) 1 mM GSH and b) 1 mM GSSG, at 
310K. 
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As shown in Figure 6.19, spectra from GSH and GSSG possess identical resonances for H10 
(δ 2.17), H9 (δ 2.56) and H11 and H14 (δ 3.79). However, an additional resonance appears for H2’ 
(δ 3.34) from GSSG and the H3 and H3’ from GSSG resonate at δ 4.78, while for GSH, H3 
resonance appears at δ 4.58. In fact, H2 or H2’ and H3 or H3’ refer to the protons that are closest 
to the disulfide bridge that is established when GSH is oxidised to GSSG, and thus are those for 
which chemical shift is more prone to be affected as consequence of the oxidation process. 
Since the drugs hereby tested, cDDP and Pd2Spm, contain the metal ions Pt(II) and Pd(II) 
(with a high affinity for glutathione’s sulphur), it is worth investigating whether the GSH signal 
chosen for integration in the cell studies (H9, at δ 2.56) can be affected by the presence of such 
agents. This will help understanding whether the measured variations in cell metabolites refer 
indeed to alterations in GSH levels or if, on the other hand, competition by GSH coordination with 
Pt(II) or Pd(II) ions are erroneously influencing the results. Therefore, competition assays of GSH 
towards cDDP or Pd2Spm were performed, in solution, with a view to assign the resonances of the 
drug-GSH adducts, for each of the two drugs. The results from these experiments are presented 
below. 
 
6.7.1. Pt (II) Drug: cDDP 
cDDP (through is Pt(II) centre) is known to display a higher affinity for sulphur donors like 
cysteines and methionines than for nitrogen donors such as the purine bases of DNA (Pearson et 
al., 1968). Nevertheless, the drug’s mode of action is known to primarily involve the 
establishment of intra- and interstrand crosslinks with DNA (mostly with guanine and adenine), 
triggering a series of conformational rearrangements and biochemical changes that ultimately 
lead to apoptosis (Basu and Krishnamurthy, 2010). Hence, in spite of ongoing debate around this 
matter, it is generally assumed that GSH is closely associated to drug-resistance mechanisms of 
Pt-based chemotherapeutic agents. 
Up to this date, numerous studies have unequivocally correlated partial cDDP inactivation 
in several human cancer cell lines with increased GSH intracellular levels (Mistry et al., 1991; 
Komiya et al., 1998; Godwin et al., 1992). Chen and co-workers (Chen et al., 2008) concluded that 
cells with increased GSH levels become more sensitive to cDDP by up-regulation of the copper 
transporter hCtr1 (involved in transporting cDDP into cells), while other authors have suggested 
that the high affinity of the Pt(II) drugs for the glutathione’s thiol group favours the formation of 
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stable Pt-glutathione adducts thus lowering the amount of drug available for DNA binding 
(Reedijk et al., 1999). Kasherman and collaborators (Kasherman et al., 2009) determined such a 
decrease in active drug concentration to be around 20% in human ovarian cancer cells. A review 
from Chen and Kuo (Chen and Kuo, 2010) summarises the three mechanisms that have been 
proposed for the role of GSH in the regulation of cDDP sensitivities that ultimately influence its 
ability to induce cell death: 1) GSH can act as a cofactor that facilitates the efflux of cDDP in 
mammalian cell by multidrug resistance protein 2 (MDR2); 2) GSH can act as a redox-regulating 
cytoprotector; 3) GSH can act as a copper chelator. 
 
Due to the conflicting nature of results regarding this issue, the kinetics of the GSH:cDDP 
competition reaction was presently followed by liquid state 1H NMR (carrying out signals 
integration), in order to understand if our determinations of GSH in the spectra of the cell samples 
may have been miscalculated by a possible interference from Pt-GSH adducts. 
Figure 6.21 compares the spectra of fresh solutions of glutathione, both reduced (Figure 
6.20a) and oxidised (Figure 6.20b) with that of a GSH:cDDP solution (2:1 in PBS/D2O). The kinetics 
of the reaction between GSH and cDDP was followed by the continuous acquisition of one 
spectrum of the GSH:cDDP solution every 15 minutes, starting with the fresh solution (Figure 
6.21c) up to a total of 3 hours reaction time (Figure 6.21d). One last spectrum was registered 18 
days after the preparation of the solution (Figure 6.21e). Considering the minor changes observed 
when analysing the spectra, only the initial (15 minutes) and final (3 hours) spectra were chosen 
for comparison, and are represented in Figure 6.21. For increasing reaction times, the initial 
GSH:cDDP sample evidences a higher degree of glutathione oxidation, reflected by the strong 
GSSG resonances at δ 3.34 and δ 4.78. As expected, at day 18, all glutathione was in the oxidised 
form - the GSH typical resonance at δ 4.58 from H3 being absent and only one multiplet being 
detected at δ 4.78 attributed to the typical resonance of H3’ protons of GSSG. As highlighted in 
grey in Figure 6.21, the increasing GSH oxidation is accompanied by the appearance of broad 
signals at δ 2.25, δ 2.65 and δ 3.86 (more evident at day 18) which were attributed to the 
formation of the cDDP-glutathione adduct. Also, already after 3 hours upon adding cDDP and 
GSH, a signal appears at δ 2.75, possibly corresponding to an intermediate species. 
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Figure 6.21. 500 MHz 1H NMR spectra of a) GSH and b) GSSG solutions and GSH:cDDP kinetics at c) 
15 minutes, d) 3 hours and d) 18days after solution preparation, at 310 K. Grey areas highlight broad 
resonances attributed to the cDDP-glutathione adduct formation. 
Kinetic studies reported by Hagrman (Hagrman et al., 2004) evaluated the formation of 
Pt(II)-glutathione species for several platinum-based drugs (oxaplatin, carboplatin and cDDP). 
Reactions were performed at 37˚C and concentrations were selected to mimic those of GSH in 
cells in organism (6.75 mM, according to Souid et al., 2001) and those that mimic the passage of 
clinical concentrations of the drugs (4.62, 6.63 and 7.82 mM) through the cytosol (135 µM) (Oguri 
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et al., 1988; Grolleau et al., 2001; Souid et al., 2003). Regarding cDDP, formation of the metal-
glutathione adduct was monitored for a 40 hours period, almost total depletion of the free drug 
having been observed during the first 5 hours, with a t1/2 value (time necessary for a 50% 
concentration decrease) for free cDDP equal to 1.03-1.06 hours. This t1/2 value was considered in 
the present experiments when establishing the 3 hours periods to follow the reaction cDDP:GSH 
to cDDP-glutathione by NMR. 
In an attempt to quantify the extension of glutathione oxidation, as well as the formation of 
the cDDP-glutathione adduct, the following analysis was carried out: the ratios between the areas 
of the typical resonances from GSH (δ 4.58) or GSSG (δ 4.78) and the total area of the spectrum of 
each form of glutathione in fresh solutions (prepared in equal concentrations) were assumed as 
reflecting 100% of each form of glutathione. Then, using these values as a reference, the 
percentages of GSH and GSSG in the cDDP:GSH solutions were calculated over periods of 3 hours 
and 18 days, the residual percentage being attributed to cDDP-glutathione adduct formation 
(Table 6.6). 
Table 6.6. Quantification of GSH, GSSG and cDDP-glutathione in a solution containing 0.5mM cDDP 
and 1 mM GSH, upon increasing reaction times. 
Spectra Time Total Area % of GSH1 % of GSSG2 
% of cDDP-
glutathione adduct3 
cDDP-glutathione_1 0h15 4.88E+08 90.9 6.10 3.00 
cDDP-glutathione _2 0h30 4.90E+08 89.1 8.40 2.50 
cDDP-glutathione _3 0h45 4.90E+08 85.8 7.40 6.80 
cDDP-glutathione _4 1h00 4.86E+08 81.0 8.40 10.6 
cDDP-glutathione _5 1h15 4.83E+08 75.7 8.20 16.1 
cDDP-glutathione _6 1h30 4.84E+08 72.7 11.0 16.2 
cDDP-glutathione _7 1h45 4.81E+08 69.1 10.3 20.6 
cDDP-glutathione _8 2h00 4.83E+08 70.6 12.0 17.4 
cDDP-glutathione _9 2h15 4.83E+08 64.4 13.1 22.5 
cDDP-glutathione _10 2h30 4.82E+08 63.5 13.0 23.5 
cDDP-glutathione _11 2h45 4.81E+08 61.0 12.3 26.6 
cDDP-glutathione _12 3h00 4.79E+08 53.5 13.9 32.6 
cDDP-glutathione 
_18days 
18 days 4.55E+08 -1.60 22.4 79.2 
1 δ 4.58 signal integration – extrapolation based on the assumption that GSH/Total Area of fresh GSH 
solution is 100%; 2 δ 4.78 signal integration – extrapolation based on the assumption that GSSG/Total Area 
of fresh GSSG solution is 100%; 3 % ( cDDP-glutathione adduct) = 100 - (%GSH + %GSSG), assuming that no 
other species are formed/altered during the experiment. 
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According to these calculations, after a 3 hours kinetics, only 53.5% of GSH is present in 
solution, the percentage of GSSG increasing up to near 14%, thus yielding a 32.6% formation of 
cDDP-glutathione adduct during this time (assuming that no other chemical species is formed). 
After 18 days, around 20% of glutathione was oxidised to GSSG and the other 80% seems to be 
complexed with cDDP. 
Due to the complexity of the 1H HRMAS NMR spectra obtained for the cells treated with 
cDDP, coupled to the low intensity of the glutathione signals detected, it was impossible to infer 
about the presence of the base-broadened patterns here suggested to be associated to the 
presence of the cDDP-glutathione adducts. Nevertheless, the formation of such adducts should 
account for a minor fraction of the measured GSH signal once its time course (Figure 6.22) shows 
either maintenance (until 24 hours) or decrease (24 hours onwards) relative to the control. If the 
peak assumed as GSH was instead mainly assigned to the cDDP-glutathione adduct, it would be 
expected that for treated cells, after an initial increase (cDDP addition is performed at the very 
beginning of the experiment), the levels of this signal would remain quite stable along the rest of 
the experiment (assuming the high stability of the adduct, since no other competing species are 
present in solution). 
 
Figure 6.22. Time course variation of GSH (δ2.56) in controls (z), 30 µM cDDP- (c) and 12µM 
Pd2Spm-treated (c) MG-63 cells (controls are indicated with full lines and drug-treated with dashed lines). 
Besides reacting with free cDDP, a second GSH molecule can also react with the drug-
glutathione adduct. This process was well described by Singh and collaborators (Singh et al., 
2005), who proposed the reaction scheme depicted in Figure 6.23. The binding of cisplatin to a 
second GSH molecule may be explained by the trans-ammine labilisation effect of the first 
coordination of Pt(II) to glutathione’s sulphur atom, which facilitates the substitution of cDDP’s 
NH3 groups by GSH. 
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Figure 6.23. Reaction scheme proposed for the formation of Pt(glutathione)2 species (adapted 
from Singh et al., 2005). 
 The maximum GSH:cDDP ratio of 2 considered in the present competition assay is far 
lower than that occurring intracellularly, which once more reinforces the proposed hypothesis of 
a minor contribution of the drug-glutathione adduct for the NMR signal of GSH considered for 
integration in cell samples, meaning that a decrease of GSH integral is most probably attributed to 
its increased degradation (probably by oxidation). 
 
6.7.2. Pd (II) Drug: Pd2Spm 
Due to the chemical similarity between the Pt(II) and the Pd(II) ions, the Pd2Spm complex is 
also expected to react with intracellular GSH in cell cultures. The following set of experiments 
aimed at understanding whether this reaction occurs and to what extent, through the analysis of 
the GSH NMR resonance at δ 2.56, chosen for signal integration. 
Figure 6.24 compares the spectra of fresh solutions of glutathione (both reduced and 
oxidised forms) with the spectra of GSH:Pd2Spm solution (1 mM: 0.5 mM in PBS/D2O) analysed 
fresh and 3 hours after the preparation of the solution (one spectrum was registered each 15 
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minutes). Due to the very small magnitude of the observed changes, only the initial and final 
spectra are shown, for simplicity sake. 
  
Figure 6.24. 500 MHz 1H NMR spectra of a) GSH and b) GSSG solutions and GSH:Pd2Spm kinetics at c) 
15 minutes and  d) 3 hours after solution preparation, e) Pd2Spm and f) Spm, at 310 K. Grey areas highlight 
broad resonances attributed to Pd2Spm-glutathione adduct formation. 
As shown in Figure 6.24c, 15 minutes of reaction (time needed for spectral acquisition) are 
enough to remove all typical resonances from GSH and GSSG (δ 4.58 and δ 4.78, respectively), 
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showing that the great majority, if not all, of the free GSH reacted with Pd2Spm during this time 
and did not undergo oxidation to GSSG. In fact, when GSH and Pd2Spm solutions were mixed 
together, an exothermic reaction took place and the solution immediately turned yellow-orange 
(characteristic of the formation of a Pt-S or Pd-S bond). 
As expected, there are some similarities between the signals yielded by the Pd2Spm-
glutathione solution and those from Pd2Spm and Spm solutions. Resonances from GSH also seem 
to contribute to the NMR signals that appear in the spectrum of the adduct, but due to the 
considerable changes in chemical shift in relation to the reference samples, it was not possible to 
unequivocally assign the peaks from the Pd2Spm-glutathione solution. Despite this fact, it seems 
quite reasonable to conclude that no GSH oxidation to GSSG occurred and that reduced Pd(II) 
coordination with glutathione took place. The broadening of the glutathione signals, clearly 
depicted in Figure 6.24c and Figure 6.24d, can thus be attributed to the larger dimension and 
lower mobility of this adduct, this effect being particularly clear at δ 3.78, where neither Pd2Spm 
nor Spm display any signals. 
Studies by Sovago and Martin (Sovago and Martin, 1981) showed that, in an equimolar 
solution of Pd(II) and GSH, broadening of the NMR signal arising from –CH2CH part of the γ-
glutamate residue at δ 2.56 occurs as a consequence of metal chelation at the α-amino terminus, 
in addition to thiol coordination. In this study, Pd(II) and GSH are in equimolar conditions (2 Pd(II) 
ions are present per molecule of Pd2Spm) and a broad signal is detected at δ 2.56, immediately at 
15 minutes of reaction, suggesting that the refered chelation may have take place. 
As for cDDP, the 1H HRMAS NMR spectra of Pd2Spm-treated cells have a low intensity GSH 
signal which makes it impossible to infer about broadening effects coming from adduct formation, 
that may account for an erroneous interpretation of the results of GSH peak integration (δ 2.56). 
However, taking into consideration the above refered results that seem to indicate a significant 
chemical shift change of the peak of GSH at δ 2.56 when coordinated with Pd(II), and once HRMAS 
spectra of treated cells do show a GSH peak at this chemical shift comparable in magnitude to 
that of control cells, it seem plausible to assume that the formation of the Pd2Spm-glutathione 
adduct would account for a small peak at slight higher chemical shifts. Thus, the GSH peak at δ 
2.56 chosen for integration does seem to reflect free GSH variation, either in the presence or 
absence of the drug. 
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These drug:GSH competition assays showed that both drugs chelate glutathione but, 
according to the alterations observed in the spectra, the most dramatic ones are seen in 
Pd2Spm:GSH solution. Together with the release of heat when mixing Pd2Spm with GSH solution 
(pointing to chelation of metal ion to sulfur of GSH), NMR spectral analysis showed that Pd more 
easily and strongly coordinates with GSH. Regarding the differences in GSH time course in the 1H 
HRMAS NMR spectra of cDDP- and Pd2Spm-treated MG-63 cells (Figure 6.22), the drug:GSH 
kinetic assays strongly suggested that the signal that is integrated is, in fact, mainly attributed to 
GSH (and not the GSH-drug complex). Therefore, the presented time course can not be 
interpreted as reflecting higher or lower coordination power of the metal ions (Pt(II) or Pd(II)) of 
the drugs to GSH, instead it seems to reflect the consequence of drug action in the metabolism of 
GSH.  
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7. Metabolic Impact of Drug Combination on 
Osteosarcoma MG-63 Cells 
This chapter intends to go a step further in the understanding of the metabolic impact of 
drugs currently used for osteosarcoma treatment, through experiments that aim to closely mimic 
the combination regiment in which these agents are administered in the clinic. By comparing 
these with the data previously described for single drug administration, synergistic effects may be 
identified. Moreover, the possible benefits of replacing cDDP by the Pd(II) agent Pd2Spm in 
combination regimens are discussed, by comparing nature and magnitude of the metabolic 
alterations induced by cDDP- and Pd2Spm-cocktails in MG-63 cells. 
7.1. Antiproliferative Activity and Cytotoxic Results 
The EURAMOS protocol (http://212.219.75.232/euramos/euramos_i_trial.asp) defines that 
the first cycle of chemotherapy for an OS patient consists of a five week treatment protocol, in 
which cDDP and DOX are administered simultaneously in the first week and then MTX is given 
twice at weeks 4 and 5. A second cycle of this regimen is repeated prior to surgery and, at that 
time, a histological evaluation of treatment response is performed, in order to decide on a 
possible new cycle of treatment that includes ifosfamide and etoposide administration. 
In an attempt to translate the first cycle of treatment performed in the clinic to cell culture 
assays, we reduced the timescale from weeks to days and performed preliminary tests to 
determine the concentrations of drugs (cDDP, DOX and MTX) that were in agreement with the 
proportion in which they are used in the clinic (120 mg: 75 mg: 12 g), while ensuring that at the 
end of the experiment the number of cells still enabled the analysis by NMR, i.e. a minimum of 
around 5 million cells (obtained, if necessary, by replica samples). According to this and 
considering the lowest determined IC50 concentration of 3 µM for DOX, the cDDP and MTX 
concentrations should be of 4.8 and 480 µM, respectively. Our preliminary cytotoxicity tests (not 
shown), showed that the time needed for a second dose of MTX induces an even higher reduction 
in the number of cells and, on the other hand, control groups would be under an additional 24 
hours period of stress induced by extremely high cell densities and for these reasons we decided 
to stop the experiments after just one dose of MTX. Additionally, our cytotoxicity results (not 
shown) also showed that, interestingly, 4.8, 48 or 480 µM of MTX resulted in similar decreases in 
Metabolic Impact of Drug Combination on Osteosarcoma MG-63 Cells 
 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
238 
 
MG-63 cells survival and for this reason, the lowest MTX concentration (4.8 µM) was chosen, 
despite it not respecting the proportion in relation to the other 2 drugs in clinics. A schematic 
representation of the experimental procedure adopted is presented in Figure 7.1, showing the 
time points of addition of drug-cocktails and of sample collection. 
  
Figure 7.1. Schematic representation of the experimental procedure followed in drug combination 
metabolic assays, showing the time points of sample collection and addition of drug-cocktails. 
 
Figure 7.2 shows the cytotoxic results reflecting the impact of treatment with 4.8 µM cDDP 
+ 3 µM DOX and 4.8 µM Pd2Spm + 3 µM DOX cocktails in both MG-63 (Figure 7.2a) and HOb 
(Figure 7.2b) cells’ survival after 24, 48, 72 and 96 hours of treatment. Moreover, the impact of 
the addition of 4.8 µM MTX during the last 24 hours of the total 96 hours period of continuous 
exposure to either cDDP- or Pd2Spm-combination treatments is also shown. 
The cytotoxic results of the MG-63 cells exposed to either cDDP- or Pd2Spm-combination 
treatments (Figure 7.2a) yielded similar results in terms of cell survival: after 24 hours of 
treatment with either cDDP or Pd2Spm, in combination with DOX, an inhibition of cell growth of 
about 50% was achieved. Larger exposure times resulted in a slight decrease in cell survival, 
without significant differences being detected for the regimens based on either cDDP or Pd2Spm. 
When compared to the results previously obtained for MG-63 cells exposed to DOX, for only 48 
hours (Figure 5.1b, Chapter 5), a similar decreasing tendency in cells survival was detected. 
Interestingly enough, administration of MTX for the last 24 hours (of a total drug incubation 
period of 96 hours), at a concentration higher than the corresponding IC50 for these cells (4.8 µM 
as opposed to the IC50 value of 3 µM) does not induce a detectable change in cells’ survival 
relative to cDDP+DOX or Pd2Spm+DOX. From this first experiment, two interesting conclusions 
can be drawn: 1) despite the considerable differences in the IC50 values for cDDP and Pd2Spm (the 
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latter being about half of the first), the combination of each of these drugs with DOX (at its IC50 
dosage) induces identical levels of cell death; 2) MTX addition, at a concentration higher than its 
IC50, does not seem to cause additional cell death. 
 
Figure 7.2. Cytotoxic results and antiproliferative activity of several drug combinations towards the 
MG-63 and HOb cell lines: a) MG-63 cells (Trypan blue assay); b) HOb cells (SRB assay). The cells were 
exposed to cDDP- or Pd2Spm-cocktails. Control (), 4.8 µM cDDP+3 µM DOX (), 4.8 µM Pd2Spm+3 µM 
DOX (), 4.8 µM cDDP+3 µM DOX+3 µM MTX (), 4.8 µM Pd2Spm+3 µM DOX+3 µM MTX (). The data 
represent the average ± mean standard deviation from a) n=3 experiments, carried out in duplicate and b) 
n=3 experiments, carried out in triplicate. 
The evaluation of the impact of these drug-cocktails on the non neoplastic HOb cells was 
carried out only through the SRB colorimetric assay, due to the already mentioned difficulties in 
achieving the large number of cells needed for the NMR experiments. For both cDDP+DOX and 
Pd2Spm+DOX combination regimens, a significant decrease in cells’ survival was achieved after 48 
hours of drug exposure (Figure 7.2b). This inhibition of cell proliferation seems to be maintained 
throughout the whole duration of the experiment (96 hours), whereas the number of osteoblasts 
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kept the increasing tendency in the controls. Again, addition of the antimetabolite MTX was not 
found to enhance the effects of either the cDDP- or Pd2Spm-cocktails. 
Comparison of cell survival data obtained for the neoplastic (MG-63) and non-neoplastic 
(HOb) cells seems to indicate that: 1) the two combination schemes induce very similar cell 
survival rates for each of the two cell lines; 2) the measured growth-inhibition effect is detected 
for shorter drug incubation times for the MG-63 cells than for the osteoblasts, meaning that drug 
cocktails seem to be more effective in cancer cells than in healthy ones; 3) administration of MTX 
does not seem to induce a synergistic effect for either cDDP- or Pd2Spm-combination regimens. 
 
7.2. 1H HRMAS NMR Analysis 
7.2.1. cDDP-Cocktail 
Based on the results of Trypan blue assays that show a marked decrease of MG-63 cells 
survival as a consequence of cells treatment with the cDDP-cocktail, the next step was to 
understand which metabolic changes underlie this decreased number of living cells and whether 
they are in agreement with those identified in single drug treatment assays (both cDDP, DOX or 
MTX) or if new changes emerge, reflecting a synergistic action of these drugs when administered 
in combination. Once again, HRMAS NMR metabolomics was the chosen approach to perform this 
evaluation, in which only MG-63 cells were studied due to the already mentioned difficulties to 
obtain large numbers of HOb cells for NMR analysis. 
The metabolic impact of simultaneous administration of cDDP (4.8 µM) and DOX (3 µM) to 
the MG-63 cells was evaluated over 96 hours, with samples being collected every 24 hours. Visual 
inspection of cDDP+DOX-treated spectra compared to the control spectra (Figure 7.3) reveals 
relevant drug-induced changes already at 24 hours of treatment: strong increases in choline, GPC, 
UXP and glucosylated derivatives, increased alanine and clear changes in other metabolites 
(namely higher amounts of acetates and creatine and a marked decrease of m-Inositol). For 
longer exposure periods (72 and 96 hours), the metabolic changes are intensified relative to the 
48 hours time-point: increase of lipid resonances, choline and GPC levels, as well as of uridine, 
UXP and UDP-GNAc derivatives, global decrease of amino acids (Ala, Lys, Glu, Gln, Thr, Gly, Tyr, 
Phe and His), decreased m-Inositol and increased hypoxanthine (δ 8.19 and δ 8.21) and Un. at δ 
7.86 (d). 
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Figure 7.3. Average 500 MHz 1H HRMAS NMR spectra of MG-63 cells: a) control and b) exposed to 
cDDP+DOX, at 24 hours; c) control and d) exposed to cDDP+DOX, at 72 hours. Insets show expansions of 
choline compounds (3.2-3.3 ppm) and aromatic (5.2-8.5 ppm) regions. Main assignments are noted and 
visible spectral changes due to drug exposure are marked by arrows. 
a) Control MG-63 cells  at 24 hours
b) cDDP+DOX-treated MG-63 cells  at 24 hours
c) Control MG-63 cells  at 72 hours
d) cDDP+DOX MG-63 cells  at 72 hours
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Changes in acetates (δ 1.92 and δ 2.02) show some fluctuations over time, with frequent 
dispersion between samples. At 96 hours there are some variations that deserve special 
attention: all choline compounds (Cho, PC and GPC) are increased relative to the control 
(including PC) and a new signal (a shoulder of the choline peak) appears at δ 3.21; increases in 
UDP-GNAc are detectable just for UDP-GalNAc (δ 5.62) since the resonances of these glucosylated 
metabolites decrease already at 72 hours. No clear changes in GSH were detected between 
control and treated cells over the 96 hours of the experiment. 
According to the cytotoxic results (by the Trypan blue assay), addition of MTX subsequently 
to the cDDP+DOX cocktail does not induce considerable alterations in MG-63 cells survival. 
Nevertheless, it is worth investigating if this antimetabolite has indeed no effect on the metabolic 
profile of MG-63 cells. A comparison with the metabolic changes induced by exposure to MTX 
alone should be performed. Figure 7.4 compares the average metabolic profile of control, 
cDDP+DOX- and cDDP+DOX+MTX-treated cells for a total period of 96 hours. 
In general, the addition of MTX for 24 hours does not alter the metabolic profile of MG-63 
cells treated with only cDDP+DOX for 96 hours. Visual inspection of the results reveals an increase 
in the NMR signal at δ 7.86 (d) only when MTX is added to the drug cocktail, as well as the 
absence of the unassigned shoulder of the choline peak (at δ 3.21) with cDDP+DOX treatment. 
Additionally, the increase in lipids, choline compounds (choline and PC) and uridine seem to be 
enhanced by MTX administration (Figure 7.4c). 
Further investigations on the most relevant metabolic alterations that underlie drug-
induced effects were performed by multivariate analysis of the 1H HRMAS spectra of both 
controls and drug-treated cells with cDDP+DOX and cDDP+DOX+MTX (Figure 7.5). PCA analysis 
(Figure 7.5a) led to a clear separation between controls and drug-treated cells mostly along PC1. A 
time course tendency from negative PC1 and PC2 to positive PC1 and PC2 can be clearly assigned 
for treated samples, whereas no such temporal tendency can be addressed for control samples. 
Moreover, a clear separation between treated samples is achieved when MTX is added to the 96 
hours treatment with cDDP+DOX, strongly suggesting that, despite the absence of considerable 
changes in Trypan blue results, changes in metabolism do occur as consequence of MTX addition 
to the cocktail. 
Chapter 7 
 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
243 
 
  
Figure 7.4. Average 500 MHz 1H HRMAS NMR spectra of MG-63 cells, at 96 hours: a) under control 
conditions, b) exposed to cDDP+DOX and c) exposed to cDDP+DOX+MTX. Insets show expansions of choline 
compounds (3.2-3.3 ppm) and aromatic (5.2-8.5 ppm) regions. Main assignments are noted and visible 
spectral changes due to drug exposure are marked by arrows. 
For PLS-DA analysis, UV scaled data were chosen since time course tendency of samples in 
scores plot is similar to that of Ctr scaling, with increased ability to identify variations of lower 
magnitude. PLS-DA scores plot (Figure 7.5b) showed very good separation between groups (Q2 
0.838, considering only two classes: control and drug-treated) with the maintenance of the time 
course tendency for treated samples. The robustness of group discrimination achieved was 
reflected in a very low Q2 distribution overlap and good MCCV results (97.5% sensitivity, 99.3% 
specificity and 98.3% classification rate) shown in Figure 7.5c and 7.5d.  
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Figure 7.5. Multivariate analysis of controls (z) and cDDP-cocktail treated (c/c) cells: (a) PCA 
scores plot, Ctr scaled data (b) PLS-DA scores plot , UV scaled model with 2 components calculated with R2X 
= 0.379, R2Y = 0.930 and Q2 = 0.838. MCCV results of PLS-DA model obtained for MG-63 cells exposed to 
cDDP-cocktail vs control: c) Q2 distributions and d) ROC plots of true and permuted models. TPR: true 
positive rate, FPR: false positive rate, Sens.: sensitivity, Spec.: specificity, CR: classification rate. 
 
The identification of the most relevant changes underlying this group separation is assisted 
by VIP-colored loadings (Figure 7.6). According to this analysis, increased lipid contents, choline 
compounds, uridine and UDP-GNAc metabolites coupled to significantly decreased m-inositol and 
amino acids contents (namely Ala, Lys, Met, Tyr and Phe) are the most relevant variations induced 
by cDDP-cocktail treatment in this type of cancer cells. These cDDP-cocktail-induced changes 
pointed out by MVA, confirm those previously suggested by visual inspection. 
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Figure 7.6. Multivariate analysis of controls and cDDP-cocktail-treated cells, using the full spectral 
range: UV scaled PLS-DA LV1 loadings plot, colored as function of VIP values. 
 
In order to obtain further information on the time course of metabolites in response to 
cDDP-cocktail treatment, signal integration was performed and time course plots for several 
metabolites were constructed (Figures 7.7, 7.8 and 7.9). 
The time course response of lipids and lipid ratios to cells exposure to cDDP-cocktail is 
shown in Figure 7.7. The cocktail cDDP+DOX induces a clear increase of all measured resonances 
which get more pronounced for longer periods of exposure with lipid ratios increasing in the same 
way. This effect over lipids resembles that of cDDP in sole administration (Figure 5.6, Chapter 5) 
while for DOX, in the same conditions, only slight increases were registered for PUFA and lipids 
ratios. Thus, even in combination regimens, cDDP seems to exert a dominant effect in the 
metabolism of lipids. Remarkably, and despite the absence of this behaviour in sole 
administration, the addition of MTX to the cDDP-cocktail potentiates this increasing tendency, as 
observed by the relative increases in CH3, (CH2)n, HC=CH and =CHCH2CH= resonances (the latter is 
not shown). Although with a reduction in magnitude, this effect of MTX addition over lipids also 
resulted in a slight increased CH2/CH3 ratio (suggesting increased mean chain length of fatty acid 
chains) and a slight reduction in HC=CH/CH3 (degree of unsaturation) when compared to the 
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results obtained for cDDP+DOX. This suggests that, in combination regimens, MTX enhances the 
lipidic response to chemotherapy by the metabolome of cells. 
 
Figure 7.7. Time course of lipids and lipid ratios varying with cDDP- (orange) or Pd2Spm-cocktail 
(green) treatments. Dashed lines represent the effect of the addition of MTX to drug-cocktail). *p < 0.05 
and **p < 0.01. 
 
In relation to choline compounds (Figure 7.8), increases in choline and GPC had already 
been seen as a consequence of cDDP or DOX in sole administration, thus suggesting a synergistic 
effect of these two drugs over these compounds. However, slight decreases in PC and the absence 
of variations in PE upon combined treatment are coincident to DOX-treatment (Figure 5.10, 
Chapter 5), pointing to a slight dominant effect of DOX over choline compounds when used in 
combination with cDDP. Choline compound ratios (Figure 7.8) behave similarly to when the two 
drugs are administered alone (Figures 5.6 and 5.10, Chapter 5). When MTX is added to the cDDP-
based cocktail, only the PC levels seem to be slightly enhanced, but no significant influence is 
observed on choline compound ratios. 
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Figure 7.8. Time course of choline-compounds and ratios varying with cDDP- (orange) or Pd2Spm-
cocktail (green) treatments. Dashed lines represent the effect of the addition of MTX to drug-cocktail. *p < 
0.05 and **p < 0.01. 
 
In general, a time-dependent decrease of amino acids is observed upon cells’ exposure to 
cDDP+DOX (with the exception of Ile, for which increases are seen at 72 and 96 hours) (Figure 
7.9). The alterations induced by this cDDP-based cocktail at 48 hours more closely reflect those 
resulting from single exposure to DOX (Figure 5.10, Chapter 5), but the measured decreases in 
Gly, Lys and Thr were also detected upon cells’ treatment with 30 μM cDDP (Figure 5.6, Chapter 
5). On the other hand, the absence of variations in Tyr and the decrease in Val upon cDDP+DOX 
were not coincident with those registered for single drug administration (with either cDDP or 
DOX). Interestingly, the majority of the variations detected in amino acids upon addition of MTX 
to the cocktail, although small, seem to reduce the differences between treated and control cells. 
Exception for the branched amino acids Val and Ile, for which MTX addition potentiate the 
difference between treated and control cells, in relation to what happens upon treatment with 
cDDP+DOX. Nevertheless, single administration of MTX (section 5.2.3, Chapter 5) did not result in 
any significant change of Val or Ile levels, thus suggesting some degree of synergism of 
cDDP+DOX+MTX combination over amino acids variation upon treatment.  
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Figure 7.9. Time course of other compounds varying with cDDP- (orange) or Pd2Spm-cocktail (green) 
treatments. Dashed lines represent the effect of the addition of MTX to drug-cocktail. *p < 0.05 and **p < 
0.01. 
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7.2.2. Pd2Spm-Cocktail 
As mentioned before, and similarly to what was observed for cDDP-cocktail experiments, a 
marked decrease of MG-63 cells survival was determined by the Trypan blue assay after 
administration of the Pd2Spm-cocktail. The following results describe the metabolic changes that 
accompany the corresponding drug-induced growth inhibition of MG-63 cells. 
The metabolic impact of the Pd2Spm-based cocktail was studied following the same 
experimental setup and sample collection scheme as that referred for cDDP-cocktail studies. 
Visual inspection of drug-treated vs control samples at 24 hours (Figure 7.10a and 7.10b) revealed 
significant drug-induced alterations: marked increases of choline, GPC, uridine, UXP and 
glucosylated derivatives (both at δ 5.52 and δ 5.62), increased alanine and significant changes in 
other metabolites (namely increased creatine and decreased m-inositol). When comparing the 
metabolic profile of Pd2Spm+DOX-treated cells with that of controls, for increasing periods of 
drug-exposure, it becomes clear that the metabolic changes observed at 72 and 96 hours are the 
same to those detected at 48 hours of treatment, but with an increased magnitude. In general, an 
increase in all lipid signals, choline, GPC, hypoxanthine and UN (δ 7.86, d), as well as in 
nucleotides and its derivatives (Ino/Ado, UXP, UDP-GNAc and uridine), and a global decrease in 
amino acids (Ala, Lys, Glu, Gln, Thr, Gly, Tyr, Phe and His). Despite the maintenance of increased 
UDP-glucosylated metabolites in treated cells, at 72 and 96 hours the intensity of these 
resonances were found to undergo a marked decrease such as that at 96 hours only UDP-GalNAc 
(δ 5.62) was detected. Resonances assigned to acetates (δ 1.92 and δ 2.02) suffer some 
fluctuations upon chemotherapy administration, but the dispersion between samples makes it 
difficult to address the direction of the change. These described changes for MG-63 cells upon 
Pd2Spm+DOX-treatment are coincident with those detected upon cDDP+DOX-treatment, 
evidencing that Pd2Spm may be an interesting alternative to cDDP, namely in combination with 
DOX. In other words, Pd2Spm seems to substitute cDDP efficiently when combined with DOX, as 
viewed by HRMAS metabolomics of treated MG-63 cells. 
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Figure 7.10. Average 500 MHz 1H HRMAS NMR spectra of MG-63 cells: a) control and b) exposed to 
Pd2Spm+DOX, at 24 hours; c) control and d) exposed to Pd2Spm+DOX, at 72 hours. Insets show expansions 
of choline compounds (3.2-3.3 ppm) and aromatic (5.2-8.5 ppm) regions. Main assignments are noted and 
visible spectral changes due to drug exposure are marked by arrows. 
a) Control MG-63 cells  at 24 hours
b) Pd2Spm+DOX-treated MG-63 cells  at 24 hours
c) Control MG-63 cells  at 72 hours
d) Pd2Spm+DOX MG-63 cells  at 72 hours
7.50 5.00 2.50 ppm
7.50 5.00 2.50 ppm
8.00 7.50 7.00 6.50 6.00 5.50 ppm
x10
x10
x10
x10
3.400 3.300 3.200 ppm
m-inositol
Cho
PC
GPC
Lf.a.
CH3AlaPhe, Tyr, His L f.a.
CH=CH
GSH
Creatine
Lys
Val, 
Leu, 
Ile
UXP
Urd
Ino/Ado
Urd
UDP-GNAc
UXP
Creatine
m-inositol Lf.a. (CH2)n, 
Thr, Lac
Chapter 7 
 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
251 
 
Similarly to what was observed for the cDDP+DOX cocktail, addition of MTX to the 
Pd2Spm+DOX cocktail does not seem to alter the survival of MG-63 cells (Figure 7.2a). Even so, the 
metabolic profile of these cells exposed to either Pd2Spm+DOX or Pd2Spm+DOX+MTX may unveil 
eventually (if any) specific metabolic changes associated with MTX addition to the drug cocktail. 
Figure 7.11 compares the average metabolic profile of the control, Pd2Spm +DOX and 
Pd2Spm+DOX+MTX-treated cells, at 96 hours. 
  
Figure 7.11. Average 500 MHz 1H HRMAS NMR spectra of MG-63 cells, at 96 hours: a) under control 
conditions, b) exposed to Pd2Spm+DOX and c) exposed to Pd2Spm+DOX+MTX. Insets show expansions of 
choline compounds (3.2-3.3 ppm) and aromatic (5.2-8.5 ppm) regions. Main assignments are noted and 
visible spectral changes due to drug exposure are marked by arrows. 
The addition of MTX to the Pd2Spm+DOX-cocktail globally preserves the metabolic changes 
attributed to the treatment with Pd2Spm+DOX: an increase in lipids and choline compounds, slight 
a) Control MG-63 cells
b) Pd2Spm+DOX-treated MG-63 cells
c) Pd2Spm+DOX+MTX-treated MG-63 cells
8.00 7.00 6.00 5.00 4.00 3.00 2.00 1.00 ppm
8.00 7.00 6.00 5.00 4.00 3.00 2.00 1.00 ppm
8.00 7.50 7.00 6.50 6.00 5.50 ppm
x10
x10
x10
3.400 3.300 3.200 ppm
m-inositol
Cho
PC
GPC
Lf.a.
CH3AlaPhe, Tyr, His L f.a.
CH=CH
Creatine
Lys
Val, 
Leu, 
Ile
UXP
Urd
Ino/Ado
Urd
UDP-GNAcUXP
Creatine
m-inositol
Lf.a. (CH2)n, 
Thr, Lac
Metabolic Impact of Drug Combination on Osteosarcoma MG-63 Cells 
 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
252 
 
increase in uridine, UXP and UDP-GNAc, and a global decrease in amino acids and m-Inositol. 
However, a decrease in Ino/Ado was observed only after treatment with the MTX-containing 
cocktail (Figure 7.11c), which seems to be a marker for this particular drug combination (as it did 
not occur for cDDP+DOX+MTX-treated cells, Figure 7.4c). 
The results from multivariate analysis of the 1H HRMAS spectra of controls and drug-treated 
cells, both with Pd2Spm+DOX and Pd2Spm+DOX+MTX are presented in Figure 7.12. 
  
Figure 7.12. Multivariate analysis of controls (z) and Pd2Spm-cocktail treated (c/c) cells, using the 
full spectral range. (a) PCA scores plot, Ctr scaled,(b) PLS-DA scores plot, UV scaled, 2 components, R2X = 
0.389, R2Y = 0.925 and Q2 = 0.853. Monte Carlo Cross-Validation (MCCV) results of PLS-DA model obtained 
for MG-63 cells exposed to Pd2Spm-cocktail vs control: c) Q
2 distributions and d) ROC plots of true and 
permuted models. TPR: true positive rate, FPR: false positive rate, Sens.: sensitivity, Spec.: specificity, CR: 
classification rate. 
PCA analysis (Figure 7.12a) resulted in a clear separation between controls and drug-
treated cells mostly along PC1. A time course tendency can be clearly assigned for treated 
samples from negative PC1 and PC2 to positive PC1 and PC2, whereas no such temporal tendency 
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can be addressed for control samples. Moreover, similarly to what was seen for the cDDP-cocktail, 
MTX addition to the Pd2Spm+DOX-treatment induces a separation between samples treated for 
96 hours, suggesting metabolic alterations that specifically emerge upon addition of this agent. 
PLS-DA scores plot (Figure 7.12b) showed a very good separation between control and drug-
exposed groups (Q2 0.853) with the maintenance of the time course tendency for treated 
samples. The robustness of achieved group discrimination was reflected in a very low Q2 
distribution overlap and good MCCV results (98.1% sensitivity, 99.7% specificity and 98.8% 
classification rate) shown in Figure 7.12c and 7.12d. These results are once again very similar to 
those obtained for the multivariate analysis of the data of cDDP-cocktail treated samples. 
The loadings analysis (Figure 7.13) yields qualitative information on the metabolic 
alterations underlying this class separation upon treatment with Pd2Spm-cocktails: increased lipid 
contents and choline compounds (Cho, PC and GPC) as well as slight increased uridine and UDP-
GNAc (especially the Gal derivative at δ 5.62). Additionally, significantly decreases in amino acids 
(Ala, Lys, Met, Tyr and Phe) coupled to marked decreases in m-inositol seem also to be associated 
with Pd2Spm-cocktail treatment. 
 
 
Figure 7.13. Multivariate analysis of controls and Pd2Spm-cocktail-treated cells, using the full 
spectral range: UV scaled PLS-DA LV1 loadings plot, colored as function of VIP values. 
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The plots of the time course variation of several compounds with Pd2Spm-cocktail 
treatment were shown in Figures 7.7, 7.8 and 7.9. Concerning lipids (Figure 7.7), Pd2Spm-cocktail 
induced a pronounced increase in all measured resonances as well as an increase in all calculated 
lipid ratios in relation to control conditions. In sole administration Pd2Spm did not cause lipids 
increase (Figure 6.6, Chapter 6) but, interestingly, in combination regimen it induces their marked 
increase, resembling one of the most determinant effects of cDDP, indicating that in combination 
to DOX, Pd2Spm might be possibly used in substitution of cDDP. Moreover, MTX addition to the 
Pd2Spm-based cocktail also slightly potentiates this increase, resembling once more, the effect of 
cDDP-based cocktail over these tumour cells. 
The time course of choline compounds (Figure 7.8) also show identical time course 
fluctuations for Pd2Spm- and cDDP-based cocktails: marked increases in choline and GPC levels 
and also pronounced increases in PC (although only at 96 hours). Generally, the direction of 
variation suggests a central role of DOX in the regulation of choline compounds levels, since, in 
sole administration, Pd2Spm was found to slightly affect only the PC levels. The addition of MTX to 
the Pd2Spm+DOX cocktail seems to slight potentiate the change in PC contents, an interesting 
result reminding that PC was the only choline compound significantly affected (decrease) by single 
administration of MTX (Figure 5.14, Chapter 5). Concerning choline compounds ratios (Figure 7.8), 
marked decreases of PC/Cho and PC/GPC and increased GPC/Cho emerge upon cells exposure to 
Pd2Spm+DOX with no further alteration in their levels when MTX is added to the drug cocktail. 
These alterations in choline compounds ratios are opposite from those found upon single 
exposure to Pd2Spm, and thus they arise as consequence of combination with DOX. 
In relation to the variation of amino acids (Figure 7.9) in response to Pd2Spm+DOX 
treatment, a global decreasing tendency with treatment is seen for Ala, Glu, Gln, Gly, Lys, Phe, 
Met, Thr and Tyr, while slight increases are only detected for Ile. The time course plots of Gly and 
Phe, suggest that MTX addition to the Pd2Spm-based cocktail slightly reduce the magnitude of 
variation of these amino acids relative to controls, eventually pointing to a special interference of 
MTX in the pathways in which these metabolites participate. 
In response to Pd2Spm+DOX, concomitant increases in uridine are measured together with 
a time course decrease of UXP (Figure 7.9). Additionally, Pd2Spm+DOX-treated cells show 
increased levels of UDP-GalNAc and UDP-GlcNAc. Interestingly, while a very slight increase in 
Ino/Ado occurs upon 96 hours treatment with Pd2Spm+DOX, a slight decrease relative to control 
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is measured when MTX is added to the cocktail, as already suggested by visual inspection (Figure 
7.11c). M- and s-Inositol markedly decrease with Pd2Spm+DOX treatment but MTX addition does 
not interfere with the levels of these compounds. GSH does not seem to be significantly altered 
by treatment with Pd2Spm-based cocktail. 
 
7.3. 1H NMR Analysis of TCA Extracts of cDDP- and Pd2Spm-Cocktail-Treated MG-63 Cells 
After HRMAS analysis, samples of both control and treated MG-63 cells with either 
cDDP+DOX or Pd2Spm+DOX cocktails for 48 hours were recovered and extracted with TCA, for 
1H 
NMR analysis. This time point was chosen to enable a comparison with the results from single 
drug exposure. The average spectra of triplicates for each of the three conditions are shown in 
Figure 7.14. Since TCA extraction was performed with the objective of revealing additional 
information on nucleic acids and derivatives, the analysis focused on the aromatic region of the 
spectra. 
As indicated in Figure 7.14b (arrows), upon 48 hours treatment with cDDP+DOX a 
considerable number of alterations is detected in the aromatic region of the spectra: increases in 
UXP, ADP/ATP and UDP/UTP and decreases in NAD+. UXP was also found to increase in MG-63 
cells exposed to cDDP alone but decreased upon DOX exposure. On the other hand, ADP/ATP 
dramatically decrease upon single exposure to either cDDP or DOX, revealing a synergistic effect 
of these two agents when combined. UDP/UTP levels remained essentially stable upon cDDP 
exposure but markedly decrease upon DOX treatment, once again suggesting a synergistic effect 
of drug combination. In agreement with the results from cDDP-cocktail, NAD+ levels decreased in 
cells exposed to cDDP as well as to DOX. 
Regarding Pd2Spm+DOX-treated cells (Figure 7.14c), the analysis of the extracts reveal the 
following changes: increases in UXP, ADP/ATP, UDP/UTP and UMP and decreases in uridine, 
Ino/Ado and NAD+. In Pd2Spm-based cocktails, a synergistic effect with DOX seems to account for 
the increases in ADP/ATP, since these signals are absent from spectra of cells treated with each of 
the two drugs in sole administration. Increases in UXP in Pd2Spm+DOX-treated cells, point to drug 
synergism (as such change is absent in sole administration of these drugs). Decreases in NAD+ 
follow those registered in drugs’ sole administration. 
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Figure 7.14. Average 500 MHz 1H NMR spectra of TCA extracts of MG-63 cells, at 48 hours: a) under 
control conditions, b) exposed to cDDP+DOX and c) exposed to Pd2Spm+DOX. Expansion of aromatic (5.0-
9.5 ppm) region is shown. Main assignments are noted and visible spectral changes due to drug exposure 
are marked by arrows. 
The spectra of TCA extracts also show increases in glucose (not detected in the 1H HRMAS 
NMR spectra of the same cells) in cDDP+DOX treated cells. This may reflect its reduced utilisation 
by these cells, eventually suggesting a reduction in their energetic demands. This possibility is also 
supported by the detected accumulation of ADP/ATP, since glucose is needed for the formation of 
ATP: since both accumulate in cDDP+DOX treated cells, it seems plausible to assume that treated 
cells are lowering their energetic demands. A similar deduction can help explain the increased 
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levels of UXP, especially due to increased UDP/UTP (as no relevant changes in UMP are detected). 
In addition, ATP production requires reduction of NAD+ to NADH what may explain its decrease 
upon treatment. 
Regarding Pd2Spm+DOX treatment, similar increases in glucose, UXP, ADP/ATP and 
UDP/UTP as well as identical NAD+ decreases were found in relation to cDDP+DOX treatment. 
However, additional decreases in uridine and Ino/Ado and increases in UMP were detected when 
cells were treated with the Pd2Spm-based cocktail. Both uridine and inosine can be used to 
produce UMP and AMP compounds, respectively, which in turn can generate UDP/UTP and 
ADP/ATP. Together with the slightly increased accumulation of glucose in relation to that 
observed in cDDP+DOX and the increased UMP levels (registered for Pd2Spm+DOX), the decreases 
in uridine and Ino/Ado possibly point to preferences for distinct pathways involving the synthesis 
of UXP/AXP compounds according to the metal (Pt or Pd) used in the drug cocktail. 
Apart from the compounds that are newly detected by analysis of sample extracts (glucose, 
ADP/ATP, UMP/UDP/UTP and NAD+) changes detected for UXP are coincident with those revealed 
by HRMAS for the treatment with both cDDP- and Pd2Spm-based cocktails, but no relevant 
changes were detected in Ino/Ado upon 48 hours treatment with Pd2Spm+DOX. 
 
7.4. Comparison of the Metabolic Impact of cDDP- and Pd2Spm-Cocktails 
Signal integration results were used to construct two summary tables in which all variations 
of metabolites and compound ratios (both in % and ES values) are compared, including with those 
from single drug assays, in order to more easily identify eventual synergistic or antagonistic 
effects of drug combination. 
As already refered, a marked change in lipid levels was measured during the metabolic 
response of MG-63 cells to both cDDP- and Pd2Spm-cocktails. In the case of cDDP+DOX 
combination, this increase seems to result from cDDP action, since a marked increase of lipids was 
already recognized in Chapter 5, as a characteristic metabolic response of MG-63 cells to cDDP in 
single administration while no significant variations were detected upon single exposure to DOX. 
The percentages of variation of lipid resonances at 96 hours exposure to cDDP+DOX are in the 
range 73-826%, to which correspond ES values of 3.1-6.9. Interestingly, both percentages of 
variation (106-972%) and ES values (8.4-19.5) suffer very significant increases when MTX is added 
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to the cDDP+DOX cocktail, although the results in Chapter 5 have shown that, in single 
administration, MTX does not alter the lipids profile. Nevertheless, when comparing the lipid 
ratios at 96 hours with and without MTX, identical values are seen. Pd2Spm+DOX also increase the 
lipids levels, with maximum increases being registered at 96 hours, ranging from 53-584% and ES 
values in the range 4.1-18 ES. When MTX is added to the cocktail, no additional variations are 
detected and both percentage of variation (67-695%) and ES values (4.6-13). 
Regarding choline compounds, for cDDP+DOX no significant variations are detected in PE 
while increases in choline, GPC and PC occur. However, when MTX is added, the positive 
variations are kept but a negative variation appears in PE (-30.4% and ES value of -1.7). When the 
analysing the Pd2Spm+DOX, this negative variation in PE already emerges at 96 hours (-45% and 
ES of -3.4) and the tendency is preserved when MTX is added. 
In terms of amino acids, upon 96 hours of treatment, cDDP+DOX induces decreases is 
several amino acids (Ala, Glu, Gly, Lys, Met, Phe, Ser, Thr and Tyr) and increases in Ile and Val, all 
maintained when MTX is added to the drug cocktail. For Pd2Spm+DOX, at 96 hours, all the 
previously described decreases in amino acids are seen and an additional negative variation is 
registered for Gln (-18% and ES value of -1.8), while positive variations are only addressed to Ile. 
All amino acids variations are kept when MTX is added, with exception of the newly observed 
variation in Gln, which disappears. 
Furthermore, in relation to nucleotides, 96 hours of exposure to cDDP+DOX induces non 
significant increases of UDP-GlcNAc (59% and ES of 1.6) which disappear upon addition of MTX, 
giving rise to the new and non significant increase of UXP resonances (58.2%), which is particularly 
interesting considering that MTX alone did not change it levels. The Pd2Spm+DOX treatment 
induces a slight increase of Ino/Ado and UXP at 96 hours (of around 13 and 52%). When MTX is 
added to this Pd2Spm-based cocktail, a significant decrease in the former is detected (-16% and ES 
of -2.8) and, although previous variation in UXP disappears, a newly detected decrease in UDP-
GlcNAc (-81% and ES of -2) was significant. This suggests that MTX displays a slightly different 
influence over nucleotides and derivatives levels, depending on the use of cDDP or Pd2Spm in the 
drug cocktail. 
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 Table 7.1: M
etabolite and com
pound ratio variations in M
G
-63 cells exposed to cD
D
P-based cocktail for 24, 48, 72 and 96 hours, com
pared to control cells. * p < 0.05, ** p 
< 0.01. Sym
bols 3
 and ³
 show
 variations that are in agreem
ent or different, respectively, from
 those seen in single drugs (cD
D
P, D
O
X and M
TX). 
M
etabolite 
Signal 
(δ,ppm
) a 
cD
D
P+D
O
X 
24h 
48h 
72h 
96h 
96h+M
TX 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
Lipids 
-CH
3  
0.91 
nv 
nv 
19.7±5.4*3
³
 
2.2±0.9 
87.8±9.1* 
4.40±1.43 
102.5±17.5 
2.5±1.0 
156.2±5.8**³
 
10.0±2.9 
-(CH
2 )n  
1.30 
nv 
nv 
46.2±9.2*3
³
 
2.6±1.0 
262.4±6.3** 
11.7±3.45 
378.2±15.7* 
5.4±1.7 
538.8±4.9**³
 
19.5±5.7 
-CH
2 CH
2 CO
 
1.60 
nv 
nv 
16.6±4.3*3
³
 
2.3±0.9 
78.8±6.8** 
5.41±1.69 
99.8±14.0* 
3.1±1.1 
140.4±6.4**³
 
8.4±2.5 
-CH
2 CO
O
 
2.25 
nv 
nv 
7.3±3.03
³
 
(+) 
44.1±5.8* 
4.10±1.35 
72.7±9.5* 
3.7±1.2 
105.6±4.5**³
 
10.0±3.0 
=CH
CH
2 CH
= 
2.83 
13.5±2.5* 
3.29±1.15 
41.5±3.0**3
3
 
7.5±2.2 
101.2±8.4* 
5.22±1.64 
159.4±12.6* 
4.6±1.5 
217.4±7.5**3
 
9.1±2.7 
-CH
=CH
- 
5.33 
nv 
nv 
142.3±13.1**3
³
 
4.2±1.4 
577.3±8.2** 
11.9±3.50 
826.1±15.2** 
6.9±2.1 
972.1±11.1**³
 
9.8±2.9 
Choline and Phospholipids 
Choline 
3.21, s 
115.0±9.0** 
5.30±1.66 
110.9±12.9*3
3
 
3.6±1.2 
216.1±21.5* 
3.15±1.12 
207.0±19.0* 
3.5±1.2 
267.2±17.9**3
 
4.2±1.4 
G
PC 
3.24, s 
98.7±10.3* 
4.20±1.38 
427.6±7.3**3
3
 
12.1±3.6 
608.4±21.7* 
4.53±1.46 
449.6±59.1 
(+) 
548.6±50.23
 
1.9±0.8 
PC 
3.23, s 
nv 
nv 
-24.0±11.6³
3
 
(-) 
nv 
nv 
133.9±13.6** 
3.8±1.3 
175.6±19.4*³
 
3.2±1.1 
PE 
3.25, s 
nv 
nv 
nv³
3
 
nv 
nv 
nv 
nv 
(-) 
-30.4±13.8³
 
-1.7±0.8 
A
m
ino acids 
Alanine 
1.48, d 
12.6±3.2* 
2.42±0.96 
nv³
3
 
nv 
-18.3±8.0 
-1.65±0.81 
-23.0±8.2 
-2.1±0.9 
-15.6±5.9³
 
-1.9±0.8 
G
lutam
ate 
2.34, m
 
31.8±12.7 
nv 
nv³
3
 
nv 
-12.1±6.3 
(-) 
-33.0±5.8* 
-1.6±0.8 
-17.9±7.83
 
-1.6±0.8 
G
lutam
ine 
2.45, m
 
nv 
nv 
-24.2±7.9* 
-2.3±0.9 
nv 
nv 
nv 
nv 
nv 
nv 
G
lycine 
3.56, s 
-12.2±5.4 
(-) 
-35.4±13.73
3
 
-2.1±0.9 
nv 
nv 
-45.1±8.4** 
-2.3±0.9 
-39.8±9.3**³
 
-3.5±1.2 
Isoleucine 
1.02, d 
nv 
nv 
nv3
 
nv 
18.5±4.3* 
2.05±0.93 
36.6±7.7 
3.6±1.3 
44.3±3.9**³
 
6.0±1.8 
Lysine 
1.72, m
 
nv 
nv 
-15.8±2.5*3
3
 
-4.4±1.4 
-22.0±5.0* 
-2.24±0.92 
-19.7±6.4 
-2.2±0.9 
-15.1±3.1*³
 
-3.4±1.2 
M
ethionine 
2.13, s 
nv 
nv 
-23.7±8.6 
-2.0±0.9 
-26.5±9.2* 
-2.16±0.90 
-32.8±4.7** 
-5.4±1.7 
-26.4±5.1** 
-3.9±1.3 
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 Table 7.1 (cont.): M
etabolite and com
pound ratio variations in M
G
-63 cells exposed to cD
D
P-based cocktail for 24, 48, 72 and 96 hours, com
pared to control cells. * p < 
0.05, ** p < 0.01. Sym
bols 3
 and ³
 show
 variations that are in agreem
ent or different, respectively, from
 those seen in single drugs (cD
D
P, D
O
X and M
TX). 
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Effect size
 c 
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 c 
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Effect size
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Effect size
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%
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Effect size
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Phenylalanine 
7.32, d 
nv 
nv 
-24.5±11.23
³
 
-1.6±0.8 
-45.6±11.0* 
-3.51±1.21 
-62.0±11.6** 
-5.1±1.6 
-53.7±10.4*³
 
-4.6±1.5 
Serine 
3.84, d 
nv 
nv 
-14.3±5.8 
-1.7±0.8 
-21.8±6.3* 
-2.53±0.98 
-23.9±7.5 
-2.4±0.9 
-23.9±4.6* 
-3.8±1.3 
Taurine 
3.42, t 
nv 
nv 
nv3
 
nv 
nv 
nv 
nv 
nv 
nv³
 
nv 
Threonine 
3.58, d 
-23.3±10.2 
-1.69±0.82 
-34.5±10.3*3
3
 
-2.6±1.0 
-38.7±11.4* 
-2.75±1.03 
-39.9±7.7** 
-4.2±1.4 
-41.8±5.1**³
 
-6.7±2.1 
Tyrosine 
6.89, d 
nv 
nv 
nv³
³
 
(-) 
-45.3±19.6 
-1.95±0.86 
-65.6±26.1 
-2.4±1.0 
-61.8±25.4³
 
-2.3±0.9 
Valine 
1.05, d 
-3.9±1.9 
nv 
-9.3±4.6³
³
 
(-) 
nv 
nv 
20.6±10.1 
1.6±0.8 
27.7±4.6*3
 
3.5±1.2 
N
ucleotides and derivatives 
Inosine 
8.36, s 
nv 
nv 
nv³
3
 
nv 
nv 
nv 
nv 
nv 
nv3
 
nv 
U
D
P-G
alN
Ac 
5.62, m
 
71.0±18.4 
1.86±0.85 
233.3±12.7* 
5.5±1.7 
nv 
nv 
nv 
nv 
nv 
nv 
U
D
P-G
lcN
Ac 
5.52, m
 
70.1±25.8 
(+) 
161.6±56.33
3
 
nv 
263.8±51.5 
1.92±0.90 
59.0±16.0 
1.6±0.8 
nv3
 
nv 
U
XP 
5.99, d 
68.5±14.5 
1.86±0.84 
142.5±44.23
3
 
(+) 
121.0±38.5 
(+) 
nv 
nv 
58.2±25.9³
 
(+) 
U
ridine 
5.89, d 
nv 
nv 
nv3
3
 
nv 
91.8±25.5 
1.61±0.80 
91.2±8.4** 
4.9±1.6 
132.4±12.5**3
 
4.2±1.4 
O
ther com
pounds 
Acetate 
1.92, s 
nv 
nv 
nv 
nv 
nv 
nv 
nv 
nv 
-18.5±7.8 
-1.7±0.8 
Creatine 
3.93, s 
79.3±9.0* 
3.18±1.21 
nv3
³
 
nv 
nv 
nv 
-19.9±5.6* 
-2.5±1.0 
nv³
 
nv 
Form
ate 
8.46, s 
nv 
nv 
47.9±17.4 
(+) 
nv 
nv 
nv 
nv 
nv 
(-) 
G
SH
 
2.56, m
 
nv 
nv 
-18.9±6.5³
3
 
-2.1±0.9 
nv 
nv 
nv 
nv 
nv3
 
nv 
H
ypoxanthine 
8.18, s 
nv 
nv3
 
nv3
3
 
nv 
125.8±16.7* 
3.02±1.09 
78.8±28.5 
(+) 
102.9±20.53
 
nv 
m
-Inositol 
4.05, t 
-50.0±17.2 
-2.53±0.98 
-55.0±4.5**3
3
 
-10.2±3.0 
-45.6±10.3* 
-3.74±1.26 
-32.5±15.0 
-1.7±0.8 
-27.7±12.2³
 
-1.7±0.8 
s-Inositol 
3.34, s 
-17.1±6.8 
(-) 
-41.0±12.23
3
 
-2.5±1.0 
-71.9±11.9* 
(-) 
-66.9±27.0 
(-) 
-49.4±15.8³
 
-1.6±0.8 
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 Table 7.1 (cont.): M
etabolite and com
pound ratio variations in M
G
-63 cells exposed to cD
D
P-based cocktail for 24, 48, 72 and 96 hours, com
pared to control cells. * p < 
0.05, ** p < 0.01. Sym
bols 3
 and ³
 show
 variations that are in agreem
ent or different, respectively, from
 those seen in single drugs (cD
D
P, D
O
X and M
TX). 
M
etabolite 
Signal 
(δ,ppm
) a 
cD
D
P+D
O
X 
24h 
48h 
72h 
96h 
96h+M
TX 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
N
-acetyl 
2.02, s 
nv 
nv 
nv³
3
 
nv 
nv 
nv 
nv 
(+) 
44.0±4.1**³
 
5.8±1.8 
 
 
Controls 
D
rug 
Controls 
D
rug 
Controls 
D
rug 
Controls 
D
rug 
Controls 
D
rug 
Lipid ratios 
CH
2 /CH
3  
1.88±0.10 
1.86±0.04 
1.80±0.15 
2.20±0.05*3
³
 
1.54±0.12 
2.96±0.09** 
1.34±0.05 
3.16±0.22** 
1.34±0.05 
3.34±0.05**³
 
CH
=CH
/CH
3  
0.04±0.00 
0.04±0.00 
0.04±0.01 
0.08±0.01**3
3
 
0.03±0.00 
0.12±0.00** 
0.04±0.00 
0.16±0.03* 
0.04±0.00 
0.14±0.01**³
 
=CH
CH
2 CH
=/ CH
3  
0.21±0.03 
0.21±0.01 
0.19±0.01 
0.23±0.00*3
3
 
0.23±0.02 
0.25±0.01 
0.24±0.01 
0.31±0.02* 
0.24±0.01 
0.30±0.01**3
 
Choline com
pounds ratios 
PC/Cho 
2.15±0.69 
0.95±0.21 
1.61±0.26 
0.58±0.04*3
3
 
1.81±0.80 
0.45±0.12 
0.68±0.32 
0.52±0.07 
0.68±0.32 
0.51±0.073
 
G
PC/Cho 
0.86±0.18 
0.80±0.05 
0.92±0.07 
2.29±0.42*3
3
 
1.35±0.21 
3.03±0.73 
1.48±0.41 
2.65±0.99 
1.48±0.41 
2.61±0.89³
 
PC/G
PC 
2.49±0.28 
1.19±0.31* 
1.75±0.26 
0.25±0.26*3
3
 
1.34±0.60 
0.15±0.06 
0.46±0.12 
0.20±0.10 
0.46±0.12 
0.20±0.093
 
a resonance chosen for signal integration, b %
 of variation and c effect size in relation to control cells. 
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Table 7.2: M
etabolite and com
pound ratio variations in M
G
-63 cells exposed to Pd
2 Spm
-based cocktail for 24, 48, 72 and 96 hours, com
pared to control cells. * p < 0.05, ** 
p < 0.01. Sym
bols 3
 and ³
 show
 variations that are in agreem
ent or different, respectively, from
 those seen in single drugs (Pd
2 Spm
, D
O
X and M
TX). 
M
etabolite 
Signal 
(δ,ppm
) a 
Pd
2 Spm
+D
O
X 
24h 
48h 
72h 
96h 
96h+M
TX 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
Lipids 
-CH
3  
0.91 
nv 
nv 
18.1±5.2*³
³
 
2.1±0.9 
61.5±10.2* 
3.02±1.09 
91.0±7.8** 
5.2±1.6 
89.7±8.8**³
 
4.6±1.5 
-(CH
2 )n  
1.30 
nv 
nv 
38.1±10.0*³
³
 
2.1±0.9 
183.4±12.5* 
5.01±1.59 
305.3±4.4** 
18.0±5.2 
342.7±6.2**³
 
13.2±3.9 
-CH
2 CH
2 CO
 
1.60 
nv 
nv 
13.4±4.0³
³
 
2.0±0.9 
53.5±8.3* 
3.32±1.16 
79.9±8.5* 
4.4±1.4 
86.7±4.3**³
 
9.2±2.7 
-CH
2 CO
O
 
2.25 
nv 
nv 
6.0±2.6³
³
 
(+) 
26.1±6.6 
2.29±0.93 
52.9±6.6** 
4.1±1.4 
67.1±4.2**³
 
7.8±2.4 
=CH
CH
2 CH
= 
2.83 
18.1±1.2** 
9.13±2.71 
36.6±2.8**3
³
 
7.2±2.2 
69.4±11.0* 
3.07±1.01 
130.7±8.4** 
6.2±1.9 
142.5±4.3**3
 
12.6±3.7 
-CH
=CH
- 
5.33 
33.3±8.7 
2.15±0.90 
107.0±13.0**³
³
 
3.5±1.2 
423.6±15.1** 
5.88±1.82 
583.8±8.7** 
11.2±3.3 
695.3±9.0**³
 
11.3±3.3 
Choline and Phospholipids 
Choline 
3.21, s 
102.5±7.5** 
5.92±1.83 
133.8±9.5*3
³
 
6.5±2.2 
198.3±8.9** 
7.32±2.21 
199.6±21.2* 
3.1±1.1 
256.5±17.0**3
 
4.3±1.4 
G
PC 
3.24, s 
84.6±26.1 
(+) 
429.3±3.5**3
³
 
25.7±7.4 
616.0±15.4** 
6.40±1.96 
437.3±37.8 
2.4±1.0 
548.9±40.53
 
2.4±0.9 
PC 
3.23, s 
nv 
nv 
nv³
³
 
nv 
nv 
nv 
209.2±11.2** 
6.0±1.8 
275.6±14.8**³
 
5.1±1.6 
PE 
3.25, s 
nv 
nv 
nv3
3
 
(-) 
nv 
nv 
-44.9±11.2* 
-3.4±1.2 
-26.3±12.8³
 
(-) 
A
m
ino acids 
Alanine 
1.48, d 
16.4±4.9 
2.03±0.88 
nv3
3
 
nv 
-18.3±7.0 
-1.89±0.85 
-22.7±9.6 
-1.7±0.8 
-18.4±6.4³
 
-2.1±0.9 
G
lutam
ate 
2.34, m
 
39.0±12.5 
nv 
nv3
3
 
nv 
nv 
nv 
-24.2±7.3* 
-2.4±1.0 
-15.2±6.63
 
nv 
G
lutam
ine 
2.45, m
 
nv 
nv 
nv 
(-) 
nv 
nv 
-17.7±7.1 
-1.8±0.8 
nv 
nv 
G
lycine 
3.56, s 
-13.4±6.2 
(-) 
-30.4±13.83
3
 
-1.7±0.8 
nv 
-1.68±0.81 
-42.3±8.5* 
-4.1±1.4 
-37.1±9.4*³
 
-2.8±1.1 
Isoleucine 
1.02, d 
3.7±1.5 
(+) 
nv3
 
nv 
12.6±5.9 
(+) 
24.7±9.0 
1.6±0.8 
29.8±8.6³
 
2.7±1.1 
Lysine 
1.72, m
 
nv 
nv 
-14.0±2.8*3
3
 
-3.6±1.2 
-23.3±4.0** 
-4.30±1.40 
-20.8±8.1 
-1.9±0.8 
-17.0±4.3**³
 
-2.8±1.1 
M
ethionine 
2.13, s 
nv 
nv 
-17.8±8.7 
-1.5±0.8 
-24.3±9.1 
-1.99±0.87 
-32.1±5.3** 
-4.7±1.5 
-21.6±5.3* 
-3.0±1.1 
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Table 7.2 (cont.): M
etabolite and com
pound ratio variations in M
G
-63 cells exposed to Pd
2 Spm
-based cocktail for 24, 48, 72 and 96 hours, com
pared to control cells. * p < 
0.05, ** p < 0.01. Sym
bols 3
 and ³
 show
 variations that are in agreem
ent or different, respectively, from
 those seen in single drugs (Pd
2 Spm
, D
O
X and M
TX). 
M
etabolite 
Signal 
(δ,ppm
) a 
Pd
2 Spm
+D
O
X 
24h 
48h 
72h 
96h 
96h+M
TX 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
Phenylalanine 
7.32, d 
nv 
nv 
nv3
3
 
(-) 
-43.3±11.1* 
-3.26±1.15 
-56.2±12.1* 
-4.2±1.4 
-44.7±11.8³
 
-3.2±1.1 
Serine 
3.84, d 
nv 
nv 
-11.1±5.4³
 
(-) 
-21.4±4.6* 
-3.36±1.17 
-26.4±6.6* 
-3.0±1.1 
-21.9±3.3* 
-4.9±1.6 
Taurine 
3.42, t 
nv 
nv 
nv3
3
 
nv 
nv 
nv 
nv 
nv 
nv³
 
nv 
Threonine 
3.58, d 
-21.0±10.0 
(-) 
-28.5±10.13
3
 
-2.2±0.9 
-41.4±11.6* 
-2.94±1.07 
-44.4±4.9** 
-7.6±2.3 
-38.6±7.2**³
 
-4.3±1.4 
Tyrosine 
6.89, d 
nv 
nv 
nv³
³
 
(-) 
-41.6±19.1 
-1.79±0.83 
-67.7±26.2 
-2.6±1.0 
-57.7±27.4³
 
-1.9±0.9 
Valine 
1.05, d 
nv 
nv 
nv3
3
 
nv 
nv 
nv 
nv 
nv 
nv3
 
(+) 
N
ucleotides and derivatives 
Inosine 
8.36, s 
nv 
nv 
nv3
³
 
nv 
nv 
nv 
13.4±5.7 
(+) 
-15.5±4.0*³
 
-2.8±1.0 
U
D
P-G
alN
Ac 
5.62, m
 
60.2±21.5 
(+) 
177.0±12.7* 
4.8±1.5 
160.8±35.0 
1.66±0.81 
nv 
nv 
nv 
nv 
U
D
P-G
lcN
Ac 
5.52, m
 
64.3±23.1 
(+) 
178.3±41.33
³
 
(+) 
219.5±83.1 
(+) 
nv 
(-) 
-81.0±4.0*³
 
-2.0±0.9 
U
XP 
5.99, d 
53.3±16.5 
(+) 
122.7±49.23
³
 
nv 
182.6±39.8 
(+) 
52.1±25.4 
nv 
nv3
 
nv 
U
ridine 
5.89, d 
nv 
nv 
nv3
3
 
nv 
55.9±23.5 
(+) 
81.7±15.2* 
2.5±15.2 
93.2±8.9**3
 
4.7±1.5 
O
ther com
pounds 
Acetate 
1.92, s 
nv 
nv 
nv3
 
nv 
-27.2±7.1* 
-2.91±1.06 
nv 
nv 
nv3
 
nv 
Creatine 
3.93, s 
82.6±9.0* 
3.26±1.23 
18.4±8.73
³
 
(+) 
nv 
nv 
nv 
nv 
8.10±3.50³
 
(+) 
Form
ate 
8.46, s 
nv 
nv 
nv 
nv 
-61.4±26.3* 
-2.20±0.91 
nv 
(-) 
nv 
nv 
G
SH
 
2.56, m
 
nv 
nv 
nv³
³
 
nv 
nv 
nv 
nv 
nv 
nv3
 
nv 
H
ypoxanthine 
8.18, s 
nv 
nv 
33.9±15.4 
(+) 
59.1±11.1* 
2.69±1.01 
86.6±22.2 
1.8±0.8 
nv 
nv 
m
-Inositol 
4.05, t 
-52.3±17.3 
-2.68±1.01 
-48.4±3.7**3
³
 
-11.2±3.3 
-46.4±10.2* 
-3.86±1.29 
nv 
(-) 
nv3
 
nv 
s-Inositol 
3.34, s 
nv 
nv 
-49.6±13.33
³
 
(-) 
-39.9±12.2* 
-1.78±0.83 
-62.9±12.2* 
(-) 
-61.5±14.6³
 
-1.7±0.8 
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Table 7.2 (cont.): M
etabolite and com
pound ratio variations in M
G
-63 cells exposed to Pd
2 Spm
-based cocktail for 24, 48, 72 and 96 hours, com
pared to control cells. * p < 
0.05, ** p < 0.01. Sym
bols 3
 and ³
 show
 variations that are in agreem
ent or different, respectively, from
 those seen in single drugs (Pd
2 Spm
, D
O
X and M
TX). 
M
etabolite 
Signal 
(δ,ppm
) a 
Pd
2 Spm
+D
O
X 
24h 
48h 
72h 
96h 
96h+M
TX 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
%
 var. b 
Effect size
 c 
%
 var. b 
Effect size
 c 
%
 var. b 
N
-acetyl 
2.02, s 
nv 
nv 
7.6±3.0³
 
1.6±0.8 
nv 
nv 
nv 
nv 
19.2±5.7* 
2.0±0.9 
 
 
Controls 
D
rug 
Controls 
D
rug 
Controls 
D
rug 
Controls 
D
rug 
Controls 
D
rug 
Lipid ratios 
CH
2 /CH
3  
1.88±0.10 
1.85±0.03 
1.80±0.15 
2.11±0.05³
³
 
1.54±0.12 
2.70±0.12** 
1.34±0.05 
2.84±0.16** 
1.34±0.05 
3.13±0.23**³
 
CH
=CH
/CH
3  
0.04±0.00 
0.04±0.00 
0.04±0.01 
0.07±0.01**3
³
 
0.03±0.00 
0.11±0.00** 
0.04±0.00 
0.12±0.00** 
0.04±0.00 
0.14±0.02*³
 
=CH
CH
2 CH
=/ CH
3  
0.21±0.03 
0.22±0.00 
0.19±0.01 
0.22±0.00*3
3
 
0.23±0.00 
0.24±0.01 
0.24±0.01 
0.29±0.00* 
0.24±0.01 
0.31±0.043
 
Choline com
pounds ratios 
PC/Cho 
2.15±0.69 
1.11±0.18 
1.61±0.26 
0.69±0.09*3
³
 
1.81±0.80 
0.70±0.08 
0.68±0.32 
0.71±0.16 
0.68±0.32 
0.72±0.02³
 
G
PC/Cho 
0.86±0.18 
0.79±0.22 
0.92±0.07 
2.07±0.11*3
³
 
1.35±0.21 
3.24±0.16** 
1.48±0.41 
2.65±1.20 
1.48±0.41 
2.69±1.21³
 
PC/G
PC 
2.49±0.28 
1.41±0.39* 
1.75±0.26 
0.33±0.03*3
³
 
1.34±0.60 
0.22±0.02 
0.46±0.12 
0.27±0.07 
0.46±0.12 
0.27±0.113
 
a resonance chosen for signal integration, b %
 of variation and c effect size in relation to control cells. 
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Regarding other compounds, acetate (δ 1.92) and N-acetyl (δ 2.02) resonances remain 
unchanged upon 96 hours of exposure to cDDP+DOX, but are altered when MTX is added, 
particularly N-acetyl (44% and ES value of 5.8). MTX action also leads to the disappearance of the 
significant variation in creatine at 96 hours of treatment with cDDP+DOX (-20% and ES value of -
2.5). Pd2Spm+DOX+MTX induces a similar effect over N-acetyl (increase of 19%, ES of 2) but 
opposite change in creatine (8%) in relation to Pd2Spm+DOX at 96 hours. 
 
The effect size values from drug-cocktail variations in relation to control conditions were 
also calculated from signal integrals, and were used to construct heatmaps of time course 
response for metabolites and compound ratios (Figure 7.15). 
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Figure 7.15. Heatmaps of effect size values of the time course response for a) several metabolites 
and b) compound ratios in MG-63 cells exposed to cDDP- and Pd2Spm-based cocktails. The effect size values 
are shown in a colour scale from minimum (dark blue) to maximum (dark red) values. * p < 0.05 and ** p < 
0.01 refer to the results of significance tests with integrals. 
This global analysis of drug-induced metabolic changes (Figure 7.15a) corroborates the 
findings pointed out by both visual inspection and multivariate analysis: cells undergo very similar 
alterations with both drug cocktails, globally described by a marked increase in lipids content and 
choline compounds (with slight decreased PE), a decreasing tendency for the majority of amino 
acids (exception for alanine at initial stages and isoleucine) and changes in other compounds as 
decreased m- and s-inositol. Also worth noting are the changes in the creatine, hypoxanthine and 
N-acetyl levels which show slight fluctuations over time that seem to be characteristic of either 
cDDP- or Pd2Spm-based cocktails. Regarding the compound ratios (Figure 7.15b), changes are 
once again common to cDDP- and Pd2Spm-based cocktails. In what concerns the lipid ratios, a 
global increase occurs reflecting enlargement of the corresponding chain length (CH2/CH3), as well 
as higher unsaturation (CH=CH/CH3) and polyunsaturation (=CHCH2CH=/CH3) degrees. Choline 
ratios show a quite opposite variation, with marked changes in PC/Cho and PC/GPC at initial times 
of drug exposure, while an increase in GPC/Cho is observed at intermediate times. Remarkably, 
such changes in lipid and choline compounds ratios seem to take place at different stages of 
treatment: for choline compounds until 72 hours and for lipids essentially from 48 hours onwards. 
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The clear decreasing tendency observed for the majority of the amino acids for both 
cDDP+DOX and Pd2Spm+DOX, was also a mark associated with cDDP treatment (single exposure, 
section 5.2.1) and probably reflect their enhanced catabolism via de Krebs cycle. For Val and Ile a 
slightly different trend is found (for both cocktails), consistent with that found for single exposure 
to cDDP, and their catabolism were associated with the biosynthesis of branched chain fatty acids. 
Finally, the absence of significant changes in Tau and GSH levels suggest a low level of oxidative 
stress (Duarte et al., 2013) in cells exposed to either cDDP+DOX or Pd2Spm+DOX. However, the 
decreases in both Glu and Gly (GSH precursors) possibly indicate the activation of antioxidant 
protection mechanisms by the cells (associated with cell cycle arrest and apoptosis) (Santini et al., 
2006; Garcia-Alvarez et al., 2011; Mirbahai et al., 2011; Santini et al., 2001; Triba et al., 2010). In 
fact, STOCSY analysis revealed strong positive correlations between GSH and the two referred 
amino acid precursors (not shown), suggesting that Glu and Gly usage to form GSH occurs in such 
an efficient rate that (despite being used for antioxidant protection purposes) GSH levels are kept 
around control levels. 
 
Figure 7.16. STOCSY results obtained for PUFA resonance at δ 2.83 for cDDP+DOX-treated MG-63 
cells. 
STOCSY results obtained for the PUFA resonance (Figure 7.16) yielded similar results for the 
two cocktails: strong positive correlations between lipids resonances and the GPC and uridine 
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peaks. A positive correlation between GPC and PUFA resonance was already detected in MG-63 
cells exposed to cDDP (sole administration, Chapter 5), which was interpreted as revealing a close 
metabolic link to PTC hydrolysis. With regard to PUFA and GPC, this interpretation might possible 
apply for the similar results obtained for cDDP+DOX and Pd2Spm+DOX, however, differently from 
single exposure conditions, positive correlations were also assigned with uridine and PC, 
eventually pointing to specific PTC pathway adaptations when cells are treated with the drug 
cocktails. 
Figure 7.15a, shows significant increases of UDP-GalNAc, at 48 hours, for MG-63 cells 
treated with either cDDP+DOX or Pd2Spm+DOX. This compound was previously found to increase, 
along with UDP-GlcNAc in cDDP-treated brain tumour (Pan et al., 2011) and lung cancer cells 
(Duarte et al., 2013) and was correlated to mobile lipids associated with apoptotic cells death. In 
fact, STOCSY results obtained for UDP-GalNAc show a positive correlation with lipid resonances 
for cDDP+DOX-treated cells (Figure 7.17) but fail to reveal any correlation to lipid resonances for 
Pd2Spm+DOX-treated cells (not shown), pointing to different pathways of this nucleotide 
derivative.  
 
Figure 7.17. STOCSY results obtained for UDP-GalNAc resonance at δ 5.62, in cDDP+DOX-treated 
MG-63 cells. 
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However, for both cocktails, positive correlations were found between UDP-GalNAc and 
membrane degradation products (GPC and Cho). Although not significant, increases of UXP levels 
are seen in Figure 7.15a, and its resonances also strongly correlate with UDP-GalNAc, possibly 
arising from the drugs interaction with DNA. On its turn UDP-GlcNAc, which show just very 
tenuous increases in cDDP+DOX-treated cells, shows strong positive correlations with UXP and 
negative correlations with lipid resonances for both cocktails (shown in Figure 7.18 for 
cDDP+DOX). Additional positive correlations were found with GSH peaks (stronger for 
Pd2Spm+DOX combination) as seen previously for cDDP in sole administration (but not for DOX), 
suggesting a relation between UDP-GlcNAc and antioxidative mechanisms. 
 
Figure 7.18. STOCSY results obtained for UDP-GlcNAc resonance at δ 5.52, in cDDP+DOX-treated 
MG-63 cells. 
Another interesting finding is the effect of MTX when administered after these drug 
combinations. The analysis of the NMR spectra for MTX-induced metabolic changes in 
osteosarcoma cells exposed to cDDP- or Pd2Spm-based cocktails, suggests very scarce 
modifications due to the addition of this antimetabolite to the drug-cocktails. However, the 
heatmap of lipid ratios (Figure 7.15b) reflects a different role for MTX: in cDDP-cocktail, MTX 
clearly increased lipid ratios CH2/CH3 and CH=CH/CH3 in comparison to cDDP+DOX exposure while 
in Pd2Spm-cocktail exposure MTX is responsible for a decrease of the lipid ratios. Figure 7.15a also 
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shows that marked increases of PUFA levels (=CHCH2CH=) are induced by MTX addition. Regarding 
the choline compounds ratios, MTX does not seem to influence their mobilisation (no 
considerable changes in choline compounds contents after MTX administration are seen in Figure 
7.15a, with just a non statistically relevant decrease of PE in cDDP-based cocktail exposure). 
Furthermore, MTX addition does not seem to significantly interfere with amino acids dynamics, 
but seems to considerable alter N-acetyl moieties (δ 2.02) (in both drug-based formulations) and 
induce important decreases in Ino/Ado contents when added to the Pd2Spm-cocktail (Figure 
7.15a). 
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8. Conclusions and Future Perspectives 
The work described in this thesis employed NMR metabolomics to evaluate the response of 
osteosarcoma cells to conventional (cDDP, DOX and MTX) and a new possible anticancer drug 
(Pd2Spm), as well as to drug-combination treatments. The metabolic impact of cDDP and Pd2Spm 
was also investigated in normal osteoblast cells. Following an introduction to the subject (Chapter 
1) and to the methods employed (Chapter 2) and the description of the experimental procedures 
followed in this work (Chapter 3), an initial study carried out to select the acquisition parameters 
that yielded the best high resolution 1H HRMAS NMR spectral profile was described, as well as the 
influence of handling and storage conditions on the obtained spectra evaluated (Chapter 4). The 
results obtained from the drug-cell assays are presented in Chapters 5 to 7 of this thesis, and the 
main conclusions are hereby summarised. 
 
The study described in Chapter 4 aimed at defining the acquisition parameters that give the 
best 1H HRMAS NMR spectra of cells, understand the impact of different sample handling and 
storage conditions on the cell spectral profile and evaluate the reproducibility of the entire 
experimental protocol. The HRMAS NMR analysis of MG-63 cells enabled the simultaneous 
identification of hydrophilic and lipophilic compounds and results showed that the analysis of 
mechanically lysed cells increase the information recovery by improving the detection of choline 
compounds and sharp peaks arising from metabolites released from the intracellular shell. 
Regarding sample spinning rate (SR), the most significant improvements in spectral resolution 
were achieved until 4 kHz. The choice of 4 kHz as the best SR value was also motivated by the 
slight increases in lipids resonances and deviations in chemical shift for some compounds at 
higher SR, which were associated with sample heating phenomena and/or sample degradation. 
An increase in the temperature of the sample during acquisition (4 to 25˚C range) entailed 
identical consequences in the spectra: lightly increased visibility of lipid moieties and considerable 
changes in the chemical shift without a substantial increase of signal intensities. For long periods 
of acquisition, the temperature of sample revealed to be determinant for the profile obtained 
over time: at 4˚C, lipids, choline compounds and amino acids vary from around 10 % while at 
room temperature (22˚C) some of the variations reach the 100%. T2 measurements enabled the 
evaluation of the relative overall molecular mobility of different metabolites in the sample and T1 
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measurements revealed that the relaxation delay time (D1) chosen of 4 s ensures quantitative 
analysis of PC, lactate, Ala, Glu, Ser and Val, while for other compounds (such as Cho, Gly, Phe and 
Ino/Ado) measurements are only semi-quantitative. Reproducibility assays showed that choline 
compounds (particularly GPC and PC), the amino acids Gly, Phe and Pro as well as m- and s-
inositols showed statistically significant variations between assays. These variations then will have 
to be taken into account when studying the metabolites drug-induced changes. Despite their 
exploratory nature, the results of different number of passages suggested that the profile of cells 
that differ in about 20 passages are very similar, although slight variations namely in choline 
compounds, creatine, m-inositol, Tau, Glu and Thr were detected when cells were treated with 
cDDP. Finally, and despite some considerable variations in signals with low S/N (experimental 
error), the high stability of lipids and choline compounds suggested that sample stability is high 
during at least 27 months of storage at -80˚C. 
MG-63 cells exposed to cDDP were assumed to undergo extensive membrane degradation 
accompanied by a marked increase of lipids, while DOX- and MTX-treated cells showed no 
significant lipid variations and different phospholipid signatures. DOX-induced changes in 
metabolites in MG-63 were associated with membrane degradation, decreased membrane 
synthesis and (apparent) inhibition of de novo lipids synthesis. MTX-induced alterations were 
described by decreased membrane synthesis, without any signs of membrane disruption or de 
novo synthesis of lipids. Amino acids and nucleotide metabolisms as well as oxidative state of cells 
treated with each of the three drugs were also distinct. Changes in nucleotides seem to reflect 
different mechanisms of action, a link having been advanced for cDDP and DOX (both targeting 
DNA), between UDP-GlcNAc and the metabolically active pathways of membrane degradation and 
energetics. NMR analysis of TCA extracts added information on ADP/ATP, UMP/UDP/UTP and 
NAD+ variations. The results suggested similar variations of nucleotides and derivatives upon DOX- 
and MTX-treatment, both different from those appearing upon cDDP-treatment particularly in 
what regards to UXP and Ino/Ado. Furthermore, a relation between oxidative state and DNA 
degradation was suggested upon cDDP-treatment. Moreover, specific antioxidative metabolite 
signatures were unveil by correlation studies for each drug, suggesting a decisive influence of m- 
and s-inositols, Tau, Glu/Gln and possibly creatine in GSH metabolism. 
A new Pd(II) agent (Pd2Spm) was investigated as potentially active against osteosarcoma by 
comparing its impact on MG-63 and non-neoplastic (HOb) cells, compared to that of cDDP. Trypan 
blue results showed that, at 24 hours, Pd2Spm has an increased cytotoxic potential over MG-63 
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cells than cDDP (expressed by the much lower IC50 value, 12 µM, than half of that of cDDP, 30 
µM). However, this effect remains essentially constant for longer exposure periods (36 and 48 
hours) while for cDDP, cytotoxicity increases with the time of exposure to the drug.  
 The metabolic alterations that accompanyed these cytotoxic differences were clear from 
HRMAS NMR metabolomics: these comprised no changes in lipids, contrary to cDDP exposure, 
and lesser alterations in other metabolites. The results of TCA extracts NMR analysis showed that 
the metabolic consequences upon their administration are different in what relates to nucleotides 
and derivatives, namely in regard to UXP and ADP/ATP. This reinforces the idea that the two drugs 
act through different mechanisms of action. Interestingly, in this respect, the metabolic profile of 
MG-63 cells treated with Pd2Spm more closely resembles that of DOX or MTX treated, than that 
of cDDP. The results from Annexin assays, revealed that the reduction in the number of living cells 
upon Pd2Spm-exposure was not due to apoptotic cell death (proven to take place as a response to 
cDDP) or necrosis (since no significant PI labelling was detected). Additionally, the reversibility 
assays performed by HRMAS NMR showed that after the recovery period (three days in drug-free 
medium) the metabolic alterations that persist upon Pd2Spm-treatment are globally reverted or 
attenuated, while, for cDDP, a considerable number of drug-induced changes persist or emerge de 
novo, suggesting that cells are able to overcome the Pd2Spm-induced toxicity. Considering now 
the drug-induced effects in HOb cells, and although no significant differences regarding the 
number of living cells (Trypan blue assay) have been detected, a higher number of alterations in 
the metabolic profile of cells were detected in response to Pd2Spm, relative to cDDP exposure. 
The reversibility assays showed that, even in the absence of the drug, new additional changes 
appeared in HOb cells in response to cDDP-treatment and the marked alterations due to Pd2Spm-
exposure were maintained, suggesting an increased and sustained cytotoxic power of Pd2Spm in 
healthy cells. Together, the above results showed that Pd2Spm induces more tenuous metabolic 
changes in cancer cells than cDDP, whereas the opposite trend was noted for osteoblasts. This 
suggests that Pd2Spm may not be a good option for cDDP substitution in osteosarcoma treatment, 
at least in sole administration. 
Since no important alterations in the GSH levels were detected through HRMAS NMR of 
cells treated with either cDDP or Pd2Spm, studies were performed in order to understand 
whether drug-glutathione competition phenomena could have masked real GSH changes as 
response to drug exposure.  The results from 1H NMR, suggested the formation of adducts with 
both Pt(II) and Pd(II), reflected in the broadening of particular resonances. Nevertheless, in none 
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of the cases the formation of these adducts seemed to interfere with the integral of the measured 
GSH integral in the 1H HRMAS NMR spectra. 
Combination assays intended to unveil the metabolic alterations induced by exposure to 
the drug-cocktail used nowadays in osteosarcoma treatment. Additionally, the metabolic effects 
of the substitution of cDDP by Pd2Spm in the drug-cocktail were investigated. Cytotoxic results 
showed that exposure to cDDP-based and Pd2Spm-based cocktails induce similar decreases in the 
number of MG-63 and HOb cells. 1H HRMAS NMR results demonstrated that the metabolic 
consequences that follow this drug-induced decrease in the number of MG-63 cells are similar for 
both cDDP+DOX and Pd2Spm+DOX combination treatments. Observed alterations encompassed 
dramatic increases in lipid contents and altered levels of choline compounds, pointing to cell 
death by apoptosis. Several amino acids decreased upon treatment with each of the two tested 
cocktails and identical changes were also measured for the both cDDP- and Pd2Spm-based 
cocktails in nucleotides and derivatives and other compounds as m- and s-inositol. Results of NMR 
analysis of TCA extracts showed identical response profiles in the aromatic region of cDDP+DOX- 
and Pd2Spm+DOX-treated MG-63 cells, which resembled those seen in cDDP for UXP levels. The 
accumulation of energetic compounds (AXP and UXP) may suggest that the carcinogenicity of the 
cells is being reverted in some way, revealing the success of the treatment. Moreover, the 
addition of MTX to each of the two cocktails was not translated into an alteration in the number 
of living cells, when compared to the effect induced by both cocktails without MTX. Regarding its 
influence over cell metabolism, it was shown that when MTX is added to the cocktails, a slight but 
consistent potentiation of the effect of the cocktail over lipids (augment) was detected, 
suggesting that MTX somehow sensitises cells for the exposure to cocktails. In Pd2Spm-cocktail, 
MTX addition induced important decreases in Ino/Ado levels, thus suggesting a different influence 
over DNA in relation to cDDP-based cocktail. In conclusion, these results showed that, differently 
from when used in sole administration, when combined to DOX, Pd2Spm induces metabolic 
changes that resemble those resulting from cDDP+DOX exposure. 
 
The work presented in this thesis demonstrated the potential of HRMAS NMR 
metabolomics to understand the metabolic consequences of drugs already used in the clinic, thus 
helping to unveil their metabolic impact and potentially defining markers of action and efficacy. 
HRMAS NMR was also proven to be a very useful approach to investigate the effect of potentially 
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active drugs alone or in combination. Despite the time-consuming task of cell culture procedures, 
the amount of information revealed by metabolomics together with the ease of sample 
preparation for NMR experiments strongly encourage the use of HRMAS NMR metabolomics in 
drug-testing assays.  
As future work, additional cell metabolomic studies could be performed to understand how 
does Pd2Spm works in cells with acquired resistance to treatment (namely to cDDP), especially in 
cocktail formulations. Furthermore, and since in this work HOb cells were analysed upon 24 hours 
treatment (far from their doubling time), assays that evaluate the drug-induced metabolic 
changes upon an exposure period closer to their doubling time (around 72 hours) would reveal 
additional long term treatment-induced consequences. In order to get a broader knowledge on 
the metabolic consequences or drug-combination treatment, it would be interesting to 
understand the metabolic consequences of osteoblasts treatment with cDDP- and Pd2Spm-based 
cocktails. Future work would also necessarily entail enzymatic studies and metabolic pathway 
network analysis, to follow in a more target way the metabolism of lipids and choline compounds 
upon drug-treatments. In this line, 31P NMR experiments and assays using hyperpolarised 13C 
substrates would also certainly be of crucial relevance to unveil more clues on the metabolic 
pathways in which these compounds are involved. Further insights into Pd2Spm mode of action 
would necessarily entail cell cycle analysis of treated cells, since annexin assays already showed 
that this Pd(II) drug does not induce cell death (either by apoptosis or necrosis). Finally, in cell 
Raman techniques would certainly offer additional information on the status of different cellular 
organelles upon drug-exposure. 
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